TW466117B - Pharmaceutical compositions of the retinoblastoma susceptibility gene product - Google Patents

Pharmaceutical compositions of the retinoblastoma susceptibility gene product Download PDF

Info

Publication number
TW466117B
TW466117B TW83111748A TW83111748A TW466117B TW 466117 B TW466117 B TW 466117B TW 83111748 A TW83111748 A TW 83111748A TW 83111748 A TW83111748 A TW 83111748A TW 466117 B TW466117 B TW 466117B
Authority
TW
Taiwan
Prior art keywords
protein
cells
cell
gene
tumor
Prior art date
Application number
TW83111748A
Other languages
Chinese (zh)
Inventor
Wen-Hwa Lee
Eva Y-H P Lee
David W Goodrich
Nan Ping Wang
H Michael Shepard
Original Assignee
Univ California
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/306,513 external-priority patent/US5851991A/en
Application filed by Univ California, Canji Inc filed Critical Univ California
Application granted granted Critical
Publication of TW466117B publication Critical patent/TW466117B/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention provides a method of preventing or inhibiting the proliferation of a pathologically proliferating cell, wherein the pathological proliferation of the cell is the result of the absence of a functional retinoblastoma protein or polypeptide in the cell. The method requires contacting the cell with an effective amount of retinoblastoma protein or polypeptide. This method also is useful to prevent or treat retinoblastoma or a secondary cancer to retinoblastoma by administering to a patient a functional retinoblastoma protein or polypeptide.

Description

466117 Α7 Β7466117 Α7 Β7

經濟部中央標準局員工消費合作社印製 五、發明説明(1 ) ’ 本确係於政府資肋下完成,其係來自中央衛生研究院 研究經費第EY 05758號··美國政府對本發明具某種程度之 權利。 在本專利說明書中’對於出版品之參考係嵌參考書目引 用。該類出版品之掲示併人本專利說明書供參考以更詳盡 描述與本發明相關之技藝。 本發明概括而言ί系關於預防病態增殖細胞之增殖作用的 一種细胞療法,亦即,施用有效之預防或掐療劑量之癌抑 制基因蛋白質如R Β蛋·白質或多胜呔Μ達到腫.瘤抑制作用。 發明背景 ‘. 對於基因在維持生物健康之功能的了解,已有長足之進 步。其通則可說是因為细胞的基因無法產生適當之蛋白質 ’造成生物體內_的許多病態現象。埴棰功能的喪失可能是 因為失去整個基因,或是因為基因本身基於各種原因而受 損。由於辨識出這類因素,使得基因療法有明顯的進步。 舉例來說,腎臟胚性肉瘤,一種兒童期腎臟癌,被認為 是肇因於染色體11上之基因的失活作用。使用單染色體微 细胞融合一媒-介轉移之技術,已証明納人一涸正常的染色 體11至腎臟胚性肉瘤之腫瘤细胞内可抑制腫瘤之生成。另 一方面*納人染色體X和1 3則不具此功效。 雖然在實驗的基礎上整個人體染色體之轉移可能有某些 價值,但笤考量將瑄種轉移運用在治療基因缺陷上,則並 不實際。由於一點,供翳療應用之適當染色體之製備是非 常費力,耗時,竑且昂貴。结果顯示這種技術在許多的應 -4, 本紙張碎埤赞*國理赛碑準 (請先閲讀背面之注意事展再填寫本頁〕 〕裝_ 4 661 1 7Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of the invention (1) 'It was indeed completed under the government's support. Degree of right. In this patent specification 'references to publications are incorporated by reference. The publications of this type of publication are incorporated herein by reference for a more detailed description of the techniques related to the present invention. In summary, the present invention is a cell therapy for preventing the proliferative effect of pathologically proliferating cells, that is, the administration of effective preventive or therapeutic doses of cancer suppressor gene proteins such as R Β protein · white matter or more than 呔 M to achieve swelling. Tumor inhibition. BACKGROUND OF THE INVENTION ‘. There is considerable progress in understanding the function of genes in maintaining biological health. The general rule can be said to be because the cells' genes cannot produce appropriate proteins, which causes many pathological phenomena in the body. The loss of tritium function may be due to the loss of the entire gene, or because the gene itself is damaged for various reasons. The identification of such factors has led to significant advances in gene therapy. For example, renal embryonal sarcoma, a childhood kidney cancer, is thought to be due to the inactivation of genes on chromosome 11. Using single-chromosome microcell fusion-media-mediated transfer technology, it has been shown that tumor cells that contain normal chromosomes 11 to kidney embryoblastic sarcoma can inhibit tumor formation. On the other hand, * human chromosomes X and 1 3 do not have this effect. Although the whole human chromosome transfer may have some value on the basis of experiments, it is not practical to consider the use of this kind of transfer for the treatment of genetic defects. Because of this, the preparation of appropriate chromosomes for holistic applications is very laborious, time consuming, costly and expensive. The results show that this technology is used in many applications -4, this paper is shattered and praised * Guo Lisai Tablet Standard (please read the notice on the back before filling in this page)] _ 4 661 1 7

A7 B7 五、發明説明(2 .用上木合適。 由於整個染色體治療用途的不適當性,另一埋輯考量是 输送適當基因的全部或至少可操作的部份至病患。雖然該 方法比輸送整個染色體較為實際,但基因療法僅適用於某 些應用。 關於此點,離析,序列分析,和選殖適當之核酸材料是 非常昂貴並且耗時。此外,在世界上只有非常少的地方具 有該類技術所需之高度精密的分子遺傳技術。再者,目前 該類技術尚無法大量·生產適合於豳療使用之材料。 綜観上述各點,若能有一種特定的醫療方法,在细胞層 面,使用生物科技技術,並採用相當價廉,可靠,更廣泛 可得 > 且具特定生化作用之材料者,是非常理想的。再者 *更為理想的是·能有一種治療方法•能在妞胞曆面输送治 療產物K引起改變,如抑制作用或腫瘤抑制作用。當然, 更希望有一種產物能Μ大量,一定純度之方式製造,可Μ 细 胚 膜 .網 視 是 就 療 治 式 方 If _ Ο β 胞這 綑Μ 陷合 缺適 至常 送非 的病 敦疾 有種 而一 速有 快 赘年 ο 三 .瘤第 腫 的 性命 惡生 的在 層是 覺常 感通 之 * 膜成 網組 視胞 是細 瘤膜 S 聞 斜 细.視 胚原 膜由 網是 視瘤 CE 〇 瘤之 胞生 經濟部中央標準局員工消費合作社印製 核局 色過 染透 深往 具往 是。 徵胞. 特細 的長 瘤延 胞的 细體 胚薇 瞑薔 網成 視彤 。和 側’ 二胞 於細 生形 發圓 往的 往小 前的 最遺 是 〇 它 一 。 之 的表 天代 後的 有型 也原 但症 ,癌 的性 傳傳 延遺.遺 是是是 其能且 尤可並 , 瘤一瘤 亡胞腫 死细内 成胚"球 造膜眼 人網的 侵視見 部 常 經 神 視 著 卜----------V 裝------1T-----故--------- (請先聞请背面之注意事呢#'·填寫本页) , I. pm 國_> 21 /^- ...,· u.·. Λ1| 466彳彳7 A7 B7 經濟部中央標準局貝工消費合作社印製 五、發明説明(5 ) .傳形-式έ持徵是早期發作和多重腫瘤病巢。後天的肜式是 發生在生命的晚期並且是單一單側腫頫(Proc. Hatl. Acad. S c i · (1971 丨 68:820-823; Hum, Genet. ( 1 979 ) 5 2:1 -54: S e i ft η n e (1984) 223:1028-1033 。 對遺傳性視網膜胚细胞廇之感受性,是以90¾遺傳特質 表琨頻度之正染色體顯性特質遺傳給後代*該腫瘤因而已 經成為並且仍是研究癌症中遺傳因素之原型模型(Am. J . Hum. Genet. ( 1 978) 30 : 406 - 4 1 0; Cancer ( 1 975 ) 35 : 1022-1025 ° - 關於視網膜胚细胞瘤之腫瘤生成作用,至少有二種假銳‘产 。第一種假說建議腫頫是由二個突變事寅所造成的 (Proc. Natl. Acad, Sci. (1971) 68 :820-823; Cancer (1 975) 35:1 022 - 1026 。另一假銳則提出正染色體顯性遺 傳性腫瘤如視網膜胚细胞瘤,代表在正常情形下調節一群 轉化基因,最可能是原-腫瘤基因之缺陷調節基因或抑制 基因之遺傅。視網膜細胞發育時,假設突夔造成Κβ基因之 第二複製本之喪失。因而未在渔尊時機產生ϋΒ蛋白質>乂致 無法發生分化舴用。 在較高等生物之發展過程中,如動物和人類,有次序之 -細胞循環進化是一關鍵因素。由於這種進化*發生有次序 和有系统之细胞分化作用,最終自一單一未分化细胞發展 成具有各種特殊姐織之高度结構化生物。概括言之,生理 上正常的细胞循環進化對生物是非常重要的,不只是在早 期生長時期*並且在生物之整個生命週期中。因此,即使 "6 - ---------...-------1;装------11------------ (請先閱讀背面之注再填寫本頁) i 的名 '夺^^4用中國國家揉^CNS )ίΑ4^ ( 210Χ297公釐〉 4661 1 7A7 B7 V. Description of the invention (2. It is suitable to use wood. Due to the inappropriateness of the entire chromosomal therapeutic use, another consideration is to deliver all or at least operable parts of the appropriate gene to the patient. Although this method is more than It is practical to transport the entire chromosome, but gene therapy is only suitable for certain applications. In this regard, isolation, sequence analysis, and selection of appropriate nucleic acid materials are very expensive and time consuming. In addition, there are very few places in the world that have This type of technology requires highly precise molecular genetic technology. Furthermore, this type of technology has not yet been able to mass-produce materials suitable for use in holistic therapy. To sum up the above points, if there is a specific medical method in the cell, At the level, it is ideal to use biotechnology technology and to use materials that are relatively cheap, reliable, more widely available and have specific biochemical effects. Furthermore * more ideally, there is a treatment method • The treatment product K can be delivered on the girl's cell surface to cause changes, such as inhibition or tumor suppression. Of course, it is more desirable to have a product that can be a large amount, one It can be manufactured with a method of determining purity, and can be used for the germinal membrane. Netview is based on the therapeutic formula If _ β β cells, this bundle of mitochondrial diseases is suitable for the diseases that are often sent to the non-disease. The life-threatening part of the tumor is sensational in the layers. The membranous reticulum group is a thin tumor membrane S and the oblique is thin. The retinal membrane is the retina of the tumor. The Central Bureau of Standards Consumer Cooperatives printed the nuclear bureau ’s dyeing and deep dyeing. Zhengzheng. Extra fine long tumor and spores of the somatophyte Weiwei Qiang rose into the network. And the side 'two cells in the fine life The last thing about the shape of the round and the small ones is 0. One of them is the type and the symptoms of the post-generation generation, and the sexual transmission of cancer is inherited. The thing is that it can and can be especially combined with tumors. A tumor dead cell swollen dead fine endoblasts " ball osteoplasty eye human net's invasion of the seeing section often looked at by God ---------- V equipment ----- 1T --- --So --------- (please listen to the notice on the back first # '· Fill in this page), I. pm country_ > 21 / ^-..., · u. ·. Λ1 | 466 彳 彳 7 A7 B7 Shellfish, Central Bureau of Standards, Ministry of Economic Affairs Printed by Fei Cooperative Society 5. Description of the Invention (5). The epiphenomenon-type sign is an early-onset and multiple tumor disease nest. Acquired patterns occur in the later stages of life and are unilateral swelling (Proc. Hatl. Acad. S ci · (1971 丨 68: 820-823; Hum, Genet. (1 979) 5 2: 1 -54: S ei ft η ne (1984) 223: 1028-1033. The susceptibility to hereditary retinal germ cell 遗传 is inherited to the offspring with a positive chromosomal dominant trait at a frequency of 90¾ genetic traits. This tumor has thus become and remains a prototype model for studying genetic factors in cancer (Am. J. Hum Genet. (1 978) 30: 406-4 1 0; Cancer (1 975) 35: 1022-1025 °-Regarding the tumorigenic effect of retinoblastoma, there are at least two kinds of false sharp births. The first hypothesis It is suggested that the swelling is caused by two mutations (Proc. Natl. Acad, Sci. (1971) 68: 820-823; Cancer (1 975) 35: 1 022-1026. Another false sharp proposed positive Chromosomal dominant hereditary tumors, such as retinoblastoma, represent a group of transforming genes that are regulated under normal circumstances, most likely the defect-regulating genes of the proto-tumor genes or the remnants of suppressor genes. When retinal cells develop, it is assumed that keratinocytes cause Kβ The loss of the second copy of the gene. Therefore, the ϋΒ protein > was not produced at the timing of the fishermen and could not be used for differentiation. In the development of higher organisms, such as animals and humans, there is an orderly-cell cycle evolution is One The key factor. Due to the orderly and systematic cell differentiation of this evolution, it eventually developed from a single undifferentiated cell into a highly structured organism with various special structures. In short, physiologically normal cell cycle evolution It is very important for living things, not just in the early growth stage * but also in the whole life cycle of living things. Therefore, even " 6----------...------- 1 ; Install ------ 11 ------------ (Please read the note on the back before filling out this page) i's name '夺 ^^ 4Use Chinese country rubbing ^ CNS) ίΑ4 ^ (210 × 297 mm) 4661 1 7

Α7 Β7 Μ濟部中央標準局貝工消費合作社印製 五、發明説明(4 ) 是在-生#1已達成熟期,正常之細胞進化仍是健康的一個非 常重要的因素。這一覬點,舉例來說,可在血液形成和生 殖器官之適當细胞調節的重要性上清楚的看到。 在某種情況下,正常的细胞循環進化無法進行時,經常 對生物造成毀滅性的影媒。這種異常,舉例來說,在各種 形式之癌症中可Μ看到,因為未經檢测和無法控制之细胞 進化經由細胞循環發生,從完成有絲分裂到细胞分裂之間 期並再回到有絲分裂,在許多案例中,腫瘤生成作用赛成 對生命造成威脅的事$。因此,有時嘗試限制無法控制之 细胞循環進化Μ治療或控制腫瘤生成之狀況。 根據埴些假說,遺傳性視網膜胚细胞瘤可能是由視網_ 胚細胞前驅體引起,該前驅體攜帶一個另外受困於體突變 之遺傅的缺陷對偶基因,而非遺傳性的情形則是在同一細 胞内需要二個體突變。最新的間接証據支持在視網膜胚细 胞瘤中Κ及又名為腎瞞之胚性肉瘤之腎胚细胞瘤,神經母 细胞溷和骨肉瘤中有這類癌抑制基因之存在。 由於觀察到腫瘤染色體姐型中染色體13之頻繁異常現象 和腫瘤中衰減货酯酶D活性,顯示RB限位涉及非遺傳性視 網膜胚细胞^ 瘤(Cancer Genet. Cytogp. net .( 1983)10: 3 1 1 -333; Cancer Genet. C.yt〇gfinp.t. , (1 982) 6 :213- 221。已有人提出使位於區域I3ql4之RB基因的二個對偁 基因失去活性’可造成視網膜胚細胞瘤。該提案—部份乃_ 是根據一個遺傳性視網膜胚细胞瘤之案例,其中二個以對 偶基因推定並不存在(Science (.1983 ) 219-973-975)。但 (諳先聞讀背面之注意事灰界填寫本頁) 紙择,尺度適用X國國家橾準《):..210X.297公釐.) 4661 彳 7 A7 B7 五、發明説明( 經濟部中央標準局貝工消費合作社印製 .是,-該提案所根據之假設,亦即醋酶D活性之喪失意指酯 酶D和RB基因的喪失已被推翻(Hum. (1987 ) 76:3 3- 40)。然而,其它的發現顯示在體细胞中是異合 子的染色體丨3標記*在視網膜胚细胞瘤腫瘤中往往變成同 種接合子或半接合子,因此,在3 / 3 7視網膜胚细胞瘤細胞 源之區域13<?14發生同棰接合子刪除作用(Mature (1983) 305: 779-784; Proc. Hatl, Acad. Sci , <19δ6) S3: 739 1 - 7394。這些實驗提供証據顯示所提及 之RB基因,確實在细·胞靥面以陳性的方式作用(Science (1987) 235:305-311 ; Cancer Res. Π 9 8 6) 46 : 157 3-〗580 ),有別於Μ移轉感染測試所測得之傅統腫 瘤基因的”顯性”活_ 性(S c i e in c e (1985) 223:669-B76; Nature ( 1985 ) 315:190- 195 )。 二種形式之視網膜胚细胞瘤現在均可治療,而且大多數 病患可以到成年期。但是,遺傳性視網膜胚細胞瘤之病患 具有高危險發展出第二種非哏球惡性腫瘤(Ophthalmology (1984) 91:1351~1355; Hew Engl. J. Hed (1971 )2δ 5 : 307- 3 Π ; Cancer (1 974 ) 34 : 2077 -2079 ,在初次 診斷3 0年内有高至90¾之出琨率(0 p h t. K a ] m n ] 〇gv (1984) 91 :13卜136)。最常出現之續發性癌症是平常反而 少見的骨肉瘤。相反的,治癒之非遺傳性視網膜胚細胞瘤 病患顯示與常人相同之癌症機率。此一發現十分有趣,因 為暗示RB基因可能在調節其它腫瘤上有關鍵性之任務。. 人體視網膜胚細胞瘤基因已經成功的選殖,鑑定並且序 8 _丰碎^卑國羁家揉率(CNS ) ( 210X 297公着), 諳 先 聞 讀 背 之 注 % 頁 4 6 61 1 7 A7 B7 五、發明説明(6) 經濟部中央橾準扃負工消費合作社印製 列分4彳? (Science (1987)23 5 : 1394-1399)。視網膜胚细胞 瘤基因位於和酯酶D基因非常邨近之區域1 3 q 1 4 : Π中的 染色體1 3中|亦已被鑑定,選殖和序列分析(Proc . K a t i . Sc i . (1986) 8 ,3 :6790-6794: Pore. Ha t 1 . Acad . Sc i . ( 1 986 ) 83 : 6337-634 1 ; Proc , Nat ί , Acad , Sc i , (1986) 83 : 6 337-6341)。透過自酯酶D基因之染色體游走 ,根據染色體之位置,同種接合子之刪除和表現時腫瘤-特定變異•鑑定出視網膜胚细胞瘤(1ΪΒ)基因。RB基因顯示 具有47 23個核苷酸並媚碼一個4.8千個鹼基(kb)之信使 RNA (mRNA) 〇 在視網膜胚细胞瘤病患體内發現RB DNA轉錄至RB mRNA 並不正常。不是完全無法測得轉錄作用,表示R B基因的不 存在或完全失去活性*或者所轉錄之mR N A分子尺寸減少約 4,0 kb,表示缺陷的RB基因。 序列分析R B互補D N A ( cDH A )選殖株*得到一個單一長的 開故密碼,表示其可編碼816個胺基酸之假設蛋白質。經 過電腦輔助在蛋白質序列資料庫存中尋找並未顯示緊密相 關之蛋白質建II所預測蛋白質之獨特肢基酸序列 (Science (19 8 7 ) 2 3 5 ·· 1 3 9 4-1 3 9 9 。所預測之蛋白質似乎 具有數個脯胺酸富集區,與過去在其它核腫瘤基因蛋白質 如蛋白質” in y c ”和” m y b "中所觀察到者類似(RH A Tumor Vircuses, Cold Spring Harbor Laboratoyr , Cold Spring Harbor, New York (1985))° 亦與本發明相關者,在較高等生物之發展過程中,如動 9 麥紙張尺度適用,中固囷家揉準:印NS )::A4規格(210X297公釐:Α7 Β7 Μ Printed by the Central Laboratories of the Ministry of Economic Affairs of the Central Bureau of Standards and Labor Cooperatives Fifth, the description of the invention (4) is at the maturity period of -sheng # 1, and normal cell evolution is still a very important factor for health. This puppet, for example, is clearly seen in the importance of proper blood regulation of the blood-forming and reproductive organs. In some cases, when normal cell cycle evolution cannot be carried out, it often causes a devastating film to the organism. This abnormality, for example, can be seen in various forms of cancer, because undetected and uncontrollable cell evolution occurs through the cell cycle, from the completion of mitosis to the period between cell divisions and back to mitosis, In many cases, tumorigenesis is a life-threatening event. Therefore, sometimes attempts have been made to limit the cyclic evolution of uncontrollable cells to treat or control tumorigenesis. According to some of these hypotheses, hereditary retinoblastoma may be caused by the retina_ germ cell precursor, which carries a defective dual gene that is also trapped by the survivor of the somatic mutation, but the non-hereditary case is Two individual mutations are required in the same cell. The latest indirect evidence supports the existence of such cancer suppressor genes in retinal embryocytomas and K. pelvic sarcomas, also known as renal blastomas, neuroblastomas, and osteosarcomas. The frequent abnormalities of chromosome 13 in the chromosome sister of tumors and the attenuation of esterase D activity in tumors have shown that the RB restriction involves non-hereditary retinoblastoma cells (Cancer Genet. Cytogp. Net. (1983) 10: 3 1 1 -333; Cancer Genet. C.ytogfinp.t., (1 982) 6: 213- 221. It has been proposed that the inactivation of the two antigenes of the RB gene located in the region I3ql4 'can cause retina Germ cell tumors. This proposal—partially—is based on the case of a hereditary retinoblastoma, two of which are presumed to be non-existent based on dual genes (Science (.1983) 219-973-975). But (谙 先Note on the back of the reading. The gray world fills in this page.) Paper selection, the standard is applicable to the national standards of country X. ": .. 210X.297 mm.) 4661 彳 7 A7 B7 V. Description of the invention (Central Bureau of Standards, Ministry of Economic Affairs) Printed by Industrial and Consumer Cooperatives. Yes,-the assumption on which this proposal is based, that is, the loss of acetase D activity means that the loss of esterase D and RB genes has been overturned (Hum. (1987) 76: 3 3- 40) However, other findings show that chromosomes that are heterozygous in somatic cells are labeled 3 * in the retinal embryo. Tumor tumors often become homozygous or hemizygous. Therefore, isozygous deletions occur in regions 13 <? 14 of 3/3 7 retinoblastoma cell sources (Mature (1983) 305: 779-784; Proc. Hatl, Acad. Sci, < 19δ6) S3: 739 1-7394. These experiments provide evidence that the RB gene mentioned does indeed act in a sensible manner on the cell surface (Science (1987) 235 : 305-311; Cancer Res. Π 9 8 6) 46: 157 3-〗 580), which is different from the "dominant" activity of the Fu Tuo tumor genes measured by the M-migration infection test (S cie in Ce (1985) 223: 669-B76; Nature (1985) 315: 190-195). Both forms of retinoblastoma are now treatable, and most patients reach adulthood. However, patients with hereditary retinoblastoma have a high risk of developing a second non-globus malignant tumor (Ophthalmology (1984) 91: 1351 ~ 1355; Hew Engl. J. Hed (1971) 2δ 5: 307-3 Π; Cancer (1 974) 34: 2077-2079, with an incidence rate as high as 90¾ within 30 years of initial diagnosis (0 ph t. K a] mn] 〇gv (1984) 91: 13 136 136). Most Frequent secondary cancers are usually osteosarcomas. Rather, cured non-hereditary retinoblastoma patients show the same chance of cancer as ordinary people. This finding is very interesting because it suggests that the RB gene may be regulating Other tumors have a critical task .. Human retinoblastoma genes have been successfully cloned, identified, and sequenced. 8 _Feng Su ^ Beiguo Jianjia Kneading Rate (CNS) (210X 297), read first Note on the back Page 4 6 61 1 7 A7 B7 V. Description of the invention (6) Printed by the Central Ministry of Economic Affairs of the Ministry of Economic Affairs and Consumer Cooperatives 4 (?) (Science (1987) 23 5: 1394-1399). Retina The blastoma gene is located in a region very close to the esterase D gene 1 3 q 1 4: Chromosome 1 3 | has also been identified, selected and sequenced (Proc. K ati. Sci. (1986) 8, 3: 6790-6794: Pore. Hat 1. Acad. Sci. (1 986 ) 83: 6337-634 1; Proc, Nat ί, Acad, Sci, (1986) 83: 6 337-6341). Through the migration of chromosomes from the esterase D gene, the deletion of the same zygote according to the position of the chromosome Tumor-specific mutations during expression • Identified retinoblastoma (1ΪΒ) gene. The RB gene shows a messenger RNA (mRNA) with 47 23 nucleotides and a code of 4.8 kilobases (kb). It is found that the transcription of RB DNA to RB mRNA is not normal in blastoblastoma patients. It is not completely impossible to measure the transcription, indicating the absence or complete inactivation of the RB gene * or the size of the transcribed mR NA molecule is reduced by about 4,0 kb, which indicates a defective RB gene. Sequence analysis of RB complementary DNA (cDH A) clones * yields a single long open code, which indicates that it can encode 816 amino acid hypothetical proteins. Computer-assisted protein sequence data Search for Inventory Proteins That Did Not Show Close Correlations The unique limbic acid sequence (Science (19 8 7) 2 3 5 · 1 3 9 4-1 3 9 9. The predicted protein appears to have several proline-rich regions, similar to those observed in other nuclear tumor gene proteins such as the proteins "in yc" and "myb " (RH A Tumor Vircuses, Cold Spring Harbor Laboratoyr , Cold Spring Harbor, New York (1985)) ° Also relevant to the present invention, in the development of higher organisms, such as moving 9 wheat paper standards are applicable, Zhongguo Jiajia standard: India NS) :: A4 size (210X297 mm:

4661 17 A7 B7 _^_ 五、發明説明(7 ) 物和-人為,有次序之细胞循環進化是一關鍵因素。由於這 種進化,發生有次序和有糸统之细胞分化作用,最终自一 單一末分化細胞發展成具有各種特殊組織之高度結構化生 物。槪括言之,生理上正常的妞胞循環進化對生物是非常 重要的,不只是在早期生長時期,並且在生物之整個生命 週期中。因此,即使是在生物已達成熟期,正常之细胞進 化仍是健康的一個非常重要的因素。這一観點,舉例來說 ,可在血液形成和生殖器官之適當细胞調節的重要性上清 楚的看到。 + 在某種情況下,正常的細胞循環進化無法進行時,經常 對生物造成毀滅性的影W。這種失常,舉例來說,在各種 形式之癌症中可以看到,因為未羥檢測和無法控制之细胞 進化經由細胞循·環發生,從完成有絲分裂到細胞分裂之間 期並再回到有絲分裂*在許多茱例中,腫瘤生成作用變成 對生命造成威脅的事實。因此,有時嘗試限制未經控制之 细胞循環進化以治療或控制腫瘤生成之狀況。 經濟部中央標準扃貝工消费合作社印製 在目前之情況下,在腫瘤開展之地區採用猛烈的治療措 旛如放射線療_法和化學療法。這二種方法均非常昂貴並且 在某些情形___下對生物造成很大損害。化學療法,舉例來說 ,可能造成病患的死亡,而當化學療法成功的控制腫瘤生 成作用時,可能對身體有長期的副作用。這種副作用苛能 造成病患的早期心臟問題。因此,雖然傳統的治療方法, 如-放射線和化學療法可有效的破壞某些無法控制之细胞, 但也會產生破壞有用细胞和使器官糸統衰弱的不希望效果 -10- 用史國國㈣举fCNS::)囔4^ (110X297公釐. v、 4 广第83^ 1 1748號專利申請案 6 6 彳 Ί *7 中1Τ銳明喜核TFW fS5i钜11员1 A7 B74661 17 A7 B7 _ ^ _ V. Description of the invention (7) Object and-man-made, orderly cell cycle evolution is a key factor. Due to this evolution, sequential and systematic cell differentiation occurred, and eventually developed from a single undifferentiated cell into a highly structured organism with various special tissues. In a nutshell, the cyclical evolution of a physiologically normal girl cell is very important to the organism, not only during the early growth period, but also throughout the life cycle of the organism. Therefore, even when the organism has reached maturity, normal cell evolution is still a very important factor for health. This puppet, for example, is clearly seen in the importance of blood formation and proper cellular regulation of the reproductive organs. + Under certain circumstances, when normal cell cycle evolution cannot be performed, it often causes devastating effects on living things. This abnormality, for example, can be seen in various forms of cancer, because unhydroxylated detection and uncontrollable cell evolution occur through cell cycle and cycle, from completion of mitosis to cell division and back to mitosis In many cases, tumorigenesis has become a life-threatening fact. Therefore, sometimes attempts have been made to limit the uncontrolled evolution of the cell cycle to treat or control tumorigenesis. Printed by the central standard of the Ministry of Economic Affairs, the Shellfish Consumer Cooperative. Under the current circumstances, violent treatment measures such as radiation therapy and chemotherapy are used in areas where tumors are developing. Both of these methods are very expensive and in some cases___ cause great damage to living things. Chemotherapy, for example, can cause patient death, and when chemotherapy successfully controls tumor formation, it can have long-term side effects on the body. This kind of side effect can cause early heart problems in patients. Therefore, although traditional treatment methods, such as radiation and chemotherapy, can effectively destroy some uncontrollable cells, they can also have the undesired effect of destroying useful cells and weakening the organ system-10- Use Shi Guoguo to raise fCNS : :) 囔 4 ^ (110X297 mm. V, 4 Guang No. 83 ^ 1 1748 patent application 6 6 彳 Ί * 7 in 1T sharp bright nuclear TFW fS5i 钜 11 members 1 A7 B7

五、發明説明( 經濟部中央標準局貝工消費合作社印製 綜觀前述各點,非常需要具有能調節不希 ,如腫瘤生成作用|又可同時雄持细胞生活 合物。此外,也非常需要該類技術和姐合物 小或無副作用,在细胞層面不致造成無法回 止腥瘤生成作用之發展。 這種新穎技術和姐合物之明顯優點,在腫 情況中是可Μ調節不希望细胞之增殖作用, 間施用其它癌症治療程序。因此*使用該類 避免傅统放射線和化學療法之破埭作用但可 作用。因而,病患可保持體力和活力Κ致傳 科手術,可更安全的使用。 發明摘要 本發明提供預防或抑制病態增殖细胞之增 细胞之病態增殖作用是因為细胞内缺乏功能 胞瘤蛋白質或多胜肽。該方法细胞需要與有 膜胚细胞瘤蛋白質或多胜肽接觸。該方法透 功能性視網膜胚细胞瘤蛋白質或多胜肽,亦 治療視網膜胚细胞瘤或續發性癌症。 圖表簡述 圖1是曆析譜,闡述在各種细胞源中Κ兔 藉免疫沉澱法鑑定〇蛋白質。人塍细胞如神 LAN-1 (第1和2行)*亞力山大肝癌(第3行 U20S (第4行)·正常纖維母细胞(第5行), 望之迪胞進化 力的技術和姐 對细胞產生很 轉的改變下終 瘤生成作用之 Κ提供足夠時 技術可減少或 中止腫瘸生成 铳技術*如外 殖作用,其中 性視網瞑胚细 效劑量之視網 過對病人施用 可用Μ預防或 子抗-RB IgG 經母细胞瘤 ),骨肉瘤 和5種視網膜 ——, . 、裝-- • V (請先閲讀背面之注意事項#.填寫本頁) 11 表纸珉尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 4 6 61 1 7 經濟部中央標準局員工消費合作社印製 i:· A7 .__B7___ 五、發明説明(9 ) 胚細(第δ至10行)权“S -甲硫肢酸標記旅以幼時免疫 之兔子IgG(第1行)或兔子抗-rb .[gG(第2-10行)進行兔疫 沉’殿。Μ 7 * 5 % S D S -聚丙酿胺凝膠電泳和放射自頚術分析 -免疫沉澱物。 圖2是完全的R B c D Μ /\核苷酸序列和R Β蛋白質之推測胺 基酸序列。該蛋白質指定為ppRB110或pll〇RB 。最多的 5’約240個核苷酸是得自視網膜胚细胞瘤细胞源Y79之 cDNA選殖株。得自該選殖株之核苷酸序列和原正常rb選殖 株Μ序列重鹾對齊。·第1和第2起始位置被框起來,而丙 胺酸和脯胺酸團盡以下線。 圖3是層析譜,閲釋RB蛋白質之修飾。LAN-1细胞Μ 3SS-甲疏胺酸(第;[-3行)或32f>-磷酸(0.5 taci/毫升)(第― 4和5行)標記3小時。细胞之溶胞產物以幼時免疫之兔子 1§〇(第1和4行)或抗-!^18〇(第2,3和5行)兔疫沉澱。以 核苷内切酶H (ICH ImmunoBiologicals)消化36S-甲硫胺 酸-標記之RB蛋白質整份過夜(第3行)。該類免疫沉殺物 再以圖1所述之7,5¾ SDS-聚丙醯胺凝膠分析。结果發現 R B基因產物被爾酸化但未被糖基化。 画4是屑析譜,閜釋在不同的脊椎動物品種中RB基因產 — 物之保留。人體神經母细胞瘤,LAN-5 (第1和2行),猴子 C0S ,(第3和4行),鵪鶉纖維母细胞,QT6,(第5和6行) ( 小鼠纖維母细胞,NIH73T3),(第7和8行),和老鼠纖维母· 细胞’ rat-2,(第9和10行)之細胞源以32P-磷酸標記再以 - 幼時免疫之ISG (奇數行)或抗-RB UG(偶數行)免疫沉澱 -12- :.p離妒、 1661 1 7五、發明説明(i〇 ) A7 B7 經濟部中央標準局貝工消費合作社印製 並依過f所述分析。在不同的脊椎物動品種間發現類似但 不同大小之RB蛋白質。 圖5A是層析譜,顯示蛋白質之定位作用。3SS -甲硫胺 酸標記之U N - 1细胞.(第4行)分级分離至细胞_ (第1行 ),细胞質(第2行)和细胞核(第3行.)’蛋白質Μ抗-pRB110 IgG免疫沉澱。免疫沉澱物Μ圖1所述之SDS-P AGE分析。 圖5B是層析譜,顯示在骨肉瘤细胞源U20S内RB蛋白質定 位作用之免疫螢光研·矣之结果。细胞與U )抗-ϋΒ I sG和 (Π)幼時免疫之兔子IsG反應。在细胞核内發現最多的螢 光。 是單股纖維素中RB基因磷蛋白之管柱層析照片 «人體神經母細胞瘤细胞L A Ν - 1之蛋白質溶胞產物Μ 32Ρ-磷酸新陳代謝標記並通過單股DNA管柱’再KNaC丨增 加梯度雛析(第3行=0.05;第4行=0_1;第5行=0.2;第 6行=0,3;第7行=0.5;和第8行=1.0舆耳濃度NaCl)。第1 行顯示與抗-IsG免疫沉澱之全部细胞溶胞產物° 圖6B是雙股DNA纖維素中RB基因磷蛋白之管柱層析照Η 。人體神經.母细胞瘤細胞LAN-ΐ之蛋白質溶胞產物以 32Ρ-磷酸新陳代謝標記並通過雙股DNA管柱’再M NaCI增 加梯度離析(第3行第4 ·ίτ=0.1;第5打=0.2;第 6行=0.3;第7行=〇,5;和第8行=1.0箅耳濃度NaCl)。第1 行顯示與抗-RB UG免疫沉澱之全部姻胞溶胞產物 圖7Α是圖示,閫述TRP E-RB融合蛋白質之產生。EcoRl -13- 本紙張尺度逍用中國固家揉準体卿从鱗妒21〇X?97公釐)斯 —r-l n I---- ______ τ__ (#先聞讀背面之注意事f#'填寫本頁) I. 鯽V. Description of the invention (Printed by the Shellfish Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. Looking at the foregoing points, it is very necessary to have the ability to regulate malaise, such as tumorigenicity | and also to hold the cell life composition at the same time. In addition, it is also very much needed This kind of technology and sister compound have little or no side effects, and do not cause the development of tumour formation that cannot be stopped at the cellular level. The obvious advantages of this novel technology and sister compound are that it can regulate undesired cells in the case of swelling. Proliferative effect, and other cancer treatment procedures are occasionally applied. Therefore * use this type to avoid the destructive effects of futon radiation and chemotherapy but can work. Therefore, patients can maintain physical strength and vitality κ caused by medical surgery, can be used more safely Summary of the Invention The present invention provides the ability to prevent or inhibit the proliferation of diseased proliferating cells due to the lack of a functional cytoma protein or polypeptide in the cell. In this method, the cell needs to be contacted with a membranous blastoma protein or polypeptide. The method penetrates functional retinoblastoma protein or polypeptide, and also treats retinoblastoma or secondary cancer Brief description of the diagrams Figure 1 is a historical analysis showing that K rabbits identified proteins by immunoprecipitation in various cell sources. Human 塍 cells such as the god LAN-1 (lines 1 and 2) * Alexander Hepatocellular carcinoma (3 Line U20S (line 4) · Normal fibroblasts (line 5). The technology of Wang Zidi's evolutionary ability and the change of the cell to change the cell. Under the terminal tumor formation effect, the technology can reduce or discontinue when sufficient. Swelling technology * such as exogenous effect, in which a small effective dose of retinal retinal embryos can be administered to the patient can prevent or prevent anti-RB IgG (blastoblastoma), osteosarcoma and 5 kinds of retina—— ,,--V (Please read the notes on the back # .Fill in this page first) 11 The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 4 6 61 1 7 Ministry of Economic Affairs Printed by the Consumer Standards Cooperative of the Central Bureau of Standards i: · A7 .__ B7___ V. Description of the invention (9) Embryo fines (lines δ to 10) Right "S-Methionate labeled rabbit IgG immunized in childhood (line 1 ) Or rabbit anti-rb. [GG (lines 2-10) for rabbit epidemic sinking. M 7 * 5% SDS-PP Gel electrophoresis and autoradiography analysis-immunoprecipitates. Figure 2 is the complete RB c D M / \ nucleotide sequence and the putative amino acid sequence of the RB protein. This protein is designated as ppRB110 or pllORB. At most The 5 ′ about 240 nucleotides are cDNA clones derived from retinoblastoma cell source Y79. The nucleotide sequence obtained from this clone is aligned with the original normal rb clone M sequence. The first and second starting positions are framed, and the alanine and proline groups are underlined. Figure 3 is a chromatogram showing the modification of the RB protein. LAN-1 cells M 3SS-methionine ( Lines [[-3]) or 32f > -phosphoric acid (0.5 taci / ml) (lines-4 and 5) are marked for 3 hours. The lysates of the cells were precipitated in rabbits immunized as a child 1§0 (lines 1 and 4) or anti-! ^ 180 (lines 2, 3 and 5). An entire portion of the 36S-methionine-labeled RB protein was digested with endonuclease H (ICH ImmunoBiologicals) overnight (line 3). Such immunosuppressants were analyzed on a 7,5¾ SDS-polyamidamine gel as described in Figure 1. It was found that the R B gene product was acidified but not glycosylated. Drawing 4 is a crumb analysis spectrum, explaining the retention of RB gene production in different vertebrate species. Human neuroblastoma, LAN-5 (lines 1 and 2), monkey COS, (lines 3 and 4), quail fibroblasts, QT6, (lines 5 and 6) (mouse fibroblasts, NIH73T3 ), (Lines 7 and 8), and mouse fibroblasts' rat-2, (lines 9 and 10) The cell source is labeled with 32P-phosphate and then-ISG (odd line) or anti-immune -RB UG (even-numbered row) immunoprecipitation -12-: .p Liyan, 1661 1 7 5. Invention Description (i〇) A7 B7 Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs and analyzed according to f. Similar but different sizes of RB proteins were found among different spinal animal species. Figure 5A is a chromatogram showing the localization of proteins. 3SS-Methionine-labeled UN-1 cells. (Line 4) fractionated to cells_ (line 1), cytoplasm (line 2) and nucleus (line 3). 'Protein M anti-pRB110 IgG immunoprecipitation. Immunoprecipitate SDS-P AGE analysis as described in Figure 1. Fig. 5B is a chromatogram showing the results of immunofluorescence studies of RB protein localization in osteosarcoma-derived U20S. The cells reacted with U) anti-ϋΒ I sG and (Π) immunized rabbit IsG in childhood. The most fluorescence is found in the nucleus. A column chromatography photo of the RB gene phosphoprotein in single-stranded cellulose «Protein lysate M 32P-phosphate metabolism marker of human neuroblastoma cell LA Ν-1 and passed through a single-stranded DNA column 'KNaC 丨Gradient analysis (line 3 = 0.05; line 4 = 0_1; line 5 = 0.2; line 6 = 0, 3; line 7 = 0.5; and line 8 = 1.0 concentration NaCl). The first line shows the total cell lysate of immunoprecipitated with anti-IsG. Figure 6B is a column chromatography picture of the RB gene phosphoprotein in double-stranded DNA cellulose. Human neuroblastoma cell LAN-ΐ protein lysates are labeled with 32P-phosphate metabolism and passed through a double-stranded DNA column and then M NaCI to increase gradient isolation (line 3, line 4 · τ = 0.1; line 5 = 0.2; line 6 = 0.3; line 7 = 0, 5; and line 8 = 1.0 浓度 concentration NaCl). The first line shows the total marital lysates immunoprecipitated with anti-RB UG. Figure 7A is a diagram illustrating the production of a TRP E-RB fusion protein. EcoRl -13- The size of this paper is free from the Chinese Gu family, and the quasi-body secretary is jealous from 21 × X to 97 mm) srl — I n ---- ______ τ__ (# 先 闻 读 的 后 事事 ## (This page) I. 鲫

CC

I 4 6 611 A7 B7 經濟部中央標準局貝工消費合作社印製 五 '發明説明(u ) -EcoRl cDN/\ RBH段(0.7 kb)融合構連至pATH3載體之 E co R 1位置。从詳细限制每位置圖確認其排列〇重姐質體 再轉化至大腸稈菌mm294内。 圖7B是重姐體TRP E-RB融合蛋白質之聚丙烯醯胺凝膠電 泳之照Η。重姐質體再轉化至大腸桿菌m 2 9 4内,並在補 充以20毫克/ 20毫升色胺酸之M9最低營養要求培養基中生 長。培養物在M9中稀釋至1 : 100加酩蛋白胺基酸和胺苄青. 酶素。在0 , 2 S00 nra之光密度下,添加在100Si乙醇中之 10毫克/毫升吲哚基·丙烯酸之1 : 1000稀釋液从誘發TRP E 放動基因之表現。粒子化细菌细胞,在Laemmli凝膠樣本 緩衝液中煮沸细菌细胞1 5分鐘,再Μ聚丙烯醢肢凝膠電泳 分析。再Μ考禺斯藍染色凝膠。58 kD蛋白質可在誘發之 培養物(第2行)' 中找到但在對照培養物(第1行)中則未'出 現。 圖8 A和8B顯示來自各種妞胞源之RB蛋白質之免疫沉殺物 0 圖8 A是層析圖*顯示來自各種人體细胞源之RB蛋白質/ 抗RB蛋白質U*D之免疫沉殺物。製備自人體肝癌亞力山大 细胞源(第丨,行),人體骨肉瘤细胞源,U 2 0 S (第2_行),正 -常人體缴維母细胞(第3行),人體神經母细胞瘤细胞源, LAN-5 (第4行),和Μ幼時免疫之兔子IsG沉濂自人體神 經母Μ胞瘤溶胞產物(第5行)之35S-甲硫胺酸-標記之细· 胞提取物以經鈍化之兔子抗-RB IgG免疫沉澱。在第1 -4行觀察到具有表面分子重量約110-114 kD之一對帶子。 -14- --------- 裝------訂---- (諳先聞讀背面之注ϊπ#·,填寫本頁) M: 466117 A7 B7 五、發明説明(12 ) 圖B鲁層析圖,顯示來自數個視網膜胚細胞瘤细胞之 RB蛋白質/抗-RB蛋白質UG之免疫沉澱。 來自5種不同視網瞑胚,细胞瘤细胞源之细胞提取物以 3 2 S -甲硫胺酸標記,.再从經純化之兔子抗-Ο I g G進行免 疫沉澱。一對帶子出現在來自肝癌,骨肉瘤,纖維母细胞 瘤和神經母细胞瘤之细胞源之一對帶子,未出現在全部5 種視網膜胚细胞瘤细胞源RB 355(第1行),Y79(第2行), WERI-1(第 3 行),WERI-24(第 4 行 > ,和 WERI-27(第 5 行 ),人體神娌母细胞尨细胞源LAN-5 (第6行)和來自K幼 時免疫之兔子UG沉澱之神經母细胞瘤溶胞產物中。根據 這些结果鑑定RB蛋白質。 圖9是層析圖,.顯示生化分级分離作用K証明RB蛋白質 之作用。經3SS “甲硫胺酸標記之LAN 5全部细胞(第4行) 分级分離至細胞膜(第1行),细胞質(第2行)和细胞核( 第3行)並接著K兔子抗-rb igG免疫沉澱。大多數的 RB11〇_114蛋白質在细胞核内發現,少數部份出現在細胞 膜或细胞質中。 經濟部中央標準局員工消費合作社印製 — -^ϊ. m - n^— I I .窣 (請先閲讀背面之注意事Mi寫本頁) 訂 圖10Α和10Β谰述南西方ΟΝΛ结合测試。6微克經純化之 TRΡΕ-RΒ融合蛋白質,Μ及經純化之桿狀病毒-表現之 pp110rb 加至 10« SDS-PAGE。 圖10A閫述加至10¾ SDS-PAGE,考馬斯藍染色之融合蛋 白質和桿狀病毒表規之p11〇m之南西向DHA结合測試。使 用考馬斯鲜藍並與經3 2 P -標記之D N A片段培養,再以放射 自顯術分.析。顯示如下:第1行:RB19-22 ;第2行: -1 5 - ,ί «£ " 翁 Γ.: 4 6 6117 A7 B7 經濟部中央標隼局貝工消費合作社印製 五、發明説明(u) 、RB2 3~-27;第 3 行:RB19-27;第 4 行:來自 AcNPV_Y4 RB 感 染之昆蟲细胞之經纯化RB蛋白質。 圖10B是自平行凝膠至用以產生圖i〇A之凝膠之塗抹物 的放射自顯術譜。巳.証明含有與D N A交互作用之主要功能 部位的融合蛋白質RB19-27對DNA之親和力較二個副區域 RB19-22和RB23-27,高20倍。關於此點,可比較圖10B 之第3行和第1和2行,亦展示經純化之全長蛋白質( 圖10B ;第4行)。來自昆蟲细胞經純化RB蛋白質之DNA-结合 活性亦可經由DNA-缴維素對蛋白質之留滯和來自管柱以約 400毫莫耳濃度NaCl之後續離析加Μ証明。 圖11是層析譜,顯示經桿狀病毒表現之RB蛋白質 (ρ110βΒ)與SV40 I-抗原之複雜的形成作用。在一試管中 ,亦即體外,經鈍化之全長R Β蛋白質與經纯化之Τ -抗原混 合。相同之混合物整份再以P A Β 41 9 (第2行)或抗 -i?B0,47(第3行}免疫沉澱,Μ西向塗抹分析。第1和4 行分別顯示經純化之SV40 Τ-抗原與ΡΑΒ419免疫沉澱*經 純化之稈狀病毒表現之RB蛋白質與抗- RB0.47抗體免疫沉 澱° * 體外混合蛋白質和SV40 Τ抗原產生蛋白質和 ΡΑΒ419之共-免疫沉澱物(第2行),Μ及Τ和抗-RB0.47 抗體之共-免疫沉澱物(第3行)。 圖12是照Μ,關述微注射至Soas-2細胞之细胞質後.經純 化蛋白質之細胞核的移位作用。MSDS-PAGE分析微注射所 用之蛋白質製備物。第1行:來自以重姐體RB稈狀病毒感 16- ----------U ^-- (諳先聞讀背面之注意事填寫本頁). P.I 4 6 611 A7 B7 Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5 'Inventory (u) -EcoRl cDN / \ RBH (0.7 kb) fusion constructs to the E co R 1 position of the pATH3 vector. From the detailed restriction map of each position, its arrangement was confirmed. The plastids were re-transformed into Escherichia coli mm294. Fig. 7B is a photograph of a polyacrylamide gel electrophoresis of a heavy body TRP E-RB fusion protein. The major plastids were transformed into E. coli m 2 9 4 and grown in M9 minimum nutrient requirements medium supplemented with 20 mg / 20 ml tryptophan. The culture was diluted to 1: 100 in M9 plus prion amino acid and ampicillin. Enzyme. At a light density of 0, 2 S00 nra, a 10: 1 mg / ml indolyl · acrylic acid 1: 1000 dilution in 100Si ethanol was added to induce TRP E gene expression. Bacterial cells were pelleted, and the bacterial cells were boiled in Laemmli gel sample buffer for 15 minutes, and then analyzed by polyacrylamide gel electrophoresis. The gel was stained with Cox's blue. The 58 kD protein was found in the induced culture (line 2) 'but not in the control culture (line 1). Figures 8A and 8B show immunosuppressants of RB protein from various cellular sources. Figure 8A is a chromatogram * showing immunosuppressants of RB protein / anti-RB protein U * D from various human cell sources. Prepared from human hepatocellular carcinoma Alexander cell source (line 丨, line), human osteosarcoma cell source, U 2 0 S (line 2_), normal-ordinary human dystrophin (line 3), human neuroblast Cell tumor source, LAN-5 (line 4), and rabbit IsG immunized in childhood immunized with 35S-methionine-labeled details of human neuroblastoma lysate (line 5) · Cell extracts were immunoprecipitated with passivated rabbit anti-RB IgG. One pair of bands with a surface molecular weight of about 110-114 kD was observed in lines 1-4. -14- --------- Install ------ Order ---- (谙 Read the note on the backϊπ #, fill out this page) M: 466117 A7 B7 V. Description of the invention ( 12) Figure B Lu chromatogram showing immunoprecipitation of RB protein / anti-RB protein UG from several retinoblastoma cells. Cell extracts from 5 different optic retina embryos and cell tumor cells were labeled with 3 2 S -methionine, and then immunoprecipitated from purified rabbit anti-O I g. One pair of bands appeared in one of the cell sources from liver cancer, osteosarcoma, fibroblastoma, and neuroblastoma, but not in all five retinoblastoma cell sources, RB 355 (line 1), Y79 ( (Line 2), WERI-1 (line 3), WERI-24 (line 4 >, and WERI-27 (line 5), human orthoblasts and cell-derived LAN-5 (line 6) And neuroblastoma lysates precipitated from rabbit UG immunized by K in childhood. The RB protein was identified based on these results. Figure 9 is a chromatogram showing the biochemical fractionation of K. The effect of RB protein was demonstrated by 3SS "A All thioic acid-labeled LAN 5 cells (line 4) were fractionated into the cell membrane (line 1), cytoplasm (line 2) and nucleus (line 3) and then K rabbit anti-rb igG immunoprecipitation. Large Most of the RB11〇_114 proteins are found in the nucleus, and a few appear in the cell membrane or cytoplasm. Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs--^ ϊ. M-n ^-II. 窣 (Please read Note on the back Mi write this page) Figures 10A and 10B describe the South and West 〇ΝΛ knot Tested. 6 micrograms of purified TRPE-RB fusion protein, M and purified baculovirus-expressed pp110rb were added to 10 «SDS-PAGE. Figure 10A illustrates the addition to 10 ¾ SDS-PAGE, Coomassie blue staining The fusion protein and baculovirus watch gauge p110m south-westward DHA binding test. Coomassie blue was cultured with 3 2 P-labeled DNA fragments and analyzed by autoradiography. The display is as follows : Line 1: RB19-22; Line 2: -1 5-, ί «£ " Weng Γ .: 4 6 6117 A7 B7 Printed by the Shellfish Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs ), RB2 3 ~ -27; Line 3: RB19-27; Line 4: Purified RB protein from AcNPV_Y4 RB-infected insect cells. Figure 10B is from the parallel gel to the coagulation used to generate Figure iOA. The self-explanation spectrum of the glue smear. 巳. It is proved that the fusion protein RB19-27, which contains the main functional site that interacts with DNA, has a 20-fold higher affinity for DNA than the two subregions RB19-22 and RB23-27. In this regard, compare line 3 and lines 1 and 2 of Figure 10B, and also show the purified full-length protein (Figure 10B; line 4 ). The DNA-binding activity of purified RB protein from insect cells can also be confirmed by the retention of protein by DNA- fulvicin and subsequent isolation from the column with about 400 millimolar NaCl plus M. Figure 11 is the layer The analysis showed the complex formation of RB protein (ρ110βB) and SV40 I-antigen expressed by baculovirus. In a test tube, i.e. in vitro, the inactivated full-length RB protein is mixed with purified T-antigen. The same mixture was whole and then immunoprecipitated with PA Β 41 9 (line 2) or anti-i? B0,47 (line 3), and analyzed by western blotting. Lines 1 and 4 show purified SV40 T- Antigen and PAB419 immunoprecipitation * RB protein expressed by purified baculovirus and anti-RB0.47 antibody immunoprecipitation ° * Co-immunoprecipitate of protein and PAB419 produced by mixing protein and SV40 T antigen in vitro (line 2), Co-immunoprecipitates of M and T and anti-RB0.47 antibodies (line 3). Figure 12 shows the translocation of the nucleus of the purified protein after microinjection into the cytoplasm of Soas-2 cells according to M. MSDS-PAGE analysis of protein preparations used for microinjection. Line 1: From the HBsAg virus susceptibility to RB 16- ---------- U ^-(谙 First read the note on the back Fill out this page). P.

-T *-T *

II

五、發明説明(u) ..染之名為细胞之p 110 R β ;第2行:經生物素化之兔子抗^ 羊抗體;第3行:抗-RB.495抗體;第4行:抗-RB R2抗 體;第5行:抗RB.47抗體;第6行:姐織凍HI (histone) ;第7行:來自大腸.桿菌之?56〃。1微升之各樣本加在 15¾丙烯醯胺凝膠上。以考馬斯鲜藍染色凝膠。顯示棵準 分子量之位置,Μ千道耳吞為單位。 圖13闌釋用作微注射之蛋白質製備物之濃度和純度之 SDS-PAGE分析。 圖14至14F是顯微溷片;閫釋經標記之Saos-2细胞之微 注射和免疫染色。 圃15以圖表閘釋經標記之細胞直至注射後4夭之百分比 0 圃16K圖表蘭'釋經標記细胞之百分比和ϊ>56濃度之關係 〇 圖17以圖表閱釋當?>561^在3期注射對细胞之影響。 圖18A至18C Μ圖表閭釋細胞循環對注射截短蛋白質之期 間之依賴。 經濟部中央標準局員工消費合作社印製 J--------裝-- (請先聞讀背面之注意事w-^t窝本頁) 訂 圖19顯示ρΓ10κβ抑制在Rb蛋白質表現中是缺陷之小细胞 和非小细晦.肺癌细胞源之生長。本實驗结果証明?11〇1*8可 抑制NCL-H596(HSCLC; Rb陰性)之增殖作用。口11〇*^在 A5 49 (NSCLC ; Rb-賜性)腫瘤细胞源上具較弱之活性。用於 本發明之p110rb是衍生自桿狀病毒(B-Rb;依Cell Growth (1990) supra所述經化)或來自大腸桿菌(E_Rb).。採用 之對照蛋白質是牛血清白蛋白(BSA)。出現在生長培養基 4 6 61 1 7 Α7 Β7 經濟部中央標準局員工消费合作社印製 五、發明説明(15) .上之-全爺蛋白質均是2 5微克/毫升。 圖2 0是R B -介質生長抑制作用之時間過程研究之結果。 3 Η -胸腺核苷併入作用是表現為緩衝液控制+/ - S . D .之百 分比。 圖2 1 Α至2丨D顯示細胞之吸收和1 2 s I - ρ 1 1 Ο β 8之细胞核定 位。 圖2 1 Α顯示1 2 Μ - ρ 1 1 0 R Β對各次细胞部份之時間-依賴 性定位作用。 圖2 1 Β顯示在N C丨-'H 5 9 6细胞核部份1 2 5 I - ρ 11 0 R Β之免疫 沉殺和鑑定。顯示出分子尺寸之標準。第1行:0小時;第 2行:1小時;第3行:48小時;第4行:12SI-蛋白 質標準。 . 圖2 1 C顯示1 2 Μ - p 11 0 R B在肺癌细胞源细胞核部份之免 疫沉殺和鑑定。第1行:N C卜Η 5 9 6 N S C L C (R Β ηβ* );第2 行:Λ549 HSCLC(RBP°S):第3行:MRC-9正常肺上皮细胞 (R B p ° 3 );第4行:1 2 5卜p 1 1 0 R B蛋白質標準。 圖21D顯示在NC1-H596 KSCLC细胞中經细胞核-定位之 1251之定量。_在0, 8, 24, 48,和72小時收取细胞,定量 细胞核 12S.[-P110SS (_ )或 125I-p56rb (擊 >。 圖22顯示腫瘤週圍注射RB蛋白質對裸鼠皮下肺腫瘤生長 之影響。 圖22A顯示所示之NC〖-H596 腫瘤尺寸表示各實 驗組3種動物之平均值土 S.D.。第87天之腫瘤尺寸(平方 毫米)是:pllORB 處理者:169, 13 0., 100; p56RB-處理 L--------"::)裝-- (請先聞讀背面之注意事呢私填寫本頁) 訂 _ 紙張尺度適用中國國家揉準(CNS ) A4規格{210X297公釐) 五、發明説明(16 ) A7 B7 經濟部中央標準局—工消費合作杜印製 者:400, 360, 252:緩衝液處理者:δ58, 420, 770 ( 卜ρ 11 0 κ Β,(籲)-Ρ 5 6 R Β , ( ▲)-媛衝液對照姐。 圖22Β顯示所示之Α549 (RBP°S)腫瘤尺寸表示各實驗組 3種動物之平均值土 S.D.。在第87天個別動物之腫瘤尺寸 (平方毫米)是:p ll〇RB -處理者:120 , 136 , 1 18 ; p56rs-處理者:丨18, 132, 121;鑀衝液處理者:11〇, 1 39, 126 。(·)-ρ110κβ,(鲁 >-p56Re, (▲)-緩衝液對 照組。 圖2 3顯示p 110 R B之谮脈注射對裸鼠内人體肺腫瘤细胞生 長之影響。活性P 1 1 0 R B , 5 0微克/劑量(顯 > ;活性 p110rb, 200微克/劑量(Δ);或失活pll〇RB200微克/則 量(Ο 1。所示之数,值是平均值(土 SEM >。箭頭顯示鏟理之 天數。 圖2 4顯示p 110RB可體外抑制非小細胞肺癌细胞之生長, 但對正常细胞源之增殖作用不具影響。pll〇KB是製備自大 腸桿菌菌株BL21,含有驅動全長Pn〇RB表琨之Τ7啟動基因 (描述於 S. Huang et al.,infra-)。根據 Cell Growth and Diff. (Γ990 ) 1 :429-437所描述之實驗計剷純 Pi 10RB。圖24所示之實驗,在賁驗期間每8小時添加所示 濃度之p110rb以培養细胞。3H-胸線核苷在最後8小時過 夜添加以測量细胞之D N A合成作用。用於該類賁驗之細胞 種類是購自美调式培養物收集所American Type Culture C ο 1 1 e c t i ο η。包括:Η 5 9 6 ( R b -陰性;非-小细胞肺癌 >,MRC-9(Rb-陽性;正常肺上皮细胞源),wi-38( Rb-陽 19 +紙張尺度適用中國理家揉参々} A4規格(21〇χ297公废广 1- nn pm ^^^1 Bn tn^v ^^1 、1 、豸 (請先閲讀背面之注意事灰系填寫本頁) I. 訂 P+ —Γ 4661 1 7 A7 B7 五、發明説明(17) .性,丑常肺上皮細胞源>.CCD 597 SK (Rb-陽性,正常 包皮上皮佃胞源),F S Η 7 3 8 B L ( R b -陽性;正常膀胱上皮 细胞源),.H I Η 3 T 3 ( R b -陽性,非-轉化鼠细胞源)。 圖2 5顯示p 110 R β抑制在R b蛋白質表現中是缺陷之小细胞 和非小细胞肺癌细胞源之生長。本茛驗结果証明p 11 〇 β β可 抑制Η 1 2 8和Η 6 9细胞源(均為R b,陰性)和Η 5 9 6 ( N S C L C ; R b -陰性)之增殖作用。ρ I 1 0 s Β在A 5 4 9 ( R b -暘性)腫瘤细 睢源上具較弱之活性。用於本實驗之p110rb是衍生自桿狀 病毒(B - R b ;依本專利說明書所述纯化)或來自大腸桿菌 (E-Rb)。採用之對照蛋白質是牛血清白蛋白(&SA)。出現 在生長培綦基上之全部蛋白質均是25微克/毫升。該測試 否則依圖24說明所.示進行。 圖2 6顯示p U Ο κ B可進人細胞並定位於細胞核。所示之 11 2 s -標記之p U 0 R β是Μ畤間-依賴性之方式進入细胞並 定位於细胞核。細胞依Nature (1 9 8 7 ) 3 2 9 : 6 4 2 - 6 4 5所述 分级分離。 圖27顯示完整之p110R3可在以Ila5-標記之pllOfcB處理 之H596腫瘤细胞之®胞核中測得。本圖顯示當细胞核部份 (依所述製偁(I b i d )被變性S D S凝膠電泳和放射自顯技術 檢測時*培養4 8小時後在细胞核内看見全長p 11 0 R B。碘化 之p 11 0 R B用作放射自顯術之標記。 圖28顯示p 1 1 0 R B和p 5 6 R B對動物模體内非-小细胞肺癌 之皮下治療具生物活性。二種蛋白質均是使用本專利說明 書所述之純化方法,製備自如上述之大腸桿菌BL21, 100 -20- W本紙張逋用中S國家揉半( CNS ) A4規格(210X297公簸) 訂V. Description of the invention (u) .. The stained cell is named p 110 R β; line 2: biotinylated rabbit anti-sheep antibody; line 3: anti-RB.495 antibody; line 4: Anti-RB R2 antibody; line 5: anti-RB.47 antibody; line 6: sister weaving HI (histone); line 7: from the large intestine. Bacillus? 56〃. One microliter of each sample was applied to a 15¾ acrylamide gel. Coomassie stained gel. The position showing the quasi molecular weight is measured in units of M thousand channels. Figure 13 SDS-PAGE analysis of the concentration and purity of protein preparations used for microinjection. Figures 14 to 14F are micrographs; microinjection and immunostaining of labeled Saos-2 cells. Figure 15 shows the percentage of labeled cells up to 4% after injection. Figure 16 shows the relationship between the percentage of labeled cells and the concentration of β> 56 in Figure 16K. Figure 17 > 561 ^ Effects of injection on cells in phase 3. Figures 18A to 18C are graphs showing the dependence of the cell cycle on the period of truncated protein injection. Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs J -------- install-- (please read the notice on the back of this page first) Defective small cells and non-small small cells. Growth of lung cancer cells. What is the result of this experiment? 11〇1 * 8 can inhibit the proliferation of NCL-H596 (HSCLC; Rb negative). Mouth 11〇 * ^ has weak activity on A5 49 (NSCLC; Rb-donor) tumor cell source. P110rb used in the present invention is derived from baculovirus (B-Rb; modified as described by Cell Growth (1990) supra) or from E. coli (E_Rb). The control protein used was bovine serum albumin (BSA). Appears in the growth medium 4 6 61 1 7 Α7 Β7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of the invention (15). The above-all grandfather proteins are 25 μg / ml. Figure 20 is the result of the time course study of the inhibitory effect of R B -media. 3 Η-thymidine incorporation is manifested as buffer control + /-S.D. percentage. Figures 2A through 2D show cell uptake and cell nucleus localization at 12 s I-ρ 1 10 β 8. Figure 2 Α shows the time-dependent localization effect of 12 M-ρ 1 1 0 R Β on each cell fraction. Figure 2 Β shows the immune killing and identification of 1 2 5 I-ρ 11 0 R Β in the nuclear part of N C 丨 -'H 5 9 6 cells. Shows molecular size standards. Line 1: 0 hours; Line 2: 1 hour; Line 3: 48 hours; Line 4: 12SI-protein standard. Figure 2C shows the immunodepletion and identification of 12 M-p 11 0 R B in the nucleus of lung cancer cells. Line 1: NC Η 5 9 6 NSCLC (R Β ηβ *); Line 2: Δ549 HSCLC (RBP ° S): Line 3: MRC-9 normal lung epithelial cells (RB p ° 3); Line 4 Row: 1 2 5 p 1 1 0 RB protein standard. Figure 21D shows nucleus-localized quantification of 1251 in NC1-H596 KSCLC cells. _ Cells were harvested at 0, 8, 24, 48, and 72 hours to quantify the nucleus 12S. [-P110SS (_) or 125I-p56rb (click). Figure 22 shows the injection of RB protein around the tumor on the growth of subcutaneous lung tumors in nude mice. Fig. 22A shows the NC-H596 tumor size shown as the mean ± SD of 3 animals in each experimental group. The tumor size (mm2) on day 87 was: pllORB. Processor: 169, 13 0., 100; p56RB-Handle L -------- ": :) Packing-(Please read the notes on the back first and fill in this page privately) Order _ Paper size applicable to China National Standards (CNS) A4 Specification {210X297 mm) V. Description of the invention (16) A7 B7 Central Standards Bureau of Ministry of Economic Affairs-Industrial-Consumer Cooperation Du Maker: 400, 360, 252: Buffer processor: δ58, 420, 770 (ρρ 11 0 κ Β, (Yu) -P 5 6 R Β, (▲)-Yuan rinse solution control sister. Figure 22B shows the A549 (RBP ° S) tumor size shown, which represents the mean SD of 3 animals in each experimental group. The tumor size (mm2) of individual animals on day 87 was: p ll0RB-processor: 120, 136, 1 18; p56rs- processor: 18, 132, 121; Subject: 11〇, 1 39, 126. (·) -ρ110κβ, (Lu > -p56Re, (▲) -buffer control group. Figure 23 shows that the injection of p 110 RB into the veins of human lung tumors in nude mice Effect of cell growth. Active P 1 10 RB, 50 μg / dose (significant); active p110rb, 200 μg / dose (Δ); or inactivated p110RB 200 μg / dose (0 1. The values are average values (± SEM). The arrows show the number of days of scavenging. Figure 24 shows that p 110RB can inhibit the growth of non-small cell lung cancer cells in vitro, but has no effect on the proliferation of normal cell sources. PllKB It is prepared from E. coli strain BL21 and contains a T7 promoter gene (described in S. Huang et al., Infra-) that drives the full-length PnORB epitope. It is described according to Cell Growth and Diff. (Γ990) 1: 429-437 The experimental shovel was pure Pi 10RB. In the experiment shown in Figure 24, p110rb was added every 8 hours during the test period to culture the cells. 3H-thymidine was added overnight in the last 8 hours to measure cell DNA synthesis The type of cells used for this test was purchased from American Type C Collection ulture C ο 1 1 e c t i ο η. Including: Η 5 9 6 (R b -negative; non-small cell lung cancer), MRC-9 (Rb-positive; normal lung epithelial cell source), wi-38 (Rb-yang 19 + paper size applicable to Chinese theorists 々 参 々} A4 size (21〇χ297 public waste 1- nn pm ^^^ 1 Bn tn ^ v ^^ 1, 1, 豸 (please read the note on the back first, fill out this page) I. Order P + —Γ 4661 1 7 A7 B7 V. Description of the invention (17) Sexual, ugly lung epithelial cell source> CCD 597 SK (Rb-positive, normal foreskin epithelium cell source), FS Η 7 3 8 BL (R b-positive; normal bladder epithelial cell source), .HI Η 3 T 3 (R b-positive, non-transformed mouse cell source). Figure 2 5 shows that p 110 R β inhibition is the smallest defect in R b protein expression Growth of cell and non-small cell lung cancer cell sources. The results of this test showed that p 11 〇β β can inhibit Η 1 2 8 and Η 6 9 cell sources (both R b, negative) and Η 5 9 6 (NSCLC; R b-negative). ρ I 1 0 s Β has weak activity on A 5 4 9 (R b-normal) tumor cells. p110rb used in this experiment is derived from baculovirus ( B-R b; according to this patent specification (Purified) or from E. coli (E-Rb). The control protein used is < Bovine Serum Albumin (& SA). All proteins appearing on the growth medium are 25 μg / ml. The test otherwise follows FIG. 24 The description proceeds. Figure 26 shows that p U 0 κ B can enter human cells and localize to the nucleus. The 11 2 s-labeled p U 0 R β shown enters the cell in an inter-M-dependent manner and Localized in the nucleus. Cells were fractionated as described in Nature (1 9 8 7) 3 2 9: 6 4 2-6 4 5. Figure 27 shows that intact p110R3 can be used in H596 tumor cells treated with Ila5-labeled pllOfcB® Measured in the nucleus. This figure shows that when the nucleus part (according to the system I bid) was detected by denaturing SDS gel electrophoresis and autoradiography technology * full length p 11 0 was seen in the nucleus after 4 8 hours of culture RB. Iodized p 11 0 RB is used as a marker for autoradiography. Figure 28 shows that p 1 1 0 RB and p 5 6 RB are biologically active for subcutaneous treatment of non-small cell lung cancer in animal phantoms. Two types Proteins were prepared from E. coli BL21 as described above using the purification method described in this patent specification. , 100 -20- W This paper is used for half a country (CNS) A4 size (210X297). Order

C 經濟部中央標準局員工消費合作杜印装 弟83111748號專利申請案 4 6 6 Ί U說明書修正頁(9〇年8月一 五、發明説明() · _ 丨年"ff1 微克之?110*^或?56111»每天皮下施用於腫瘤细胞區域。二 種蛋白質均具有如圈示可証明之生物活性。雖然p56rb具 有較?110*8弱之活性,該實驗確實証實p110rb片段具有生 物活性。 圖2 9顯示在適當棋體中使用pllORB之肺癌非纆腸療法。 200微克之pllORB經由尾靜脈注射至很快長有皮下H596人 體NSCLC腫瘤之Balb/c裸鼠賭肉,每週注射三次。該劑量 與人賵劑量約每公斤1奄克之劑量對懕。該實驗依所示進 行超過1個月期間。於治療期間*未經處理之腥痼快速生 長而經處理之腫瘤不生長或是K非常減級之速率生長。 圖30顯示在大腸桿菌内產生之視網膜胚细胞瘤蛋白質之 胺基酸序列。與圓2相較,當辑白質在大臈桿菌內產生時 •為選殖方便第2胺基酸(脯胺酸)改為丙胺酸。 画31画示供pp110rb合成作用之桿狀病毒表現載體之構 - > 築。’ 圃32A和3 2B是ppRB感染昆蟲细胞之西向塗抹物(圖32A) 和鑑定细胞提取物之塗抹0 ·該细胞提取物是來自感染後 72小時之感染细胞。 經濟部中央標準局貝工消费合作社印製 (請先閲讀背面之注意事項再填寫本頁) 圔33是放射自顯譜•闌釋在昆蟲细胞内RB蛋白質之璘酸 化作甩和去瞵酸化分析之结果。 發明詳述 本發明之主要目的是提供普遍安全但特定之治療方法和 產物,可甩於控制生物體内细胞循瓌之進化和控制癌的抑 制0 ...... -21 - 本紙張尺度適用中國國家標準(CNS > A4規格(210X297公釐) 4 661 1 7 A7 B7 9 IT /V 明説 明發 物 合 組 和 法 方 之 C. 玫化 有進 並之 全環 安循 供胞 提细 是内 的體 目物 i 生 另滞 之停 •明的 礓逆 .本.可 其 術 技 之 用 使 併 合 法 方 療 治。 與甩 可作 供成 提生 是瘤 的腫 目之 - 內 另體 之物 明生 發滯 本停 % ,和 法法 方方 和之 物化 產用 之使 制是 抑且 的並 癌’ 制除 控根 供和 提制 是抑 的之 目瘤 一 腫 另癌 之於 明定 發特 本係 其 症用或 癌作瘦 理間突 處胞, 性细陷 療和缺 治面由 供層理 提胞處 是细供 的在提 目是/是 I物法 另合方 之組一 明該.另 發中之 本其明 ^ , 發 物物本 產合 姐 藥 0 之 抑 癌 乏 缺 性 活 之 物 合 姐 該 中 其 物 合 0 姐物 藥產 翳之 之造 況製 狀成 之合 成或 造然 所天 因是 基份 制成 .白 蛋 因 基 制 抑 。 癌制 定抑 特之 中瘤 其匯 , 成 法完 方 Μ 之胞 療细 治染 胞"感 细受 含至 包送 明榆 發物 本產 質 癌外於 理此向 處。傾 供要因 提需基 明之現 發法發 本療在 學指 症 癌 化係 和, 射用 放採 之期 統早 傳常 對非 低在生 減可瘤 其術腫 - 技生 法明發 方發但 之本後 前 用 作 成 使用 式作 方制 之抑 價癌 廉.之 分面 十層 且胞 並细 ga i 方完 於, 在物 是產 點質 儍白 顯,蛋 明因 之基 明制 發抑 本癌 用 (請先閲讀背面之注意事承界填寫本頁) 經濟部中央標準局負工消費合作社印裝 造 M 足 否 是 活 失 之 因 基 制 抑 癌 個 數 或 一 内 包 细 於 對 然 雖 是優 物 I 產另 質之 白明 蛋發 因+本 基。 入法 納方 之之 胞利 细有 是 且 但並 ’ 穎 點新 疑個 些 一 一 瘤 有腫 尚性 ’ 惡 癌理 成處 所造 書物 明生 說,對 利一但 專, 本變 於改 在之 是利 ’有 同成 不完 法面 療層 症胞 癌细 性在 毒法 胞療 統咆 傳细 與之 ’ 示 點揭C Consumers' cooperation with the Central Bureau of Standards of the Ministry of Economic Affairs of the People ’s Republic of China Du Yinzhuangdi 83111748 Patent Application 4 6 6 Ί U Specification Revised Page (August 15, 1990, Description of Invention () · _ YEAR " ff1 Microgram? 110 * ^ Or? 56111 »is administered subcutaneously to the tumor cell area daily. Both proteins have biological activity as demonstrated by circle. Although p56rb has weaker activity than? 110 * 8, this experiment did confirm that the p110rb fragment was biologically active. Figure 2-9 shows non-intestinal therapies for lung cancer using pllORB in an appropriate chess body. 200 micrograms of pllORB was injected via the tail vein to Balb / c nude mice with subcutaneous H596 human NSCLC tumors, which were injected three times a week. This dose is at a dose of about 1 g per kilogram of human radon. The experiment was performed over a period of 1 month as shown. During the treatment period * the untreated fish was growing rapidly and the treated tumor did not grow or K Very degraded growth rate. Figure 30 shows the amino acid sequence of the retinoblastoma protein produced in E. coli. Compared with circle 2, when white matter is produced in E. coli, it is convenient for colonization. 2 Amino acid (proline) was changed to alanine. Draw 31 to show the structure of a baculovirus expression vector for pp110rb synthesis-> Building. 'Pumps 32A and 3 2B are westward smears of ppRB infected insect cells (Figure 32A) and smearing of the identified cell extract 0 The cell extract is from infected cells 72 hours after infection. Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs (please read the precautions on the back before filling out this page) ) 圔 33 is the result of self-emission spectrum analysis of RB protein release and dephosphorylation analysis of RB protein released in insect cells. Detailed description of the invention The main purpose of the present invention is to provide a universally safe but specific treatment method and product, Can be used to control the evolution of cell cycle in vivo and control the inhibition of cancer 0 ... -21-This paper size applies to Chinese national standards (CNS > A4 size (210X297 mm) 4 661 1 7 A7 B7 9 IT / V Explains that the combination of the hair and the French side of C. Meihua has merged the whole cycle of the Anxun donor to refine the internal objects and objects i. . Can be used for its technical skills and legal prescription Can be used as a supply to produce a tumor is the tumor's swelling-the internal and external body material is stagnation of hair growth%, and the law of France and France and the physical and chemical properties used to make the system is combined with cancer 'system In addition to the control of root supply and control, the tumor is swollen and cancerous to Ming Dingfa. This is the disease or cancer for thin interstitial cells, and the treatment of sexual pitting and defect is provided by the supply layer. The cell is a fine confession. It should be clearly stated in the list of items that are / are the other parties of the I matter method. The essence of the issue is ^, the hair substance is the same as the drug 0. The combination of the physical and chemical properties of the physical and chemical properties of the physical and chemical properties of the physical and chemical products is based on the basic ingredients. The white egg is inhibited by the basic ingredients. The cancer system has a special feature of the tumor, which is the confluence of the cells, and the method to complete the formula M. The treatment of the staining cells " sense is included in the package of Mingyu hair products. Confession of the cause of the need to provide the basis of the current method of the development of the treatment of the current indications of cancer, and the early release of the radioactive period is often transmitted to the non-low-lived patients can reduce their tumors-Technical Health Law Mingfa Fadan has been used as a price-cutting cancer-prevention system based on the use of the formula system. The facet is ten layers and the cells are thin and fine. The square is finished. The quality of the product is stupid and white, and the foundation of the egg is clear. For suppressing cancer (please read the notice on the back to fill in this page) Printed by the Consumer Standards Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs Although the opposite is excellent, I produced a whitening egg hair cause + base. The enlistees who entered Fana Fang are right, but they do n’t have the following points: “The new point is that there are some tumors that are swollen.” Mingsheng, a book made by the malignant cancer management department, said that for Li Yi, but the book is changed. The advantage is that "there is a completeness of the facial therapy layer cell carcinoma and the fineness of the cell therapy in the poisonous cell therapy system"

-T 國 國 中 料 - r' 公 97 2~x A7 B7 4661 17 五、發明説明(20 ) - 成最斗創傷。 本發明是一種细胞治療之方法,其中输送持定之癌抑剌 基因蛋白質產物至受感染细胞以完成腫瘤之抑制。已知细 胞其缺陷可能是失去或具有缺陷基因,因而導致畑胞內缺 乏蛋白質之表琨。 本發明方法係關於使用與缺陷基因有關之基因蛋白質產 物。羥純化之蛋白質產物輸送至受感染细胞以完成,舉例 來說,腫瘤之抑制。該產物是在豁藥上適當之載體内输送 ,因而使該蛋白質產物得以在细胞,或次细胞厨面作用。 作為該方法之實例| RB基因蛋白質已被送至失去或具有 缺陷RB基因之细胞,該缺陷RB基因是一種癌抑制基因。 在較佳具SI實胞.例中,視網瞑胚細胞瘤,一種罕見之視 網膜發育之兒童期癌症是研究陳性腫瘤生成作用之原型模 型。根據染色體13ql4相關之基因元素之定位和其隱性本 質之跡象,選殖推定之癌抑制基因,視網膜胚綑胞瘤感受 性基因(RB.)。該基因含有27個表現序列,分散在2⑽萬鹼基 之基因姐D N A内,並旦在全部檢驗之正常組織中表琨4 , 7 鹼基之ibRN A轉蘼本。互補DN A選殖株之序列分析顯示一涸 長的開啟密碼,可編碼928個胺基酸之假設蛋白質。使用 -對抗經選擇之抗原決定部位所誘發之抗體,該抗原決定部 位是預測自R B cD N A序列,R B基因產物已鑑定為核的磷蛋 白具110,000-114,000之相對分子質(Mr),已經命名為 PPllORB ° 除了視網膜胚细胞瘤以外| R B基因功能之喪失亦與其它 -23- 〜本紙張尺皮逍用中國國家揉準(CNS ) A4規格(210^297公釐) (請先鬩讀背面之注意事項再填寫本頁)-T State China National Materials-r 'public 97 2 ~ x A7 B7 4661 17 V. Description of the invention (20)-It is the most traumatic. The present invention is a method of cell therapy, wherein a fixed tumor suppressor gene protein product is delivered to infected cells to complete tumor suppression. It is known that the defect of the cell may be the loss or the presence of a defective gene, resulting in a lack of protein in the cell. The method of the present invention relates to the use of a gene protein product related to a defective gene. Hydroxypurified protein products are delivered to infected cells to complete, for example, tumor suppression. The product is delivered in a suitable carrier on the exogenous drug, thus allowing the protein product to act on the cell, or sub-cell surface. As an example of this method | The RB gene protein has been delivered to cells that have lost or have a defective RB gene, which is a cancer suppressor gene. In the preferred case with SI cells, retinoblastoma, a rare childhood cancer of retinal development, is a prototype model that studies the role of old tumors. Based on the location of genetic elements associated with chromosome 13ql4 and evidence of its recessive nature, the putative cancer suppressor gene, the retinoblastoma tumor susceptibility gene (RB.), Was cloned. The gene contains 27 expression sequences, which are dispersed in a DNA gene of 2 million bases D N A, and in all normal tissues tested, it expresses transcripts of ibRN A of 4, 7 bases. Sequence analysis of complementary DNA-selected strains revealed a long opening code that encodes 928 amino acid hypothetical proteins. Use-against antibodies induced by a selected epitope, which is predicted from the RB cD NA sequence, the RB gene product has been identified as a nuclear phosphoprotein with a relative molecular mass (Mr) of 110,000-114,000 and has been named PPllORB ° In addition to retinoblastomas, the loss of RB gene function is also related to other -23- ~ This paper is used in Chinese National Standard (CNS) A4 (210 ^ 297 mm) (please read the back first) (Notes for filling in this page)

G 衄濟部中央標準局貝工消費合作社印製 —^^--------^ 、裝------訂-----V ^--------- Α7 Β7 466117 五、發明説明(21 ) .數種.备之發展有關,包括乳房癌,骨肉瘤,前列腺癌军口 小细胞肺癌。最近証明經由逆轉錄晦病毒-媒介之基 移,重新納人R B基因至視網瞑胚細胞瘤,骨肉瘤或前列腺 癌細胞,明顯抑制其瘤表現型之數個特質,包括裸鼠内十 腫瘤生成作用,提供R B基因之腫瘤抑制功能之直接証彳康。 但是,該生物活性之分子基礎直至目前尚未定義出來。 直至目前為止,因為該類蛋白質在细胞内非常稀少,$ 易獲得足虽之該類蛋白質使癌仰制基因產物之生化特性甲口 生物功能之閱釋受阻、 已發明出一種细胞治療方法,输送特定基因蛋白質產物 至具有缺陷或喪失基因之细胞。使用本發明,適霣之當 純化,完整並具生,化活性之基因產物蛋白質,能以治療上 之有效劑虽输送至缺陷细胞。 本發明之细胞療法具廣泛之應用範圍。該蛋白質產物之 用途不僅治療缺陷細胞,並閫釋在畑胞層面基因間相互作 用之基因功能。 玆提供一個特定簧例,其中該視網膜基因蛋白質產物, pp110rb ,可·廣泛的應用在治療具有缺陷或喪失RB基因之 真核細胞。__ 頃發現經純化之蛋白質可结合DNA ,並如同真正之人臈 pp110rb Μ類似方式與SV40 T抗原形成特定複合物。微注 射後蛋白質之即時核移位作用,進一步建議經純化之基因 產物蛋白質之活性本質和醫療上之應用。 本發明之另一目的是提供细胞循環控制組合物和方法’ -24 - 本紙張尺度逋用中國國家揉準(CNS ) Α4规格C 210 X 297公釐) ---------:5- / 裝-- (請先閱讀背面之注意事π填寫本頁} -訂G Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs — ^^ -------- ^, equipment -------- Order ----- V ^ --------- Α7 Β7 466117 V. Description of the invention (21). Several kinds of preparations are related, including breast cancer, osteosarcoma, and prostate cancer. Small cell lung cancer. Recently, it has been shown that the retrograde transfer of human RB gene to the retinoid blastoblastoma, osteosarcoma or prostate cancer cells via retrovirus-mediated base transfer significantly inhibits several characteristics of its tumor phenotype, including ten tumors in nude mice. Generating effect, providing a direct proof of the tumor suppressive function of the RB gene. However, the molecular basis of this biological activity has not yet been defined. Until now, because this kind of protein is very scarce in cells, it is easy to get enough. Although this kind of protein hinders the interpretation of the biochemical properties of cancer control gene products, the mouth ’s biological function is blocked, and a cell therapy method has been invented to deliver Gene-specific protein products to cells with defective or lost genes. With the present invention, a gene product protein which is purified, intact, and biochemically active can be delivered to a defective cell with a therapeutically effective agent. The cell therapy of the present invention has a wide range of applications. The purpose of this protein product is not only to treat defective cells, but also to explain the gene functions that interact between genes at the cell level. A specific case is provided here, in which the retinal gene protein product, pp110rb, can be widely used in the treatment of eukaryotic cells with defective or lost RB genes. __ It was found that the purified protein can bind to DNA and form a specific complex with SV40 T antigen in a similar manner as real human 臈 pp110rb Μ. The immediate nuclear translocation effect of the microinjected protein further suggests the active nature of the purified gene product protein and its medical application. Another object of the present invention is to provide a cell cycle control composition and method. 5- / Install-(Please read the notes on the back first, fill out this page}-Order

Q 經濟部中央標準局貝工消費合作社印製 4661 1 7 A7 B7 經濟部中央標準局男工消費合作社印製 五、發明説明(22) .其嗓捱南類似之組合物和方法以控制活體生物内细胞循環 之進化。 本發明之另一目的是提供'' 一種安全並且有效的方法與組 合物,能可逆的終止生物體内细胞循環之進化° 本發明之另一目的是提供二種技術,其能與醫療方法合 併使用Μ停滯生物體内之腫瘤生成作用。 因此,本發明包括控制細胞循環化進化之方法和組合物 ,其係在细胞有絲分裂之間期納人循環調節姐合物至欲控 制之细胞内。該姐合'物是選自基因蛋白質產物和蛋白質之 Η段,以可逆的獎更细胞之细胞循環之進化•但仍維捋其 生活力。頃發琨蛋白質片段具有可溶於低濃度甘油之意外 且驚人之特點,因而促進其醫療上應用之廣值。 本發明之儍點,是得以方便且安全的方式可逆轉的停滯细 胞循環之進化,不致有害於生物ρ因此,匯瘤生成作用, 舉例來說*可被控制。 本發明之另一優點是用Μ控制细胞循環進化之組合物是 十分廉價並且易於獲得。 本發明之另二馒點是其中所用之姐合物對健康细胞具很 少或不具亀_性影響,並可與其它癌症治療方法連同使用。 本發明姐合物和i術可與調節 容使用,並且與調節體内某些生理過程之其它方法和器材 在生理上相容,如血细胞之產生和配子之產生。 發明詳細說明 因此’本發明提供預防或抑制病態增殖細胞之增殖作用 25" L--------U ^-- (請先閱讀背面之注意事^寫本頁) 訂Q Printed by the Central Laboratories of the Ministry of Economic Affairs, Shellfish Consumer Cooperative, 4661 1 7 A7 B7 Printed by the Central Laboratories of the Ministry of Economic Affairs, Male Workers Consumer Cooperative, V. Description of Invention (22). Its composition and method are similar to those used to control living organism Evolution of the inner cell cycle. Another object of the present invention is to provide `` a safe and effective method and composition that can reversibly terminate the evolution of the cell cycle in living organisms. Another object of the present invention is to provide two technologies that can be combined with medical methods Use M to arrest tumorigenesis in vivo. Therefore, the present invention includes a method and a composition for controlling the cyclic evolution of cells, which are adapted to regulate the human circulation to the cells to be controlled during the mitosis of the cells. This sister compound is selected from the gene protein product and the segment of the protein to reversibly reward the evolution of the cell cycle of the cell, but still maintain its viability. The hairpin protein fragments are unexpectedly and surprisingly soluble in low concentrations of glycerol, thus promoting their wide range of medical applications. The silly point of the present invention is that the evolution of the stagnant cell cycle can be reversed in a convenient and safe manner without causing harm to the organism. Therefore, the tumorigenic effect, for example, * can be controlled. Another advantage of the present invention is that the composition for controlling cell cycle evolution using M is very cheap and readily available. Another aspect of the present invention is that the sister compound used therein has little or no effect on healthy cells and can be used in conjunction with other cancer treatment methods. The compound and the method of the present invention can be used with regulating capacity and are physiologically compatible with other methods and equipment for regulating certain physiological processes in the body, such as the production of blood cells and the production of gametes. Detailed description of the invention Therefore, the present invention provides the effect of preventing or inhibiting the proliferation of pathologically proliferating cells 25 " L -------- U ^-(Please read the notes on the back first ^ write this page) Order

G ---- 本紙張Α度逍用中國國家梯準: ——~ Λ661 1 Ί A? B7 經濟部中央梯準局貝工消費合作杜印製 五、發明説明(25 ) ,其中i胞之病態增殖作用是细胞内缺乏功 綑胞瘤多胜肽或蛋白質之结果。包括细胞與 網膜胚細胞瘤多胜肽或蛋白質接觸。藉此預 之增殖作用。 用於本專利說明書之名詞”‘抑制增殖作用 胞複製作用之減緩作用。在一個具體實胞例 用之待徵是無群落增生(apoptosis)或標的 另一具體實胞例中,該減媛作用之特徴是標 表現型轉化成為分化的,成热或良性表琨型 或多胜肽之喪失可能發生在視網膜胚细胞瘤 因之突婆(定義如下),或突變影饗基因之表 不足所需之塘度。_ 用於本專利說明書之名詞"突變的"定義為 異形式或是一棰強迫指定為正常者。基因突 刪除,單點刪除,添加,取代和移位。所有 之該類基因變異與視網膜胚细胞瘤和視網瞑 之病赛有關。 本發明亦提供具有非眼部惡疾,癌,或腫 病變與突變.之RB蛋白質有關者’,治療和預防 擧例來說,對視網膜胚细胞瘤具遺傳感受性 疾病或經治癒者,有較正常高之危險接觸其 -眼部之主要癌症。該類非眼部主要癌症, 明特命名為”續發性視網膜胚细胞瘤相關癌” 细胞瘤續發"病變。 -26- 能性視網膜胚 有效劑量之視 防或抑制细胞 ”意指標的细 中,該減緩作 细胞死亡。在 的细胞自惡性 。功能蛋白質 基因或對偶基 現,因而表現 天然常見之變 變可以是大體 在1 3 q 1 4位置 胚細胞瘤續發 瘤之病患,其 的治療方法。 但從未接觸該 它某些其它非 為適甩於本發 或”視網膜胚 請 先 聞 面 之 注 裝 訂G ---- This paper Αdegree freely uses China's national ladder standards: —— ~ 661 1 1 Ί A? B7 Printed by the consumerism cooperation of the Central Bureau of the Ministry of Economic Affairs of the People's Republic of China 5. Production Description (25), of which i Morbid proliferation is the result of a lack of intracellular peptides or proteins. This includes contacting cells with omental blastoma tumor peptides or proteins. This is used to predict the proliferation effect. As used in this patent specification, the term "'suppressive effect of inhibiting the proliferation of the cell's replication effect. In a specific case, the absence of colony proliferation (apoptosis) or the target of another specific case of the cell, the reducing effect The special feature is the transformation of the target phenotype into differentiation. The loss of the pyrogenic or benign phenotype or polypeptide may occur in the retinal germ cell tumor (defined below), or the mutant insufficiency gene is insufficiently expressed. Pond degree._ The term " mutation " as used in this patent specification is defined as a different form or forced to be designated as normal. Gene deletion, single point deletion, addition, replacement and shift. All of this should Gene-like mutations are associated with retinoblastoma and retinopathy. The present invention also provides RB protein related persons with non-ocular malignancies, cancer, or swollen lesions. Treatment and prevention, for example, Patients with retinoblastoma with genetically susceptible diseases or cured have a higher risk than normal. They are the major cancers of the eye. This type of non-ocular major cancer is named by Mingte as "continuation" Retinoblastoma-related cancer, "tumor cell renewal "., As the disease prevention or inhibition of cell with an effective dose of retinoblastoma can -26-" means fine indicators, which slows for cell death. The cells in are self-malignant. Functional protein genes or dual genes are present, so they appear naturally common. The changes can be patients with secondary tumors of germ cell tumors that are generally at 1 3 q 1 4 positions, and their treatment methods. But I have never touched it. It is not suitable for the hair or retinal embryo.

經濟部中央標準局員工消費合作社印裝 • ,c::i' •4661 1 ( A7 ______ B7_____ 五、發明説明(24 ) ”縝發性視網膜胚細胞瘤相關癌”包括散發二測之病例, 其中二個單獨突變發生在13ql4之各對偶基因,造成病態 的突變R B蛋白質。續發性視網膜胚妞胞瘤癌或腫瘤之簧例 m括,但不限於骨肉瘤,骨癌,滑液肉瘤,乳房癌,小细 胞和非小細胞肺癌,膀胱癌,聚細胞癌,胃癌,前列腺癌 ,白血病,頸癌,纖維肉瘤,神經膠母畑胞瘤,_凳神經 瘤,慢性淋巴细胞白血病,和急性骨髄性白血病。 在臨床層面,本發明意圖提供癌症,腫瘤或惡疾之預防 治療和/或治療,該4貞疾病是在腫瘤或癌組織之细胞中缺 乏或具病態突變之RB蛋白質之结果。如热於本技藝者所知 *癌是定義為動物之一疾病,其特徽是無法控制之细啤生 長,例如,白血病,,淋巴瘤,肉瘤,癌,崎胎瘤,轉移生 長物,和赘涸。·腫瘤是由於不正常增殖作用造成之一團细 胞。因此,本發明提供治療以終止病患體内無控制之细胞 生長,並因而緩和疾病之徴候或病患之惡病質。該治療或. 預防治療之影響包括延長病患之存活,減小腫塊或fi載或 滅少循環之腫瘤细胞的數目。 亦包括在本H明之範圍内者是结合蛋白質療法和傅統治 療,如外科..手術,化學療法和放射線療法Μ治療腫瘤和癌 為本發明之目的,名詞”病患”和”患者”是同義,意圖包 括人類病患以及脊椎動物患者,如哺钆類動物。 在细胞層面,本發明提供預防或抑制與細胞内缺乏正常 或野生-型R .Β蛋白質有關之無法控制之细胞生長之方法。 -27- :本巧^4¾用康® S家揉率(CMS〇 A4^ ( 2l〇X 297公釐) 46 61 1 7 Λ7 A/ B7 五、發明説明(25 ) 換言-之,RB蛋白質發生 胚细胞瘤蛋白質之喪失 因此,本發明提供預 之方法,其中细胞之病 網膜胚细胞瘤多胜肽或 功能性或生物活性之視 *藉此可預防或抑制细 當用以預防時•本方 之病態增殖。因為需'治 分裂之各種階段的綑胞 某呰與RB蛋白質接觸之 它细胞亦同時被抑制而 名詞”病態增殖细胞” 力之细胞*亦即存在並 细胞是病態的,因為偏 態有關。該類细胞之實 線细胞,牛皮癣细胞, ,肺细胞,肉细胞, 具癌徵象之.腫瘤细胞如 瘤,神經膠母细胞瘤, 小细胞肺癌,非-小細 舉例而言。 本發明之方法需要細 瘤蛋白質或多胜肽接觸 柄態突犖造成细胞内功能性視網膜 請 先 閲 讀 背 面 之 注 意 經濟部中央標準局貝工消費合作社印製 防或抑 態增殖 蛋白質 網膜胚 胞之增 法預防 療之腫 (有時 细胞可 免於無 意指包 獨立再 離於正 例包括 甲狀線 白血病 視網膜 乳房癌 胞肺癌 制病態 作用是 之结果 细胞瘤 殖作用 無法控 摑或癌 是不同 預防無 法控制 括但不 生正常 常綑胞 但不限 细胞, 细胞或 胚细胞 ,肺癌 ,腎细 增殖綑胞 妞胞内缺 >细胞與 多胜肽或 0 制之细胞 含有大量 细胞種類 法控制之 之生畏。 限於具有 的調節性 •不論是 於視網膜 乳房细胞 淋巴瘤细 瘤,骨肉 ,膀胱變 胞癌,聽 之增殖作用 乏功能性視 有效劑蛋之 蛋白質接觸 生長或細胞 處於生長或 ),腫瘤内 生長*而其 自主生長能 機制。該類 否與疾病狀 細胞,前列 ,结腸细胞 胞。莎意指 瘤,纖維肉 形细胞癌, 覺神經瘤, 胞與有效量之 。體外或體内 功能性視網膜胚细胞 接觸皆可。當體外接 2 8 - 法;本紙張尺度逋用中爾國家揉牟冬CNS ) ( 210X297公釐) 經濟部中央標準局貝工消費合作社印製 A7 B7 五、發明説明(26) ..觸畤-,i患者取出细胞樣本再將視網膜胚细胞瘤蛋白質或 多胜肽與细胞混合。或者,R B蛋白質可微注射至細胞内。 亦可使用己知種類之細胞培養物,尤其是用以蒒選相信與 1? B蛋白質功能相當之蛋白質’如β B蛋白質相等物。或者, 多胜肽或蛋白質可加至细胞培養基而再加至細胞樣本内。 體外方法可用Μ測試以鑑定本發明之蛋白質療法是否可用 以治療患者無法控制之细胞生長或腫瘤.。若細胞體外被抑 制,下所提供之實例顯示該方法之體外功效和體内功效間 之直接關連。或者*可疑姐纈之樣本可注人小鼠或老鼠體 内.,靜待其在動物體内形成腫瘤。蛋白質或多胜肽可注 人動物體内以鑑定該蛋白質療法是否可單獨,或與傳統抗 癌療法一起作用於/病患體内。若有效,相同或類似療程可 施用於病患。因此,在细胞或姐織層面成功的使用該療法 ,可預測該方法在有過度增殖性细胞存在之患者體内之醫 療用途,舉例來說,腫瘤或癌。 體细胞有絲分裂完成後,在细胞分裂末期结束時,细胞 進入間期,該間期視各種因素可能是短期間或者拖延一段 長時間。因此 '舉例來說,神經組纈之細胞分化和發菏後 ,神經细暇.可能有很長的間期。傳統來說,細胞之間期被 認作具有三個階段:G1,在其間發生無DIU複製之细胞生 長,S期,其間發生DNA複製,和G2,其間DNA複製完成 並细胞準備分裂。如本專利說明書下所詳细描述者,某些 基因之蛋白質產物,或其片段透過可,轉逆的終止G1期之進 化*具有在整個綑胞循環過程中控制進化之能力。根據本 -29- ί· m n - - —^ϋ ^^1.. 、——-.n ί ... cl·. (請先閲讀背面之注$項再填寫本頁) 訂 0.Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs •, c :: i '• 4661 1 (A7 ______ B7_____ V. Description of the Invention (24) "Secondary retinoblastoma-associated cancer" includes cases with secondary testing, of which Two separate mutations occurred in each of the dual genes of 13ql4, causing pathological mutations in RB protein. Examples of secondary retinoblastoma or tumor spring include, but are not limited to, osteosarcoma, bone cancer, synovial sarcoma, breast Cancer, small cell and non-small cell lung cancer, bladder cancer, polycellular carcinoma, gastric cancer, prostate cancer, leukemia, neck cancer, fibrosarcoma, glioblastoma, swan neuroma, chronic lymphocytic leukemia, and acute epiphyseal Leukemia. At the clinical level, the present invention intends to provide preventive treatment and / or treatment of cancer, tumor or malignant disease, which is the result of RB protein lacking or pathological mutation in cells of tumor or cancer tissue. As known to the skilled artisan * cancer is defined as a disease of animals, and its special emblem is the uncontrollable growth of thin beer, such as leukemia, lymphoma, sarcoma, cancer, sarcoma, Metastatic growth, and extraneous diseases. Tumors are a cluster of cells due to abnormal proliferation. Therefore, the present invention provides treatment to stop uncontrolled cell growth in patients, and thus alleviate the symptoms of the disease or the disease. Cachexia. The effects of this treatment or preventive treatment include prolonging the patient's survival, reducing the number of tumor cells in the mass or reducing or reducing circulation. It is also included within the scope of this H is a combination of protein therapy and traditional treatment For the purpose of this invention, the terms "patient" and "patient" are synonymous, and are intended to include human patients as well as vertebrate patients such as mammals At the cellular level, the present invention provides a method for preventing or inhibiting uncontrolled cell growth associated with a lack of normal or wild-type R.B protein in the cell. -27-: Ben Qiao ^ 4¾Using Kang S Home Rubbing Rate ( CMS〇A4 ^ (210 × 297 mm) 46 61 1 7 Λ7 A / B7 V. Description of the invention (25) In other words, the RB protein loses the blastoma protein. Therefore, the present invention provides The method, in which the diseased omental germ cell tumor polypeptide or functional or biological activity * can be used to prevent or inhibit the disease when it is used for prevention. • The pathological proliferation of the party. Other cells that are in contact with the RB protein are also inhibited at the same time, and the cells that are called "pathologically proliferating cells" * are also present and the cells are diseased because of the metamorphosis. The solid line cells of this type of cells, psoriasis Cells, lung cells, meat cells, with signs of cancer. Tumor cells such as tumors, glioblastomas, small cell lung cancer, non-small cells, for example. The method of the present invention requires the contact of a tumor cell protein or a peptide. Functional retina caused by stalk dysfunction, please read the note on the back first. Printed by the Central Standards Bureau of the Ministry of Economic Affairs, Shellfish Consumer Cooperative, printed on the prevention or suppression of proliferation of omental blasts. It does not mean that the package is independent and then separated from the positive cases including thyroid leukemia, retinal breast cancer, lung cancer, and pathological effects. The result is no cell colonization. Controlling cancer or cancer are different preventions that cannot be controlled, but do not produce normal cells, but are not limited to cells, cells or germ cells, lung cancer, kidney proliferation cells, cells lacking cells > cells and peptides or 0-cells Contains a great deal of fear of cell type control. Limited to regulatory properties • Whether it is in retinal breast cell lymphoma leiomyomas, bone and flesh, bladder cell carcinoma, lack of proliferative effects, functionally effective opioids, protein in contact with growth or cells in growth or growth in tumors * And its autonomous growth energy mechanism. This category is not related to disease-like cells, forefront, colon cells. Sha means tumor, fibrosarcoma cell carcinoma, sensory neuroma, cells and effective amount. Contact with functional retinal germ cells in vitro or in vivo is acceptable. External body 2 8-law; this paper size is printed in the CNS in China (210X297 mm) A7 B7 printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (26) -, i Patients take the cell sample and mix the retinoblastoma protein or polypeptide with the cells. Alternatively, the RB protein can be microinjected into the cell. Cell cultures of known species can also be used, especially to select proteins that are believed to be equivalent to the function of 1? B protein, such as β B protein equivalents. Alternatively, the peptide or protein can be added to the cell culture medium and then to the cell sample. In vitro methods can be tested with M to identify whether the protein therapy of the present invention can be used to treat cell growth or tumors beyond the control of a patient. If cells are inhibited in vitro, the examples provided below show a direct correlation between the in vitro and in vivo efficacy of the method. Or * The sample of suspicious sister can be injected into human or mouse. Wait for it to form a tumor in the animal. Proteins or peptides can be injected into human animals to identify whether the protein therapy can be used alone or in combination with traditional anticancer therapies. If effective, the same or similar course can be applied to the patient. Therefore, the successful use of the therapy at the cellular or tissue level predicts the medical use of the method in patients with hyperproliferative cells, such as tumors or cancer. After somatic mitosis is completed, at the end of the cell division phase, the cells enter the interphase, which may be a short period or a long period of time depending on various factors. Therefore, 'for example, after the cells of the neural group have differentiated and minted, the nerves can have a long interval. Traditionally, the intercellular phase is considered to have three phases: G1, during which cell growth occurs without DIU replication, S phase, during which DNA replication occurs, and G2, during which DNA replication is completed and the cell is ready to divide. As described in detail under this patent specification, the protein products of certain genes, or fragments thereof, can be terminated reversibly to terminate the G1 phase evolution * and has the ability to control evolution throughout the entire cell cycle. According to this -29- ί · m n--— ^ ϋ ^^ 1 .., ——-. N ί ... cl ·. (Please read the note on the back before filling this page) Order 0.

466117 A7 B7 五、發明説明(27 ) 經濟部中央標準局員工消費合作社印製 ..發明-I 入细胞 之生活 後,可 化0 有關 胞内有 討論· 终止間 質注人 0 接著 瞑呸细 劑量之 Μ治療 或蛋白 胞瘤多 另外 與本專 〇 當體 受之載 於任何 油,甘 涵胞循環控制姐合物是在其细胞循環之 ,以造成细胞循環進化之可逆變異•但 力。經過一段期間後,當姐合物在細胞 觀察到细胞循.環回復朝向間期之下一階 生物體内之病態吠況,如腫瘤生成作用 顯示加速進行不希望之细胞循環。如下 癌抑制基因蛋白質產物,如1ΪΒ蛋白質或 期之G1階段内·之Saos-2骨肉瘤细胞。頃 細胞内,封細胞不造成毒性作用,並且 ,本發明之^方法可用以治療具有,或易 胞瘤相關·之病變或惡疾之病思,其係透 蛋白質或多胜肽至病患體内。因此, 特徵是细胞無法表現功能性視網膜胚細 質之病變,該治療是透過细胞與功能性 胜肽接觸。 ,具有1¾網膜胚细胞瘤相闞病變之動物 利說明書所述蛋白質療法相連使用之新 内接觸時,多胜肽或蛋白質先與施藥用 體混合。”醫藥上可接受之載髏”意圖包 標準醫藥載體,如娌磷酸鹽媛衝之食鹽 露醇,蔗糖人體血清白蛋白,吐溫80, 間期部份納 仍維持細胞 内充分降解 段之细胞進 ,在某些细 更加詳細之 其片段用以 發琨,蛋白 是可逆轉的 感受與視網 過注入有效 本方法可用 胞瘤多胜肽 視網膜胚细 可用Μ測試 藥或新療法 醫藥上可接 括,但不限 水,水,甘 三羥甲基胺 請 先 聞tit 背 fir 之 注 意 事 再'、\ 本水 頁 訂 !「466117 A7 B7 V. Description of the invention (27) Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs .. Invention-I After entering the cell, it can be reduced to 0. There are discussions within the cell. Termination of interstitial injection. The dose of M treatment or protein cytoma is also related to this oil. It is contained in any oil. The control of the cell cycle of the Gan-Han cell is in its cell cycle, so that the cell cycle evolution is reversed. After a period of time, when the eosinophil was observed in the cell, the cell cycle was observed to return to the first stage below the interphase. The pathological bark in the organism, such as tumorigenicity, showed an accelerated undesired cell cycle. The following are tumor suppressor protein products, such as 1ΪΒ protein or Saos-2 osteosarcoma cells in the G1 phase. In cells, sealed cells do not cause toxic effects, and the method of the present invention can be used to treat diseases with or susceptible to cytoma-related diseases or malignant diseases, which penetrate proteins or peptides into patients . Therefore, it is characterized by the inability of cells to express functional retinal embryo fine lesions, and the treatment is through contact of cells with functional peptides. For animals with 1¾ omental blastoma tumor-associated lesions, the neo-peptide or protein is first mixed with the medicinal substance when the protein therapy described in the instruction manual is used in conjunction with the new internal contact. "Pharmaceutically acceptable crossbones" intends to include standard pharmaceutical carriers, such as sodium phosphate hydrochloride, sucrose, human serum albumin, Tween 80, and some cells in the interphase still maintain a fully degraded cell within the cell In some finer details, its fragments are used for cyanosis, the protein is reversible and the effect of over-injection of the visual network is effective. Including, but not limited to water, water, glycerol, please smell the notice of tit before firing it again, '\ This water page order!

C -30- -r 本紙張尺度適用中國國家揉準(CNS ) 7ι4规格(210 X 297公釐> A7 B7 4661 1 7 五、發明説明(28 ) ..基甲葙「碳酸納和乳fb物,如油/水乳化物和各種型式之 (讀先閲讀背面之注意事甲"填寫本頁) 澗濕劑。 用於本專利說明軎之名詞體内”施用”意思是提供患者有 效劑量之R B多胜肽或蛋白質,有效的預防或抑制標的细胞 之增殖作用或腫瘤之生長。施用段藥姐合物之方法已廣為 具有此藝者所知,包括但不限於腫揠内注射,口服,靜脈 注射或非經腸狍用。藥物施用可在整個療程内連續或間敗 豳用。決定最有效之途徑和劑量之方法是廣為热於此藝者 所热知,並因療法所·培之蛋白質或多胜肽,治療目的,被 處理之細胞或腫瘤,和治療之患者而異。舉例來銳,適當 劑垦範圍是自約0.1毫克/公斤/體重至10毫克/公斤/ 體重。 / 用於本專利說·明書之”功能性視網膜胚细胞瘤蛋白質H 意圖包括下述實例所述自人體细胞源離析之天然存在之視 網膜胚细胞瘤蛋白質*或重組產生之視網膜胚细胞瘤蛋白 質,舉例來說,示於圖2由c DH A所編碼者。在一個本發明 之具體賁施例中,視網膜胚细胞瘤蛋白質是被指定為 PRB110之蛋白省。pRB11。之胺基酸序列示於圖2 。在本定 經濟部中央橾準局員工消費合作社印裝 i 義内另包括純化之視網膜胚细胞瘤蛋白質或重姐產生之蛋 白質PRB11Q之功能性相等物。功能性相等物是具有與純化 之視網膜胚細胞瘤蛋白質或pRB 11(5不同之胺基酸序列但具 有能力產生相同預防效果之蛋白質。該類相等蛋白質可具· 有不致明顯影響蛋白質抑制细朐增殖之能力之添加物,刪 除物或取代物。鑑定相等蛋白質之方法是如上述之體外測 -31- ·〆 ΐ紙^逋用中國國家揉準(TNSTi^规格(210 X 297公釐), , - ~~~ 經濟部中央標準局員工消費合作社印製 4661 1 7 A? B7__ 五、發明説明('29) .試。相邊蛋白質或多胜肽包括涇純化之視網膜胚细胞蛋 白質或PRB110之Η段。具生物活性之Η段之簧例包括’但 不限於,Ρ56κβ ,和圖2所閫釋自胺基酸393-772,393至 870和871至928之Η段。. 本發明操作之逋當细胞是動物细胞’舉例來說,哺乳類 妞胞如人類或小鼠细朐。適當之患者是哺乳類動物,如小 鼠或人類。 上述方法不谨可用Μ抑制病態增殖细胞之增殖作用’亦 可用以預防细胞感受·於該類增殖作用。舉例來説’遺傳性 視網膜胚細朐瘤之病患有發展如上定義之續發性癌之危險 0 如具本技铥者所/热知者,預防用之有效量或劑量可和治 療用量或劑量不·同|但可由具此技藝者所決定。 本發明亦提供治療因患者缺乏功能性視網膜胚细胞瘤或 •多胜肽,或缺乏或存在突變之視網膜胚細胞基因所造成 之病變之方法。如上述,該方法需要對患者施用有效量之 功能性視網瞑胚细胞瘤蛋白質或多胜肽。 如下所詳示' RB基因蛋白質產锪或RB蛋白質是可替代之 磷酸化蛋白.質,於SDS-PAGE上具有約llOkDa至n6kDa之表 -面分子量。Μ正常,亦即非-轉化之细胞存在於各種脊椎 動物品種中。 在某些情況下,病態的或缺乏RB蛋白質是RB基因染色體 位置突變之结果。在正常细胞中* RB蛋白質是位於13ql4 區域之基因之轉錄產物。在視網膜胚细胞瘤之家族性案例 -32- 本紙張尺度適用中國铒家揉率i CNS ) Μ規格(210X297公釐1 (請先閱讀背面之注意事^ί填寫本頁) 訂 1b6l 17 A7 B7 五、發明説明(30 ) 中,-(”会族性二脚視網_胚细胞瘤"]在胚胎視網瞑上該基 因之對偶基因上之突愛,最終導致發育中孩童之視網膜胚 细胞瘤腫瘤,對於無家族傾向之該疾病之單或二測型式, 影響二涸對偶基因之體突變必須發生在同一視網膜胚细胞 ° 參看 Proc. H a t i · Acad. S c i . USA (1971.) 68 :820-823。®是,本發明提供由該類突變所造成之單和 雙側視網瞋胚细胞瘤之治療和預防之發療方法。 RB蛋白質是可替代之磷酸化蛋白質,可自细胞之提取物 中加以親和力-純化、由於蛋白質磷酸化作用中之笺異, 在SDS-PAGE上遷移為分子虽110至114 kDa之滲透帶。RB.蛋 .自質之磷酸化作用發生在絲胺酸和蘇胺酸。(Ce丨1 (1 9 8.9 )56:57-65 and Oncogene Res· 1:205-214);該特性在细 胞分裂之循環中·變動。低度磷酸化之型式在细胞循環之 G。和G τ期中佔優勢而高度磷酸化之型式在G 2,Μ和S期中 佔優勢。對於R Β蛋白質之生物特性之綜合研究可參看 Biochemica Biophysica Acta ( 1993) 1 1 55 : 4: 3 - 6 1。在细 經濟部中央標準局負工消費合作社印装 (請先聞讀背面之注意事f , J寫本頁) 胞分裂循環中,R B蛋白質之磷酸化作用夔動。如本專利說 明書中名詞” 蛋白質”是意圖包括該蛋白質所有種類或可 替代之磷酸化型式。在某些具體實施例中,超過一種以上 之型式將用於本發明之方法中,而可替代之型式可同時施 用0 用於本專利說明書之”功能性視網膜胚细胞瘤蛋白質·’, ” R B蛋白質”或” I? B多胜肽”亦意圖包括示於下述踅例離析自 人體或脊椎動物细胞源之天然存在之視網膜胚细胞瘤蛋白 本紙張尺度適用中國國家#準(CNS ) A4规格( 210X297公釐) 4 6 61 1 7 Α7 Β7 經濟部中央標準局員工消費合作社印製 五、發明説明(31 ) •質或·Μ由產生之視網膜胚细胞瘤蛋白質,舉冽來說,在原 核和真核表現糸統中如圖2所示之c D Ν Α所编碼者。在本發 明之一個具體寊拖例中,該視網膜胚細胞瘤蛋白質是被指 定為P P R β °之蛋白質。p p R B 11。之胺基酸序列示於圖2 和3 0。用於本專利說明書之名詞 '純化”或·’相當純化”是 指經由如下所述之實驗程序所獲得大約程度之程度。純度 可用本技拯所知之任何方法測量,如藉凝_影象或使用光 密度計。 亦包括在本定義内名是纯化之視網膜胚细胞瘤蛋白質( ppRB110)或重姐艢產生之蛋白質pRB110之功能性相等物。 θ 用於本專利說明書之功能性相等物具有與纯化之梘網膜胚 細胞瘤蛋白質p P ” 11 (>不同之胺基酸序列但有能力產生相 同預防效果之蛋‘白質。該類相等蛋白質可具有不致明顯影 響蛋白質抑制無法控制之細胞增殖之能力之添加物,刪除 物或取代物。鑑定相等蛋白質之方法是如上述之體外測試 。相等蛋白質或多胜肽包括純化之視網膜胚细胞瘤蛋白質-或PllORB2fi段。該類片段之數個實例描述如下。 甩於本專利"說明書之名詞"重姐體蛋白質或多胜肽” 是定義為C&NA之重組體表現之產物(如圖2所示)或其片段 -。重組體表現糸統是重姐髏表琨載體穩定的轉化成適當之 宿主细胞供RB蛋白質重姐體之產生。 ”重組體表規載體”包括能表現其所含之D N A序列之載體 ,而該序列是操作連结能影響其表規之其它序列。範示如 下者是數個表現載體。雖然未必均明白表示’但暗指該類 請 先 閲 面 之 注 r 頁 訂 丰紙張尺变遥用.中國興家揉準( CNS jA4%4M 210X297公釐广:Λ ί 嚷顿:;5 4661 1 7 Α7 Β7 經濟部中央標準局員工消費合作社印装 五、發明説明(32 ) . 表現’體必須可在宿主生物内複製為基因副體,染色體 ΰ N A之整合部份或其它染色體。缌而言之,載體,.是給予 功能性定義’任何D Η A序列能影饗排列於其中之持定D Ν Λ 序列之表現者如同其.適用於特定之序列包括於該名詞。 '’宿主-載體糸统,,是指以使用重姐體D Ν Α技術構築之載 體轉化感染之宿主妞胞。載體或DNA之插入可以微细胞轉 移’逆轉錄每病毒-媒介之基因轉移,轉化感染,细胞融 合等方式完成。本專利說明書所揭示之載體和方法適用於 廣範園之原核和真核·生物之宿主细胞。 包含茛行本發明所包括之基本技術之定義,方法和器材 之分子生物搮準教科書用作參考文獻。參看,舉例來說, Man i a t i s e t a 1 . , Molecular C I ο n i n g : A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1982.) and Sainbrook et al., Holecualr Cloning: A Laboratory Manual . Cold Spring Harbor Laboratory , New York (1989)和具中所引用之各種參考文獻σ 此外,目前熟於此藝者所使用之重組體D Ν Α方法包括聚 合酶鏈反應(PtR),舉寡核甘酸合成作用结合,使DNA序 列易於再生..。多至約6000個鹼基對長度之DNA片段,可用 PCR方法指數擴大自小至單一之基因複製本。在本技術中 ,變性之DNA樣本Μ二個寡核甘酸引物培養,導引需DNA 聚合酶之合成作用,各產生約雙倍量之搮的序列。以變換 溫度劈制各循環促使D N A股之變性作用,黏接引物,和合 成新DNA股。使用酎熱之DHA聚合酶可省去添加新酶至各 -35- I 1 I > 裝 訂 (請先聞讀背面之注意事^¢1^寫本頁) S·C -30- -r This paper size is applicable to China National Standard (CNS) 7ι4 (210 X 297 mm > A7 B7 4661 1 7 V. Description of the invention (28): carbazide "Sodium carbonate and milk fb Substances, such as oil / water emulsions and various types (read the precautions on the back of the first and fill in this page) moisturizer. The term "in vivo" used in the description of this patent means to provide an effective dose to the patient RB peptide or protein can effectively prevent or inhibit the proliferation of target cells or the growth of tumors. The methods of administering the drug compound are widely known to those skilled in the art, including but not limited to intratumoral injection, Oral, intravenous or parenteral administration. Drug administration can be used continuously or intermittently throughout the course of treatment. The most effective way and dosage method is to be widely known by the artist, and because of the therapeutic · Protein or polypeptide, the purpose of treatment, the cells or tumors to be treated, and the patients to be treated. For example, to sharpen, the appropriate dosage range is from about 0.1 mg / kg / body weight to 10 mg / kg / body weight . / For the function of this patent explanation and clear book The retinoblastoma protein H is intended to include naturally occurring retinoblastoma protein * isolated from a human cell source as described in the examples below or a recombinantly produced retinoblastoma protein, as shown, for example, in FIG. 2 by c DH A Encoded. In a specific embodiment of the present invention, the retinoblastoma protein is designated as the protein province of PRB110. PRB11. The amino acid sequence is shown in Figure 2. In the Central Ministry of Economic Affairs The employee's consumer cooperative printed version also includes functional equivalents of purified retinoblastoma protein or PRB11Q protein produced by the elder sister. Functional equivalents are different from purified retinoblastoma protein or pRB 11 (5 The amino acid sequence of the protein has the ability to produce the same preventive effect. This type of equivalent protein can have additives, deletions or substitutions that do not significantly affect the ability of the protein to inhibit the proliferation of pupae. The method for identifying equivalent proteins is The above-mentioned in vitro test -31- · Paper 逋 逋 逋 Use Chinese national standard (TNSTi ^ specifications (210 X 297 mm),--~~ Economic Printed by the Central Consumers Bureau Consumer Cooperatives 4661 1 7 A? B7__ 5. Description of the Invention ('29). Trial. Phase proteins or peptides include purified retinal germ cell protein or PRB110 segment. Biologically active Examples of this segment include 'but not limited to, P56κβ, and the segments released from amino acids 393-772, 393 to 870, and 871 to 928 as shown in Fig. 2. The operation of the present invention is performed when the cell is an animal cell' For example, mammalian cells such as humans or mice are suitable. The appropriate patients are mammals, such as mice or humans. The above method may not be used to inhibit the proliferation of pathologically proliferating cells. It can also be used to prevent cell perception. This type of proliferation. For example, 'hereditary retinoblastoma's disease has the risk of developing secondary cancer as defined above. As known to those skilled in the art / who knows, the effective amount or dose for prevention can be the same as the therapeutic amount or Dosages are not the same | but can be determined by those skilled in the art. The present invention also provides a method for treating a disease caused by a patient's lack of a functional retinoblastoma or polypeptide, or a lack or mutation of a retinoblastoma gene. As described above, this method requires administering to a patient an effective amount of a functional retinoid blastoma cell protein or polypeptide. As detailed below, the RB gene protein or RB protein is an alternative phosphorylated protein. It has a surface-surface molecular weight of about 110 kDa to n6 kDa on SDS-PAGE. M is normal, i.e. non-transformed cells are present in various vertebrate breeds. In some cases, a pathological or lack of RB protein is the result of a mutation in the chromosomal position of the RB gene. In normal cells * RB protein is the transcription product of a gene located in the 13ql4 region. In the family case of retinoblastoma -32- This paper size is applicable to the Chinese family kneading rate i CNS Μ size (210X297 mm 1 (please read the note on the back first ^ fill this page) Order 1b6l 17 A7 B7 5. In the description of the invention (30),-("Hui ethnic bipedal vision_embryocytoma "] the sudden love of the gene's dual gene on the embryonic vision, eventually leading to retinal embryos in developing children Cell tumors. For one- or two-test versions of the disease without familial inclinations, somatic mutations that affect the dual gene dual genes must occur in the same retinal germ cell. See Proc. Hati · Acad. S ci. USA (1971.) 68: 820-823.®Yes, the present invention provides a method for the treatment and prevention of unilateral and bilateral retinoblastoma cell tumors caused by such mutations. RB protein is an alternative phosphorylated protein, which can be Affinity-purification in cell extracts, due to differences in protein phosphorylation, migrated to osmotic bands of molecules from 110 to 114 kDa on SDS-PAGE. RB. Egg. Phosphorylation occurs in silk Amino acid and threonine. (Ce 丨 1 (1 9 8.9) 56 : 57-65 and Oncogene Res 1: 205-214); This characteristic changes during the cell division cycle. The pattern of low phosphorylation is in the G of the cell cycle. And the pattern of dominating and highly phosphorylated in the G τ phase. Dominated in G 2, M and S phases. For a comprehensive study of the biological properties of RB protein, please refer to Biochemica Biophysica Acta (1993) 1 1 55: 4: 3-61. 1. Off-line consumption at the Central Standards Bureau of the Ministry of Fine Economy Cooperative printed (please read the note on the back f, write this page first) In the cell division cycle, the phosphorylation of RB protein is agitated. As the term "protein" in this patent specification is intended to include all kinds of protein or Alternative phosphorylation patterns. In some embodiments, more than one pattern will be used in the method of the present invention, and alternative patterns can be administered simultaneously. 0 is used for "functional retinal germ cells in this patent specification" Oncoproteins, "RB proteins" or "I? B polypeptides" are also intended to include naturally occurring retinoblastoma tumor proteins isolated from human or vertebrate cell sources as shown in the following examples. Paper ruler Degree Applicable to China National Standard #CNS (A4) (210X297 mm) 4 6 61 1 7 Α7 Β7 Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (31) • Retinal embryos produced by quality or M Cell tumor proteins, for example, are encoded by c D N A as shown in Figure 2 in the prokaryotic and eukaryotic expression systems. In a specific example of the invention, the retinoblastoma protein is a protein designated P P R β °. p p R B 11. The amino acid sequences are shown in Figures 2 and 30. The terms "purified" or "'equivalently purified" used in this patent specification refer to a degree of approximation obtained through the experimental procedure described below. Purity can be measured by any method known in the art, such as by imaging or using a densitometer. Also included in this definition are functional equivalents of purified retinoblastoma protein (ppRB110) or pRB110, a protein produced by the sister-in-law. θ The functional equivalents used in this patent specification have egg's white matter with a different amino acid sequence than the purified zygomatic omental blastoma protein p P "" 11 (> egg white protein capable of producing the same preventive effect. Such equivalent proteins Additives, deletions or substitutions that do not significantly affect the ability of the protein to inhibit uncontrollable cell proliferation. The method for identifying equivalent proteins is as described above in vitro testing. The equivalent protein or peptide includes purified retinoblastoma protein -Or PllORB2fi segment. Several examples of this type of fragment are described below. The term "synonymous protein or polypeptide" in this patent " specification " is a product of recombinant expression defined as C & NA (as shown in the figure) (2) or a fragment thereof. The recombinant expression system is the stable transformation of the epidermal epidermal vector into a suitable host cell for the production of the RB protein epidermal body. The vector containing the DNA sequence, and the sequence is other sequences that can affect its gauges. The following are examples of several expression vectors. Although not shown All must understand clearly, but implied that this kind of paper, please read the note on the first page. The paper ruler is used for remote control. China Xingjia Junzhe (CNS jA4% 4M 210X297 mm wide: Λ 嚷 嚷 :: 5 4661 1 7 Α7 Β7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of the Invention (32). The expression body must be able to replicate in the host organism as a gene accessory body, chromosome ΰ NA integration part or other chromosomes. In other words, the vector is a functional definition given that any D Η A sequence can influence the arrangement of the fixed D N Λ sequence in which it behaves as if it is suitable for a particular sequence to be included in the noun. System, refers to the transformation of infected host cells with a vector constructed using double-body DNA technology. The insertion of the vector or DNA can be microcellular transfer, retrovirus-mediated gene transfer, transformation infection, and cell fusion. The vectors and methods disclosed in this patent specification are applicable to the prokaryotic and eukaryotic and biological host cells of Guangfanyuan. It includes the definitions of basic technology, methods and equipment for molecular biology of the present invention. Physics textbooks are used as references. See, for example, Maniatiseta 1., Molecular CI ο ning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1982.) and Sainbrook et al., Holecualr Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, New York (1989) and various references cited in the document. In addition, the recombinant DNA method currently used by this artist includes polymerase chain reaction (PtR). The combination of oligonucleotide synthesis makes DNA sequence easy to regenerate ... DNA fragments up to about 6000 base pairs in length can be expanded exponentially from a single gene copy by PCR. In the present technology, two oligonucleotide primers of denatured DNA samples are cultured to guide the synthesis of DNA polymerase, each of which generates approximately double the amount of tritium. Splitting each cycle by changing the temperature promotes the denaturation of DNA strands, attaches primers, and synthesizes new DNA strands. Using hot DHA polymerase can eliminate the need to add new enzymes to each -35- I 1 I > Binding (please read the notes on the back first ^ ¢ 1 ^ write this page) S ·

VV

V n«l I 纸張^適用中國國家揉準:(⑶反以4規格T 210乂迚7公龙) 4661 17 a? B7 經濟部中央梯準局另工消費合作社印製 五、發明説明(35 ) 婚環之_要,因而促使完全自動之 大作用循瑁可增加約10 0倍之搮的 國專利第 4,683, 195, 4,800,159, 4 , SS3 , 202號之標的物。 因此,核酸分子(示於圖2 )或其 用作R B蛋白質之重姐體表現。重組 本發明之方法。 本發明操作之適當细胞是動物细 動物细胞如人類,老扁或小鼠细胞 乳類,如老鼠,猴子,小鼠或人類 上述方法不僅可用Μ抑制病態增 可用Μ預防細胞!受於該類增殖作 细胞生長。舉例·來說,遺傳性視網 展定義如上之續發性癌之危險。本 患。 如具本技藝者所熟知者,預防用 療用量或劑S不同,但易於為具此 本發明亦提供治療因患者缺乏功 多胜肽,或.缺乏或存在突變之視網 之病變之方法。如上述,該方法需 功能性視網瞋胚细胞瘤蛋白賣或多 下列賁例是用Μ閾述而非對本發 1抗-R Β抗體和R Β蛋白質純化作用 使用染色體游之方法自其它之染 DKA擴大作用。25倨擴 序列量。p C I?科技是美 4 ,754,065,和 片段可插入表現載體並 體蛋白質經純化再用於 胞,舉例來說,哺乳類 。適當之患者因而是哺 0 . 殖细胞之增殖作用,亦 用,而免於無法控制之 膜胚細胞瘤之病患有發 方法特別適用於該類病 之有效量或劑量可和治 技藝者所決定。 能性視網_胚細胞瘤或 膜胚細胞瘤基因所造成 要對患者施用有效量之 胜肽。 明設限。 色體1 3標記,在1 3 q 1 4 -36- 本 0 囷 用 Α< X ο 21 • J- 々'V n «l I Paper ^ Applicable to Chinese national standards: (3) 4 size T 210 乂 迚 7 male dragon) 4661 17 a? B7 Printed by the Central Laboratories Bureau of the Ministry of Economic Affairs and a separate consumer cooperative. 35) The key of the wedding ring, and thus the promotion of a fully automatic cycle can increase the subject matter of the national patent No. 4,683, 195, 4,800,159, 4, SS3, 202 by about 100 times. Therefore, the nucleic acid molecule (shown in Figure 2) or its use as a heavyweight of the RB protein. Restructuring the method of the invention. Appropriate cells for operation of the present invention are animal cells, animal cells such as human, old flat or mouse cells, milk, such as mice, monkeys, mice or humans. The above method can not only inhibit morbid increase but also prevent cells by M! Subject to this type of proliferation for cell growth. For example, the hereditary vision network defines the risk of secondary cancer as described above. This suffers. As is well known to those skilled in the art, the amount of prophylactic treatment or agent S is different, but it is easy to do so. The present invention also provides a method for treating a disease caused by a patient's lack of functional peptides, or lack of or mutation in the visual network. As mentioned above, this method requires the functional retinoblastoma protein to be sold or more. The following examples are described by M threshold rather than purification of the anti-R Β antibody and RB protein of the present invention. DKA expanded effect. 25 倨 sequence. PIC technology is US 4,754,065, and fragments can be inserted into expression vectors and purified in vivo and used in cells, for example, mammals. Appropriate patients are therefore fed with the proliferation effect of germ cells, and also used to prevent the disease of uncontrollable mesoblastoma. The method is particularly suitable for the effective amount or dose of such diseases. Decide. Capsule retinoblastoma or mesangioblastoma genes cause an effective amount of peptide to be administered to a patient. Clearly set limits. Color body 1 3 mark, in 1 3 q 1 4 -36- present 0 囷 for Α < X ο 21 • J- 々 '

4661 17 五、發明説明(34 ) .:U嶇^,I 3染色體中鑑定出琨網膜胚细胞瘤基因和編踽 之胺基酸序列。透過使用酯_ D c D N A選殖株和篩選基因姐 和c D Μ A庫存,可擭得敷涸選殖株。自該類選殖株,在人類 c D N A庫存中鑑定出分別是1 6 k b和0 · 9 k b之二涸c D.ff A重壘 選殖株RB-1 (如圖2所示約核苷酸100至約核苷酸1 , 700 )和 RB-2 (如圖2所示約核苷酸至約核苷酸1 , 000 )。稍後, 亦鑑定出另一 g殖株R B -5 (如圖2所示約核苷酸1 , 2 5 0至約 核苷酸4,7 5 ? >。 RB-1選殖株在人類胎兒視網膜和胎盤中與4.8 kb raRNA 轉錄本雜交。在視網膜胚细胞瘤樣本中,R β - 1選殖株偵測 出不正常之mRNA轉錄本或完全無法觀察到πίίΝΑ轉錄本。之 後鑑定出之RB-5Sf.殖株,具3.5 kb插入序列,可得如 R B -1在ra R N A雜化作甩中相同之结果。限制酶分析建議 RB-5和RB-1選殖株在一個0.4 kb區域重蠱,二者一起定義 約4.6 1^之0“月段,尺寸與正常之1^>^^^轉錄本接近 0 MProc, Natl . Acad , $c i . (1977) 74:546 3-5 46 7所述 經濟部中央標準局員工消費合作社印製 (請先聞讀背面之注意事π#'.填寫本頁〕 之二脫氧-終結劑方法進行選殖株RB-1和0-5之核苷酸序 列分析,產.生再構築之完全c D N A序列。Μ ”胞選殖株 eye丨one”方法(Ibid)在單股Μ13噬菌體選殖株中產生不 同之刪除模板,獲得超過Q 5 %之序列。刺餘之缝隙以雙股 中引.物之延伸作為序列。依此方法鑑定之完全序列含有 4,523個核苷酸。 自5'端至鹼基2δδ8出現開啟之密碼,更向下有數個其它 :邊,_本紙張欠度逋用牛國國家揉準(CNS )制現格{ ηοχ297公釐) A7 B7 經濟部中央標準局貝工消費合作社印袈 466117 五、發明説明(55) 的结肩(¾終止密碼子°轉譯自第一甲硫胺酸密碼子(驗基 241)產生816個胺基睃之假設蛋白質(尺寸94,〇〇〇道耳呑 )。第二结構内甲.硫胺酸是在鹼基3 4 6 。由於圍繞第一 ATG之核苷酸序列並非典型之其它已知mRNA (Nucleic Acid Res . (1984) 12:857-863) ’改始密碼子之指定被認 為是暫時的。電腦搜尋國家生物研究基金之蛋白質序列資 料庫,在超過4 , 0 0 0個公佈之胺基酸序列中竑未測得任何 強力同種者。但是,一些核酸-结合蛋白質和病毒蛋白質 顯示與具有最高同種性分數之酵母-専引之RNA聚合酶之 微弱序列同種性。 推測之蛋白質序列包含1 〇個可能的糖基化作用位置. (CRC Crit. Rev. Biochem (1981) 10:307-366)但並未發 現可能之穿透膜功能部位(至少2 0個連續的忌水性殘基)。 胺基酸水療法圖顯示在靠近推定之胺基端子和羧基端之親 水性區域有一溫和之忌水性區域。鑑定出之二對短的胺基 酸序列,Μ在核酸-结合蛋白質中所見之金屬-结合功能 部位之方式被半胱胺酸和组嫌胺酸併在一起(Science (1986) 232: 4*8 5-487)。自位置663至716的54個胺基酸區 域含有14個腩胺酸或在核腫瘤基因蛋白質royc和myb中亦觀 察到約26¾該類脯胺酸-富集區域(RNA Tumor Viruses ( 1 9 8 5 ) Cold Spring Harbor Laboratory Cold Spring Harbor) ° 當尚未建立該類觀察之早期意義時,有人建議RB基因蛋 白質可能是核酸-结合蛋白質。但考慮過去之發現以及 -.38-4661 17 V. Description of the invention (34) .: U 岖 ^, I 3 Chromosome omentoblastoma gene and amino acid sequence of the edited sequence were identified. By using the ester-D c D N A selection strain and screening gene and c D M A stocks, the selection strain can be obtained. From this type of selected strains, 16 kb and 0.9 kb were identified in the human c DNA stock, respectively. C D.ff A heavy barrier selective strain RB-1 (as shown in Figure 2 Acid 100 to about nucleotides 1,700) and RB-2 (as shown in Figure 2 about nucleotides to about nucleotides 1,000). Later, another g clone RB-5 was also identified (approximately nucleotides 1,250 to approximately 4,75? As shown in Fig. 2). The fetal retina and placenta hybridized with 4.8 kb raRNA transcripts. In retinoblastoma samples, R β-1 selections detected abnormal mRNA transcripts or were unable to observe πίΝΑ transcripts. Later identified The RB-5Sf. Colony has a 3.5 kb insertion sequence, which gives the same results as RB-1 in ra RNA hybridization. Restriction enzyme analysis suggests that the RB-5 and RB-1 clones are in a 0.4 kb region. Again, the two together define a period of about 4.6 1 ^ 0 ", the size is 1 ^ > ^^^ transcript is close to 0 MProc, Natl. Acad, $ ci. (1977) 74: 546 3-5 46 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (please read the note on the back π # '. Fill out this page) 2 Deoxy-terminator method for breeding strains RB-1 and 0-5 Nucleotide sequence analysis yields complete c DNA sequences that are reconstituted. The M "cell selection strain eye 丨 one" method (Ibid) generates different deletion templates in single M13 phage selection strains, A sequence of more than Q 5% was obtained. The gap between the thorns is based on the extension of the primers in the double strand. The complete sequence identified by this method contains 4,523 nucleotides. The open code appears from the 5 ′ end to the base 2δδ8. There are several others down: Edge, _ This paper is inadequate, using the National Standard for Cattle (CNS) system of the cattle country {ηοχ297 mm) A7 B7 Central Standards Bureau of the Ministry of Economic Affairs, Shellfish Consumer Cooperative Seal 466117 5. Invention Explanation The (55) end-shoulder (¾ stop codon ° translated from the first methionine codon (chaeme 241) produces a hypothetical protein of 816 amino groups (size 940,000 channels). Section The second structure is A. Thiamine is at base 3 4 6. Since the nucleotide sequence surrounding the first ATG is not typical of other known mRNAs (Nucleic Acid Res. (1984) 12: 857-863) The designation of codons is considered to be temporary. The computer searched the protein sequence database of the National Biological Research Fund and found no strong homologues in more than 4,000 published amino acid sequences. However, some nucleic acids -Binding proteins and viral proteins show the highest homology score The weak sequence homology of several yeast-inducible RNA polymerases. The putative protein sequence contains 10 possible glycosylation sites. (CRC Crit. Rev. Biochem (1981) 10: 307-366) but does not No possible sites of membrane penetration were found (at least 20 consecutive water-repellent residues). The amino acid hydrotherapy chart shows a region of mild water repellency in the hydrophilic region near the putative amine terminal and carboxyl terminal. Two pairs of short amino acid sequences have been identified, and the metal-binding functional sites seen in nucleic acid-binding proteins by M are merged by cysteine and histidine (Science (1986) 232: 4 * 8 5-487). 54 amino acid regions from positions 663 to 716 contain 14 amino acids or about 2626 were also observed in the nuclear tumor gene proteins royc and myb (RNA Tumor Viruses (1 9 8 5) Cold Spring Harbor Laboratory Cold Spring Harbor) ° When the early significance of this type of observation has not been established, it has been suggested that the RB gene protein may be a nucleic acid-binding protein. But consider past discoveries and -.38-

-T-T

4661 1 7 A7 :_____B7 五、發明説明(56 ) R B c~0 N A選殖株之核脊酸序列分析,証實編碼假設蛋白質 之長-開啟密碼,該密碼具有D N A结合功能之特質,本發 明之最初目的就是鑑定和描述用以作為抗原以獲得特定抗 體之RB蛋白質和測定其推測之dna结合。 透過表現融合蛋白質於大腸桿菌中可製備蛋白質抗原 。為達此目的,卫B棊.因—.胜肤Η段與TRP Ε蛋白質 融合1而該融.合蛋白質表琨於大腸桿菌中。 自816個胺基酸和約98 kD分子虽之假設RB蛋白質序列 資料可‘構築3個表現"TRP E融合蛋白質之pATH質體。完全 之cDNA選殖株分成3個部份,成為0.7 kb,0.9 kb和1.S kb之Η段。該三個片段含有RB cDNA之密碼序列。質體 pATO-0.9 RB是缚築自插人於PATH3之EcoRI-EcoRI位置 的Η段5’ 0.9 kb 。插人RB-1選殖株之中0,7 kbH段至 PATH3之EcolU-EcoRI位置可構築質髏PATH3-0.7 RB,插入 3· 1.8 kb片段至PATH3載體之Bglll-Bglll位置可構築 質體PATH3-1.8 RB。限制酶位置之詳细位置圖可確定其排 列。 經濟部中央標準局員工消費合作社印製 重組體質體 %ATH3-〇.9RB,MTH3-0.7RB 和 pATH3-1*8RB 再轉化至大腸桿菌mni294中,在補充Μ較好是濃度約2〇毫 克/毫升色胺酸之Μ9最低營養要求培養基中生長。Μ添加 酪蛋白胺基酸和胺苄青霉素之Μ9培養基稀釋.培養物混合物 自 1 : 10至 1 : 150 ,較好是 1 : 100 。J· V iro 1 . ( 1984) 49:132-141記載構築重組體質體之程序。.P r 〇 c . NatU Acad. Sci . (1986) 83:4685-4689記載在限制酶位置融合 (.<<1:1 .,»; · · · 觸減p本紙張尺度逋用寺國國家揉準呀⑼爱私4规楼·"r2i〇X 297公釐)* 4 G β 1 t 7 A7 B7 五、發明説明(57 經濟部中央標準局員工消費合作社印製 Η段圣P*ATH載體架構中。 三個PATH3構築體中僅一個,即pATH3-0,7RB表琨融合 蛋白質。所得之融合蛋白質之分子最是57 kD。由於TRYP E之分子量已知是衍生自RB蛋白質之融合蛋白質之37 ,_2 〇 k D之胥白筲部分。 其它二個質體構築體完全不產生蛋白質,gp使是TRyp本 身。由於RB選殖株含有許多假設之蛋白酶斷裂位置,在大 腸禪菌内無法產生蛋白質並不令人意外,並且可能是因為 融合蛋白質之不安定'性。 使用上述程序融合pATH3和RBH段,可製備大虽的融合 蛋白質’再根據Nature (1970) 227:680-685所記載之程 序Μ製備性S D S琴丙烯醯胺凝膠電泳純化。融合蛋白質以 過夜之提取物和’SDS離析,可溶丙烯醯胺从透析除去。再 濃縮蛋白質。 在生產特定抗-RB蛋白質抗體時經純化之融合蛋白質是 用作為抗原。 依 Proc. Natl, Acad Sc i . (1986) 83:6790-6794所記 載之程序製備、抗〇蛋白質之特定兔子多選殖抗體。 Μ混合有.完全佛瑞得佐助劑(Freund'.s adjuvant)之 卜2微克,較好是1〇微克之純化融合蛋白質(最初注射), 較好是每14天間隔重複注射兔子,再追加注射在不完全佛 瑞得佐助劑中等量之融合蛋白質(重複注射 >。完全彿瑞得 佐助劑通常包括在鹽水和乳化劑混合物中之抗原乳化物, 在本案例中是融合蛋白質,如同.舉例來說,Ariacel A,在 40- 释頷擊本轉張从逍用中國國家搮準;歡阳濟以说轄今21攸297公支)' 請 先 閲 讀 背 之 注 Ψto 袭 訂I* 4 661 1 T A7 B7 五、發明説明(58 ) 礦油啪‘死之分枝菌中。不完全佛瑞得佐肋劑是一樣的, 除了不含分枝菌。 重複注射直至測得足夠高價之抗-融含蛋白質以與τ R P E和融合蛋白質反應,約需2個月。為增加僅辨識R B決定 子之抗體,Natl; Acad. Sci (195 1) 37:. 5 7 5 - 578 ·和 Immunoadsorbents in Protein P u r i f i c_^Jl 匕ion, Scand,.J. 〖mmunol . (1976) Suppl 。3 中所述方 法製備.2或多®親和力管柱。至少一個管柱裝TRP E蛋白 質,至少一個管柱裝·融合蛋白質。各管柱均適當的預循瓌 。抗體先通過融合蛋白質-瓊脂糖管柱,M pH 2.3之甘胺 酸緩衝液離析。中和離析液再通過TRP E管柱數次Μ除去 特別導引Κ對抗Ti? Ρ Ε之抗體。經純化之抗:』!— IgGffCj豊 用在免疫沉澱或免疫染色上供RB蛋白質之定位作用,對人 體姐織樣本中RB蛋白質之診斷鑑定亦同揉有用。 經濟部中央標準局員工消費合作社印裂 為鑑定RB蛋白質*選擇數個已知具有正常或變異之基 因表現之人體细胞源。L A N - 1神纆母細胞瘤细胞源,正常 人體纖維母细胞,人體肝癌亞力山大细胞源和骨肉瘤 U20S姻胞源用Ί乍含正常RB mRNA之陽性對照姐。所有該類 细胞均得自美國式培養收集(ATCC)貯藏所。具預定較短或 不具RB roRNA之细胞源,如視網膜胚细胞瘤细胞源Y79 (.ATCC) * RB355 (Robert Philips Toronto; Canada 贈送 ),WERI-l, WEH-24 和 WERI-27 (T. Sery Wills' Eye Hospital, Philadelphia贈送)用作陰性對照組。. 以3 s S -甲硫胺酸標記上述之全部正常人體细胞源和得自 -41- 妙本紙張天jS:进用中國國家«準忒CNS )210 X 297公}^寒: '々Ψ &4 6 61 1 7 Α7 Β7 經濟部中央標準局員工消費合作社印装 五、發明説明(59 ) 5種喁網膜胚细胞瘤之全部細胞,並以幼畤免疫之兔子抗 體IsG或兔子抗-RB IgG免疫沉殺。 根據J · V i「〇 1 · (.1981 ) 38 : 1064- 1076所記載之程序以 3 5 S -甲硫胺酸新陳代謝的'標記全部人體细胞源,K卜2 0微 升,較好是10微升之自50微克/毫升-200微克/毫升,較 好是100微升之抗-RB抗體UG ,使用J Virol, (19.81) 38:1064-1076所述之程序免疫沉殺標記之细胞混 合物。 在全部對照细胞源'中,測得Π0-Π4 kD分子量之蛋白質 對似物。在視網膜胚细胞瘤细胞源’或在以幼時免疫血清 免疫沉澱之细胞中*並未測得蛋白質對Μ物。 Μ兔子抗-RB IpG免疫沉澱之RB蛋白質用SDS /聚丙醯胺 凝膠電泳分析並放射自顯。結果示於圖1 。在第2 - 5行, 約110 kD區域可看見RB蛋白質出琨,閫釋正常陽性之免疫 沉殺物,亦即含有3SS -甲硫胺酸標示之RB蛋白質。第1行 是K幼時免疫物免疫沉澱之視網膜胚细胞瘤细胞之對照细 胞源,因而不具抗-RB蛋白質抗體,兔子IgG 。第6-10行 是免疫沉澱來~自5種視網膜胚细胞瘤經3SS-甲硫胺酸標記 之細胞源所_獲得者。在任何該類细胞源中沒有R B蛋白質之 出現。 在視網膜细胞中無可抗原偵測之RB蛋白質,支持突箋型 RB基因造成之腫瘤生成是肇因於完全喪失基因產物功能之 觀念,即使是在含有截短之RB mRKA之细胞源中。. 自核苷酸序列推測之假設蛋白質被認為具有約98 kD之 -42- (請先閲讀背面之注意事項再填寫本頁) 訂4661 1 7 A7: _____B7 V. Description of the invention (56) Sequence analysis of nucleotides of RB c ~ 0 NA clones confirmed the long-on code encoding hypothetical protein, which has the characteristics of DNA binding function. The original purpose was to identify and characterize RB proteins used as antigens to obtain specific antibodies and to measure their putative DNA binding. Protein antigens can be prepared by expressing fusion proteins in E. coli. In order to achieve this, Wei B. The fusion protein of T. sapiens and TRP E protein 1 should be fused in E. coli. From the 816 amino acids and about 98 kD molecules, although the hypothetical RB protein sequence data can 'build three pATH plastids that express " TRP E fusion proteins. The complete cDNA clones were divided into 3 parts and became 0.7 kb, 0.9 kb, and 1.S kb. These three fragments contain the coding sequence of the RB cDNA. The plastid pATO-0.9 RB is a 5 ′ 0.9 kb segment inserted into the EcoRI-EcoRI position of PATH3. Plasma PATH3-0.7 RB can be constructed by inserting the 0,7 kbH segment of the RB-1 clone to the PATH3 EcolU-EcoRI position, and inserting a 3.1.8 kb fragment into the Bglll-Bglll position of the PATH3 vector can construct the plastid PATH3 -1.8 RB. A detailed location map of the restriction enzyme positions determines its ranking. The Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs printed the recombined physique% ATH3-0.9.9RB, MTH3-0.7RB and pATH3-1 * 8RB and transformed it into E. coli mni294. The concentration in supplement M is preferably about 20 mg / M9 tryptophan is grown in medium with minimum nutritional requirements of M9. The M9 medium was diluted with casein amino acid and ampicillin. The culture mixture was from 1:10 to 1: 150, preferably 1: 100. J. Viro 1. (1984) 49: 132-141 describes the procedure for constructing a reconstituted constitution. .P r 〇c. NatU Acad. Sci. (1986) 83: 4685-4689 describes fusion at the restriction enzyme position (. ≪ < 1: 1., »; National Standards and Regulations ⑼ Love Private 4 Rules Building " r2i〇X 297 mm) * 4 G β 1 t 7 A7 B7 V. Description of Invention (57 Printed by Duan St. P * ATH vector architecture. Only one of the three PATH3 constructs, namely pATH3-0,7RB, represents the fusion protein. The maximum molecular weight of the resulting fusion protein is 57 kD. Since the molecular weight of TRYP E is known to be derived from the RB protein Fusion protein of 37, 2 〇k D of the white pupa part. The other two plastid constructs do not produce protein at all, and gp is TRyp itself. Because the RB selection strain contains many hypothetical protease break locations, it is not possible in E. coli The production of protein is not surprising, and it may be due to the instability of the fusion protein. Using the above procedure to fuse pATH3 and RBH segments, a large fusion protein can be prepared. Then according to Nature (1970) 227: 680-685 Procedure M Preparative SDS Gel Acetamide Gel Electrophoresis Purification Fusion protein was isolated with overnight extract and 'SDS, soluble acrylamide was removed from the dialysis. The protein was then concentrated. The purified fusion protein was used as the antigen in the production of specific anti-RB protein antibodies. According to Proc. Natl, Acad Sc i. (1986) 83: 6790-6794, a rabbit polyclonal antibody specific to 0 protein prepared by the procedure. Μ mixed with 2 micrograms of complete Freund's adjuvant , Preferably 10 micrograms of purified fusion protein (initial injection), preferably repeated injections of rabbits every 14 days, followed by additional injections of a medium amount of fusion protein in incomplete Fredezol auxiliary (repeated injection > complete Fredezo auxiliaries usually include antigenic emulsions in a mixture of saline and emulsifiers, in this case fusion proteins, like. For example, Ariacel A, in a 40-release testimonial from the Chinese version (Jun Zhuan; Huanyang Jiyi has jurisdiction over 21 297 public branches)) Please read the note of the back to the order I * 4 661 1 T A7 B7 V. Description of the invention (58) Mineral oil pops' Dead Mycobacterium Medium. Incomplete Fred The rib adjuvant is the same, except that it does not contain mycobacteria. Repeat the injection until the high-priced anti-melt protein is measured to react with τ RPE and fusion protein, which takes about 2 months. In order to increase only the RB determinant is identified Antibodies, Natl; Acad. Sci (195 1) 37: .5 7 5-578 · and Immunoadsorbents in Protein Purification, Scand, .J. Mmunol. (1976) Suppl. Prepare a .2 or more® affinity column as described in 3. At least one column is packed with TRP E protein, and at least one column is packed with fusion protein. Each column is properly pre-circulated. Antibodies were first isolated through a fusion protein-sepharose column, glycine buffer at M pH 2.3. The neutralized eluate was passed through a TRP E column several times for M removal. The antibody directed against Ti? PE was specifically guided. Purified antibody: "! IgGffCj 豊 is used for immunoprecipitation or immunostaining for the localization of RB protein. It is also useful for the diagnosis and identification of RB protein in human tissue samples. For the identification of RB proteins *, select several human cell sources that are known to have normal or mutated gene performance. L A N-1 Kobe blastoma cell source, normal human fibroblasts, human hepatocellular carcinoma Alexander cell source and osteosarcoma U20S marital cell source containing normal RB mRNA positive control sister. All such cells were obtained from American Type Culture Collection (ATCC) storage. Cell sources with predetermined short or no RB roRNA, such as retinoblastoma cell source Y79 (.ATCC) * RB355 (gift from Robert Philips Toronto; Canada), WERI-l, WEH-24 and WERI-27 (T. Sery Wills' Eye Hospital, Philadelphia) was used as a negative control group. All normal human cell sources mentioned above were labeled with 3 s S -methionine and obtained from -41- Miao Ben Zhi Tian JS: used in the Chinese country «JunSCNS} 210 X 297 public} ^ Han: '々Ψ & 4 6 61 1 7 Α7 Β7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of the invention (59) All cells of 5 kinds of tadpole omental blastoma, and rabbit antibodies IsG or rabbit anti- RB IgG immunosuppression. According to the procedure described in J.V.i. 〇1. (.1981) 38: 1064- 1076, all human cell sources are labeled with 3 5 S-methionine metabolism ', and K 20 μl, preferably 10 microliters from 50 micrograms / ml to 200 micrograms / ml, preferably 100 microliters of anti-RB antibody UG, using the procedure described in J Virol, (19.81) 38: 1064-1076 to immunize the labeled cells Mixture. Protein pair analogs of Π0-Π4 kD molecular weight were measured in all control cell sources '. Proteins were not measured in retinoblastoma cell sources' or in cells immunoprecipitated with immunized serum in childhood. The RB protein of Μ rabbit anti-RB IpG immunoprecipitation was analyzed by SDS / polyacrylamide gel electrophoresis and self-radiated. The results are shown in Figure 1. In lines 2-5, the RB protein can be seen in an area of about 110 kD.琨, release the normal positive immunosuppressant, that is, the RB protein labeled with 3SS-methionine. Line 1 is the control cell source of retinoblastoma cells that immunoprecipitated by K immunogen in childhood, so it is not resistant -RB protein antibody, rabbit IgG. Lines 6-10 are from immunoprecipitation ~ 5 kinds Omental blastoma is obtained from 3SS-methionine-labeled cell sources. There is no RB protein in any of these cell sources. There is no antigen-detectable RB protein in retinal cells, which supports abrupt type. The tumorigenesis caused by the RB gene is due to the idea that the function of the gene product is completely lost, even in a cell source containing truncated RB mRKA. The hypothetical protein inferred from the nucleotide sequence is considered to have about 98 kD- 42- (Please read the notes on the back before filling this page)

0.0.

V 6 6 4 Η: 經濟部中央標準局貝工消費合作社印製V 6 6 4 Η: Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs

1 7 A7 B7 — 一 — ' 發明説明(40) μ w。-免§沉澱之蛋白質具有約110 _ 114 k D之M w °完全R B胺 基酸序列示於圖2 。該完全序列是得自重新構築之選殖株 ,含有最多在原cDN A選殖株中不見之5 ’端延伸序列! Science U 987) 235 : 1 394- 1 399)。第 1和第 2啟始甲硫胺 酸被框起來,丙胺酸和脯胺酸團則劃以下線。胺基酸序列 (圖2丨以本技藝可辨識之單字母縮寫碼書寫。 RB ^nhiAFg^il (Science (1987) 235:1394-1399)含有核 苷酸ΐ至2 6 8 8之長的開啟密碼’是轉譯自第一甲硫胺酸密 碼子,產生816個胺'塞酸和分子量98 kD之假設蛋白質。 另一離析之RB cDNA選殖株在5’端含有另外的23 4個鹼基 對。重新修正之R B c D N A序列(圖2 )仍保有在原選殖株中 相同的開故密碼,而在核苷酸139發規另一甲硫胺酸密碼 子。當該甲硫胺·酸用作起始密碼子時,推測之R Β蛋白質具 有928個胺基酸和100 kD之分子虽--與SDS-PAGE所測定之 表面M.W.相同。額外的5‘序列含有GC-富集區域*轉譯成 為異於平常之丙胺酸和脯胺酸殘基團(圖2 >。 在真正和SDS-PAGE上表面之分子量間之不同可以第二蛋 白質修飾解釋'在圖2所見推測之胺基酸序列中有數個可 能的N-連结..糖基化作用‘位置。但是,當1^11細胞在補充 -半乳糖或3H-葡萄糖胺之培養基中生長時,即使延 長的放射自顯影術亦無法測得標記之R B蛋白質。此外,根 據 J . li 〇 U C h e m ‘ (1975 ) 250 : 8569 -8579 所記載之方法 以糖脊内切酶消化35S -標記之RB蛋白質,並未減少表面之 分子量。 — -43- -T —---------裝-- - ο. (請先閱讀背面之注意事一寫本頁) \ __ Η. _ --------- 4本紙張尺复逍用.中國囷家揉準..ί CNS ).A4規格.(.-210X297公釐〇 16611 A7 B71 7 A7 B7 — One — 'Description of the invention (40) μ w. -The precipitation-free protein has a Mw ° complete R B amino acid sequence of about 110-114 k D is shown in Figure 2. This complete sequence was obtained from reconstituted clones and contains up to the 5'-end extension sequence not found in the original cDN A clones! Science U 987) 235: 1 394-1 399). The first and second starting methionines are framed, while the alanine and proline groups are underlined. Amino acid sequence (Figure 2 丨 written with a single-letter abbreviation code recognizable by this technique. RB ^ nhiAFg ^ il (Science (1987) 235: 1394-1399) contains nucleotides ΐ to 2 6 8 8 open The codon 'is translated from the first methionine codon, producing 816 amine' thio acids and a hypothetical protein with a molecular weight of 98 kD. Another isolated RB cDNA clone contains an additional 23 4 bases at the 5 'end Yes. The re-modified RB c DNA sequence (Figure 2) still retains the same initiation code in the original selected plant, while another methionine codon is issued at nucleotide 139. When the methionine acid When used as a start codon, the RB protein is speculated to have 928 amino acids and a molecule of 100 kD, though--the same as the surface MW measured by SDS-PAGE. The extra 5 'sequence contains a GC-rich region * The translation is different from the usual alanine and proline residues (Figure 2 >. The difference between the surface molecular weights on the real and SDS-PAGE can be explained by the second protein modification 'the putative amino acid seen in Figure 2 There are several possible N-linkages in the sequence .. 'Glycosylation' positions. However, when 1 ^ 11 cells are in the supplement-galactose When grown in a 3H-glucosamine medium, the labeled RB protein could not be measured even by prolonged autoradiography. In addition, sugar was sugared according to the method described in J. li UC hem '(1975) 250: 8569 -8579. The endonuclease digests the 35S-labeled RB protein without reducing the molecular weight of the surface. — -43- -T —--------- pack --- ο. (Please read the first note on the back first (Write this page) \ __ Η. _ --------- 4 paper rulers for easy use. China's family standard. Ί CNS). A4 size. (-210X297 mm 〇16611 A7 B7

五、發明説明(u) 經濟部中央梯準局貝工消費合作社印装 齒-視阑瞑胚细胞瘤U N - 1以32卜磷酸新陴代謝的標記並 免疫沉澱*免疫沉澱之蛋白質跑成單一帶,分子量與 3 s S -標紀之R B蛋白質相同。圖3閫釋之结果顯示第2和3 行顯110-114 kD之35S-標記帶,而第5行顯110-140 kD之 u P -標記帶。第丨(3 5 s )和4 ( 3 2 P )行是以幼跨免疫之兔子 IgG免疫沉澱。當35S -甲硫胺酸標紀之RB樣本之整份Μ糖 苷内切酶Η消化過夜時,無可測得之分子量11 〇 - 11 4 k D減 少作用。上述發現証明純化之視網膜胚细胞瘤是 MW110-140 k0之磷蛋白〇該磷蛋白因而命名為ppRB110 。 在其它脊椎動物之DMA層面亦可測得RB基因(亦記載於 Science (1987) 235:1394-1399和圖4 ),建議 RB基因在 演化過程中存在於許多品種中,並建議一個非常重要之生 理任務。來自数種脊椎動物品種之细胞如QT6 (鷗鶉), N I Η / 3 T3 (小鼠),R a t - 2 (老鼠)和 c 〇 s (猴子)Μ 3 2 P -.磷酸 依前述標示,蛋白質以抗-RB IsG使用用於人體之相同程 序免疫沉澱。如圖4所示,在全部细胞内可測得抗原相關 之蛋白質,在鵪鶉中具108 kD之表面類Μ分子童,120 kD於小鼠中,128 kD於老鼠中10δ-110 kD於猴子中,相較 於人體细胞之110 - 11 4 k D。 在不同脊椎動物如鵪鶉,小鼠*老鼠和猴子中所觀察到 具不同分子量之抗原相關蛋白質建議在演化過程中RB蛋白 質被保存,最可能是與演化關係成比例。由於抗原和分子 量同時保存於該類脊椎動物中,RB基因產物可能亦存在於 其它品種且功能類似。 44- 本紙張尺度逍用t國國家標準(CNS } A4^㈡功X 297公釐:)城缺 • HI 1^1 i 先閔讀背面之注意事^^寫本頁) ----、訂-----V. Description of the invention (u) Printed tooth-optic epiphyseal germ cell tumor UN-1 of the Central Laboratories of the Ministry of Economic Affairs, Shellfish Consumer Cooperative, is labeled with 32 phosphonium phosphate metabolite and immunoprecipitated * The immunoprecipitated protein runs into a single Band, molecular weight is the same as 3 s S-standard RB protein. The interpretation of Figure 3 shows the 35S-labeled bands of 110-114 kD on the second and third lines, and the u P-labeled bands of 110-140 kD on the fifth line. Lines 丨 (3 5 s) and 4 (3 2 P) are immunoprecipitated with young cross-immunized rabbit IgG. When a whole M-glycosidase digestion of 35S-methionine standard RB samples was digested overnight, there was no measurable molecular weight reduction of 110-114 kD. The above findings prove that the purified retinoblastoma is a phosphoprotein of MW110-140 k0. This phosphoprotein was named ppRB110. The RB gene can also be measured at the DMA level of other vertebrates (also recorded in Science (1987) 235: 1394-1399 and Figure 4). It is suggested that the RB gene exists in many species during the evolution process, and a very important Physiological tasks. Cells from several vertebrate species such as QT6 (gull quail), NI Η / 3 T3 (mouse), Rat-2 (mouse), and c 0 (monkey) M 3 2 P-. The protein was immunoprecipitated with anti-RB IsG using the same procedure used in humans. As shown in Figure 4, antigen-associated proteins can be measured in all cells. There are 108 kD M-like molecules in quail, 120 kD in mice, 128 kD in mice, and 10δ-110 kD in monkeys. Compared with 110-11 4 k D of human cells. Antigen-associated proteins with different molecular weights observed in different vertebrates such as quails, mice, mice and monkeys suggest that the RB protein is preserved during evolution, most likely in proportion to the evolutionary relationship. Because the antigen and molecular weight are stored in this type of vertebrate, the RB gene product may also exist in other breeds and function similarly. 44- The national standard of this paper (CNS} A4 ^ ㈡ X 297mm :) City shortage • HI 1 ^ 1 i Read the notes on the back ^^ Write this page) ---- 、 Order -----

4661 IT A7 B7 經濟部中央標準局貝工消費合作社印製 五、發明説明(42 ) p p*R 1 〇蛋白質推測之整個胺基酸序列具有數個類似於 出現在其它腫瘤基因上之持徴。因此,以妞胞之分級分離 作用偵査p p R B 1 1。亞次細胞之定位。 必須採用二種方法.以探求在细胞核,细胞質和细胞膜部 份ppRB110之分佈情形。 與化學特性一致,p p R B ^ ^。序列建議可能之D N A結合作 用’鑑定出8 5 S;之p p 〇 11。出現在核的部分,比例上較小 虽之P P R B 1 1。(少於丨〇 u位於膜。在細胞質的部分無可測 得存在。 / 為進一步証明PP〇u〇主要是位於细胞核,使用已知對 / 免疫組織化學染色具有利之細胞形態之骨肉瘤细胞源 U 2 0 S。作為實驗組..,υ 2 0 S细胞Μ抗ρ P R Β 11 0 I g G免疫沉澱。 作為對照姐,[J 2 0 S细胞以幼時免疫之U G免疫沉澱。二姐 均K商業上購自Sigma之紅胺(rhodamine)共軛化羊抗-兔IgG培養。與抗- ρρ〇ι igG反應之細胞内可觀察到免 疫螢光’即在細胞核内(圖5 )。與幼時免疫之對照姐反應 之细胞並未顯示螢光(圖5Bii>。 在核部分ΡρΤίΒ110之次亞细胞定位建議蛋白質在調節 +其它基因上_.具有非常重要之調節功能,並具有DNA-结合活 -性。 某些細胞源,特別是來自腫瘤而非視網膜胚細胞瘤者, 如神經母细胞瘤LAN-1細胞是K 32P-磷酸放射標記。該類 標記细胞混合物之细胞溶胞產物根據Mol. Cell. Biol. (1986 ) 6:4450-44 57中所記載之方法,Μ單或雙股牛胸腺 -4 5 ~ (請先閲讀背面之注意事項再填寫本瓦) i裝· II----------„--.--- ,0: 蚨張尺度速用木國國家揉丰冶2ΪΟΧ297公* )妒由較妨:兔齡?:⑼ ifei 0 4661 1 7 A7 B7 五、發明説明(u ) 0 N A〜ini素管柱分離。 所得之结果建議PpRB^o僅與易於飽和, D Μ A位置结合。過去顧示其它原-腫廇基因 η - m y c,c - m y b,和c - f 〇 s是具.D N A结合活性 (Mol. Cell. Biol. (19δ6) 6:445〇-4457; U982) 296: 262- 266 )。該類原-腫廇基 .活化作用因基因表現失去調0或结構修飾而 產物是腫瘤生成所必須。 ppRB110之缺乏,·而非存在,似乎是致腫 部分或完全使RB基因失活。因此,ppRBii〇 方式抑制其它基因之腫瘤生成活性並不使惡 ppRB11。因而是$常重要之調酣性蛋白質, 防並抑制,因其不存在而引發惡性生長。因 要性在於調節其它基因。p p R B U 〇之缺乏或 的生成。RB蛋白質具數棰效用。首先ρρκβΛι。之存 有限數目之 如 c - m y c, 之核碟蛋白 Nature 因之腫瘤基因 發生,基因之 瘤的,由於其 之存在以某種 性细胞生長。 因其存在而預 此,p p R B之重 喪失媒介腫瘤 在或缺乏可作 和傾 瘤或 胞在 细存 胚之 膜瘤 ao* iH 0 0 視或 兒變 生病 新部 或眼 眙非 胚之 ’ 關 兒相 胎瘤 物胞 動-细 和胚 類膜 人網 噺視 判它 為其 請 先 聞 之 注 意 r i 袭 訂 踩· 經濟部中央橾準局貝工消资合作社印製 细 胚 膜 網 視。 療展 治發 並之 意瘤 注腫 期性 早發 Μ績 得防 斷預 診及 期Μ 早, 。瘤 IV -iE I.它 斷其 診和 之瘤 向胞 細產 胚性 膜防 網預 視作 性用 傳,圖 遺意 具亦 選法 篩方 以斷 用診 可該 別’ 特是 亦但 法 。 方族 斷家 診之 之史 示歷 揭瘤 胞 癌房 性乳 發:, 績瘤 測胞 預细 K母 用膠 可經 亦神 法, 方瘤 斷/肉 診维 該纖 者瘤 再肉 〇 骨 選 , 篩說 之來 後例 產舉 前 >4661 IT A7 B7 Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (42) p p * R 1 〇 The predicted amino acid sequence of the protein has several similarities to those found in other tumor genes. Therefore, p p R B 1 1 was detected by the fractionation effect of girl cells. Localization of sub-cells. Two methods must be used. To find out the distribution of ppRB110 in the nucleus, cytoplasm and membrane parts. Consistent with chemical properties, p p R B ^ ^. The sequence suggested a possible D N A binding interaction 'to identify 8 5 S; p p 〇 11. Appears in the nuclear part, the proportion is smaller, although P P R B 1 1. (Less than 丨 〇u is located in the membrane. No measurable presence in the cytoplasm. / To further prove that PP〇u〇 is mainly located in the nucleus, use a source of osteosarcoma cells known to have beneficial cell morphology for immunohistochemical staining. U 2 0 S. As an experimental group. Υ 2 0 S cells were anti-PR PR Β 11 0 I g G immunoprecipitation. As a control sister, [J 2 0 S cells were immunoprecipitated with UG immunized in childhood. Both sisters were K commercially purchased rhodamine conjugated sheep anti-rabbit IgG culture from Sigma. Immunofluorescence was observed in cells that reacted with anti-pρig igG, that is, in the nucleus (Figure 5). The cells of the control response of the immunized children did not show fluorescence (Figure 5Bii). The subcellular localization of ρρίΒ110 in the nuclear part suggests that the protein is in regulation + other genes. It has a very important regulatory function and has a DNA-binding activity. -Sex. Certain cell sources, especially those from tumors other than retinoblastoma, such as neuroblastoma LAN-1 cells, are radiolabeled with K 32P-phosphate. Cell lysates of such labeled cell mixtures are based on Mol. Cell. Biol. (1986) 6: 4450-44 57, single or double-stranded bovine thymus-4 5 ~ (Please read the precautions on the back before filling this tile) „--.---, 0: 尺度 Zhang scale quick-use wood country countries knead Fengye 2ΪΟΧ297 公 *) The jealousy is better: Rabbit age?: ⑼ ifei 0 4661 1 7 A7 B7 V. Description of the invention (u) 0 NA ~ ini element column separation. The obtained results suggest that PpRB ^ o only binds to the saturable, DM A position. In the past, other proto-tumor genes η-myc, c-myb, and c-f 〇s are With .DNA binding activity (Mol. Cell. Biol. (19δ6) 6: 4450-4457; U982) 296: 262- 266). This type of proto-tumor group. Activation due to gene expression loss of modulation or structural modification The product is necessary for tumorigenesis. The absence of ppRB110, but not its existence, appears to be a tumor that partially or completely inactivates the RB gene. Therefore, the inhibition of tumorigenic activity of other genes by ppRBii0 does not make ppRB11 evil. It is an important regulatory protein that prevents and inhibits, and causes malignant growth due to its absence. The essentiality lies in regulating other genes. Pp RBU 〇 Deficiency or production . Problem, the RB protein with several first ρρκβΛι utility of such a limited number of memory c -. M y c, the core protein dish Nature consequent tumor gene, a tumor gene, due to the presence of some cell growth. Predicted by its existence, the loss of pp RB mediator tumors in the absence or absence of membranous tumors that can act as tumours or cells in fine embryos ao * iH 0 0 Vision or children become sick new or non-embryonic ' Guan Erxiang fetal tumor cell movement-fine and germ membrane human network scrutiny judged it to be the first to listen to it ri strike order · Central Ministry of Economic Affairs, Central Bureau of quasi bureau shellfish consumer cooperatives printed fine embryo membrane network . Treatment and treatment of tumors and tumors associated with swelling of the tumors and early-onset Μ results can prevent pre-diagnosis and early Μ. Tumor IV -iE I. It diagnoses and diagnoses the tumor's embryonic membrane defense net to be used as a sexual pass. The picture of the figure can also be selected by the method of screening. law. The history of the Fang family's home diagnosis reveals the atrial papilloma of the tumor cell carcinoma: The pre-thinning of the tumor cell cytometer K master gel can be used by the method of the god, the Fang tumor is broken / meat diagnosis, the fibrous tumor and the flesh. Bone selection, after the sieve is said to be precedent >

-T '本紙張尺度適用中國國家揉準(CNS ) ( 210X 297公釐): .w,dB6l 17 A7B7 五、發明説明(u:) 癌等~,示論是否發生在過去曾罹患過視網膜胚细胞瘤之病 患0 2.重姐髏RB融合蛋白質之製備及其描述. 製蔺重姐體融合蛋白質用作免疫之抗原。保留之RB cDNA 之 5, 0.9kb,中 0.7 kb和 3, 1.8 kb區 et; a 1 . Molecular Γ ΐ π n t n g*___L· Laboratory Manual (1982) Cold Spring Harbor Laboratory, Co丨d Sping Harbor, N. Y.中所記載之標準 程序次選殖人可誘發·高度TRP E表現之載體中,pATH-3 (University of California San Diego)。 含有密碼序列之三個RB cDNA次片段,即5*-T 'This paper size applies to China National Standards (CNS) (210X 297 mm): .w, dB6l 17 A7B7 V. Description of the invention (u :) Cancer, etc., indicating whether it has occurred in the past with retinal embryo Patients with cell tumors 0 2. Preparation and description of the RB fusion protein. The BB fusion protein is used as an antigen for immunization. 5, 0.9 kb, 0.7 kb and 3, 1.8 kb regions of the retained RB cDNA et; a 1. Molecular Γ ΐ π ntng * ___ L · Laboratory Manual (1982) Cold Spring Harbor Laboratory, Co 丨 d Sping Harbor, NY Among the vectors described in the standard procedure for subpopulation selection to induce high TRP E expression, pATH-3 (University of California San Diego). Contains three RB cDNA subfragments of the codon sequence, ie 5 *

EcoRi-EcoRI),中 0.7 kb (RB-1 之 EcoRI-EcoRI)和 3’ 请 先 閲 讀 面 之 注 意 f 裝 订 經濟部中央標準局员工消費合作社印製 1.8 kb( Bgin-Bglll) PATH3-0 7 質體之 TRP ί19δ4) 49:132-141 所 PATH3-0 . 7 RB是依圖示 構内插人pATH-3質體之 酶位置圖可確 >認排列。 中,再於補..充Μ 20毫克 養基内生長。培養物在 Μ9中稀釋至1:1〇〇 。光 醇中10毫克/毫升吲(I朵 Ε敢動基因之表現。 粒化细菌細胞並在拉 分別架構内融人ΡΑΤΗ3載體。 Ε - R β基因產物使用J, Virol.· 記載之方法表規在大腸桿菌中" 7A所閫逑者構築。cDNA RB片段架 EcoRI核苷内切酶位。詳细之限制 重組體質體轉化至大腸桿菌mm294 /毫升色胺酸之M9最低營養要求培 加酪蛋白胺基酸和胺苄青酶素之 密度(K2之6 00 nm,.添加在100¾乙 丙烯酸之1:1000稀釋液Μ誘發TRP 母力(Laensmli)凝膠樣本緩衝液中 -47- 本紙張尺度逋用中困國家標準(CNS ) A4規格( 210X297公釐) 寐 經濟部中央標準扃員工消費合作社印製 4 6 61 t « A7 •_ B7 五、發明説明(45 ) 煮神4 5 ;鐘,再以聚丙烯醯胺凝膠電泳分析β以考馬斯藍 染色凝膠。製備出大量融合蛋白質,通過製備性聚丙烯醯 胺凝膠電泳予以纯化,以過液提耽物離析,:,s D s和可溶丙 胺Μ透析去除。蛋白質再濃縮並與佐肋劑混合以免疫 兔子。約回收6毫克蛋白質*再用Κ免疫兔子。 三個ΡΑΤΗ3構築體中僅一個,即ΡΑΤΗ3-0.? RB表規融合 蛋白質。所得之融合蛋白質分子量是57kD 。由於TRPE 之分子量已知為衍生自蛋白質之融合蛋白質之37 kD和 20 kD之蛋白質部分'。 其它二個質體構築體完全不產生蛋白質*即使TRP E本 身。由於RB選殖株含有許多假設蛋白酶分裂位置,在大腸 桿菌中無法產生蛋白質並不令人意外,並且可能是因為融 合蛋白質之不安定性。 ' 在誘發作甩後,大腸桿菌之表琨產生含有20¾全部大腸 桿菌蛋白質之57 kD融合蛋白質。pATH-0.7表現MW 57 kD之融合蛋白質,其中37 kD是衍生自TRP E , 20 kD是衍 生自RB。 在圖7A中可_見到TRP E-RB融合蛋白貧之產生,7B是 P AG E /凝膠電泳之结果。58 kD蛋白質出現在誘發之培養 物中(第2行),但對照之培養物中則未出現(第參行)。 使用上述融合PATH3和RB片斷之程序,可製備大量融合 蛋白質,根據Nature (1970) 227:680-685所記載之程序 K製備性S D S聚丙烯醯胺凝膠電泳予K鈍化。以過夜提取 物離析融合蛋白質;SDS和可溶丙烯醯胺以透析去除。再 -48- ft右;張尺变逍用中國國家揉準:(CNS ) A4M^:( 210 X 297公釐:)乂 ;--------Ί 逢-- ·. V (請先閱讀背面之注意事窝本頁) -5 經濟部中央標準局貝工消費合作社印裝 4661 1 7__b7 _ 五、發明説明(衫) .濃縮-蛋a質。 經纯化之融合蛋白質用作生產特定抗-R β蛋白質抗體之 抗原。 抗R Β -特定抗體 對抗RB蛋白質之持定兔子多選殖抗體依Proc. Natl . Acad. Sci . U 9 8 6 ) S 3 : 6 7 Q 0 - ¢3 7 9 4 所記載之程序製備。 如上所述,紐西蘭紅兔按標準實驗計副从所得之TR p E-RB融合蛋白質免疫0兔子Μ混合自完全佛瑞得佐助劑( Freund’s adjuvant)_乏卜2微克,較好是10微克之純化融 合蛋白質(最籾注射)’較好是每14天間隔重複注射兔子, 再追加注射在不完全佛瑞得佐助劑中等虽之融合蛋白質( 重複注射)。完全.佛瑞得佐助劑通常包括在鹽水和乳化劑 混合物中之抗原乳化物,在本荼例中是融合蛋白質,如同 舉例來說,Arlacel 在礦油和殺死之分枝菌中。不完全 佛瑞得佐助劑是一樣的’除了不含分枝菌。 二個月後,兔子均產生與TRP E和融合蛋白質反應之高 價抗體。.自兔子油血,收集血液至塑膠容器内並予以凝结 。丨y、iooo s離心ίο分鐘Μ獲得血清。兔子抗- ρρ〖βΐι。免疫 球蛋白(IgG >經由二個親和力管柱通過抗血清加以純化。 為增加僅識別R B.決定子之抗體,製備2個親合管柱,一個 装trp ε蛋白質,而另一個裝融合蛋白質。抗血清通過融 合蛋白質-壤脂糖管柱並Μ 0,1奠耳濃度甘胺酸HC1緵衝 液< pH 2· 3)離析。使用相同的緩衝液,離析液通過TRp E 管柱數次以除去導引對抗TRP E之抗體。重複離析數次。 -49- (請先閲讀背面之注$項再填寫本頁) --------------1 i--- οι- κ. V Η II an· m ί i ¾.. 4661 1 /__—---- 五、發明说明(47 ) A7 B7 經濟部中央標準局員工消費合作社印製 逐:欠為縴 澱 1 5 x 在後缠之 賁含有完 沉澱RB蛋 以抗-R B 參照h 賁驗計劃 均含有 體纖維a (ϋ 2 〇 s)綑 式掊養物 細胞源如 WERI-24 上述獲得 為了 Μ 蓋培養皿 約 1 . 5 X C i/毫升) 續操作在 甲烷-鹽 Non i det Ap r o t i η ΐAV 下, 透過上述步驟製備之抗體,該稀釋液足以免疫沉 103细胞中之RB蛋白質。該纯化之抗-RB抗體用 全部莨驗中供免疫沉澱或免疫染色.並在上所証 整RB mRNA之數種细胞源中,根據上述程序免疫 白質。 抗體免疫沉澱鑑定RB蛋白質 —Urol.. (1981) 38:1064-1076 中所記載之標準 正常RB raRKA之LAN-1神經細胞瘤细胞源,正常人 细胞*人體肝癌亞力山大细胞源和骨肉瘤 胞源用作陽性對照姐。所有該類细胞均得自美國 收集貯㉟所。具有預朗之截短或缺乏RB ibRNA之 視網膜’胚细胞瘤细胞源Y79, RB355, WERI-1, 和WER 1-27用作陰照性對照姐。該類细胞源均依 Ο 3BS -甲硫胺酸標記细胞之蛋白質,在60毫米之有 中,37 °C,以無甲硫胺酸之培養基培養30分鐘使 10s ^细胞虮餓|再在補充以35S -甲硫胺酸(150微 之_. 3毫升無甲硫胺酸培養基培養3小時。所有後 4T:下進行。在含有25毫莫耳濃度三羥甲基胺基 酸鹽(pH ?.4), 50毫莫耳濃度NaC!,0.2¾ P-40, 0.5¾脫氧膽酸和200單位/毫升之 η去活化劑之溶胞緩衝液中製備细胞提取物。在 Μ20,000 X g離心15分鐘使溶胞產物澄清。 -50- 你、&本紙張炫逋/9步困國家揉準(CNS ) A4規各(21〇)<297公簸) 請 先 閲 面 之 注 寫 本衣 頁 > ll. 訂_ 4 661 A7 B7 五、發明説明(48 ) f請先閑讀背面之注意事項再填寫本頁j 免-疫沅澱是以5微升之幼時免疫兔子抗血清進行’接蕃 吸收至得自Enzyme Center, Inc.之福禺林-固定之金黃 色葡萄球菌。各寊驗樣本之上清液中添加1 0微升1 0 0微克 /毫升之抗-ppRBtl0 IsG ,而各對照樣本之上清疲中添 加10微升之幼時免疫血清作為對照。再添加入蛋白質Λ璦 指糖珠體(S i s raa )。以下列試劑依序清洗免疫沉毅物1)溶 胞緩衝液,21在溶胞緩衝液中之[莫耳濃度之NaC1,3)在 溶胞緩衝液中之0 . 15冥耳濃度之Hac 1 ,和4)溶胞緩衝液Μ 除去非特定结合之蛋·白質。該免疫沉澱之蛋白質以7. 5¾ SDS-聚丙烯醯胺凝膠電泳和放射自顯術分析。K乙酸-鹽基之2.5-二苯甚草酸飽和後,在-70¾下進行槱記 之蛋白質凝膠之蟹.光譜測定。 結果閱明於圖110-114 kD之蛋白質發現能以抗 -P P R Β 11 ° I g G免疫沉澱。 基因產物之描述 為進一步描述纯化自细胞提耽物之蛋白質,细胞以 32P-璘酸或14C或3H-糖胺標記,之後再以糖脊内切酶消化 〇 - 經濟部中夬標準局員工消費合作社印製 為測試蛋白質磷酸化作用* U N - 1细胞以3 2 P -璘酸新陳 代謝標記。 為了 Μ 32P標記LAN-1细胞,在60毫米之有蓋培養皿中 ,3 7 °C,以無磷酸鹽之培養基培養8 0分鐘使約1. 5 X 1 0 6 细胞飢餓,再莅補充以3Ρ〇43-(1毫Ci/毫升.)培養基之2 鸯升無磷酸鹽焙養基培養1至2小時。在含有2 5毫莫耳濃 :^轉:::本紙張尺度壤用涞國國家揉準飞CNS ) ( 210 X297公翁K' 4 6 61 1 7 A7 B7 經濟部中央標準局貝工消費合作社印製 五、發明説明(49 ) .度三Jg申基胺基甲烷-鹽酸鹽(P丨! 7.4 ) . 5 0毫莫耳濃度 , hC 1,0. 2¾ Mon ideb P-4 0, 0.5¾ 脫氧膽酸和得自 Ca ! b i〇chera 200單位/毫升激呔釋放酶去活化劑之溶胞緩:; 衝液中製備细胞提取.物。在4 t:下’以2 0,0 0 0 x s離心 20分鐘使溶胞產物澄清。 免疫沉澱是Μ抗ppRB11。IgG.根撺標準程序進行。免疫 沉·殺物吸收至得自Enzyme Center,Inc.之福馬林-固定 之金黃色葡萄球菌,並Μ下列試劑依序清洗丨)溶胞緩衝液 * 2) 1莫耳濃度之Na.Cl,10奄莫耳濃度三羥甲基胺基甲院 -鹽酸鹽(p 丨1 7 . 4 > 和 0 . 15: Ν ο n i d e t P - 40 ; 3 ) 0 . 1 5 舆耳 濃度之HaCl, 10毫箕耳濃度三羥甲基胺基甲烷-鹽酸鹽 (P 丨丨 7 · 4 ) , 0 . 1 Ν ο η i d e t P - 4 0 ;和 4 )溶胞緩衝液。 桉照J . V丨rn 1. . ( 19δ0) 36 : 6 1 7 -62 1所記截之程序製備 免疫沉澱之蛋白質供電泳。免疫沉·殺蛋白質跑出單帶,其 分子量與3SS -標記之ppRB11。蛋白質之分子最相同•顯示 RB蛋白質是一磷蛋白。 全長RB蛋白質之次细胞定位 人體神經母B胞瘤细胞L A N - 1依上述以3 2 S -甲硫胺酸標 記,再分级分離至细胞膜,細胞質和核中。標記之蛋白質 -之後再以抗- RB UG免疫沉澱。 細胞分级分離之實驗計劃基本上是^ J . Cell·. Βίοι. ^ (1983) 97: 1601-1611所記載者。使用前,2至5個100 _ ' 毫米培養盤總共含有2.0 X 107至7.5 X 107之细胞 Κ 3 sS -甲硫胺酸新陳代謝標記2 - 3小時。全部後續程序在 _ 5 2 · 接張尺度逋席t闺勇事標準哪)八4規格$ 210呀297公釐恥 4661 1 7 Α7 Β7 經濟部中央梯準局貝工消費合作社印製 五、發明説明(50 ) 4 t:-下i行。细胞Μ磷酸鹽緩衝之食鹽水(PBS ) i.中清二次 ,刮至PBS ,在桌上型離心機中Μ 375 X g粒子化5分鐘 。半數細胞再懸浮於溶胞鍰衝液中作為完全細胞溶胞產% 。刺餘的细胞在低張.之R S B緩衝液中(1 〇毫冥耳濃度 HEPES pH 6.2,10毫莫耳蹲度NaCl,1.5毫萁耳濃度 MsC“,200單位/毫升Aprotinin)冲洗一次,再懸浮於 RSB中。懋浮液在密合之Dounce匀漿機中播拌20次使之均 勻,KRSB緩衝液調整容量至正好3毫升。在轉動375 X g之Sorvall HB4轉·勤器上K 1 /50 0每分鐘週轉離心匀漿 ,细胞粒再懸浮於溶胞緩衝液中Μ產生核的部分。上清液 在Beckman SW50.1轉動器上,厚壁聚異質用形物polya-llomer試管内M3$,000每分鐘週轉(150,000 X s)離心 90分鐘。细胞粒‘再懸浮於溶胞媛衝液中以產生膜的部分, 而上清液調整至1 X溶胞媛衝液濃度以產生细胞質部分。 所有4個部分依上所閜述測試R B蛋白質内含物。 免疫沉澱钧以7 . 5 »: S D S聚丙烯醯胺凝膠電泳和放射自顯 術分析。结果歸納並閫釋於画5A。 亦可使用下* 列之分级分離方法q所有程序在〇至4 t下進 行。2至5傾100毫米培養盤總共含有2,0 X 1〇7至7,5 x 1 0 7之L A N - 1细胞Μ磷酸-媛衝之食鹽水(p B s )冲清二次 ,刮至P B S ,在臨床離心機中以1,〇 〇 〇 x s粒子化i分鐘 。细胞粒以低張之TKM緩衝液(20毫舆耳濃度三經甲基胺 基甲烷pH ?. 1 , 5毫莫耳濃度KC 1,1毫莫耳濃度MsCl2,' 1¾ Aprotinin)沖清一次後,细胞在ΤίίΗ中分散並瞳大15 (請先聞讀背面之注意事項苒填寫本頁)EcoRi-EcoRI), 0.7 kb (EcoRI-EcoRI of RB-1) and 3 'Please read the note above f Book binding 1.8 kb (Bgin-Bglll) printed by the Central Consumers Bureau of the Ministry of Economic Affairs (Bgin-Bglll) PATH3-0 7 The TRP of the plastid 19δ4) 49: 132-141 The PATH3-0. 7 RB is the position map of the pATH-3 plastid which can be inserted and confirmed according to the figure. Medium, and then supplemented with 20 mg of MG growth. The culture was diluted to 1: 100 in M9. The expression of 10 mg / ml indole (I) gene in photoalcohol. Granulated bacterial cells and fused human PATΗ3 vector in a separate framework. The E-R β gene product uses the method described in J, Virol. · Constructed in E. coli " 7A. CDNA RB fragment frame EcoRI endonuclease site. Detailed restrictions on the transformation of recombinant somasomes into E. coli mm294 / ml tryptophan M9 minimum nutritional requirements plus casein Density of protein amino acid and ampicillin (600 nm of K2, added to the 1: 1000 dilution of 100 ¾ acetic acid M induced TRP Laensmli gel sample buffer -47- Standards: National Standards for Difficulties (CNS) A4 (210X297 mm) 中央 Central Standards of the Ministry of Economic Affairs 印 Printed by employee consumer cooperatives 4 6 61 t «A7 • _ B7 V. Description of the invention (45) Boil God 4 5; Bell Then, the β-gel was stained with Coomassie blue by polyacrylamide gel electrophoresis analysis. A large number of fusion proteins were prepared, purified by preparative polyacrylamide gel electrophoresis, and separated by liquid extraction. s D s and soluble propylamine M were removed by dialysis. Protein was concentrated again It is mixed with a rib adjuvant to immunize rabbits. Approximately 6 mg of protein * is recovered and then rabbits are immunized with K. Only one of the three PATΗ3 constructs, namely PATΗ3-0.? RB gauge fusion protein. The molecular weight of the resulting fusion protein is 57kD Since the molecular weight of TRPE is known to be the 37 kD and 20 kD protein portion of the protein-derived fusion protein. The other two plastid constructs do not produce protein at all * even TRP E itself. Since the RB clone contains many assumptions The proteolytic cleavage position, the inability to produce proteins in E. coli is not surprising, and may be due to the instability of the fusion protein. 'After induction, the surface of E. coli produces a 57 kD fusion containing 20¾ of all E. coli proteins. Protein. PATH-0.7 represents a fusion protein of MW 57 kD, of which 37 kD is derived from TRP E and 20 kD is derived from RB. In Figure 7A can be seen the production of TRP E-RB fusion protein deficiency, 7B is P Results of AG E / gel electrophoresis. 58 kD protein appeared in the induced culture (line 2), but not in the control culture (line 2). Using the above procedure for fusing PATH3 and RB fragments, a large number of fusion proteins can be prepared and passivated by preparative SDS polyacrylamide gel electrophoresis to K in accordance with the procedure described in Nature (1970) 227: 680-685. The extracts were isolated overnight. Fusion protein; SDS and soluble acrylamide are removed by dialysis. Then -48- ft right; Zhang Chi Bianxiao uses Chinese national standards: (CNS) A4M ^: (210 X 297 mm :) 乂; ----- ----- Ί Feng-·. V (please read the notice on the back page first) -5 Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 4661 1 7__b7 _ V. Description of the invention (shirt) -Egg a quality. The purified fusion protein is used as an antigen for the production of a specific anti-R β protein antibody. Anti-RB-specific antibody The fixed rabbit polyclonal antibody against the RB protein was prepared according to the procedure described in Proc. Natl. Acad. Sci. U 9 8 6) S 3: 6 7 Q 0-¢ 3 7 9 4. As described above, New Zealand red rabbits were immunized with the obtained TR p E-RB fusion protein according to standard experiments. 0 Rabbit M was mixed with complete Freund's adjuvant_ 2 μg, preferably 10 Micrograms of purified fusion protein (most injections) is preferably repeated injections of rabbits at 14-day intervals, followed by additional injections of the fusion protein in incomplete Fredezo auxiliary (repeated injections). Completely. The Fredezo auxiliaries usually include antigen emulsions in a mixture of saline and emulsifiers, in this case fusion proteins, as, for example, Arlacel in mineral oil and killed mycobacteria. Incomplete Fredezol is the same ’except that it does not contain mycobacteria. Two months later, rabbits produced high-value antibodies that reacted with TRP E and fusion proteins. Collect oil from rabbits, collect blood into plastic containers and coagulate. Y, iooo s centrifugation ο min minutes to obtain serum. Rabbit anti-ρρ 〖βΐι. Immunoglobulin (IgG >) was purified by antiserum via two affinity columns. To increase antibodies that recognize only the R B. determinant, two affinity columns were prepared, one containing the trp ε protein and the other containing the fusion Protein. The antiserum was isolated through a fusion protein-polysaccharose column and M 0,1 Mole concentration glycine HC1 緵 wash solution (pH 2 · 3). Using the same buffer, the eluate was passed through the TRp E column several times to remove antibodies directed against TRP E. Repeat the segregation several times. -49- (Please read the note on the back before filling this page) -------------- 1 i --- οι- κ. V Η II an · m ί i ¾. 4661 1 / __—---- V. Description of the invention (47) A7 B7 Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs: owing to the fibrous lake 1 5 x after the entanglement contains precipitated RB eggs to resist -RB reference h test plan contains somatic fiber a (ϋ 2 〇s) bundled nutrient cell source such as WERI-24 obtained above for M lid culture dish approximately 1.5 XC i / ml) continued operation in methane- The antibody prepared by the above steps under the salt Non i det Aproti η ΐ AV is sufficient to immunize the RB protein in 103 cells. The purified anti-RB antibody was used for immunoprecipitation or immunostaining in all assays, and white matter was immunized according to the procedure described above among several cell sources of RB mRNA as demonstrated above. Identification of RB protein by antibody immunoprecipitation—Urol .. (1981) 38: 1064-1076 standard LAN-1 neuroblastoma cell source of normal normal RB raRKA, normal human cells * human liver cancer Alexandria cell source and osteosarcoma The cell source was used as a positive control sister. All such cells were obtained from a US collection depot. Retina ' blastoma cell sources Y79, RB355, WERI-1, and WER 1-27 with pre-stretched truncated or lacking RB ibRNA were used as shade control controls. This type of cell source is based on the protein of 0 3BS-methionine-labeled cells. It is cultured in a medium without methionine for 30 minutes at a temperature of 60 mm, at 37 ° C, and the cells are starved for 10 seconds. Incubate with 35S-methionine (150 micron _. 3 ml of methionine-free medium for 3 hours. All after 4T: at a concentration of 25 millimolar trimethylolamine (pH? .4), cell extracts were prepared in a lysis buffer of 50 mmol NaC !, 0.2¾ P-40, 0.5¾ deoxycholic acid and 200 units / ml of η deactivator. At 20,000 M g Centrifuge for 15 minutes to clarify the lysate. -50- You & this paper dazzle / 9 steps sleepy country (CNS) A4 regulations (21〇) < 297 public dust) Please read the note above first Cover page> ll. Order _ 4 661 A7 B7 V. Description of the invention (48) f Please read the precautions on the back before filling out this page. J Free-Epidemic disease is performed by immunizing rabbit antiserum with 5 microliters at an early age. 'Jiefan was absorbed into Folin Forest-Fixed Staphylococcus aureus from Enzyme Center, Inc. 10 μl of 100 μg / ml of anti-ppRBtl0 IsG was added to the supernatant of each test sample, and 10 μl of juvenile immune serum was added to the supernatant of each control sample as a control. Then added to the protein Λ 添加 refers to sugar beads (Sisraa). The immune reagents were sequentially cleaned with the following reagents: 1) lysing buffer, 21 [Mole concentration of NaC1, 3) in lysing buffer, 0.115 Hac 1 in lysing buffer, And 4) Lysing buffer M removes non-specifically bound egg white matter. The immunoprecipitated protein was analyzed by 7. 5¾ SDS-polyacrylamide gel electrophoresis and autoradiography. K-acetic acid-salt-based 2.5-diphenyoxalic acid was saturated, and the protein gel of Crab. Spectrum was measured at -70¾. The results are shown in Figure 110-114 kD. The protein was found to be immunoprecipitated with anti-P P RB 11 ° I g G. The description of the gene product is to further describe the protein purified from cell extracts. Cells are labeled with 32P-gallic acid or 14C or 3H-glycosamine, and then digested with endoglycosidase. Cooperatives are printed to test for protein phosphorylation * UN-1 cells are labeled with 3 2 P-gallic acid metabolism. For M 32P-labeled LAN-1 cells, in a 60 mm covered petri dish, 37 ° C, culture in phosphate-free medium for 80 minutes to starve about 1.5 X 106 cells, and then supplemented with 3P 〇43- (1 milliCi / ml.) Of 2 liters of phosphate-free culture medium for 1 to 2 hours. Contains 2 5 millimoles: ^ turn ::: This paper scale soil is used by the Laos country to fly to the CNS) (210 X297 male K '4 6 61 1 7 A7 B7 Shellfish Consumer Cooperative, Central Bureau of Standards, Ministry of Economic Affairs Printed V. Description of the invention (49). Degree of Jg-synylaminomethane-hydrochloride (P 丨! 7.4). 50 millimolar concentration, hC 1, 0. 2¾ Mon ideb P-4 0, 0.5 ¾ Deoxycholic acid and lysate from Ca! Biochera 200 units / ml kallikrein deactivator: Prepare cell extracts in the wash solution. At 4 t: under 2 0, 0 0 0 Centrifuge at xs for 20 minutes to clarify the lysate. Immunoprecipitation was performed with M anti-ppRB11. IgG. Radical standard procedures were performed. Immunoprecipitation and killing were absorbed into formalin-fixed Staphylococcus aureus from Enzyme Center, Inc. The following reagents were sequentially washed 丨) lysis buffer * 2) 1 Molar concentration of Na.Cl, 10 Molar concentration of trimethylolamine methylamine-hydrochloride (p 丨 17. 4 > And 0.15: Ν ο nidet P-40; 3) 0.15 HaCl, 10 millitorles concentration trimethylolaminomethane-hydrochloride (P 丨 丨 7 · 4), 0. 1 Ν ο η idet P- 40; and 4) lysis buffer. Eucalyptus J. V 丨 rn 1.. (19δ0) 36: 6 1 7 -62 1 Prepare the immunoprecipitated protein for electrophoresis. Immunoprecipitation / killing protein ran out of a single band, its molecular weight was 3SS-labeled ppRB11. The molecules of the protein are the most identical. • Shows that the RB protein is a phosphoprotein. Secondary cell localization of full-length RB protein Human neuroblast B cell tumor cells L A N-1 were labeled with 3 2 S-methionine as described above, and then fractionated into cell membrane, cytoplasm, and nucleus. Labeled protein-and then immunoprecipitated with anti-RB UG. The experimental plan for cell fractionation is basically the one described in ^ J. Cell ·. Βίοι. ^ (1983) 97: 1601-1611. Prior to use, 2 to 5 100 mm 'culture plates contain a total of 2.0 X 107 to 7.5 X 107 cells κ 3 sS-methionine metabolism markers for 2-3 hours. All the follow-up procedures are on _ 5 2 · The standard of the next step, the standard of the courageous business) 8 4 specifications $ 210, 297 mm, shame 4661 1 7 Α7 Β7 Printed by the Shell Consumer Cooperative of the Central Government Bureau of the Ministry of Economic Affairs Explanation (50) 4 t:-the next i line. The cells were buffered with phosphate buffered saline (PBS) i. The supernatant was twice, scraped to PBS, and pelleted in a table centrifuge at 375 × g for 5 minutes. Half of the cells were resuspended in the lysate solution as complete cell lysis production%. The remaining cells were washed in hypotonic RSB buffer (10 millimoles concentration HEPES pH 6.2, 10 millimoles NaCl, 1.5 millimoles concentration MsC ", 200 units / ml Aprotinin), and then washed again Suspension in RSB. 懋 Float in a tight Dounce homogenizer and mix 20 times to make it uniform. Adjust the volume of KRSB buffer to exactly 3 ml. On a Sorvall HB4 rotor that rotates 375 X g, K 1 The homogenate was centrifuged at 50 ° C per minute, and the cell pellet was resuspended in the lysing buffer to produce the nucleus. The supernatant was placed on a Beckman SW50.1 rotor and the thick-walled polya-llomer test tube was placed in a test tube. M3 $, 000 was rotated (150,000 X s) per minute and centrifuged for 90 minutes. Cell pellets were resuspended in the lysate solution to produce a portion of the membrane, and the supernatant was adjusted to a concentration of 1 X lysate solution to generate the cytoplasm. Section. All 4 sections tested the RB protein inclusions as described above. Immunoprecipitation with 7.5 »: SDS polyacrylamide gel electrophoresis and autoradiography analysis. The results are summarized and explained in Figure 5A The following classification methods can also be used q All procedures are performed at 0 to 4 t 2 to 5 tilted 100 mm culture plates containing a total of 2,0 X 107 to 7,5 x 107, LAN-1 cells, M phosphate-Yuanchong saline solution (p B s), rinsed twice, scraped to PBS The particles were pelleted for 1 minute at 1,000 × s in a clinical centrifuge. Cells were pelleted in low-tension TKM buffer (20 mmol / mL trimethylaminomethane pH?. 1,5 mmol) KC 1,1 millimolar concentration MsCl2, '1¾ Aprotinin) After washing once, the cells are dispersed in ΤίίΗ and pupil size is 15 (please read the precautions on the back first and fill in this page)

C 袭—-----ir-----V 嫌-------- I. 0Τ 民.辟j·^·承尺度連與书國爾家揉準"(:’C細>):Α4^ΐ^..:拉1 (ί >< 297公慶 A7 B7 4661 1 7 五、發明説明(51 ) 分鐘-。ά胞懸浮液在密合之勻漿機中攪拌2 0次使之均勻, (請先閲讀背面之注意事f填寫本頁) >裝· 以ΤΚΜ緩衝液調整容量至正好3毫升,取出樣本以免疫沉 源分析。 Μ低速離心產生核粒,得自該初始雛心之上清液進行高 速離心Μ產生沉澱物和可溶部分。為搜得核粒,匀漿在 s〇rvaU ΗΒ4 轉動器上(375 X s) Ot 下,MU 500 每分 鐘週轉離心10分鐘,粗核粒懸浮於1毫升之中。該核 粒在Dounce勻漿器中均勻化5次.透過裝有25 gauge針的 管子吸液3次。懋浮·液依上述粒子化,懸浮於Tkh緩衡液 並透過同一管子再吸液5次。最终離心後,核粒懸浮於 ΤΚΜ緩衝液中並分析“蛋白質之内容物和次细胞標記。原 後核上清液(p N S丨..和得自核粒洗液之上清液合併,在 “ckroan SW50.1轉動器上,厚壁聚異質用形物試管中Μ 3δ,〇〇〇每分鐘週轉(150,000 χ以,o'下離心90分鐘以產 生顆粒(Pls〇)和可溶(S15〇)部分。各部分再Μ ΤΚΜ緩衝液 調整至相等容量並直接測試ϋΒ蛋白質和次细胞標記。 經濟部中央標準局貝工消費合作社印製 血漿膜内容物是Μ測量5 1核苷酸酶鑑定。樣本溶於ΤΚΜ 緩衝液,培養策含有10毫莫耳瀨度MsCU,0. 1毫莫耳濃度 AMP, 1〇〇毫莫耳濃度甘胺酸(pH 9.0)之測試混合物中,上 清液中2微C i 3H-腺苷之測試混合物中以液體閃計數 (I b i d )測定。各邰分之可溶蛋白質是根據Proc. Natl. Acad. Sc i . (1962) 48 :2123-2130測試乳酸脫氫酶之活性' 予Μ鑑定*肉質網内容物是.根據Biochem. Biophys.C attack ------- ir ----- V susceptible -------- I. 0Τ 民. Jj · ^ · Cheng Weilian and Shu Guoer family rubbing accurate " (: 'C Fine >): Α4 ^ ΐ ^ ..: 拉 1 (ί > < 297 Gongqing A7 B7 4661 1 7 V. Description of the invention (51) minutes-. Cell suspension in a homogenizer Stir 20 times to make it uniform, (please read the precautions on the back to fill in this page) > Loading · Adjust the volume to TK buffer to exactly 3 ml, and take out the sample for immunoprecipitation analysis. Μ Low-speed centrifugation produces nuclear particles The supernatant obtained from the initial embryonic heart was subjected to high-speed centrifugation to produce a precipitate and a soluble fraction. In order to obtain nuclear particles, the homogenate was homogenized on a sorvaU ΗΒ4 rotor (375 X s) Ot, MU 500 Centrifuge for 10 minutes, and suspend the coarse nucleus particles in 1 ml. The nucleus particles are homogenized 5 times in a Dounce homogenizer. Aspirate the liquid 3 times through a tube equipped with a 25 gauge needle. And suspended in Tkh buffer solution and aspirated 5 times through the same tube. After the final centrifugation, the nucleosomes were suspended in TKM buffer and analyzed for "protein content and secondary cell markers. The original nuclear supernatant (p NS 丨 .. and The supernatants of the nuclear washings were combined, and were turned on a "ckroan SW50.1 spinner" in a thick-walled polyheterogeneous test tube at a rotation rate of 3,000,000 per minute (150,000 x, centrifugation at 90 ° for 90 minutes to Particles (Pls〇) and soluble (S15〇) fractions were generated. Each fraction was adjusted to equal capacity with TKK buffer and tested for ϋΒ protein and secondary cell markers directly. Printed by the Central Standards Bureau of the Ministry of Economic Affairs The substance was identified by M measuring 51 nucleotides. The sample was dissolved in TKM buffer, and the culture strategy contained 10 millimoles MsCU, 0.1 millimoles concentration AMP, 100 millimoles concentration glycine ( In the test mixture of pH 9.0), 2 microliters of C i 3H-adenosine in the test mixture was measured by liquid flash count (I bid). The soluble protein of each fraction was according to Proc. Natl. Acad. Sc i. (1962) 48: 2123-2130 Tested for lactate dehydrogenase activity. 'Identified * The content of the succulent web is. According to Biochem. Biophys.

Acta. U971 ) 233-334-347所記載之程序測試NADH心肌黃 -5 4 - 拉:输本紙蘇尺度適甩中國國家揉準,{CNS,A4说格:(¥2 to /297公釐.:)辟::_織輪 4661 1 7 A7 B7 經濟部中央標準局貝工消費合作社印製 五、發明説明(52 ) ..酶予-Μ ϋ丨定。 结果閫釋於圖5 Β。使用生化分級分離和免疫螢光法(如 前一賁例所述),鑑定出R Β蛋白質主要位於細胞核内。 (螢光主要是出琨在核内*幼時免疫對照姐是陰性)。 大多數(約8 5 :«) 3 5 S -標記之蛋白質位於核的部分而小部 分(少於1 0¾ >是與膜相連。在佃胞質部分無可測得之R B蛋 白質,或分泌至培養基中。 兔疫螢光所測R B蛋白質之次亞细胞定位 得自美國式培策物‘收集貯藏所之人體骨肉瘤细胞源 U20S用作免疫螢光染色使用。約之U20S细胞種至12毫 米玻璃蓋片上* 18小時後用作免疫螢先染色用。细胞从 P B S緩衝液清洗一次再於室溫下以冷丙酮固定1 0分鐘。經 固定並通透化之细胞在PBS中水合1至2分鐘。在室溫下 ,潮濕之槽室内,Μ 200微升兔子抗-RB IgG (1 : 20稀釋 >或幼時免疫血清培養各蓋片45分鐘。在PBS中清洗三次 後,蓋Η在室溫下,Μ得自S igma 200微升之紅胺-共扼 化羊抗-兔子ISG (25微克/毫升)培養45分鐘。蓋片在 PBS中再充分'清洙並以蔡司光顯微鏡I觀察。 或者,L〗N-1神經母细胞瘤之免疫螢光染色.可依下述進 行。約104之細胞種至12毫米玻璃蓋Η上,18小時後用作 免疫螢光染色用。细胞以由〇.〇6莫耳濃度Pipes, 0.025 莫耳濃度HEPES, 0.01莫耳濃度EGTA,0.002莫耳濃度 MsC U,pH 6 . 9姐成之PHEM緩衝液清洗一次,再於室溫下 於PHEM緩衝液中以2¾聚甲醛固定20分鐘。經固定並通透化 π裝-- (請先閲讀背面之注意事寫本頁) ,ίτActa. U971) 233-334-347 described in the procedure to test NADH myocardial yellow-5 4-pull: the paper size is suitable for the Chinese national standard, (CNS, A4 grid: (¥ 2 to / 297 mm. :) Pi :: _ Weaving round 4661 1 7 A7 B7 Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (52) .. The results are illustrated in Figure 5B. Using biochemical fractionation and immunofluorescence (as described in the previous example), the RB protein was identified primarily in the nucleus. (Fluorescence is mainly released in the nucleus * when the immune control sister is negative in childhood). Most (approximately 8 5: «) 3 5 S-labeled proteins are located in the nucleus and a small part (less than 10 2 > is connected to the membrane. There is no measurable RB protein in the cytoplasmic part, or secretion The secondary subcellular localization of the RB protein detected by the rabbit epidemic fluorescent light was obtained from the U.S. human osteosarcoma cell source U20S of the American-style culture collection collection store for immunofluorescence staining. Approximately U20S cells were seeded to 12 On a glass cover slip * after 18 hours for immunofluorescence staining. Cells were washed once from PBS buffer and fixed at room temperature with cold acetone for 10 minutes. The fixed and permeabilized cells were hydrated in PBS for 1 to 2 minutes. At room temperature, in a humid chamber, 200 μl of rabbit anti-RB IgG (1:20 dilution) or childhood immune serum were cultured for 45 minutes. After washing three times in PBS, cover 200 μl of erythramine-conjugated goat anti-rabbit ISG (25 μg / ml) from Sigma was incubated at room temperature for 45 minutes. Coverslips were then 'cleared' in PBS and cleared with a Zeiss light microscope I Observation. Alternatively, the immunofluorescence staining of L〗 N-1 neuroblastoma can be performed as follows OK. Cells of about 104 were seeded on 12 mm glass lids and used for immunofluorescence staining after 18 hours. Cells were made from 0.06 Molar concentration Pipes, 0.025 Molar concentration HEPES, 0.01 Molar concentration EGTA, 0.002 Molar concentration MsC U, pH 6.9. Clean the PHEM buffer once, then fix it in PHEM buffer with 2¾ polyformaldehyde for 20 minutes at room temperature. After fixing and permeabilizing pi --- (please (Read the notes on the back first and write this page), ίτ

線-----:II.—— Μ、 _ __务螞尹度逋用本®,家梯準.( CNS ),A顿洛似10X297公釐扣 ι'.ίί"'/Line -----: II .—— Μ, _ __ Wu Mao Yin Duan uses this ®, home ladder. (CNS), A Dun Luo like 10X297 mm deduction ι'.ίί " '/

MT s B Mnus^r ^ AUZM V Λ N w ο X —uloo— 3 ϋ 迪 *V>T ^ i @ w ® I 1 d- B s ^ 8 I 0 ,® s I @ 3 8 ® ® I —1 ;— 。itb * 规 s M 瓜 s d IE I 3 磁 uloa: 3 M 3 ^ s Ϊ 冰®姻® F\ C s rQw苗 3 ci>o ΙΜτφατ 1.1 Almy woΐ 8 B、s 3 w φ n e .) M< hMT s B Mnus ^ r ^ AUZM V Λ N w ο X —uloo— 3 ϋD * V > T ^ i @ w ® I 1 d- B s ^ 8 I 0, ® s I @ 3 8 ® ® I — 1 ;- . itb * gauge s M melon s d IE I 3 magnetic uloa: 3 M 3 ^ s Ϊ 冰 ® 姻 ® F \ C s rQw seedling 3 ci > o ΙΜτφατ 1.1 Almy woΐ 8 B, s 3 w φ n e.) M < h

IF rt h,IF rt h,

LbLb

D p Is ff ! ^ s ffl 1 w h,1 w wi s o ——ft- 3 $ B ^ o ^ > MaITIr^Ir c z ^ H 1 ^ < i 90OTW1 hl· ft s s s σζ> att ® 1 Ϊ w J3S i 删瓜 8 涝 s ΐ w ί Φ ® C e 二 《mqcooo) 5 私” 2T5 — 2003; S o i φ ? n e il9SQ) 24:3:03^丨to37iIzplld·· -J Ί D (10O5OOJ 33 私—124,l12QW。 1 1 s ,¾ i I ® f w 1- s s s ^ ^ i , _wa.3IWWRBI®w3^fb 皿 HSIB 謝诞渺蓠 WRB1h ® w 部口 is!n § Ln k^ w Η π ^v m- I π w s ^ e I ^ s s MK Η ΐ o 細瓜 eHfiTe 鈔 p 1 19s :。 s s s ^ ^ nell Gr-owrth artIQ. COGO>1”4:2G 丨仁 3slm^£i#^撕 iw i ^ Au-tosr-alph cal I Foi-nies Bu c o ^ ΰ Ί polyheal-osis vi「us 1 ΐ > 弈沖_许谢_ 1:6 s i ®s s i ® i wn ^ » 3 s -Π s 猶茺 ΪΙ«.ΙΙΙ Act-osraOh Ωθι i^ol-n i〇£t^>oz«v<^ft i w· ί β t N ® _ 3 8 1¾ I ibniftilss kh' A7 B7D p Is ff! ^ S ffl 1 wh, 1 w wi so ——ft- 3 $ B ^ o ^ > MaITIr ^ Ir cz ^ H 1 ^ < i 90OTW1 hl · ft sss σζ > att ® 1 Ϊ w J3S i delete melon 8 waterlog s ΐ w ί Φ ® C e two "mqcooo) 5 private" 2T5 — 2003; S oi φ? Ne il9SQ) 24: 3: 03 ^ to37iIzplld ·· -J Ί D (10O5OOJ 33 private —124, l12QW. 1 1 s, ¾ i I ® fw 1- sss ^ ^ i, _wa.3IWWRBI® w3 ^ fb HSIB Thanksgiving WRB1h ® w 口 口 is! N § Ln k ^ w Η π ^ ^ v m- I π ws ^ e I ^ ss MK Η ΐ o Fine melon eHfiTe banknote p 1 19s:. sss ^ ^ nell Gr-owrth artIQ. COGO > 1 ”4: 2G 丨 3slm ^ £ i # ^ Tear iw i ^ Au-tosr-alph cal I Foi-nies Bu co ^ ΰ Ί polyheal-osis vi 「us 1 ΐ > 冲 冲 _ 许 谢 _ 1: 6 si ®ssi ® i wn ^» 3 s -Π s茺 ΪΙ «.ΙΙΙ Act-osraOh Ωθι i ^ ol-n i〇 £ t ^ > oz« v < ^ ft iw · Ι β t N ® _ 3 8 1¾ I ibniftilss kh 'A7 B7

經濟部中央標準局貝Η消費合作社印製 4 6 61 17 at •__ Β7 五、發明説明(56) ..逢並名#適當的後-轉錄修飾,如同在原較高等真核生物 中之蛋白質。 為測試由桿狀病毒系统表現功能性r B蛋白質之可行性, 含有R B基因完全密碼.序列之選殖的人體r b c D K A納入 AcNPV表現載體,重姐體病毒在昆蟲细胞内繁殖。達成由 宿主-載體系統大量的,成功的表琨人體P 11 〇 « β。所產生 之蛋白質經磷SS化並正確的檁的於受感染妞胞之细胞核。 此外,並發展出纯化R Β蛋白質之方法。頃發琨經纯化之蛋 白質能Μ原來的人體'pp110rr相同方式結合DNA並與 SV40 ΐ抗原形成特定的複合物。微注射後蛋白質之迅速核 移位作用,進一步建議經純化之RB蛋白質的活性。 為了達成R Β蛋白/質在桿吠病毒表琨糸統中之最大生產量 ,刪除RB基因之’大部分5 ’非密碼序列以構築重姐體轉移載 體。透過位置-特定突變生成作用,二個Ba in Η I位置納入 RB cDNA之核苷酸116和2935 ,以加速重姐體轉移載體之Printed by the Central Bureau of Standards of the Ministry of Economic Affairs, Beiya Consumer Cooperative 4 6 61 17 at • _ Β7 V. Description of the Invention (56) .. Feng Bing name # Appropriate post-transcriptional modification, as in proteins in higher eukaryotes. In order to test the feasibility of expressing a functional r B protein by the baculovirus system, a human r b c D K A containing the complete sequence of the R B gene was included in the AcNPV expression vector, and the re-elder virus was propagated in insect cells. Achieved by the host-vector system a large number of successful epitopes of human P 11 〇 β. The resulting protein is phosphorylated by SS and properly gnawed to the nucleus of an infected female cell. In addition, methods for purifying RB proteins have been developed. The purified protein can bind DNA in the same way as the original human 'pp110rr' and form a specific complex with SV40 antigen. The rapid nuclear translocation of proteins after microinjection further suggests the activity of purified RB proteins. In order to achieve the maximum production of RB protein / plasma in the baculovirus epitope, the 'most 5' non-codon sequence of the RB gene was deleted to construct a heavy body transfer vector. Through position-specific mutation generation, two Ba in Η I positions incorporate nucleotides 116 and 2935 of the RB cDNA to accelerate

構築。產生之載體,編碼一個mRHA,該mRHA含有融合至 RB cDNA之5’未轉譯區域之23個鹼基對接著是完整密碼序 列的完整(6 0痼鹼基對)多面基因V非-密碼序列、該重組 體基因在核.苷酸139 *原來的RB起始位置之下游不含ATG 密碼子。因此,重組體基因編碼非—融合*全長RB蛋白質 〇 參考圖31,描述轉移載體P Ac YM1’具有多面基因之全部 上游序列,包括起故密碼子之A ’接著是獨特的BamHl位 置。該轉移載體指定為pAcYMI’具有多面基因之全部上游 -59-Framing. The resulting vector encodes an mRHA, which contains 23 base pairs fused to the 5 'untranslated region of the RB cDNA followed by the complete (60 痼 base pair) polyhedral gene V non-coded sequence of the full codon sequence, The recombinant gene does not contain the ATG codon downstream of the nucleotide position of the original nucleotide 139 *. Therefore, the recombinant gene encodes a non-fusion * full-length RB protein. With reference to FIG. 31, it is described that the transfer vector P Ac YM1 'has all the upstream sequences of the polyhedral gene, including the A' of the original codon, followed by the unique BamH1 position. This transfer vector is designated as all upstream of pAcYMI ’with a multifaceted gene -59-

4661 1 7 A7 B7 經濟部t央標隼局員工消費合作社印製 五、發明説明(57 ) 序列-,色括起始ATG密碼子之A ,接普是獨特的Bam丨丨1位置。該轉移載體已記載於Hauwa et al . j, Gen. !1 r 0 1 · (I987) 68 :1233-1250 apRB44~2 .含有自核苷酸 Π6至2935之完全RB cDHA密碼序列,其係次選殖至血獎 P G Ε Μ 1 ( P r 〇 me g a )之B a m Η Γ位置。重組體桿吠病毒載體, pAcYM1/RB2.8,之構築是以適當之排列,插人來自 PRB44-2 之 2.8 kb BamHI 片段至 P/\CYM1 之 BamHI 位置,因 此,R B基因之轉錄作用是在多面基因啟動基因的直接控制 下。 - 對於構築供RB合成作用之桿狀病毒表琨載體,考慮下列 數個事實。pRB44-2包含自核蒈酸116至2935,次選殖入 pGEMl之BamHI位,置的完全RB cDNA密碼序列。pAcYMl含 有倒位於多面基因之病毒DNA序列的約7 kb EcoRI Η段 ,其中前導序列保持完整,但是除了 ATG的第1個Α外, 所有的多面基因密碼序列被BamHI連结體取代。含有多面 基因放動基因-RB cDN A融合體之重組體桿狀病毒載體, pAcYM1/RB2.8,之構築是插入RB2.8 BamHI Η段至 pAcYMl之BamiH位置,因此,RB基因之轉錄作用是在多面 基因啟動基..因的直接控制下,在融合接鏠之序列示於圖 31之下面,小寫字體代表多面基因啟動基因,大寫字體代 表RB cDNA序列,而BamHI連接體割以下線。使用RB之 ATG (核苷酸139)融合基因之轉譯作用K箭頭顯示,而圖 312 3^=( + 1)代表多面基因之轉譯啟始密碼子ATG之第1個 A 0 -60- (請先閲讀背面之注意事¢^.¼寫本頁) .1.4661 1 7 A7 B7 Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. 5. Description of the invention (57) Sequence-indicates the A of the initial ATG codon. The connection is a unique Bam 丨 丨 1 position. This transfer vector has been described in Hauwa et al. J, Gen.! 1 r 0 1 · (I987) 68: 1233-1250 apRB44 ~ 2. It contains the complete RB cDHA codon sequence from nucleotides Π6 to 2935, followed by It was bred to the position B am Η Γ of the blood prize PG EM 1 (Pr ome ga). The recombinant baculovirus vector, pAcYM1 / RB2.8, was constructed in an appropriate arrangement, inserting a 2.8 kb BamHI fragment from PRB44-2 into the BamHI position of P / \ CYM1. Therefore, the transcription of the RB gene is in Polyhedral genes are under the direct control of genes. -For constructing a baculovirus epitope vector for RB synthesis, consider the following facts. pRB44-2 contains the complete RB cDNA codon sequence from nucleotides 116 to 2935, sub-selected into the BamHI site of pGEM1. pAcYMl contains about 7 kb EcoRI 倒 segment of the viral DNA sequence of the polyhedron gene, in which the leader sequence remains intact, except for the first A of ATG, all polyhedral gene code sequences are replaced by BamHI concatemers. The recombinant baculovirus vector containing the polyhedron gene gene-RB cDN A fusion, pAcYM1 / RB2.8, is constructed by inserting the RB2.8 BamHI segment into the BamiH position of pAcYM1. Therefore, the transcription effect of the RB gene is Under the direct control of the polyhedral gene promoter, the sequence at the fusion junction is shown below in Figure 31. The lowercase font represents the polyhedral gene promoter, the uppercase font represents the RB cDNA sequence, and the BamHI linker is underlined. The translation effect K arrow of the ATG (nucleotide 139) fusion gene using RB is shown, and FIG. 312 3 ^ = (+ 1) represents the first A 0 -60- of the translation start codon ATG of the polyhedral gene (Please (Read the notes on the back first, write this page). 1.

、1T k 4 6 6 1 1 ^ a? __ B7, 1T k 4 6 6 1 1 ^ a? __ B7

五、發明説明(58 ) 自體質體轉移RB cDNA至病毒基因姐是透過 DNA和野生型 Aut. ngrapha californica 核 多面分解病毒D K A以脂感染(B R L )共轉化感染而達成。重 姐體病毒,其中多面基因透過同源重姐以R B基因對偶質的 置換作而失去活性,因為在受感染细胞不會顗示出多面基 因吸收體,可依其不同的溶菌斑形態鑑定。病毐進行三次 溶菌斑純化作以搜得纯的含RB之桿狀病毒,指定為AcNPV -Y4 RB 〇 在受感染昆蟲细胞内·表面外源RB蛋白質 在決定是否AcHPV多面啟動基因可_勖在異種非烀椎動 物细胞中人體R B基因之表現前,先製蔺S f 9细胞。S f 9 , Spodoptera frugjpftrdn IPLB-Sf2 卜 AE 之選殖離析物 In vitro,13:213-217 (1977 )在 27Ϊ:下,在補充有 3.33 克 / 升酵母溶菌產物,乳清蛋白水解產物t G I B C 0 ),和1 0 %熱 失活之胎牛血清(G I Μ I N I > Bull. 1 5 5 5 Π 9 8 7 ),(德州農業 賁驗站,大學站,德州丨之葛瑞絲昆蟲培養基中長成單層 或懋浮液培養物。在细胞溶胞產物之大量製備中,Sf9妞 胞之蜘蛛培養_物在EX-CELL 400無血清限定培養基(J, 經濟部中央標準局員工消費合作社印製 R. Scientific)中生長。Molt-4細胞,一種人髏T细胞 白血病細胞源,以懸浮液培養於補充以20¾牛血清之 RPMI 1460中。Saos-2细胞,一種骨肉瘤细胞源,生長於 .補充Μ 7 . 5¾胎牛血清之得北氏修飾伊各氐培養基 (D u 1 b e c c 〇 ' s in 〇 d i f ί e d E a g 1 e ' s nt e d i u m > 中。 在決定是否Ac NPV多面啟動基因可驅動在異種非脊椎動 -61- i i , i » ·* A7 B7 經濟部中央標準局—工消費合作社印装 466117 五、發明説明(59) 物细掘Ψ人體RB基因之表現前,Sf9细胞先K溶菌斑-純 化之AcKPlY4 RB感染。感染40小小時後,收集受感染细 胞之溶胞產物再Μ抗-R BO . 47抗體免疫沉殺。樣本再進行 SDS-_PAGE,接著西向塗抹分析。 如圖32A所示,M PMG 3-245單選殖株抗體免疫塗抹,顧 示全長RB蛋白質之外觀與在以AcNPV-Y4感染之细胞提取物 中之哺乳類細胞類似(第3行)> 但不同於假或野生-型 AcNPV所感染之细胞(第2和4行 關於圖32B ,感染後在 不同的時間製備自/\ c'H P V - Y4 R B感染之细胞之细胞提取物 ,以決定RB蛋白質生產之適宜時機。溶胞產物Μ抗 -RB0.47抗體免疫沉澱,KpMG 3 -245單選殖株抗體免疫塗 抹。在圖3 2 B中、p p 1 1 〇 R B分別代表未磷酸化和磷酸化之 R B蛋白質。在感’染後之期間,監看R B蛋白質之生產情形Μ 決定收取细胞之適宜時機。如圖32Β所示,在感染後可 2 4小時偵測R Β蛋白質之生產,在之後的1 2小時明顯增加。 蛋白質之生產量維持在感染之約7 2小時期間,在該時段開 始明顯之病毒溶胞作用。為減少細胞溶胞作用相關之蛋白 質降解作用至_最低,感染後約40小時例行收取感染細胞。 在偵測RB.蛋白質之表現,在感染後24, 36, 48, 60和 72 小時,0.5 Μ0Ι,使用 AcNPV-Π RB 感染 Sf9 细胞,5 X 104細胞溶胞於1毫升緩衝液(50毫莫耳濃度三羥甲基胺 基甲烷- HCI,pH 7.4; 0.2¾ Nonidet P-40; 1 毫莫耳濃度 EDTA; 100毫莫耳濃度NaCl; 50毫莫耳濃度NaF和1毫莫 ----------„---------------ir-----線-----,--------- (請先閲讀背面之注意事P填寫本頁) d A7 B7 經濟部中央標準局負工消費合作社印製 4 6 611 五、發明説明(60 ) 耳濃搜P M S F ),溶胞產物以離心(4 t:,2 0 , 0 0 0 X g ) 5分 籀澄清化。溶胞產物再以抗-K B 0 . 4 7抗體培養*以7 . 5 :ϊ S D S - P A G Ε分離免疫沉澱物。蛋白質再轉移至硝基纖維素 紙*按照傳统方法。隔夜封阻後,硝基纖維素紙以 PMG3-245抗-fRB單選殖株抗體培養3小時,接著是鹼性磷 酸酶·'共轭化羊抗-鼠IgG和生色受質,如Cell (1 988 ) 54:275-283所記載者。 外源R B蛋白質之核定位作用和後-轉譯磷酸化作用 RB基因編碼約Hr 1_1 0,000之核磷蛋白。為了鑑定桿狀病 毒在昆蟲细胞所產生之RB蛋白質搮的於细胞核,感染後 AcNPV-Y4 RB -感染之Sf9綑胞Μ抗-RBP.47抗體免疫染色 40小時。該情況之/特徴是桿吠病毒感染之细胞病態影饗。 在進行免疫染·色分析時•進行列步驟。在假,野生-Μ AcNPV ,或AcNPV感染40小時後* Sf9细胞種在聚-L-離 胺酸(Sigma)塗覆之槽玻璃板上(Miles Scientific),並 培養過夜。在下列各步驟間玻璃板以.鱗酸-緩衝之食鹽水 清洗:细胞先在0 . 0 4莫耳濃度磷酸緩衝液(p Η 7 . 4 )中以 U甲醛固定2 0¾鐘*或Μ丙嗣(-20它)1〇分鐘》再浸在於 甲酵中之1芩Η2〇2 1〇分鐘。經固定之细胞在PBS中Μ23;正 常羊血清預培養1 〇分鐘,再Μ稀釋.於0 . 〇 2 $三通X - 1 0 0 之兔子抗- RB0.47焙養過夜。清洗後’添加生物素化之羊 抗-兔IsG (TAGO, Burlingame, CA)&1 小時後 * 細胞Μ 與薅萊過氧化酶(Vector Ubs, Burlingame Ca),共軛之 AB複合物培養45分鐘再M受質掊養。受質包括在0.05莫耳 -63- 隹轉^本紙張纽逋用中自國家揉準TCNS')A4規格#210X297公兼)V. Description of the invention (58) Transfer of RB cDNA from viral plastids to viral genes is achieved through DNA and wild-type Aut. Ngrapha californica nuclear polyhedrosis virus D K A co-transformation infection with lipid infection (B R L). Polypeptide virus, in which the polyhedral gene is inactivated by the replacement of the homologous gene with the R B gene pair, because polyhedral gene absorbers are not shown in infected cells, and can be identified based on their different plaque morphology. The diseased larvae were purified three times to obtain a pure RB-containing baculovirus, designated as AcNPV-Y4 RB. Within the infected insect cells and the surface of the exogenous RB protein, determine whether the AcHPV multifaceted promoter gene can be used. Before the expression of the human RB gene in xenogeneic non-sacral animal cells, 蔺 S f 9 cells were first produced. S f 9, Spodoptera frugjpftrdn IPLB-Sf2 AE selection colony in vitro, 13: 213-217 (1977) at 27Ϊ: supplemented with 3.33 g / liter yeast lysate, whey protein hydrolysate t GIBC 0), and 10% heat-inactivated fetal bovine serum (GI M INI > Bull. 1 5 5 5 Π 9 8 7), (Texas Agricultural Inspection Station, University Station, Dezhou 丨 Grace Insect Medium) Into a monolayer or maggot floating culture. In the large-scale preparation of cell lysates, the spider culture of Sf9 cells is produced in EX-CELL 400 serum-free limited medium (J, printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs R. Scientific). Molt-4 cells, a human skeletal T cell leukemia cell source, were cultured in suspension in RPMI 1460 supplemented with 20¾ bovine serum. Saos-2 cells, a source of osteosarcoma cells, were grown in. Beige-modified Igloo medium (D u 1 becc 〇's in 〇dif ed ed E ag 1 e s nt edium > supplemented with M 7. 5¾ fetal bovine serum) in deciding whether Ac NPV multi-faceted promoter gene Can drive in heterogeneous non-vertebral motion -61- ii, i »· * A7 B7 Printed by the Central Bureau of Standards of the Ministry of Economic Affairs and the Industrial Cooperatives Cooperative Association 466117 V. Description of the Invention (59) Before the performance of the human RB gene is revealed, Sf9 cells are infected with K plaque-purified AcKPlY4 RB. After 40 hours of infection, collect The lysates of the infected cells were immunized with M anti-R BO. 47 antibody. The samples were subjected to SDS-PAGE and then analyzed by westward smear. As shown in Figure 32A, the M PMG 3-245 single colony antibody was immunosmeared. The appearance of the full-length RB protein is similar to that of mammalian cells in cell extracts infected with AcNPV-Y4 (line 3) > but different from cells infected with pseudo or wild-type AcNPV (lines 2 and 4) Regarding Figure 32B, cell extracts from / \ c'H PV-Y4 RB infected cells were prepared at different times after infection to determine the appropriate timing of RB protein production. Lysate M anti-RB0.47 antibody immunoprecipitation KpMG 3 -245 single colony antibody immunostaining. In Fig. 3 B, pp 1 10 RB represents unphosphorylated and phosphorylated RB protein, respectively. During the period after the infection, monitor the RB protein. Production situation Time. As shown, four hours after infection in 2 R Β detection of protein production 32Β, increased significantly in the 12 hours following. The amount of protein produced was maintained during approximately 72 hours of infection, during which time significant viral cytolysis began. In order to reduce the degradation of proteins associated with cell lysis to a minimum, infected cells were routinely harvested approximately 40 hours after infection. In detecting the expression of RB. Protein, Sf9 cells were infected with AcNPV-Π RB at 0.5 MOI at 24, 36, 48, 60 and 72 hours after infection, and 5 X 104 cells were lysed in 1 ml of buffer (50 mmol) Ear concentration Trimethylolaminomethane-HCI, pH 7.4; 0.2¾ Nonidet P-40; 1 mmole EDTA; 100 mmole NaCl; 50 mmole NaF and 1 mmole ---- ------ „--------------- ir ----- line -----, --------- (Please read the Note P fill in this page) d A7 B7 Printed by the Central Standards Bureau of the Ministry of Economic Affairs and Consumer Cooperatives 4 6 611 V. Description of the invention (60) Ear concentration search PMSF), the lysate was centrifuged (4 t :, 2 0, 0 0 0 X g) 5 min clarification. The lysate was then cultured with anti-KB 0.4 7 antibody * 7.5: ϊ SDS-PAG EI separated the immunoprecipitate. The protein was then transferred to nitrocellulose Paper * Followed the traditional method. After overnight blocking, nitrocellulose paper was cultured with PMG3-245 anti-fRB single colony antibody for 3 hours, followed by alkaline phosphatase · 'conjugated goat anti-mouse IgG and Color substrate, as described in Cell (1 988) 54: 275-283. Verification of foreign RB protein Effect and post-translational phosphorylation The RB gene encodes a nuclear phosphoprotein of about Hr 1_1 0,000. In order to identify the nucleus of the RB protein produced by baculovirus in insect cells, the nucleus of the RB protein was infected with AcNPV-Y4 RB-infected Sf9 cells Immunostaining with Μ anti-RBP.47 antibody for 40 hours. This condition / specificity is the pathological effect of baculovirus-infected cells. When performing immunostaining, color analysis, and the following steps. In false, wild-M AcNPV, or 40 hours after AcNPV infection * Sf9 cells were seeded on poly-L-lysine (Sigma) coated trough glass plates (Miles Scientific) and cultured overnight. The glass plates were treated with Saline washing: The cells were first fixed with U formaldehyde for 20 minutes in 0.4 Molar phosphate buffer solution (pΗ7.4) or 20 minutes in M propionium (-20 it). 1-2020 minutes in yeast. Fixed cells in M23 in PBS; normal sheep serum pre-cultured for 10 minutes, and then diluted in M. 0.02 $ Tee X-100 rabbit antibody -RB0.47 is baked overnight. After cleaning, 'Biotinylated goat anti-rabbit IsG (TAGO, Burlingame, CA) & 1 Hours later * Cell M was cultured with Vector Ubs, Burlingame Ca, conjugated AB complex for 45 minutes, and then subjected to quality support. The subject matter is included in the 0.05 mol -63- 隹 ^ This paper is used in the paper and used in the country quasi TCNS ') A4 specifications # 210X297 public and)

經濟部中央標隼局員Η消費合作社印製 . 五、發明説明(61 ) 濃度-三羥甲基胺基甲烷-丨丨C丨,p H 7 . 6中之0 . 0 5 « 3,3 '-二 胺基對二胺基聯笨四鹽酸鹽和0.01¾ H2〇2 (SiSma> 。 3 - 5分鐘後以p B s濟洗細胞以终止反應。接著,细胞以 ; N ikon雙照像顯微鏡.照像。 # 看圖 3 3 和 Oncogene . <1989)1:205-214和 Ceil (1989 ) 56:57 -65, RB蛋白質之磷酸化作用發生在多重的 絲胺酸和蘇胺酸殘基上,引起SDS-PAGE上RB蛋白質分子量 之不同。為鑑定是否在昆蟲细胞内產生之RB蛋白質進行轉 譯後之隣酸化作用,·在感染後40小時,以3 SS -甲硫胺酸或 32P-正磷SS鹽新陳代謝標記AcNPV~Y4 RB-感染之S'f9綑胞 ^ 3小時。細脃提取物進行免疫沉澱並以SDS-P AGE分析,接 著進行放射自顯術.。同畤,來自同一提取物之可免疫沉澱 之RB蛋白質,以馬鈐薯酸磷酸酶(PAP)處理以測試脫磷酸 作用在SDS-PAGE中對RB蛋白質流動性之影饗。脫磷酸作用 « 後,3t5S-標記之RB蛋白質自一對減至單帶之Mr 110,000 ,政射性幾乎完全自3 2 P -標記之R B蛋白質釋放出來。 AcNPV-Y4 RB所感染之未標記細胞之溶胞產物的西向塗抹 所進行之脫磷澈作用分析顯示在PAP處理後相同之帶減少 模式。該類..觀察顯示在昆蟲细胞内所產生之RB蛋白質被磷 -酸化,而該修飾亦引起在SDS-PAGE上所觀察到之ϋΒ蛋白質 之分子量差異。 在進行Sf9昆蟲细胞之放射標記和脫磷酸分析時,進行 ^ 下列步驟。感染後40小時,在60毫米培養盤中,Sf 9妞胞 (3χ10β) K缺乏甲硫胺酸或磷酸但補充以胎牛血清之 -64- •7 每卑用中國®家標竿規格(210X297公釐> ^^^1· - - I —^1 fl^i tj— 1^1 (请先閱讀背面之注意事寫本頁) -I. 訂Printed by a member of the Central Bureau of Standards of the Ministry of Economic Affairs and a Consumer Cooperative. V. Description of the invention (61) Concentration-Trimethylolaminomethane-丨 丨 C 丨, 0. 0 5 «3,3 ' -Diamino-diamine dibenzyl tetrahydrochloride and 0.01¾ H2O2 (SiSma >. After 3-5 minutes the cells were washed with p B s to stop the reaction. Then, the cells were treated with Nikon double images Microscopy. Photographs # See Figure 3 3 and Oncogene. ≪ 1989) 1: 205-214 and Ceil (1989) 56:57 -65, the phosphorylation of RB protein occurs in multiple serine and threonine Residues cause differences in the molecular weight of the RB protein on SDS-PAGE. In order to identify whether the RB protein produced in insect cells undergoes ortho-acidification after translation, 40 hours after infection, 3 SS-methionine or 32P-orthophosphate SS salt metabolism marker AcNPV ~ Y4 RB-infected S'f9 sheaf ^ 3 hours. The extract of H. pumila was immunoprecipitated and analyzed by SDS-P AGE, followed by autoradiography. At the same time, immunoprecipitable RB proteins from the same extract were treated with lipase diphosphate phosphatase (PAP) to test the effect of dephosphorylation on RB protein mobility in SDS-PAGE. After dephosphorylation, 3t5S-labeled RB protein was reduced from a pair to a single band of Mr 110,000, and radioactivity was almost completely released from 3 2 P-labeled RB protein. Westward smear of lysates of unlabeled cells infected with AcNPV-Y4 RB. The dephosphorization analysis performed showed the same pattern of band reduction after PAP treatment. This type of observation showed that the RB protein produced in insect cells was phosphorylated-acidified, and that the modification also caused the molecular weight difference of the βB protein observed on SDS-PAGE. When performing radiolabeling and dephosphorylation analysis of Sf9 insect cells, perform the following steps. 40 hours after infection, in a 60 mm culture plate, Sf 9 cells (3x10β) K lacked methionine or phosphoric acid but supplemented with fetal bovine serum -64- Mm > ^^^ 1 ·---I — ^ 1 fl ^ i tj— 1 ^ 1 (Please read the notes on the back first to write this page) -I. Order

7 ;-· -7;-·-

經濟部中央標準局員工消費合作社印製 五、發明説明(62 ) ~ DME -培奏基培養30分籀。透過補充〇· 25 raCI/ml asS-甲硫 胺酸(1134 Ci/毫舆耳,NEN)或0‘25毫CI/毫升3:2P-正瞵 8¾鹽(無載體,I C H )新陳代謝的放射標記細胞3小時。再 於溶胞緩衝液(5 0毫莫耳濃度三羥甲基胺基甲烷-HC i ; (^7.4;0.2$^〇以<^1;卩-40;1毫莫耳濃度£0了4;100毫 _耳漶度卩aCl; 50毫莫耳濃度NaF和1毫舆耳濃度PMSF) 中製備細胞提取物,以抗-R B 〇 · 4 7抗體進行免疫沉豭。 三分之二免疫沉澱之RB蛋白質,來自3SS-或32P-標記的 以及未標記之细胞溶_胞產物進行禺鈐薯酸磷酸酶(PAP, Boehringer)脫磷酸分析(Onc.QKe..ne .Res. ( 1 989) 1:205-214 。含有RB蛋白質之免疫複合物在37 ΐ:,反應緩 衝液中(20毫莫耳裤度MES, f>H 5.5; 100毫莫耳濃度 NaCl ; 1毫箅耳濃度MSCU.;50微莫耳濃度自胜肽素 leupeptin)M1.5單位之PAP培養_60分鐘。反應後,以 7.5¾ SDS-PAGE分析RB蛋白質,接著進行放射自顯術或西 向塗珠。 按照下列程序純化來自受感染昆蟲细胞之蛋白質。以 M〇 I 1 . 0 , Ac Η·Ρ V - Y 4 R感染S f 9细胞,以懸染液培養(1 X 16β细胞/毫升,1 000毫升),感染後40小時,Μ低速離 心粒化作甩製備细胞溶胞產物。在該情況下•桿狀病毒糸 统中表現之總RB蛋白質蠆是每升受感染昆蟲細胞培養物( 約1〇β细胞)約17-1δ毫克。關於此點.,參看下表。 -65- —--------' V裝-- (諳先閱讀背面之注意#^^寫本頁) __ 一 訂Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of the Invention (62) ~ DME-Pei Tzuji training 30 minutes. Radiolabeled by metabolic supplementation with 0.25 raCI / ml asS-methionine (1134 Ci / milline, NEN) or 0'25 milliCI / ml of 3: 2P-n-sulfonium 8¾ salt (without carrier, ICH) Cells for 3 hours. Then in lysis buffer (50 millimolar concentration trimethylolaminomethane-HC i; (^ 7.4; 0.2 $ ^ 〇 to < ^ 1; 卩 -40; 1 millimolar concentration £ 0 Cell extracts were prepared in 4; 100 mM _aCl; 50 mM NaF and 1 mM PMSF), and immunoprecipitation was performed with anti-RB 0.47 antibody. Two-thirds immunization Precipitated RB proteins from 3SS- or 32P-labeled and unlabeled cytolysates were analyzed for diphosphate phosphatase (PAP, Boehringer) dephosphorylation (Onc.QKe..ne.Res. (1 989 ) 1: 205-214. Immune complex containing RB protein in 37 ΐ :, reaction buffer (20 mmoles MES, f > H 5.5; 100 mmoles NaCl; 1 mmoles MCU .; 50 micromolar concentration of PAP incubation of Leutopin) M1.5 units for 60 minutes. After the reaction, the RB protein was analyzed by 7.5¾ SDS-PAGE, followed by autoradiography or westward beading. According to the following Programmatic purification of proteins from infected insect cells. S f 9 cells were infected with MoI 1.0, Ac ΡPV-Y 4 R, and cultured in suspension (1 X 16β cells / ml, 1,000 ml) , 40 hours after staining, the cells were pelleted by low-speed centrifugation to prepare cell lysates. In this case, the total RB protein expressed in the baculovirus system is liters of infected insect cell culture (about 10 β cells per liter). ) About 17-1δ mg. For this point, see the table below. -65- —-------- 'V Pack-(谙 Please read the note on the back # ^^ write this page) __ Order

二線 ®);Α4^Τ:21〇Χ297^'):-ΐ'-' 一 _ 錫 “6U7 - “6U7 - -病、感染之昆蟲細胞之重驵體R Β蛋白質之纯化作用 •Τ 經濟部令央裸準局員工消費合作社印製· 11袭 &Second-line®); A4 ^ Τ: 21〇 × 297 ^ '): -ΐ'-'-_ Tin "6U7-" 6U7--Purification of heavy carcass R Β protein from diseased and infected insect cells Printed by the Order of the Ministry of Labor of the People's Republic of China Naked Associate Bureau · 11 Attacks &

五、發明説明(Μ) 步 驟 缌蛋白質 R B蛋白質 產量 純化 純度 (mg) (rag) (% )倍數 U) 细 胞 提 取 物 670β 16b 90c 1.0 2.3 PMG3 -245 免 疫 親 13. 5b 1 2 . g1" 79c · d 41.3 95 和 管 柱 a. 布 得 福 法(Bradford) (B io-RAD)定量蛋白質。 b. 微 BCA (PIERCE)和分 光光度測定法定量蛋白質。 c · 西 向 塗 抹和光密度測 定法定虽蛋白質。 d. 考 馬 斯 鮮藍染色和光 密度测定法定最蛋白質。 如 上 述 ,細胞破.裂後 •90!« (16毫克)表現之蛋白質出現 在 上 清 液 中,而'10%而 維在不溶部分。由於代表2 .3¾之全 部 细 胞 蛋 白質* RB蛋白 質很容易在细胞溶胞產物中測得。 單 步 驟 免 疫親和力層析 純化作用後,約13.5毫亮蛋白質可 管 柱 之 鹸性離析液中 回復。為估計離析之蛋白質的純 度 對 應 於 2.5 X 1〇5细胞之離析液整分以SDS-PAGE 和考馬 斯 鮮 藍 染 色分Iff。 玆 提 供 較.詳细之纯化 程序*清洗細胞溶胞產物, 再懸浮 於 含 有 50 毫箅耳濃度三 羥甲基胺基甲烷- HC1 >p Η 7.4; 0 . 2¾ 4〇; 1毫莫耳 濃度EDTA; 100毫莫耳濃度NaCl; 10¾ (V /v)甘油;1毫莫耳濃度DTT; 1毫舆耳濃度PMSF; 25微 克 / 毫升白胜肽素 和50單位//毫升aprotinin 之提取5. Description of the invention (M) Step 缌 Protein RB protein yield Purity purity (mg) (rag) (%) multiple U) Cell extract 670β 16b 90c 1.0 2.3 PMG3 -245 Immunophile 13. 5b 1 2. G1 " 79c · d 41.3 95 and column a. Protein quantification by Bradford (B io-RAD). b. Micro BCA (PIERCE) and spectrophotometry for protein quantification. c. Westward smear and optical density determination of legal protein. d. Coomassie blue protein staining and densitometry are legally the most protein. As mentioned above, after cell rupture • 90! «(16 mg) of the protein appeared in the supernatant, and '10% was in the insoluble part. Since all cellular proteins representing 2.33¾ * RB protein are easily detected in cell lysates. After a single step of purification by immunoaffinity affinity chromatography, approximately 13.5 milliliters of protein can be recovered from the column's alkaline eluate. To estimate the purity of the isolated protein, the eluate corresponding to 2.5 X 105 cells was fractionated by SDS-PAGE and Coomassie blue staining Iff. We provide more detailed purification procedures * Wash the cell lysate and resuspend in trimethylolaminomethane-HC1 with a concentration of 50 millitorles-Η 7.4; 0.2 2 4 4; 1 millimolar EDTA concentration; 100 mM NaCl; 10¾ (V / v) glycerol; 1 mM DTT; 1 mM PMSF; 25 μg / ml leucopeptin and 50 units / ml aprotinin

五、發明説明(64) -67- 緩紐液丰。冰上培養1 5分鐘後.以離心(1 Ο , Ο Ο Ο X g , 4 1C ,10分鐘)澄清化樣本,收集含RB之上清液。在含有與蛋 白質G-壤脂糖連结之抗-fRB單選殖株抗體(pHG 3-2 45)的 2毫升容最管柱中進行RB蛋白質之免疫親和廣析。 上清疲通過.管柱4次後,以200床容虽之下列各試劑連 ,壤清洗管柱:溶胞緩衝液,含50〇毫莫耳濃度NaC1之溶胞 緩衝液;和清洗溶液(200毫莫耳濃度NaCi;l毫奠耳濃度 EDTA ; 1毫其耳港度pMSfr ; 103!甘油 > 。结合之蛋白質再 自管柱中Μ含有20毫_耳濃度之三乙胺,pH 10.8 ; 200毫 莫耳濃度“C1;丨毫萁耳漶度EDTA; 1毫莫耳濃度DTT ; 1毫莫耳濃度PMSF和10%甘油之鹼性離析鑀衝液雔析。收 集卜毫升部分,立g卩以二十分之一容虽之1莫耳濃度三羥 甲基胺基甲烷-代1(?只7.5)中和並儲存於-7〇^:,1〇35甘油 中〇 在純化得自感染之昆蟲细胞之RB蛋白質時,測定總蛋白 質量,之後依下述進行南西向DNA-结合測試和SV40 T-抗 原结合測試。 在免疫親和瞀柱之離析部分的總蛋白質量是微BCA (PIERCE)測__定。總離析之蛋白質樣本再MSDS-PAGE分析, 在離析液中RB蛋白質之量K考馬斯鲜藍染色,接著Μ光密 度測定法估計。 在细胞提取物中總蛋白質量是以布得福法(Bradford) (Bio-Rad)測量 Anal . B iochem. (1976) 72:248-254。為 定量细胞溶胞產物中之RB蛋白質,使用糸列稀釋純化之V. Description of Invention (64) -67- After incubation on ice for 15 minutes, the samples were clarified by centrifugation (1 0, 0 0 0 0 X g, 4 1 C, 10 minutes), and the supernatant containing RB was collected. Immunoaffinity analysis of RB protein was performed in a 2 ml volumetric column containing an anti-fRB single colony antibody (pHG 3-2 45) linked to albumin G-lolipose. After the supernatant passed through the column 4 times, the column was washed with 200 beds of the following reagents, and the column was cleaned: lysis buffer, lysis buffer containing 500,000 mmol NaC1; and a cleaning solution ( 200 millimolar concentration NaCi; l millimolar concentration EDTA; 1 millimolar port pMSfr; 103! Glycerol >. The bound protein was reconstituted from the column containing 20 milliliter triethylamine, pH 10.8 200 millimolar concentration "C1; 丨 millimolar concentration EDTA; 1 millimolar concentration DTT; 1 millimolar concentration PMSF and 10% glycerol in alkaline separation 鑀 eluate decantation. Collect milliliter portion, stand g三 Trimethylolaminomethane-substituted 1 (? Only 7.5) with a molar concentration of 1 / 10th of a mole is neutralized and stored in -7 ^ :, 1035 glycerol. Purified from When the RB protein of the infected insect cells is measured, the total protein mass is measured, and then the southwest DNA-binding test and the SV40 T-antigen binding test are performed as follows. The total protein mass in the isolated portion of the immunoaffinity column is micro BCA (PIERCE ) Measure __. The total isolated protein samples were analyzed by MSDS-PAGE. The amount of RB protein in the eluate was K. Coomassie blue staining, followed by M. Densitometry estimates. Total protein mass in cell extracts was measured by Bradford (Bio-Rad) Anal. Biochem. (1976) 72: 248-254. RB protein, purified by serial dilution

4 0 61 t β Α7 Β7 經濟部中央標準局負工消費合作社印製 五、發明説明(65) RB蛋θ邊作為標準進行西向塗抹’接著進行帶密度光密度 測定比較° 蛋白質塗抹是使用傳统技術如按照ftcid Res. (1980丨8:1-21所記載之賁驗計副Μ放射標記DNA培養塗 抹物。該程序是在室溫下進行。塗抹物以水胳為冲冼’再 以6莫耳濃度之尿素和NP-40清洗三次(各20分鐘) ,接著KDNA -结合緩衝液(10毫莫耳濃度三羥甲基胺基甲 烷-HCl , pH ?·〇; 1毫莫耳濃度EDTA ; 40毫莫耳漓度 NaCl; 0.2¾ BSA; 0.2¾ Ficoll 400和 0,2¾ 聚乙烯一氮五 團銅)清洗四次(每次30分鐘塗抹物在含有3ΞΡ -標記之 (ΗΑ之DHA-结合緩衝液中培養30分鐘。EcoRl直鏈化之 pGEMI 0ΝΛ 以 〇t 32,P 去氧核苷酸(Araersham. >3000 Ci /毫 莫耳)隨機引導標記,並用作為探針。雜交後’以D N A -结 合緩衝液清洗塗抹物三次(每次各1 〇分鐘)’空氣乾爍’从 放射自顯術分析。TRP E-RB融合蛋白質包括在對照组内。 各TRP E-RB融合蛋白質根據蛋白質所含RB基因之表現序列 命名。因此,RB19-22, RB23-27和RB19-27分別越過自表 現序列19至221胺基酸612-775),表現序列23至27(胺基 酸776 -928」和表現序列19至27(胺基酸612-928)重組體 蛋白之區域。 SV40 T-抗原是Μ免疫親和層析純化自Ad-SV XI-感染之 293 個细胞,參看 J . V [ ro t (1985) 53:1〇〇卜1004 和” Eucaryotic Viral Vectors" Cold Spring Harbor . Press . ( 1 982) Cold Spring Harbor, NY PP. 1 87- 1 92 - -68 本纸張又度逍用中國國家揉单(CNS ) A4規格( 210X297公釐) 請 先 閱 背 面 之 注 p 寫 本 頁 裝 I ,一 訂_ 線 Α7 Β7 4 6 611 五、發明説明(66,) 而抗-T藥選殖株抗體(PAB419抗體)是得自Oncogene [n c ·已知複合物形成測試依ce 1 1 ( 1 988 ) 5 4 : 2 7 5 - 2 8 3稍加 修飾進行。簡而言之,800微克桿狀病毒表現之ββ蛋白質 和含有1毫莫耳濃度PMSF 25微克毫升白胜狀50單位/ aprotinin之1毫升EBC緩衝液(50毫莫耳濃度三羥甲基 胺基甲烷- HC1, pH δ.0; 120毫莫耳濃度NaCl; 0·5% Non-idet P-40)混合。800微克純化之T抗原加至混合物 中,在冰上培養90分鐘。混合物之整分以抗47或 PAB419單選殖株抗體免疫沉.殺並進行西向塗抹分析"塗抹 物連續與pMG3-245反應,接著與PAB419。在以鹼性磷酸酶 -共軛化之羊抗-鼠IgG培赛後,塗抹物从生色受質發展 ύ DN/\和蛋白質結.1合測試 圖1 0 A和1 〇 B說明南西向D N A -結合测試。6微克純化之 TRP 融合蛋白質(截短之RB蛋白質 > 和產生自上述桿狀 病毒糸統之全長重姐體RB蛋白質M 10¾ SDS-PAGE測試。在 -圖1 〇 A所說明之測試中,使用考馬斯鮮藍染色而在圖1 0 B 之测試中,平行凝膠甯轉移至硝基纖維素紙上;再以 32P_標記之J)NA Η段培養並以放射自顯術分析。 經濟部中央標準局員工消费合作社印製 在圖10Β, DHA與蛋白質结合,再Κ放射自顯術分析。頃 鑑定出融合蛋白質,RB19-27含有與DNA交互作用之主要 功能部位,具有較二個次區域,R Β 1 9 - 2 2和R Β 2 3 - 2 7,高 20倍之DHA親和力。關於此點,圖10Β之第3行可與第1 - ... - 和2行比較,而純化之全長RB蛋白質展琨類似於019-27 本紙張尺度適用中國國家搞準( CNS > Α4規格( 210X297公釐) 466117 A7 B7 五、發明説明(67 ) 經濟部中央標準局貝工消費合作社印.«. 之強力"DiTA结合活性(圖10,第4行 > 。離析自病毒糸統之 重姐體RB蛋白質之DNA-结合活性亦能由DNA-缴維素存留蛋 白質和自管柱Μ約400毫莫耳漉度NaCl之後績離析加以証 明。 如前述,Sf9妞胞ΚΜ0Ι 1.0, AcNPV-Y4感染,以懋浮 液培養(1 X 16β细胞/奄升,1000毫升)。感染後40小時 *低速離心粒化妞胞,清洗*再懸浮於含有50毫萁耳濃度 三羥甲基胺基甲烷- HC1,pH 7.4; 0.2¾ HP-40; 1奄其耳 漶度EDTA; 100奄莫耳濃度NaCl; 10¾ (v/v)甘油;1奄 萁耳湄度DTT; 1奄莫耳濃度PMSF; 25微克/毫升白胜肽素 和50單位/毫升aprotinin之提取嫒衝液中。冰上培養 15分鐘後•以離心(10,000 X 4t,10分鐘)澄清化樣 本*收集含RB之上淸液。在含有蛋白質G-瓊脂糖連结之抗 -fRB單選殖株抗髁(pMG 3-2 45)的2毫升容量管柱中依本專 利說明書所述進行RB蛋白質之免疫親和層析。 上清硖通過管柱4次後,Μ 200床-容量之下列各試劑 連續清洗管柱:溶胞緩衝液,含500毫莫耳灌度KaCl之溶 胞緩衝液;和祿洗溶液(200毫其耳濃度NaCl ; 1毫莫耳濃 度EDTA; 1毫其耳禳度DTT; 1奄萁耳濃度PMSF; 10¾甘油 )。结合之蛋白質再自管柱中以含有20毫莫耳湄度之三乙 胺,pH 10. δ ; 200毫莫耳濃度HaCI ; 1毫莫耳灌度EDTA ; 1毫莫耳湄度DTT; 1毫莫耳塘度PMSF和10¾甘油之鹼性離 析緩衝液離析。收集1-笔升部分•立即Μ二十分之一容量 之1莫耳灌度三羥甲基肢基甲烷-HC1( pH 7.5)中和並儲 存於-701:,10»甘油中。 •-r 一 70-4 0 61 t β Α7 Β7 Printed by the Central Bureau of Standards of the Ministry of Economic Affairs and Consumer Cooperatives. V. Description of the invention (65) RB egg θ side is used as a standard for westward smearing ', followed by a band density optical density measurement comparison ° Protein smearing uses traditional techniques As described in ftcid Res. (1980 丨 8: 1-21), the radioactively labeled DNA culture smears were performed. The procedure was performed at room temperature. The smears were washed with water and then washed for 6 months. Ear concentration of urea and NP-40 was washed three times (20 minutes each), followed by KDNA-binding buffer (10 mmoles of trimethylolaminomethane-HCl, pH? · 〇; 1 mmoles of EDTA; 40 millimoles NaCl; 0.2¾ BSA; 0.2¾ Ficoll 400 and 0,2¾ polyethylene-nitrogen five-copper copper) Wash four times (30 minutes each time smear on 3HA-DHA-binding Incubate for 30 minutes in buffer. EcoRl linearized pGEMI ONA is randomly labeled with ot 32, P deoxynucleotides (Araersham. ≫ 3000 Ci / mmol) and used as a probe. After hybridization, the DNA-binding buffer wash the smear three times (10 minutes each) 'air dry Shuo 'was analyzed from autoradiography. TRP E-RB fusion proteins were included in the control group. Each TRP E-RB fusion protein was named according to the expression sequence of the RB gene contained in the protein. Therefore, RB19-22, RB23-27 and RB19 -27 crossed the regions of the recombinant proteins from expression sequences 19 to 221 amino acids 612-775), expression sequences 23 to 27 (amino acids 776-928 "and expression sequences 19 to 27 (amino acids 612-928), respectively The SV40 T-antigen is purified from Ad-SV XI-infected 293 cells by M immunoaffinity chromatography, see J. V. [Rot (1985) 53: 1003 1004 and "Eucaryotic Viral Vectors " Cold Spring Harbor Press. (1 982) Cold Spring Harbor, NY PP. 1 87- 1 92--68 This paper was once again used in China National Rolling List (CNS) A4 (210X297mm) Please read the note on the back first Written on this page, I order _ line A7 B7 4 6 611 V. Description of the invention (66,) The anti-T drug selection strain antibody (PAB419 antibody) was obtained from Oncogene [nc · Known complex formation test ce 1 1 (1 988) 5 4: 2 7 5-2 8 3 slightly modified. In short, 800 micrograms of baculovirus expressed ββ protein and 1 milliliter of EBC buffer (50 millimoles of trimethylolamine) containing 1 millimolar concentration of PMSF 25 micrograms of white wins 50 units / aprotinin Methane-HC1, pH δ.0; 120 mM NaCl; 0.5% Non-idet P-40). 800 micrograms of purified T antigen was added to the mixture and incubated on ice for 90 minutes. The aliquots of the mixture were immunoprecipitated with anti-47 or PAB419 single colony antibody. Killed and subjected to a westward smear analysis " The smear was continuously reacted with pMG3-245, followed by PAB419. After culturing with alkaline phosphatase-conjugated goat anti-mouse IgG, the smear developed from chromogenic receptors to DN / \ and protein knots. 1-combination test Figures 10 A and 100B illustrate south-west orientation DNA-binding test. 6 micrograms of purified TRP fusion protein (truncated RB protein> and full-length doublet RB protein M 10¾ produced from the baculovirus system described above. SDS-PAGE test. In the test illustrated in Figure 10A, Coomassie blue staining was used. In the test of FIG. 10B, the parallel gelatin was transferred to nitrocellulose paper; it was cultured with 32P-labeled J) NA glutamate and analyzed by autoradiography. Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. In Figure 10B, DHA is combined with protein and analyzed by K-radioradiography. A fusion protein was identified. RB19-27 contains the main functional site that interacts with DNA. It has 20 times higher DHA affinity than two subregions, R Β 1 9-2 2 and R Β 2 3-27. In this regard, the third row of Figure 10B can be compared with the first-...-and the second row, and the purified full-length RB protein is similar to 019-27. This paper size is applicable to Chinese countries (CNS > Α4 Specifications (210X297 mm) 466117 A7 B7 V. Description of the invention (67) Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs " DiTA binding activity (Figure 10, line 4 >). Isolated from the virus 糸The DNA-binding activity of the RB protein of the system can also be proved by the analysis of the DNA- pheromone retention protein and the NaCl from the column M after about 400 mM NaCl. As mentioned above, Sf9 Niu cell KM0I 1.0, AcNPV-Y4 infection, cultured with maggot floating solution (1 X 16β cells / liter, 1000 ml). 40 hours after infection * Centrifuged granulated cells at low speed, washed * resuspended in trimethylol with 50 milliliters concentration Aminomethane-HC1, pH 7.4; 0.2¾ HP-40; 1 奄 Ear degree EDTA; 100 奄 Molar concentration NaCl; 10¾ (v / v) glycerol; 1 奄 萁 Maer DTT; 1 奄 Mole Concentration PMSF; 25 μg / ml leucopeptin and 50 units / ml aprotinin in the extract tincture. After 15 minutes of incubation on ice • Centrifuge 10,000 X 4t, 10 minutes) clarified sample * Collect the mash containing RB above. In a 2 ml volume tube containing the protein G-sepharose-linked anti-fRB single colony anti-horse (pMG 3-2 45) Immunoaffinity chromatography of the RB protein was performed in the column as described in this patent specification. After the supernatant was passed through the column 4 times, the column was continuously washed with the following reagents of M 200 bed-capacity: lysis buffer, containing 500 mmol Ear perfusion degree KaCl lysis buffer; and Lu washing solution (200 mmol of NaCl; 1 mmol of EDTA; 1 mg of DTT; 1 PMSF; 10¾ glycerol). Combined The protein was further extracted from the column with triethylamine containing 20 mM Molar, pH 10. δ; HaCI at 200 mol Molar; EDTA at 1 mol Molar; DTT at 1 mol Molar; 1 mM Separation of PMSF and 10¾ glycerol in alkaline isolation buffer. Collect 1-pen liter fraction • Immediately one-twentieth volume of 1 mole of trimethylol limb methane-HC1 (pH 7.5) And stored in -701 :, 10 »glycerin. -R-70-

L I---------裝-- {請先閲讀背面之注意事1 供寫本頁)L I --------- install-(Please read the note on the back 1 for writing this page)

P 0 線· 心㈣本紙張尺度逋用中菌®家搞準(CNS ) A4^fM 210 X 297公釐) 166117五、發明説明(68 ) A7 B7 經濟部中央標準局員工消费合作社印製 在·純汜得自慼染之昆蟲妞胞之p p 1 10 14 B步驟中,測定總 蛋白質量,之後進行南西向DNA -结合測試和SV40 T-抗原 結合測試。在免疫親和管柱之離析部分的總蛋白質量是以 -微B C A ( P I E R C E )測定.。離析蛋白質樣本再M s D S - P A G E分析 ,在離析液中R Β蛋白質之虽以考馬斯鲜藍染色,接著以光 密度測定法估計。在细胞提取物中之缌蛋白質最是以布得 福法(B r a d f 〇 r d) (B i 〇-R a d)測量 Anal. Biochem ( 1976) 72:248-254 。為定最细胞溶胞產物中之RB蛋白質,使用 糸列稀釋純化之R B蛋白質作為摞準進行西向塗*接著進行 帶密度光密度測定比較。關於此點,參看上表。 蛋白質塗抹是使用傳統技術。按照Nucleic Acid Res^ U 980 ) 8 : :l -2 1所記載之實驗計剿从放射標記之D N A培赛 塗抹物。該程序是在室溫下進行。塗抹物以水略為沖冼, 再以6莫耳濃度之尿素和0.2¾ NP-40清洗三次(各20分鐘 ),接著KDNA -結合媛衝液(1〇毫莫耳濃度三羥甲基肢基 甲烷-HC丨,pH ?.0; 1耷莫耳濃度EDTA; 50毫莫耳濃度 HaCl; 0.2 BSA; 0.2¾ Ficoll 400 和 0.2¾ 聚乙烯一氮五園 酮)清洗四次Γ每次30分鐘)。塗抹物在含有wp_標記之 DNA之DNA-結合緩衝液中培養30分鐘。EcoRl直鐽化之 p G Ε Μ 1 D N A Μ α - 3 2 P 去氧核 ΪΡ 酸(A hi e r s h a m,> 3 0 0 0 C 〖/ 毫 莫耳)隨機引導標記,並用作為探針。雜交後,以-結 合緩衝液清洗塗抹物三次(每次各10分鐘丨,空氣乾燥,K 放射自顯術分析。T i? P E - R B融合蛋白質包括在對照姐内。 各T R P E - R B融合蛋白質根據蛋白質所含之表現序列命名。 -71 - 請 先 鬩 面 之 注 裝 頁 訂 a 線 本紙張尺度逍用中國國家播準(CNS ) A4规格(210X297公釐> 466117 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(砂) 因此~,1 9 - 2 2 , R B 2 3 - 2 7和R β 1 <J - 2 7分別越過自表琨序列 19至22(胺基酸612-775),表琨序列23至27(胺基酸 776-92S)和表現序列19至27(胺基酸612-Q2S)之ppllORa 區域。 SV40 T-抗原是Μ免疫親和·傾析純化自Ad-SV Π-感染之 2 9 3 個细胞,J. V ir. (1985)53:1001-1004; "Eucaryotic Viral Vectors" Cold Spring Harbor Press. (1982) Cold Spring Harbor, NY pp. 1 87 - 1 92 j 而抗-T單選殖株抗體PAB419抗體是得自〇nCOgene Inc, 。稍加修飾進行已知之複含物形成測試。其中> 800微克 桿吠病毒表現之R B蛋白質和含有1毫莫耳濃度P MS F 25微 克毫升白胜肽素5 0.單位/毫升aprotinin之1毫升EBC緩 衝液(50毫莫耳濃度三羥甲基胺基甲烷-HC 1 , pH 8 , 0 ; 120 毫莫耳濃度 NaCl; 0.5% Non-idet P-40)混合。800 微克純化之T加至混合物中,在冰上培養90分鐘。混合物 之整分Μ抗-RB0.47或PAB419抗體免疫沉澱並進行西向塗 抹測試。塗抹物連鑛與PMG3-245反應,接著與ΡΑΒ419。在 Μ鹼性磷酸酶--共扼化之羊抗-鼠UG培養後,塗抹物Μ 生色受質發..展。 為了測試純lib之蛋白質和SV40 Τ-抗原形成特定複合物 之能力,混合等量之全長R B蛋白質和S V T-抗原,混合物 之整分K抗-RB0. 47抗體或抗-T抗體PAB419免疫沉澱。 圖11說明桿狀病毒一表現之RB蛋白質(pll0SB)和SV40 T-抗原之複合物之形成。在試管内亦即體外混合純化之 -72 請 it 閣 讀 背 Sr 之 注 裝 頁 訂 V_f. 線Line P 0 · Heart-size paper This paper uses Chinese bacteria ® Home Accuracy (CNS) A4 ^ fM 210 X 297 mm) 166117 V. Description of Invention (68) A7 B7 Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs · Pure pupa obtained from Qi-stained insect female cells in step pp 1 10 14 B, the total protein mass was measured, and then the southwest DNA-binding test and SV40 T-antigen binding test were performed. The total protein mass in the isolated portion of the immunoaffinity column was determined using -micro B C A (PI E R C E). The isolated protein samples were analyzed by M s D S-P A G E. Although the R β protein in the isolated solution was stained with Coomassie blue, it was then estimated by densitometry. The limulus protein in cell extracts is most commonly measured by the Bradford method (Bra-Rad). Anal. Biochem (1976) 72: 248-254. In order to determine the RB protein in the cell lysate, the RB protein diluted in the column was used as a standard to perform the westward coating * followed by a band density optical density measurement comparison. For this, see the table above. Protein smearing is using traditional techniques. According to the experimental plan described in Nucleic Acid Res ^ U 980) 8:: 2-1, radioactively labeled DN A Pei-Sai was applied. The procedure is performed at room temperature. The smear was slightly washed with water, and then washed three times (20 minutes each) with 6 mol urea and 0.2¾ NP-40, followed by KDNA-conjugated base solution (10 mM trimethylol limb methane -HC 丨, pH? .0; 1 耷 Mole concentration EDTA; 50 millimolar concentration HaCl; 0.2 BSA; 0.2¾ Ficoll 400 and 0.2¾ polyethylene monoazapentanone) Wash four times Γ 30 minutes each time) . The smears were incubated in DNA-binding buffer containing wp_labeled DNA for 30 minutes. EcoRl pG E M 1 D N A M α-3 2 P deoxynucleotide HPA (A hi e r s h a m, > 3 0 0 0 C [/ millimolar) randomly guides the label and uses it as a probe. After hybridization, the smears were washed three times with -binding buffer (10 minutes each time, air-dried, and analyzed by K-radioradiography. T i? PE-RB fusion protein was included in the control sister. Each TRPE-RB fusion protein Named according to the expression sequence contained in the protein. -71-Please make a note on the front page to order a thread. Paper size: China National Broadcasting Standard (CNS) A4 specification (210X297 mm > 466117 A7 B7 Central Standard of the Ministry of Economic Affairs) Printed by the Bureau ’s Consumer Cooperatives V. Description of the Invention (Sand) So ~, 1 9-2 2, RB 2 3-2 7 and R β 1 < J-2 7 respectively pass from Tables 19 to 22 (amino group) Acid 612-775), ppllORa region of Table VII sequence 23 to 27 (amino acid 776-92S) and expression sequence 19 to 27 (amino acid 612-Q2S). SV40 T-antigen is M immunoaffinity purification by decantation From Ad-SV Π-infected 293 cells, J. Vir. (1985) 53: 1001-1004; " Eucaryotic Viral Vectors " Cold Spring Harbor Press. (1982) Cold Spring Harbor, NY pp. 1 87-1 92 j. The anti-T single colony antibody PAB419 antibody was obtained from OnCOgene Inc., with a few modifications to make known duplicates. Containment formation test. Among them:> 800 micrograms of RB protein expressed by baculovirus and containing 1 millimolar concentration of P MS F 25 micrograms of leukopeptin 50 0. units / ml aprotinin 1 milliliter of EBC buffer (50 milliliters Molar concentration Trimethylolaminomethane-HC 1, pH 8, 0; 120 mM NaCl; 0.5% Non-idet P-40) mixed. 800 μg purified T was added to the mixture on ice Incubate for 90 minutes. An aliquot of the mixture of M anti-RB0.47 or PAB419 antibodies is immunoprecipitated and subjected to a westward smear test. The smears are reacted with PMG3-245, followed by PAB419. At M alkaline phosphatase-conjugation After the goat anti-mouse UG was cultured, the smear M produced chromogenic hair .. In order to test the ability of pure lib protein and SV40 T-antigen to form a specific complex, equal amounts of full-length RB protein and SV T- Antigen, mixture fractions K-anti-RB0.47 antibody or anti-T antibody PAB419 immunoprecipitation. Figure 11 illustrates the formation of a complex of RB protein (pllOSB) and SV40 T-antigen expressed by baculovirus. In a test tube, that is, in vitro mixed purification -72 Please read it on the back of Sr.

-T 本紙逋用中國國_率(CNS ( 210X297公羡) 猶. ν '4 6 β 1 1 Α7 __ Β7 五、發明説明(7〇 ) I I —-Ρ/ (裝 I 訂 _. . 5^#·.線 (請先閱讀背面之注意事填寫本頁) |_ 全長白質和純化之τ_抗原相同之混合物整分从 ΡΑΒ419(第2行)或抗-Rb〇.47(第3行)免疫沉·殺再以西向 塗抹分析。第1和4行分別_示和Ρ Α β 4 1 9免疫沉殿之純化 SV40 Τ-抗原,和抗—RB0 · 47抗體免疫沉澱之纯化桿狀病_ -表琨之RB蛋白筲。 在體外混合R B蛋白質和S V 4 Ο T抗原造成R B蛋白質和 PAB419之共-免疫沉澱(第2行 >,和T與抗- RB0.47抗體 之共一免疫沉殺(第3行)。該類資枓証明離析自桿狀病毒 糸统之純化,全長蛋白質能與SV40 T抗原形成特定複合 物。 經纯化R B蛋白胷之核移位 體外鑑定純化之R B蛋白質所保有之野生-型R B之二個已 知之生化活性後.’,偵測纯化蛋白質之體内行為。 纯化之R B蛋白質.p 11 0 R B,注射至骨肉瘤細胞源之 Saos-2细胞之细胞質内,該细胞具有表規序列21-27被删 除之缺陷RB基因,編碼C-端載短之RB蛋白質(p95), 經濟部中央標準局貝工消費合作社印製-T Chinese paper _ rate (CNS (210X297)). Ν '4 6 β 1 1 Α7 __ Β7 V. Description of the invention (7〇) II —-Ρ / (装 I __.. 5 ^ # ·. 线 (Please read the notes on the back to fill in this page first) | _ Full length white matter and purified τ_ Antigen The same mixture is divided from PAB419 (line 2) or anti-Rb〇.47 (line 3) Immunoprecipitation and killing are then applied in a westward direction. Lines 1 and 4 show _ and P Α β 4 1 9 purified SV40 T-antigen from immunosinking hall, and purified baculovirus immunoprecipitation with anti-RB0 · 47 antibody_ -Table RB protein. Mixing RB protein and SV 4 0 T antigen in vitro results in co-immunoprecipitation of RB protein and PAB419 (line 2>), and co-immunoprecipitation with T and anti-RB0.47 antibody Kill (line 3). This type of resource proves that the full-length protein isolated from the purification of the baculovirus system can form a specific complex with the SV40 T antigen. The nuclear translocation of the purified RB protein peptone identified the purified RB protein in vitro After two known biochemical activities of the preserved wild-type RB. ', The in vivo behavior of the purified protein was detected. Purified RB protein. P 11 0 R B. Injected into the cytoplasm of Saos-2 cells derived from osteosarcoma cells, which had a defective RB gene with deleted gauge sequences 21-27, encoding a short C-terminal RB protein (p95), Central Ministry of Economic Affairs Printed by Shell Bureau Consumer Cooperative

Proc. Kat I . Acad. Sc i . USA U990) 87:6-10 〇 位於细 胞質中之p9 5 1白質是極微M致無法為本專利說明書所使 用之抗-RB0.. 47抗體辨識,即使抗體被導引對抗RB蛋白質 之C端。注射後立即固定细胞並進行免疫染色分析。 關於微注射,純化之〇蛋白質透析至含有20毫莫耳濃度 三羥甲基胺基甲烷-HC1, pH 7.4; 10毫莫耳濃度KC1; 0 . 1毫莫耳濃度DTT和2丨甘油之注射緩衝液中至最終濃度 為0 . 5毫克/毫升。根據傳統技術,使用玻璃毛細管針( 喚基i本纸張歧逋用'中酉國家揉攀t⑽)A4规格(210X297公釐> ί ” :一 經濟部中央標準局員工消费合作杜印製Proc. Kat I. Acad. Sci. USA U990) 87: 6-10 〇 p9 5 1 white matter located in the cytoplasm is extremely M and cannot be identified by the anti-RB0 .. 47 antibody used in this patent specification, even if The antibody is directed against the C-terminus of the RB protein. Cells were fixed immediately after injection and immunostained. Regarding microinjection, the purified protein was dialyzed to an injection containing 20 mmoles of trimethylolaminomethane-HC1, pH 7.4; 10 mmoles of KC1; 0.1 mmoles of DTT and 2 丨 glycerin The buffer was brought to a final concentration of 0.5 mg / ml. According to traditional technology, glass capillary needles (for paper and paper used in China) are used in A4 format (210X297 mm > ”): 1. Consumption cooperation printed by employees of the Central Standards Bureau of the Ministry of Economic Affairs

4661 W 五、發明説明(71) E p P e n d “ f )微注射生長於玻璃槽板上之S a 〇 s - 2细胞。使用 配ί竜有真空和壓力器Μ及倒轉反向顯微鏡(N〖k ο η )之微操 作器供毛细管之微操作和觀察微注射過程。微注射後,立 即Κ 4 :ϊ甲韹固定细胞於0 . 0 4莫耳濃度之磷酸鹽緩衝液中 (pH 7.4>並進行免疫染邑分析。 圖1 2顯示微注射至S a 〇 s - 2细胞之细胞質後重姐體R B蛋白 質p 110 R β之核移位。Μ純化之RB蛋白質注射细胞並進行免 疫染色分析。圆12上箭頭指出微注射後核之深的染色,與 未經感染者比較。與耒經感染對照姐比較,注射细胞之核 的深染色顯示快速運送注射之蛋白質至细胞核内。由於 RB蛋白質已知為核蛋白,徽注射後純化之蛋白質快速而正 確的梭移位作用越a過细胞核膜,進一步建議重姐體R Β蛋白 質在體内是具活.性的。 上述结果証明人體視網膜胚细胞瘤基因產物可有效的表 現於桿狀病毒表現系統。長期以來嘗試大量表現蛋白質 被認為是很困難的,因為懷疑R B蛋白質可能阻礙细胞生長 或甚至對细胞生長”有毒”。多面敗動基因轉錄外來基因量 發生在感染之7後期,在生產體外病毒顆粒後並阻絕细胞和 大多數病毒..基因。桿狀病毒-昆蟲細胞系統因而有利於蛋 白質之合成,如RB蛋白質》在過量生產時可能有於害细胞 之生長。該糸統之另一儍點是昆蟲和哺乳類動物蛋白質處 理途徑之相似性。 在桿狀病毒表現系统產生之RB蛋白質已顯示可正確的標 的於昆蟲細胞之细胞核,意指哺乳類動物核移位訊息亦可 "74-4661 W V. Description of the invention (71) Eppend “f) Microinjection of S a 0s-2 cells grown on glass trough plates. Use a vacuum and pressure device M and inverted inverted microscope (N 〖K ο η) micromanipulator for micromanipulation of the capillary and observation of the microinjection process. Immediately after the microinjection, the cells were fixed in a phosphate buffer solution (pH 7.4) at a concentration of 0.4 mole. > An immunostaining assay was performed. Figure 12 shows the nuclear translocation of the RB protein p 110 R β after microinjection into the cytoplasm of Saos-2 cells. The purified RB protein was injected into the cells and performed Immunostaining analysis. The arrow on circle 12 indicates the deep staining of the nucleus after microinjection, compared with the uninfected. Compared with the infected control sister, the deep staining of the injected cell nucleus showed rapid delivery of the injected protein into the nucleus. Since the RB protein is known as a nuclear protein, the rapidly and correctly shuttle-shifting effect of the purified protein after microinjection crosses the nuclear membrane of cells, and it is further suggested that the heavy body RB protein is active in vivo. The above results prove that Human retinoblastoma Because the product can be effectively expressed in the baculovirus expression system. It has been considered difficult to try to express a large number of proteins for a long time, because it is suspected that RB protein may hinder cell growth or even be "toxic" to cell growth. Multifaceted genes transcribe foreign genes The amount occurs in the late 7th stage of infection. After the production of in vitro virus particles and blocks the cells and most viruses ... genes. The baculovirus-insect cell system is therefore conducive to protein synthesis, such as RB protein. The growth of harmful cells. Another silly aspect of this system is the similarity of protein processing pathways between insects and mammals. The RB protein produced in the baculovirus expression system has been shown to target the nucleus of insect cells correctly, meaning mammals. Animal nuclear shift messages can also be " 74-

A7 B7A7 B7

A 6 61 1 T 五、發明説明(72 被昆蟲细胞識別。雖然在桿狀病毒表琨糸统中重姐體蛋白 質之槌基化作用似乎是限於高甘露糖-型之0 -連结或N -連 结之_ *但已有報告指出外來蛋白質之適當磷酸化作甩可 供ciyc和HTLV-I p'4 011之表現。RB蛋白質過去已顯示是 磷酸化而非糖基化|使桿狀病毒系統適於生產功能性蛋白 質。 在受感染毘蟲細胞中產生之RB pliORB蛋白質是轉譯後 磷酸化的|西向塗抹分析可分化成多重帶,正如同原來哺 乳類R B蛋白質之情形但是,依帶密度判斷,與高度磷酸 化R Β蛋白質比較 > 未或低度磷酸化之形式佔大多數。尚不 知該現象是反映病毒溶胞感染時族群之細胞循環之狀況, 或只是因為大量外,源R Β蛋白筲出現在细胞内而昆蟲激酶未 充分磺酸化蛋白.·質。R B蛋白質上隣酸化作用之精確位置圖 可鑑定是否磷酸化模式和哺乳類蛋白質真的相同。 表現於桿狀病毒系統之重姐體R B蛋白質之缌量是每升受 感染昆蟲细胞培養物(〜1 0 0細胞)約1 7 - 1 8毫克。該表規 量相當於該系統產生之其他哺乳類蛋白質,如間白血球素 2 之 10-20 毫竞/ 升 The Banbury Report. Fields, B., et al... (ed.) (1985) 22:319-328 Cold SpringA 6 61 1 T V. Description of the invention (72 Recognized by insect cells. Although the glutamation of heavy protein in the baculovirus epithelium appears to be limited to the high-mannose-type 0-link or N -Linked_ * But it has been reported that proper phosphorylation of foreign proteins can be used for the performance of ciyc and HTLV-I p'4 011. RB proteins have been shown to be phosphorylated rather than glycosylated in the past | make rod-shaped The virus system is suitable for the production of functional proteins. The RB pliORB protein produced in infected worm cells is phosphorylated after translation | Western smear analysis can differentiate into multiple bands, just as in the case of the original mammalian RB protein. However, depending on the band density Judgment, compared with highly phosphorylated RB proteins> Un or lowly phosphorylated forms accounted for the majority. It is not known whether this phenomenon reflects the cell cycle status of the population during viral lysosomal infection, or simply because of a large amount of external R source Beta-protein peptone appears in cells and insect kinases are not sufficiently sulfonated. · The precise map of ortho-acidification on RB proteins can identify whether the phosphorylation pattern is really the same as that of mammalian proteins. The amount of RB protein expressed in the baculovirus system is about 17-18 mg per liter of infected insect cell culture (~ 100 cells). This gauge is equivalent to the other produced by the system Mammal Proteins, such as 10-20 mM of Leukoglobin 2 / L The Banbury Report. Fields, B., et al ... (ed.) (1985) 22: 319-328 Cold Spring

Harbor Laboratory Press, Cold Spring Harbor,和 P210 BCR-ABL 之 4-5 毫克 / 升,flncogenp (1 9 8 9) 4:759 -766 。使用含有完整多面基因5'未轉譯區域,該區 域與除去大多數其其5’非-密碼區域之RB cDNA融合之重 組體轉移載體|可促進大量表現R B蛋白質。R B «1 R N A之該 -75- 广L 請先閱讀背面之注意事^:填寫本頁) -裝-Harbor Laboratory Press, Cold Spring Harbor, and P210 BCR-ABL 4-5 mg / L, flncogenp (1 9 8 9) 4: 759 -766. The use of a recombinant transfer vector containing a 5 'untranslated region of a complete polyhedral gene that is fused to an RB cDNA that removes most of its 5' non-code region | promotes the large expression of RB protein. R B «1 R N A's the -75- 广 L Please read the notes on the back ^: Fill in this page) -pack-

Mr. ,丁 經濟部中央橾準局員工消費合作社印製 4S6117 A7 B7 五、發明説明(73 經濟部中央標準局貝工消費合作社印轚Mr. D. Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 4S6117 A7 B7 V. Description of the Invention

'序列非常富於G + C ,其除有利於形成安定之第二结構的因 素°當該類结構出現在起始密碼子之前時,認為將減低對 應m〇 A之轉譯效翠。以苜蓿花窠病毒(A Μ V ) R Μ A4,或召-血球蛋白mRNA取代RB 5,未轉譯序列已証明可5至1〇倍 的促進RB raRNA之體外轉譯作用,進一步建議對RB 5,非 -密碼序列之轉譯,EHBQ J. (1990) 9:1815-1822,的可 能負反應。外來基因之長5,未轉譯序列之存在已顯示影響 在桿狀病毒系统中重組體蛋白質之表現。由於多面啟動基 因非常富於A + T ’頃結論為了 rb DNA序列之最適宜表琨, 在插至轉移載體前,自RB cDHA切除長且富於G + C之5,非 -密碼子序列。 為了嘗試減少純化過程中蛋白質之變性作用,已測試數 種自親和管柱離.'析R B蛋白質之賁驗計劃。由於對R B蛋白質 之生物和生化特性不多 > 只有二個變數可用以測量經純化 之蛋白質之完整特性,DNA-结合活性和與SV40 T抗原複合 物形成活性。頃發現目前在pH 10,8使用20毫莫耳濃度三 乙胺之離析條件可有效的保存蛋白質之生化特性。微注射 後經纯化之蛋為質快速的自细胞質核移位作用進一步証明 蛋白質在該J1I析條件下具活性°在槿端之pH條件下(200 毫莫耳濃度甘胺酸’ pH 2.3或100毫莫耳濃度三乙胺’ pH 11.5)離析蛋白質’傾向於使蛋白質變性.,而前述之二 個活性亦大幅減弱°該胃&办後胃$ 集物獲得証寅。 .......... 雖然過去報告指出僅未碟酸化之*^蛋白質在D2C2细胞中 -76- (請先閱讀背面之注意事广1,七寫本頁) -裝· P: ,¾ 訂 線The 'sequence is very rich in G + C, except that it is favorable for the formation of a stable second structure. When this type of structure appears before the start codon, it is believed that the translation efficiency corresponding to m 0 A will be reduced. Replacing RB 5 with alfalfa cyanovirus (A MV) R Μ A4, or callin-hemoglobin mRNA, untranslated sequences have been shown to promote the in vitro translation of RB raRNA by 5 to 10 times. It is further suggested that RB 5 Translation of non-cryptographic sequences, EHBQ J. (1990) 9: 1815-1822, possible negative reactions. The length of foreign genes5 and the presence of untranslated sequences have been shown to affect the performance of recombinant proteins in the baculovirus system. Since the polyhedral promoter gene is very rich in A + T ', it is concluded that for the optimal expression of the rb DNA sequence, before inserting into the transfer vector, the long, G-C-rich 5, non-codon sequence is excised from the RB cDHA. In an attempt to reduce the denaturation of proteins during purification, several self-affinity column isolation tests have been tested. Since there are not many biological and biochemical properties of the R B protein > there are only two variables that can be used to measure the complete properties of the purified protein, DNA-binding activity and activity with the SV40 T antigen complex. It was found that the current isolation conditions using triethylamine at a concentration of 20 millimoles at pH 10,8 can effectively preserve the biochemical properties of proteins. Purified eggs after micro-injection are rapidly transferred from the cytoplasmic nucleus to further prove that the protein is active under the J1I analysis conditions ° At the hibiscus pH (200 millimolar concentration of glycine 'pH 2.3 or 100 millimolar concentration of triethylamine 'pH 11.5) isolated proteins' tends to denature proteins, and the aforementioned two activities are also significantly weakened. The stomach & stomach stomach aggregates obtained evidence. .......... Although past reports indicate that only non-disc acidified * ^ protein is in D2C2 cells -76- (Please read the note on the back first, write this page on seven pages)-Pack · P: , ¾ Line

在 6 6 ” 7 五、發明説明 可和SV40 T抗原结合,D2C2细胞係被SV40 T抗原穩定轉化 之猴子g细胞源CV卜P (Cell (1989) 56:5?-65),頃發現 某些低度磷酸化形式之RB蛋白質能與SV40 T抗原形成複合 物。該現象可透過體外混合T抗顦和來自AcHPV-Y4 RB感 染之-昆蟲细胞之經純化RB蛋白質或Mo It-4溶胞產物得到 重複証明。當猴子细胞用於體內複合物形成作用時亦可觀 察到該現象。由於RB蛋白質之磷酸化作用在细胞循環中Μ 特定分裂期之方式變動*而RB和病毒之腫瘤蛋白質間之複 合物彤成作用涉及低度磷酸RB化蛋白質和SV40 T抗原間之 轉化活性則有待進一步說明。 使用桿狀病毒-昆蟲细胞糸统提供大量可溶|完整且推 測具活性之RB蛋白質表示在未來研究RB基因產物之生化和 生物物理特性上之主要進步。可能之應用包括相闌之细胞 蛋白質之分析,與其交互作用之特定DHA序列之離析,和 使用X-射線結晶圖法研究RB蛋白質之三度空間结構◊亦可 加速解釋視網膜胚细胞瘤基因在癌抑制上之生物功能。目 前正直接K微注射测試研究RB和细胞生長以及分化作用之 可能闞係》 經濟部中央標準局員工消費合作社印製 85.li,06f音正丨 A7 B7 4.重姐體產生之RB蛋白質終止细胞之生長 细胞之製備 骨肉瘤细胞源,Saos-2,用於本研究。其係得自美國式 培養物收集所。該细胞源缺乏野生-型RB蛋白質之表現, 但含有無法和SVO T抗《I结合之细胞質的,羧基截短之 95 kDa蛋白質。Saos-2细胞可對编碼RB之外源添加基因之 ____- 77 -_ 本紙乐尺度適用中國國家標隼(CNS ) A4規格(210*X297公釐)In 6 6 ”7 V. The description of the invention can bind to the SV40 T antigen, and the D2C2 cell line was stably transformed by monkey S-cell-derived CV protein P (Cell (1989) 56: 5? -65). The low-phosphorylated form of RB protein can form a complex with SV40 T antigen. This phenomenon can be achieved by mixing T-resistant tadpoles in vitro with purified RB protein or Mo It-4 lysate from AcHPV-Y4 RB-infected insect cells. Repeated proof was obtained. This phenomenon can also be observed when monkey cells are used for complex formation in vivo. Due to the phosphorylation of RB proteins in the cell cycle in a specific divisional manner *, between RB and virus tumor proteins The complex formation involves the conversion activity between the low-phosphorylated RBylated protein and the SV40 T antigen, which needs to be further explained. Using the baculovirus-insect cell system to provide a large amount of soluble | Complete and presumed active RB protein indicates in the future Major advances in studying the biochemical and biophysical properties of RB gene products. Possible applications include analysis of cellular proteins in the phased phase, isolation of specific DHA sequences that interact with them, and X-ray crystal map study of the three-dimensional structure of RB protein can also accelerate the interpretation of the biological function of retinoblastoma genes in cancer suppression. Currently, direct K-microinjection tests are being used to study the role of RB and cell growth and differentiation. Probably not. "85.li, 06f, printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. A7 B7. 4. Preparation of RB protein-terminated growth cells produced by the elder sister. Osteosarcoma cell source, Saos-2. In this study, it was obtained from the American Culture Collection. This cell source lacks the expression of wild-type RB protein, but contains a 95 kDa carboxyl-truncated protein that cannot bind SVO T to cytoplasm that binds to I. Saos-2 cells can add genes __- 77 -_ which encode foreign genes to RB. This paper scale is applicable to China National Standard (CNS) A4 (210 * X297 mm)

JL___JL 五、發明説明1 35.11.08 請 先 聞 讀 背 之 注 意 事 項 | 马 本 頁 表現反應,.該基因係透過先擴大细胞尺寸並喪失轉移至裸 鼠细胞之腫瘤生成能力I由逆轉錄酯病毒媒介之基因轉移 而納入的。所Μ I頃測定該類细胞可能街於RB蛋白質之注 射特別敏感。 细胞涯SR-40可穗定的表現外源RB基因成為RB蛋白質* 該细胞涯是如Science (1988) 242 :1563-1568所記載帶有 RB基因之逆轉錄病毒感染後•透遇單细胞選殖而衍生自 53〇3-2。非洲綠猴子醫细胞源(^-1和(:05-7亦是得自美國 式培養物收集所。C0S-7是如Cell (1981 ) 23 :175-182所 記載透過K原-缺陷SV-40轉化作用而衍生自CV-1。全部细 胞依建議培養在加有103{胎牛血清之得北氐修飾伊各培養 基中。 經濟部中央標準局負工消費合作社印裂 使用 Proc. Hatl. Acad· Sci. USA· (1982) 79:4083-4087中所記載之方法,透過異亮胺酸飢餓36小時·再於分 別補充以aphidocolin或羥基脲(均來自Sigma)之完全培 養基中另外培養12或16小時*使细胞在G1/S邊界同步化。 以磷酸發緩衝之食鹽水(PBS)清洗三次自G1/S封阻體釋放 细胞並再供以完全培養棊。依Exp. Cell Res. (1 980) 126:397-40 5所描述在0.04微克/毫升尼可唑(nocoda-zo】e) (SUaia)庳理8至12小時後,收集停滯於细胞分裂中 期之细胞。為增加有絲分裂细胞之產量,细胞先Μ aphidicolin度理12小時使细胞停止在G1/S邊界。6小時 後除去蚜可林(aphidocolin),添加尼可唑至培養基中。 有絲分裂之细胞Μ輕微清洗和搖動予W收集,再塗抹於 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇X297公着) 五、發明説明(夕石)JL___JL V. Description of the Invention 1 35.11.08 Please read the notes before you read it | This page shows the response. The gene is a gene that expands the cell size and loses the tumorigenic ability to metastasize to nude mouse cells. Incorporated by vector gene transfer. It has been determined that such cells may be particularly sensitive to the injection of RB proteins. Cell SR-40 can be spiked. Exogenous RB gene becomes RB protein * This cell is after retrovirus infection with RB gene as described in Science (1988) 242: 1563-1568. • Single cell selection It is derived from 5303-2. Sources of African green monkey medical cells (^ -1 and (: 05-7) are also available from the American Type Culture Collection. COS-7 is transmitted through the K-defective SV- as described in Cell (1981) 23: 175-182. 40 transformation effect was derived from CV-1. All cells were cultured as recommended in the culture medium of Beibei modified with 103 {fetal bovine serum. The Central Laboratories of the Ministry of Economic Affairs and the Consumer Cooperatives printed and used Proc. Hatl. Acad · Sci. USA · (1982) 79: 4083-4087, starvation through isoleucine for 36 hours · Incubate in complete medium supplemented with aphidocolin or hydroxyurea (both from Sigma) for an additional 12 or 16 hours * Synchronize the cells at the G1 / S boundary. Wash three times with phosphate buffered saline (PBS) to release cells from the G1 / S blocker and resupply for complete culture. According to Exp. Cell Res. (1 980) 126: 397-40 5 After 8 to 12 hours of 0.04 μg / ml nocoda-zo e) (SUaia) treatment, collect cells that are stagnated in the middle stage of cell division. To increase the number of mitotic cells Yield, cells were first aphidicolin treated for 12 hours to stop the cells at the G1 / S boundary. Aphids were removed after 6 hours Lin (aphidocolin), add nicozole to the culture medium. Mitotic cells M are cleaned and shaken gently to be collected, and then smeared on this paper scale. Applicable to China National Standard (CNS) A4 (21 × 297). V. Invention Description (Xishi)

經濟部中央標準局負工消費合作社印裝Printed by the Consumer Standards Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs

35毫米之培養皿上。種植δ小時後,洗去未附著之细胞· 自此在不同時間注射細胞。 RB蛋白質之製備 製備2種形式之RB蛋白質供微注射實驗。重姐體全長 蛋白質(p110rb,低度璘酸化和未磷酸化之形式)自桿狀 病毒感染之昆蟲细胞純化成幾近均質。但是當湄度接近1 毫克/毫升時,蛋白質凝集成不能注射之形式,為了能部 分解決該問題* RB蛋白質是在含有10¾甘油之娌衝液內純 化,儲存和注射。未磷酸化,胺基~截短之56 kDa RB蛋 白質456〃或截短之R8蛋白質)含有完整T-抗原结合之功 能部位,表現於大腸桿菌中並純化至接近均質。由於截短 之蛋白質可濃縮至1毫克/毫升並在含有2¾甘油之標準嬡 衝液中注射*故用於大多數下列實驗中。 p56rb("RB截短之蛋白質)是RB蛋白質之Ο端半部,含有 SV40 T-抗原结合所必需之二個區域•其係在大腸桿菌中 產生自如Nature (Γ991 ) 350:160-162中所揭示之T7 UNA聚合酶表現糸统。ρΠ〇μ是在昆蟲细胞依上所揭示和 揭示在 Cell Growth and Dijff. (1990) 1:429-437 中之重 姐體方式產生的。 口110«^和P56RB蛋白質均以傳统蹰析法純化至均質。姐 織胂H1和兔子抗-羊IgG是分別購自Boehringer Mannheim和 Vector Laboratories 。抗體,495 (對抗由自 表現序列19-22之序列姐成之TRPE-RB融合蛋白質), .47 (對抗含有RB之自表現序列23-27之序列之TRP 79 - 本紙掁尺度適用中國國家揉準(CNS ) A4規格(210X297公釐) (请先閲讀背面之注意事項*·.填寫本頁) 裝· M. -5 ^35 mm petri dish. After δ hours of seeding, unattached cells were washed away. Cells were then injected at different times. Preparation of RB protein Two forms of RB protein were prepared for microinjection experiments. The full-length recombinant protein (p110rb, a low-acid and unphosphorylated form) was purified from baculovirus-infected insect cells to be nearly homogeneous. However, when the degree of Mae is close to 1 mg / ml, the protein aggregates into a form that cannot be injected. In order to partially solve the problem * RB protein is purified, stored and injected in a tincture containing 10¾ glycerol. Unphosphorylated, amine group ~ truncated 56 kDa RB protein (456〃 or truncated R8 protein) contains a complete T-antigen binding functional site, expressed in E. coli and purified to near homogeneity. Since the truncated protein can be concentrated to 1 mg / ml and injected in a standard 嫒 solution containing 2¾ glycerol *, it is used in most of the following experiments. p56rb (" RB truncated protein) is the 0-terminal half of the RB protein and contains two regions necessary for SV40 T-antigen binding. It is produced in E. coli from Nature (Γ991) 350: 160-162 The revealed T7 UNA polymerase behaves systematically. ρΠ〇μ was produced in the insect cell line and revealed in the Cell Growth and Dijff. (1990) 1: 429-437. Mouth 110 ^ and P56RB proteins were purified to homogeneity by conventional decantation. Sister Weaver H1 and rabbit anti-sheep IgG were purchased from Boehringer Mannheim and Vector Laboratories, respectively. Antibodies, 495 (against the TRPE-RB fusion protein formed by the sequence of self-expressing sequences 19-22), .47 (against the TRP 79 of sequences containing the self-expressing sequences of RB 23-27-this paper is for Chinese countries Standard (CNS) A4 size (210X297 mm) (Please read the precautions on the back * .. Fill out this page) Installation · M. -5 ^

經濟部中央標準局員工消費合作社印製 五、發明説明(:^) E-RB融合蛋白質)和R2在微注射煖衝液中濃縮至約濃度1 毫克/毫升。T胜肽和p5 3胜肽是尼古拉斯林所贈送的。該 類抗體是描述於EMBO J, (1990) 9:1815-1822。T胜肽包 括胺基101-118 ,如Cell (1939) 56:57-65所述溶於1毫 莫耳港度或5毫莫耳濃度之微注射壊衝液中。突變體T胜 肽含有一涸離胺酸對天冬胺酸之取代並K5奄莫耳濃度使 用· Cell (1989) supr?,p5 3胜呔以5毫萁耳澹度溶於 微注射缓衝液中。 蛋白質製備物,除了全長RB蛋白質外,在含有20奄萁耳 濃度三羥甲基胺基甲烷* pH 7.4; 0.1毫莫耳澹度EDT A ; 10毫莫耳湄度KC1 ; 1奄莫耳湄度2-蹢基乙酵和2ίί甘油之 注射媛衝液中》使用Centri con 30微-澹縮機濃縮 (八1〗<:〇11)。?1101^餚存在含有10:»;甘油之緩衝液中以減少 凝集作用》 對於本韋(3)中所描述之實驗,當引用視網膜胚细胞瘤 基因時*意圖表示具有臛2所閜述之核苷酸序列之棊因。 當引用RB蛋白質(pRB110)時,亦是意指具有閭釋於圖2之 胺基酸序列之蛋白質◊翮於圃2 ,閫逑截短之蛋白質片段 ,p56rb。此外,p56RBk ,片段是說明於匾2 ,始於箭頭 A而终於箭頭B 。另闞於圈2 ,闡述C端胜肽,始自胺基 酸917 (箭頭C)终於胺基酸928 (筋頭B)。 使用標準技術KSDS-P AGE分析蛋白質製備物。圖12顯示 用於討論如下之微注射技術之蛋白質製備物之塘度和純度 。用作微注射之蛋白質製備钧是KSDS-PAGE分析,第1行 (請先閏讀背面之注意事項再填寫本頁) ''裝_Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (: ^) E-RB fusion protein) and R2 are concentrated in a microinjection warm rinse solution to a concentration of about 1 mg / ml. T-peptide and p5 3-peptide were given by Nicholas Lin. Such antibodies are described in EMBO J, (1990) 9: 1815-1822. The T-peptide includes the amine group 101-118, and is dissolved in a microinjection tincture of 1 mmol or 5 mmol as described in Cell (1939) 56: 57-65. Mutant T peptide contains a substitution of aspartic acid with lysine and K5 mol concentration. Using Cell (1989) supr ?, p5 3 is dissolved in microinjection buffer at 5 mTorr. in. Protein preparations, in addition to the full-length RB protein, containing trimethylolamine methane at a concentration of 20 milliliters * pH 7.4; 0.1 millimoles degree EDT A; 10 millimoles degree KC1; 1 millimoles Degree of 2-Hydroxyacetic Acid and 2 Glycerol Injection Yuan Concentration Solution "was concentrated using a Centri con 30 micro-constrictor (Eb. 1 <: 〇11). ? 1101 ^ Food exists in a buffer containing 10: »; glycerol to reduce agglutination." For the experiments described in Benwei (3), when the retinoblastoma gene is referenced * intends to have the nucleus described in 臛 2 The cause of the nucleotide sequence. When referring to the RB protein (pRB110), it also means that the protein having the amino acid sequence as shown in FIG. 2 is derived from the protein 2 and the truncated protein fragment, p56rb. In addition, p56RBk, the fragment is illustrated on plaque 2, starting with arrow A and ending with arrow B. In the second circle, the C-terminal peptide is explained, starting from amino acid 917 (arrow C) and finally amino acid 928 (tendon B). Protein preparations were analyzed using standard techniques KSDS-P AGE. Figure 12 shows the titer and purity of a protein preparation used to discuss the microinjection technique below. Protein preparation for microinjection is KSDS-PAGE analysis, line 1 (Please read the precautions on the back before filling this page) '' pack_

I 訂 摔 本紙張尺度通用中國國家標準(CNS } Μ規格(210X 297公釐) 661 1 7 A7 U7 五、發明説明(划} 經濟部中央標準局負工消費合作社印裝 :P110RB得自Μ重組體ίϊΒ桿狀病毒感染之昆蟲细胞;第2 行;生物素化之抗-羊抗體;第3行;抗-RB. 49 5抗鴉; 第4行:抗-RB R2抗體;第5行:抗-RB.47抗體;第6行 :姐織脒Η1 ;第7行:得自大腸稈菌之p56rb 。1徵升 之各樣本放在15¾丙烯醱胺凝膠上。該凝膠K以考馬斯鲜 Μ染色。分子量標準之位置以千道耳呑顯示。 使用Eppendorf微操作器和微注射器Μ细尖毛细微滴管 直接注射於生長在35毫米之培養皿上之细胞。注射壓力典 型的設在50-100 hPa之間,注射時間.3-.5秒。估計蛋白 質製備物於注射時稀釋約2 0至50倍。假設典型细胞容量 50-100微微升而RB截段之灌度是每毫升.5-1毫克,每细胞 約注射5-50百萬個分子。 注射後,生長培餐基依廠.商建議補充MBrdU(AmershaB )。適當標記時段後·除去培養基並KPBS清洗3次。Μ 冰冷•絕對之甲酵培養30分鑪Μ固定细胞。M PBS清洗再 水合後,在室溫下,樣本K導引對抗BrdU (ABershaB)之 鼠單選殖抗餑培餐1小時。PBS清洗3次後/添加二氫螢 光素共扼化抗-鼠抗賵(Amershaia),再於室溫下可培養1 小時。MPBS清洗3次以除去抗-鼠抗體,樣本Μ德州紅 共軛化之鍵徽抗生物素(ABershaiB)培養。鏈辑抗生物索和 以所有之蛋白質製備物共注射之生物素化RctG结合,因此 作為經注射细胞之细胞質搮記。最後一次清洗後,添加等 容最之甘油和PBS姐成之溶液,樣本Μ玻璃蓋片覆蓋。在 螢光顯微鏡下Κ德州紅和二氫螢光素過滹器檢驗樣本。 —..81- 表紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) --------•、-'...裝-- (請先κ讀背Φ之注意Ϋ^-^'-邊寫本頁) 訂I Order the paper standard General Chinese National Standard (CNS) M Specification (210X 297 mm) 661 1 7 A7 U7 V. Description of the Invention (planning) Printed by the Consumers ’Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs: P110RB was obtained from M Reorganization Insect cells infected with baculovirus baculovirus; line 2; biotinylated anti-sheep antibody; line 3; anti-RB. 49 5 anti-crow; line 4: anti-RB R2 antibody; line 5: Anti-RB.47 antibody; Line 6: Sister Weaver 1; Line 7: p56rb from E. coli. 1 liter of each sample was placed on a 15 acrylamide gel. Mass fresh M staining. The position of the molecular weight standard is shown in thousands of ear ridges. Cells grown on 35 mm petri dishes were directly injected using Eppendorf micromanipulators and micro syringes with a micro-tip capillary dropper. The injection pressure is typical Set between 50-100 hPa, injection time. 3-.5 seconds. It is estimated that the protein preparation is diluted about 20 to 50 times at the time of injection. Assume that the typical cell volume is 50-100 picoliters and the RB segment irrigation is 5-1 mg per milliliter, about 5-50 million molecules are injected per cell. After injection, the growth culture is based on the plant. Supplement MBrdU (AmershaB). After appropriate labeling period, remove the culture medium and wash 3 times with KPBS. M ice-cold • Absolute formazan culture 30-minute furnace M fixed cells. After washing with PBS and rehydration, at room temperature, sample K guide Anti-BrdU (ABershaB) mice were colonized for 1 hour. After washing for 3 times in PBS / dihydrofluorescein-conjugated anti-rat anti-rat (Amershaia), it can be cultured for 1 hour at room temperature. Washed 3 times with MPBS to remove anti-mouse antibodies. Sample M Texas Red Conjugated Key Biotin (ABershaiB) was cultured. Chains of anti-biotins were combined with biotinylated RctG co-injected with all protein preparations. Therefore, it is regarded as the cytoplasm of injected cells. After the last washing, the solution of the most equal volume of glycerol and PBS is added, and the sample is covered with a glass coverslip. Under the fluorescence microscope, K Texas red and dihydrofluorescence Samples for the inspection of elementary organs. — .. 81- The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210 × 297 mm) -------- •, -'...---- Please install first κ Read me back Φ ^-^ '-while writing this page) Order

A 谦_ 五、發明説明A Qian_ V. Description of Invention

A66117 下列實例示範納入RB蛋白質至腫瘤细胞源後所得之實驗 结果。特定而言,實例顥示RB蛋白質和其片段透過细胞循 環’以外源添加之RB蛋白質所感染细胞之進化之能力。此 外,實例証明SV40 Τ抗原可解除該封阻作用之影#。 在某些特定實例中* RB基因產物是用ΜΜ全長RB蛋白質 或其片段處理之赍肉瘤细胞源,Saos-2 *之细胞循環進化 。頃發現细胞循環進化是在G1,而該進化是可逆的。 在圖14A至14P中,閫釋MBrdU所標記之Saos2-2细胞之 微注射和免疫染色之结果。Saos-2细胞依本專利說明書所 述注射。圖14 A顯示以ρ56*β注射,立即固定並間接以德州 紅免疫染色RB蛋白質。圖14Β包含MBrdU標記,再固定並 K二氫螢光素共軛化抗-BrdU抗體免疫染色之未經感染之 细胞。圖14C和14D是在早期G1JWp56rb *RctG共注射* M BrdU培養24小時,再固定和染色之同步化细胞之單一所 在。K德州紅染色之细胞標記經注射之細胞,而Μ二氫螢 光素染色之细胞顯示细胞具有併入之BrdU。圖14Ε和14F 是在早期G1K單獨RotG所注射细胞之單一所在。 經濟部中央標準局員工消費合作衽印製 為了鑑定是否蛋白質可穿越细胞孩膜並移位至核内•次 匯集,非同步生長之Saos-2细胞Mp56RB或?110〜细胞質 内微注射,之後再固定5至15分鐘。细胞再K兔子抗-RB抗SI. 47和德州紅共軛化抗-兔.抗體免疫染色。主要 在核内觀察到染色(圖14),雖然可觀察到一些染色出現在 —些經注射细胞之细胞質内。p11〇rbWp56hb蛋白質能在 15分鐘内被運至细胞核。 82 本纸張尺度適用中國國家標隼(CNS ) A4規格U丨0X297公釐) 五、發明説明(γA66117 The following examples demonstrate the experimental results obtained by incorporating RB protein into tumor cell sources. In particular, the examples show the evolutionary capacity of RB proteins and fragments thereof through the cell cycle ' In addition, examples show that the SV40 T antigen can unblock this blocking effect #. In certain specific examples * the RB gene product is a sarcoma cell source treated with MM full-length RB protein or a fragment thereof, and the cell cycle evolution of Saos-2 *. It was found that cell cycle evolution is at G1, and that evolution is reversible. In Figs. 14A to 14P, the results of microinjection and immunostaining of MBosU-labeled Saos2-2 cells are explained. Saos-2 cells are injected as described in this patent specification. Figure 14A shows RB protein injected immediately with ρ56 * β, immobilized immediately and indirectly stained with Texas Red. Figure 14B contains uninfected cells labeled with MBrdU, re-fixed and immunostained with K-dihydrofluorescein conjugated anti-BrdU antibody. Figures 14C and 14D are the single sites of synchronized cells that were fixed and stained in the early G1JWp56rb * RctG co-injection * M BrdU culture for 24 hours. K Texas Red stained cells marked the injected cells, while M dihydrofluorescein stained cells showed that the cells had incorporated BrdU. Figures 14E and 14F show the single location of cells injected by RotG alone in early G1K. Printed by the Consumers' Cooperative Standards of the Central Bureau of Standards of the Ministry of Economic Affairs in order to identify whether the protein can cross the cell membrane and be transferred to the nucleus. 110 ~ cytoplasmic microinjection, and then fixed for 5 to 15 minutes. Cells were immunostained with K-rabbit anti-RB anti-SI. 47 and Texas Red conjugated anti-rabbit. Antibodies. Staining was observed primarily in the nucleus (Figure 14), although some staining was observed in the cytoplasm of some injected cells. The p11〇rbWp56hb protein can be transported to the nucleus within 15 minutes. 82 This paper size applies to China National Standard (CNS) A4 specification U 丨 0X297 mm) 5. Description of the invention (γ

經濟部中央標準局員工消費合作社印製 對於後縝之實驗,由胞典型的KRB蛋白 多選殖之兔子抗-羊抗體(Ra G)共注射作 之標記。據估計每個细胞注射5-50百萬分 每细胞之外源RB蛋白質分子數目估計約1 之蛋白質代表至少超遇內源量之5至50倍 在含有溴脫氧尿苷(BrdU)之生長基中培兼 化過S期之细胞,將併入BrdU至其DNA 。 二氫螢光素-共轭化抗體免疫染色BrdU, 鏟徽抗生物素蛋白免疫染色R«G(圖14)。 射细胞之百分比可在螢光顧微鏡下鑑定, 性细胞部分亦是二氲螢光素-陽性。 在4小時之標記期間中,在烴RB-注射 细胞中BrdU之併入量僅略為少於未經感染 R ct G單獨注射之细胞(表1)。該反應顯示 質製傅物未必概括的對细胞有毒,可由其 DK A併入作用和细胞之附著測定。 -83 - 本紙張尺度適用中國國家標準(CNS ) A4規格(2!OX 297公釐) 質和生物素化* 為經注射细胞質 子之RB蛋白質。 百萬。因此注射 。注射後*细胞 。在棟記期間進 固定後,细胞以 K德州紅共轭化 併入BrdU之經注 因為德州紅-陽 ,非同步生長之 之细胞或K 所使用之RB蛋白 持續之生活力| 表1 非同步生長细胞之微注射 蛋白質漾本 注射细胞 BrdU染色 進入S期之烴注射 之總數β 细胞之總數b 细胞 pp110rb 1094 416 38 p56rb 1315 408 31 R ct G 1725 707 41 姐織牌 106 42 40 未經感染 41 ] :-----、裝------訂-----、'線 (請先聞讀背面之注意事項界.成寫本f) . 46611 f 五、發明説明(笱 A7 B7 經濟部中央標準局員工消費合作社印製 注 射细 胞 之 總 數 (德州紅陽性) ) 茸 白 至 少 五 個倨 別 實 驗 9 但代 表 個 實 驗 之 組 織 脒 注 射 除 外 〇 b,併 入 BrdU 之 經 注 射 细 η*-· 胞 數 1 可 由 其 與 二 氫 螢 光 素連 结 之 抗 Br dU 抗 體 之 均 染 色 得 証 〇 染 色 前 细 胞 在 生 長培 養 基 >1 B r dU培 養 4 小 時 〇 注射 於 G 1早 期 之 RB 蛋 白 質 封 阻 G r dU之 併 入 由 於 在RB 蛋 白 質 之 注 射 時 僅 可 m 察 到 很 小 的 對 BrdU 併 入 之影 響 ,细 胞 可 能 僅 在 细 胞 循 m 之 — 僩 特 定 點 對 RB蛋 白 質 敏感 0 為測 試 該一 假 設 在 同 步 细 胞 內 注 射 RB 〇 以處 理 同 步妞 胞 *使 细 胞 停 於 有 絲 分 裂 9 釋 放 並 另 培 養 6 小時 » 此 時除 去 未- 附 著 细 胞 (adher en t)並 注 射 剌 餘 之 细 胞。 在 BrdU 存 在下 培 養 24小 時 後 固 定 细 胞 並 為 Br dU和 R a G染 色 。至 少 80-90¾之 未 經 感 染 细 胞 因 Br dU染 色 〇 但 是 ,注 射 56 kD 截短 之 蛋 白 質 之 細 胞 在 標 記 期 間 幾 乎 完 全 抑制 經 G1至 S 期之 進 化 〇 該 於 此 點 請 參 看 表 2 和 圖 14C和 14D 0 在注 射 K全 長 RB 蛋 白 質 時 可 觀 察 到 相 同 之 抑 制 作 用0 相 反 的- 注 射K 姐 織 胂 和 R ct G 或 只 是 R a G 之 60 -70X 之 细胞 * 在 標記 期 可進 入 S 期 (画14Ε和 14F) 〇 雖 然 全 長 RB蛋 白質 在 該 條件 下 抑制 Br dU之 併 入 9 但 结 果 稍 許 不 同 〇 烴 過 -段 期 間 ,RB蛋 白質 製 備 物 會 凝 集 等 致 注 射 的 困 難 〇 相 對 於全 長 之 製備 物 ,截 短 之 RB 蛋 質 活 性 是 非 常 一 致 〇 為 延 伸該 觀 察 至 已 表 現 野 生 - 型 全 長 之 细 胞 , 截短 之 請 先 聞ik 背 面 ί 事 項 再 填 寫 本 頁 -Ri - 本紙浪尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 466117 年月£1Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. The experiment of Houyi was marked by co-injection of rabbit anti-goat antibody (Ra G), which is a typical KRB protein. It is estimated that each cell is injected with 5-50 million parts. The number of exogenous RB protein molecules per cell is estimated to be about 1. A protein represents at least 5 to 50 times the endogenous amount. Cells that have undergone S-phase cultures will incorporate BrdU into their DNA. Dihydrofluorescein-conjugated antibody immunostained BrdU, and avidin immunostained R «G (Figure 14). The percentage of ejected cells can be identified under a fluorescent microscope, and the sex cells are also difluorescein-positive. During the 4-hour labeling period, the incorporated amount of BrdU in the hydrocarbon RB-injected cells was only slightly less than that of the cells injected without uninfected R ct G alone (Table 1). This reaction shows that the quaternary substance may not be toxic to cells in general, and can be determined by its DK A incorporation and cell attachment. -83-This paper size is in accordance with Chinese National Standard (CNS) A4 specification (2! OX 297 mm). Biotinylated * is the RB protein with injected protons. million. So injected. * Cells after injection. After the fixation period, cells were conjugated with K Texas Red and incorporated into the BrdU via injection. Because of Texas Red-Yang, cells that grow asynchronously or the RB protein used by K have sustained viability | Table 1 Asynchronous Microinjected protein from growing cells Yang BinU stained cells Total number of hydrocarbon injections entering S phase β Total number of cells b Cells pp110rb 1094 416 38 p56rb 1315 408 31 R ct G 1725 707 41 Sister Weaver 106 42 40 Uninfected 41 ]: -----, installed ------- ordered -----, 'line (please read the notes on the back of the world first. Written copy f). 46611 f V. Description of the invention (笱 A7 B7 The total number of injection cells printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (Texas red positive)) White at least five (except for tissues that represent an experiment) except for injections 0b, injections that are incorporated into BrdU -· Cell number 1 can be confirmed by the staining of all anti-Br dU antibodies linked to dihydrofluorescein. The cells were cultured in growth medium > 1 B r dU for 4 hours before staining. RB protein shot in early G 1 blocks the incorporation of Gr dU. Since only a small effect on BrdU incorporation can be observed during the injection of RB protein, cells may only be in the cell cycle m-僩 specific point Sensitive to RB protein 0 To test this hypothesis, RB was injected intra-synchronously to treat synchrony cells * Stop cells at mitosis 9 Release and culture for another 6 hours »At this point, remove non-adherent cells (adher en t) and inject Remaining cells. After BrdU was cultured for 24 hours, the cells were fixed and stained for BrdU and RaG. At least 80-90¾ of uninfected cells were stained with BrdU. However, cells injected with the 56 kD truncated protein almost completely inhibited the evolution from G1 to S during the labeling period. At this point, please refer to Table 2 and Figure 14C. The same inhibitory effect was observed when 14D 0 was injected with K full-length RB protein. 0 Opposite-injection of K-spinweed and R ct G or cells with only 60 -70X of Ra G * can enter the S phase during the labeling phase ( (Draw 14E and 14F) 〇Although the full-length RB protein inhibits the incorporation of Br dU 9 under these conditions, the results are slightly different. During the hydrocarbon transition period, the RB protein preparation may agglutinate and cause injection difficulties. Compared to the full-length preparation The truncated RB egg activity is very consistent. In order to extend the observation to cells that have exhibited wild-type full length, for truncation, please listen to the back of ik and fill out this page-Ri-This paper applies the Chinese national standard (CNS) A4 specifications (210X297 Mm) 466117 £ 1

修正 4 M A7 B7 經濟部中央標準局負工消費合作社印製 五、發明説明 RB蛋白質注射至衍生自Saos-2之细胞源SR-40 *其毽定的 表現全長RB蛋白質。在G1早期注射之RB蛋白質對同步 SR-40细胞之影響和對Saos-2细胞之影響相同(表2 ); k 24小時之標記期間,非常少注射RB截短之蛋白質之细胞進 入S期。因此•内源野生-型全長RB蛋白質之存在並不干 擾RB截短之蛋白質對细胞循環進化之影響。 為了測定ϋΒ截短蛋白質對進入S期之封阻作用可持鑛多 久,在B「dU存在下之標記期間自1天延至2或4夭。Β 15圖示在標記期間併人BrdU之烴注射Soas-2细胞之數目。 自尼可唑處理釋放後6-7小時,Saos-2细胞M56 kD RB蛋 白質和RaG共注射。注射後,在固定和染色前细胞培養於 補充BrdU之培養基中培養所示之天數。百分比值顯示在標 記期間併入BrdU之經注射细胞之數目。該值代表至少100 個經注射之細胞。在KBrd II培養2天後,在固定和染色前 仍可観察到细胞循環進化之抑制作用。注射後4天· 80X KRB截短之蛋白質注射之细胞能併入BrdU。該類觀察顯示 Ο蛋白質對细胞循環之封阻是可逆的並且延至2和4天之間 0 截短之RB蛋白質之影響對劑量之依賴度亦經測量。稀釋 之蛋白質整分在G1早期注射至同步生長之細胞内》圖16圖 示细胞循環停滯對p56rb劑量之依賴度。Saos-2细胞在自 尼可唑處理釋放後6-8小時,K所示濃度之截短蛋白質和 1奄克/毫升RaG共注射。以BrdU培養於生長培養基24小 時後,细胞固定並為BrdU和RcxG染色。柱形围顯示併入 一 8 5_ - 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐>Amendment 4 M A7 B7 Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention RB protein was injected into the cell source SR-40 derived from Saos-2 * Its predetermined expression is full-length RB protein. The effect of RB protein injected in early G1 on synchronous SR-40 cells is the same as that on Saos-2 cells (Table 2); k 24 hours of labeling, very few cells injected with RB truncated protein enter the S phase. Therefore, the presence of endogenous wild-type full-length RB proteins does not interfere with the effect of RB truncated proteins on cell cycle evolution. In order to determine how long the ϋβ truncated protein can block the entry into the S phase, the labeling period in the presence of dU was extended from 1 day to 2 or 4 夭. B 15 shows the hydrocarbon injection of BrdU during the labeling period Number of Soas-2 cells. 6-7 hours after the release of Nicozole treatment, Saos-2 cells were co-injected with M56 kD RB protein and RaG. After injection, cells were cultured in BrdU supplemented medium before fixation and staining. Number of days shown. The percentage value shows the number of injected cells that were incorporated into BrdU during the labeling period. This value represents at least 100 injected cells. After 2 days of KBrd II culture, cell circulation can still be observed before fixation and staining Inhibition of evolution. 4 days after injection · 80X KRB truncated protein-injected cells can incorporate BrdU. This type of observation shows that the blocking of cell circulation by the 0 protein is reversible and extends to 0 and 2 truncations between 2 and 4 days The dose-dependent effect of the RB protein effect was also measured. Diluted protein fractions were injected early into G1 into synchronously growing cells. Figure 16 illustrates the dependence of cell cycle arrest on p56rb dose. Saos-2 cells Ny 6-8 hours after the azole treatment release, truncated protein at the concentration indicated by K and 1 g / ml RaG were co-injected. After cultured in BrdU for 24 hours in the growth medium, the cells were fixed and stained for BrdU and RcxG. Merge into a 8 5_-This paper size applies to China National Standard (CNS) A4 specifications (210X297 mm >

In i--- 二 ί —II 1\—/^ I ^1 (讀先閲讀背面之注意事項-%-填寫本頁) J* -丁In i --- 二 ί —II 1 \ — / ^ I ^ 1 (Read the precautions on the back-%-fill this page) J *-丁

BrdU之經注射细胞之百分比。各數值代表至少150届經注 射之妞胞。如圖14所示=自原濃度稀釋5倍之截短RB蛋白 質減弱其抑制活性*而稀釋至2倍之整分仍保有抑制效果 。因此,p56r&對進入S期之封阻作用是視注射之蛋白質 量而定。BrdtJ併入之封阻作用的最低下限是0.2和0.5毫 克/毫升注射之蛋白質。 為了証明進入S期之抑制作用是由RB蛋白質所造的•封 阻作用可用特定與截短蛋白質结合之試劑減弱。ϋΒ蛋白質 (P56RB)和1毫克/毫升之兔子多選殖抗體.495,.47 * 或R2溶液混合。該類抗體是培養以對抗獨特之RB融合蛋白 質,在西向塗抹物上識別RB截短之蛋白質(31, 49, 56) 。注射RB截短之蛋白質和.495之混合物造成約30¾经注射 细胞中之BrdU併人,相較於以單獨該萑白質注射之细胞中 幾乎完全缺乏併入之情形(表2)。以該蛋白質和抗體 .47共注射之细胞併人約16X當時之BrdU。共注射截短之 RB蛋白質和抗體R2亦展現減弱的抑制活性,雖然其影堪不 如抗體.47或.495強烈。由於和RB蛋白質结合之抗體減弱 該蛋白質之抑制影W,對於BrdU併入之封阻作用是特定的 由RB蛋白質所引起的。 (請先閲讀背面之注意事項真,填窝本頁} -裝 訂 線 經濟部中央標準局負工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210><297公釐) 4661 1 "7 五、發明説明(濟Γ Α7 Β7 經濟部中央標準局員工消f合作社印裝 表2:同部生長之细胞在G1早期之微注射 , _ . __ . 细胞源 蛋白筲 刖跑教s** !i「dU 染[i 之 迎胞之 .数目b 讹人S叩妁 浊射之則胞工 Saos-2 pll0'^c 255 8 3 RaGc 270 173 &4 ρ5δ?3 388 12 3 . RaG. 295 202 ;; S3 姐識眯 59S 333'' 5S 未經?js染 84 dSS^3 d 247 10 4 p56?3 d + . /4 9 5 80 24 30 d5S?j d -f :47 596 95 16 pSS^ d + R2 712 43 S SR-4 0 p56^ 89 3 3 - 20X 105 52 RaG 134 74 55 (請先閲讀背面之注意事項备填寫本頁) __~ η 7 一_ 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 修正 年月日、_補先 Α7 Β7 五、發明説明(拉) .經注射细胞之缌數(德州紅陽性),計算自至少三涸儷別 實驗。 b.併入BrdU之經注射细胞數,可由其與二氫螢光素連结之 抗BrdU抗體之均匀染色得証。注射後,染色前细胞在生 長培養基M BrdU培養24小時。 .在含有10¾甘油之緩衝液中進行注射 在該類實驗中注射之截短RB蛋白質之濃度是約.3-.5毫 克/毫升,而不是1毫克/毫升。 經濟部中央標準局員工消費合作社印製 截短之蛋白質若在S期注射並不 在G1早期注射RB蛋白質後所観 可解釋為DNA合成之抑制作用。 處理使Saos-2细胞停滯在S早期 。如圖17之圖示|若該蛋白質是 併作用不為該蛋白質抑制。透過 Saos-2细胞停滯在G1/S,再予K 注射後,细胞自停滯中釋放並 基脲)或4-6小時(蚜可林)*此 可唑處理使细胞亦停滯在有絲分 在約6小時後注射。注射後* K 固定並染色。 玆顯示用於注射之蛋白質製備 後,因B「dU染色之注射细胞之百 可林處理中釋放並K BrdU培養4-為BrdU和RctG免疫染色。與G1早 抑制BrdU併人作用 察之缺乏BrdU併入作用* 為測試該解釋,K蚜可林 |再注射截短之RB蛋白質 在S期注射》則BrdU之合 羥基脲或蚜可林之處理* 注射。 以BrdU培養6-δ小時(羥 時固定並染色细胞。以尼 裂。釋放後,收集细胞並 BrdU培養细胞24小時,再 物。頭示在相關標示期間 分比。注射後*细胞自蚜 6小時,固定,並如所述 期注射之细胞相反•約 L,--------裝-----— 訂-----、啸 (讀先聞讀背面之注意事項#'4!'寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 466117 年月曰The percentage of BrdU injected cells. Each value represents at least 150 injected girls. As shown in Figure 14 = A truncated RB protein diluted 5 times from its original concentration weakens its inhibitory activity *, but an integer fraction diluted to 2 times still retains the inhibitory effect. Therefore, the blocking effect of p56r & s entering S phase depends on the amount of protein injected. The lower limit of blocking effect incorporated by BrdtJ is 0.2 and 0.5 mg / ml of injected protein. In order to prove that the inhibitory effect of entering the S phase is caused by the RB protein, the blocking effect can be weakened with a reagent that specifically binds to the truncated protein. ϋΒ protein (P56RB) was mixed with 1 mg / ml rabbit polyclonal antibody .495, .47 * or R2 solution. These antibodies are cultured against unique RB fusion proteins and recognize RB truncated proteins on westward smears (31, 49, 56). The injection of a mixture of RB truncated protein and .495 resulted in approximately 30¾ of BrdU in the injected cells, compared to the almost complete lack of incorporation in the cells injected with the lutein alone (Table 2). The cells were co-injected with the protein and antibody .47 and humans were approximately 16X BrdU at that time. Co-injection of truncated RB protein and antibody R2 also showed reduced inhibitory activity, although its effect was not as strong as that of antibody .47 or .495. Since the antibody bound to the RB protein weakens the inhibitory effect of the protein, the blocking effect on BrdU incorporation is specifically caused by the RB protein. (Please read the precautions on the back first, fill in this page}-Printed by the Central Standards Bureau of the Ministry of Economic Affairs, Consumer Work Cooperative, this paper is printed in accordance with the Chinese National Standard (CNS) A4 specification (210 > < 297 mm) 4661 1 " 7 V. Description of the invention (济 Α7 Β7 Printed by the staff of the Central Standards Bureau of the Ministry of Economic Affairs and Cooperatives. Table 2: Microinjection of cells grown in the same area in the early stage of G1, _. __. Teach s **! I 「dU [[i welcomes the siblings. The number b 讹 人 S 叩 妁 turbidity is the sage worker Saos-2 pll0 '^ c 255 8 3 RaGc 270 173 & 4 ρ5δ? 3 388 12 3. RaG. 295 202; S3 sisters know 59S 333 '' 5S without dyeing 84 dSS ^ 3 d 247 10 4 p56? 3 d +. / 4 9 5 80 24 30 d5S? Jd -f: 47 596 95 16 pSS ^ d + R2 712 43 S SR-4 0 p56 ^ 89 3 3-20X 105 52 RaG 134 74 55 (Please read the notes on the back first and fill in this page) __ ~ η 7 I_ This paper size Applicable to China National Standard (CNS) A4 specification (210X297 mm) Amendment date, _ supplement first A7 B7 V. Description of the invention (pulling). Number of cells injected (Dezhou Hongyang The number of injected cells incorporated into BrdU can be confirmed by the uniform staining of the anti-BrdU antibody linked to dihydroluciferin. After injection, the cells were stained before staining. The growth medium M BrdU was cultured for 24 hours. The injection was performed in a buffer containing 10¾ glycerol. The concentration of the truncated RB protein injected in this type of experiment was about .3-.5 mg / ml instead of 1 mg / ml. If the truncated protein printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs is injected in the S phase and is not injected after the early injection of RB protein in G1, it can be explained as the inhibition of DNA synthesis. Processing causes Saos-2 cells to stagnate in the early S. Such as Figure 17 | If the protein does not inhibit the protein. Saos-2 cells are stagnated at G1 / S, and after K injection, the cells are released from the stasis and hydrazide) or 4-6 hours ( Aphids) * This coxazole treatment also stagnated the cells at the fibroblasts and injected after about 6 hours. After the injection * K was fixed and stained. It is shown that after the preparation of the protein used for injection, the cells were stained with dU staining. Released in the Becklin treatment and K BrdU culture 4- for BrdU and RctG immunostaining. Insufficient effects of BrdU and G1 in combination with G1. Absence of BrdU incorporation * To test this explanation, K aphidolin | Re-injection of truncated RB protein in S phase injection "treatment of BrdU with hydroxyurea or aphid * Injection. Cells were cultured with BrdU for 6-δ hours (cells were fixed and stained at hydroxyl time. Epithelium. After release, the cells were collected and cultured with BrdU for 24 hours, and reproduced. The head shows the proportions during the relevant labeling period. After injection * cells from aphid 6 Hours, fixed, and reversed the injection of cells as described in the period. • About L, -------- installed ------- ordered -----, Xiao (Read the notes on the back and read # '4!' Write this page) This paper size is applicable to China National Standard (CNS) A4 specification (210X297 mm)

述方」 Α7 Β7 經濟部中央標準局员工消費合作社印製 五 '發明説明(m---------------------------一 60¾之經注射截短之RB蛋白質,烴蚜可林所停滞之细胞因 BrdU併入而圼陽性染色。進入S期细胞之百分比和BrdU染 色之密度和Μ姐織胂和RctG,或單獨RaG注射之细胞類似 。為了控制注射後RB蛋白質功能之任何可能的延遲期,K RB蛋白質注射蚜可林所停滯之细胞,在釋放和KBrdU標記 前再培養額外的6小時。雖然BrdU染色之密度稍微較低· 可能是由於K蚜可林培養過久所致,其百分比相當於單獨 MRctG注射之细胞。 Μ羥基脲而不是蚜可林停滯细胞進行類似之實驗。羥基 脲在靠近G1/S邊界異於蚜可林停滯之點停滯细胞。Saos -2细胞以羥基脲處理停滯於靠近G1/S,再以截短之RB蛋白 質注射。注射後,细胞自羥基腺處理釋放並KBrdU擇記6 至8小時。再一次,注射之截短蛋白質對於BrdU併入作用 無可测得之抑制作用。不論KRB蛋白質和RaG*組織脾和 RaG,或單獨RaG注射,细胞合成DNA之百分比均相同。 該结果和MRB蛋白質注射之非同步生長细胞之觀察一致 |意指就DNA合成作用本身而言| RB截短蛋白質無法明顯 的封阻該作用。因此,DN A合成作用之抑制作用無法解釋 在G1早期注射蛋白質至同步化细胞時所見之完全缺乏 BrdU合併作用。 RB蛋白質在特定點封阻經由G1期之進化 ‘依照上述實驗之结果•截短蛋白質之抑制性作用一定是 因為封阻經由G1期之進化〇為了定義G1期内該停滞之位置 ,先測定在Saos-2细胞之细胞循環中,S期開始之精密時 本紙張尺度適用中國國家標準(CNS ) Α4規格(2Ι〇Χ2ί>7公釐) -----------裝------訂-----1) 0---------------- ” 一 (請先聞讀背靣之注意事續#,.填寫本頁) 年 B5- ,修正補充 A7 B7 五、發明説明(^?) 間刻度。圈18A至18C圖示說明细胞循環停滯對注射截短之 蛋白質之期間的依賴度。闞於圖13A, Saos-2细胞透過K 尼可唑處理停滯於有絲分裂。自停滞釋放後,细胞在 Br*dU之存在下培養所示之時數,再固定並以抗-Brdu抗體 染色。柱形圖頭示所算出因BrdU染色之细胞的百分比。各 數值表示至少200個细胞。 如圖20 A所示,未感染细胞自釋放後約20小時因BrdU而 染色。到30小時*實際上80-90¾之细胞併人BrdU。 據此*進行時間過程之實驗,其中經尼可唑處理之细胞 自停滯釋放後在不同時間以}>56RB蛋白質注射。圖18B K 小時為單位闞述自停滯之有絲分裂中釋放後•在Saos- 2 细胞中S期開始之時間。G1期長約22至24小時。S期長約 7至δ小時。G2期尚未精密測定出其時間長度。箭頭所示 是各注射時間點,用於圖18C說明中所描述之實驗。 經濟部中央標準局—工消费合作社印裝 關於圖18C, Saos-2细胞自尼可唑處理釋放後,在所示 之各時間(小時為單位)M 1毫克/毫升截短之RB蛋白質和 RcxG共注射。注射後在培養基內从BrdU持續培養至原來自 尼可唑釋放後算起30小時,BrdU標記後*固定细胞並為 BrdU和RctG染色细胞。柱形圖頭示併入BrdU之經注射蛋白 質之细胞之百分比。各數值代表至少20 0個經注射之细胞 Ο 釋放後30小時非常少的细胞進入S期,如果蛋白質在尼 可唑釋放後5-10小時注射(圈20C)。若截短之RB蛋白質在 停滯後14-16小時後注射,栢當數目之细胞併入BrdU。在 本纸張尺度適用中國國家標準(CNS ) A4规格(210X297公釐) ,661 t 五 '發明説明"The party" Α7 Β7 Printed by the Consumer Standards Cooperative of the Central Bureau of Standards of the Ministry of Economy After injection of truncated RB protein, the cells arrested by hydrocarbon aphids can be positively stained due to the incorporation of BrdU. The percentage of cells entering the S phase and the density of BrdU staining and M. weave and RctG, or RaG injection alone The cells are similar. In order to control any possible delay in the function of RB protein after injection, K RB protein was injected into the cells arrested by aphidolin and cultured for an additional 6 hours before release and KBrdU labeling. Although the density of BrdU staining was slightly lower · May be due to K aphid collin cultured for too long, the percentage is equivalent to the cells injected with MRctG alone. Similar experiments were performed with hydroxyurea instead of aphid collin arrested cells. Hydroxyurea is different from aphids near the G1 / S boundary Kolin stagnated the cells and stagnated the cells. Saos-2 cells were stagnated near G1 / S with hydroxyurea treatment, and then injected with truncated RB protein. After injection, the cells were released from the hydroxy gland treatment and KBrdU was selected for 6 to 8 hours. Again, the truncated protein injected was incorporated into BrdU No measurable inhibitory effect. The percentage of DNA synthesized by cells was the same whether KRB protein and RaG * tissue spleen and RaG, or RaG injection alone. This result is consistent with the observation of asynchronous growth cells injected with MRB protein | In terms of DNA synthesis itself, RB truncated proteins cannot significantly block this effect. Therefore, the inhibitory effect of DNA synthesis cannot explain the complete lack of BrdU pooling effect seen in the early injection of protein into synchronized cells in G1. RB protein Blocking the evolution through the G1 phase at a specific point 'according to the results of the above experiments • The inhibitory effect of truncated proteins must be due to blocking the evolution through the G1 phase. To define the location of this stagnation during the G1 period, first determine In the cell cycle of 2 cells, the precision of this paper at the beginning of the S phase applies the Chinese National Standard (CNS) Α4 specification (2Ι〇Χ2ί > 7 mm) ----------- packing ---- --Order ----- 1) 0 ---------------- "One (please read and read the note of memorabilia first continued # ,. Fill in this page) Year B5- , Amend and add A7 B7 V. Inventive (^?) Scale. Circles 18A to 18C illustrate cells Dependence of circulatory arrest on the duration of truncated protein injection. As shown in Figure 13A, Saos-2 cells are arrested by mitosis by K Nicozole treatment. After release from arrest, cells are cultured in the presence of Br * dU as shown Hours, re-fixed and stained with anti-Brdu antibody. The head of the bar graph shows the calculated percentage of cells stained with BrdU. Each value represents at least 200 cells. As shown in Figure 20A, uninfected cells are approximately 20 hours stained with BrdU. By 30 hours * cells of 80-90¾ are actually human BrdU. Based on this *, a time course experiment was performed in which cells treated with nicozole were injected with} > 56RB protein at different times after stagnant release. Figure 18B. The time in K hours describes the time since the onset of S phase in Saos-2 cells after release from stagnant mitosis. The G1 period is about 22 to 24 hours long. The S phase is about 7 to δ hours long. The length of G2 phase has not been precisely determined. The arrows indicate the injection time points for the experiments described in the description of Figure 18C. Printed by the Central Bureau of Standards, Industrial and Consumer Cooperatives, Ministry of Economic Affairs About Figure 18C, after Saos-2 cells were released from Nicozole treatment, M 1 mg / ml truncated RB protein and RcxG at each time shown (hours) Total injection. After the injection, BrdU was continuously cultured in the medium for 30 hours from the original release of Nicozole. After BrdU labeling, the cells were fixed and stained for BrdU and RctG. The head of the bar graph shows the percentage of cells injected with BrdU protein. Each value represents at least 200 injected cells. Very few cells enter S phase 30 hours after release, if the protein is injected 5-10 hours after nicozole release (circle 20C). If the truncated RB protein is injected 14-16 hours after the stagnation, the number of cells in the pardant is incorporated into BrdU. In this paper size, the Chinese National Standard (CNS) A4 specification (210X297 mm) is applied, 661 t

A7 B7 釋放後17-19小時注射,截短之蛋白質對進入s期無可 測得之影響。 假設S期在自尼可唑釋放後22至2 4小時間始,該结果建 議在G1/S過渡前約6-10小時,细胞變得對注射之RB蛋白質 之抑制作用不易控制。該结果確定RB蛋白質對细胞循環之 抑制性作用乃是因為封胆經由G1期之進化,而非封姐DNA 合成作用本身。再者,該類觀察意指RB可能在G1期内一個 特定*相當早的時間點作用。 輕濟部中央標準局員工消費合作社印製 L--------裝—I (請先閱讀背面之注意事碩再4:寫本頁) 隹 SV40 T抗原解除截短之RB蛋白質造成之經封阻妞胞循環 作為SV40 T-抗原於結合時功能性失活RB蛋白質之渥設 的測試,在SV40 T抗原之存在下或不存在下•比較截短之 RB蛋白質注射於G1進化之影響。能和p56rb结合之1毫莫 耳湄度T胜肽溶液和等容量截短之RB蛋白質混合並注射至 G1早期之同步化细胞內。在該濃度*胜肽是M100至200 倍克分子量多過RB蛋白質。在標記期間*約28X注射K截 短之RB蛋白質/T胜肽混合物之同步化细胞進入S期(表 3)。若T胜肽濃度増至5毫莫耳滬度,或過500至1000 倍克分子量,約70¾之經注射之细胞併入BrdU。相反的, K截短之RB蛋白質和過500至1000倍克分子量*未與截短 之RB蛋白質结合之羧基端P53胜肽注射後,幾乎無细胞進 化至S期。 亦比較注射截短之RB蛋白質對非洲綠猴腎细胞源CV-1和 C0S-7之影響。選釋C0S-7细胞是因為其係透過以原-缺 陷SV-40突爱種轉化而衍生自CV-1细胞,大fi之T-抗涯》 91 表紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)A7 B7 was injected 17-19 hours after release. The truncated protein had no measurable effect on entering the s phase. Assuming that the S phase begins 22 to 24 hours after the release of nicozole, the results suggest that about 6-10 hours before the G1 / S transition, the cells become difficult to control the inhibitory effect of the injected RB protein. This result confirms that the inhibitory effect of RB protein on cell circulation is due to the evolution of gall bladder through the G1 phase, not the DNA synthesis of the sister. Furthermore, this type of observation implies that RB may be acting at a specific * fairly early point in time during the G1 period. Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Light of the People's Republic of China —---- install—I (please read the precautions on the back, then 4: write this page) The blocked cell cycle is used as a test for functionally inactivating RB protein when SV40 T-antigen is bound, in the presence or absence of SV40 T antigen. • The truncated RB protein was injected into G1 evolution. influences. A solution of 1 millimolar T-peptide capable of binding to p56rb and an equal volume of truncated RB protein was mixed and injected into the early synchronized cells of G1. At this concentration * peptide is M100 to 200 times more molecular weight than RB protein. Synchronized cells injected with K-truncated RB protein / T-peptide mixture during the labeling period * approximately 28X entered S phase (Table 3). If the concentration of T-peptide is 増 to 5 mmol, or the molecular weight is 500 to 1,000 times, the injected cells of about 70¾ are incorporated into BrdU. In contrast, after injection of the K-truncated RB protein and the carboxy-terminal P53 peptide that did not bind to the truncated RB protein after 500 to 1000 times the molecular weight *, almost no cells progressed to the S phase. The effect of truncated RB protein injection on CV-1 and COS-7 derived from kidney cells of African green monkeys was also compared. The COS-7 cells are selected for release because they are derived from CV-1 cells by transformation with the original-deficient SV-40 gene. The T-resistant of the big fi 91. The paper size applies the Chinese National Standard (CNS) A4. Specifications (210X297 mm)

經濟部中央標準局員H消費合作社印製 五、發明説明(sp 因此,可作為內源之T-抗原的存在對於注射之RB蛋白質活 性之影響的良好測試系統。在G1早期K截短之RB蛋白筲注 射之同步化CV-1细胞併入BrdU之百分比*至少低於以單獨 RG注射者之5倍(表3)。但是,同步化之C0S-7细胞完全 未被抑制進化至S期。該類結果顯示内源之T-抗並且表現 大量之T-抗源。因此,可作為内涯之T-抗原的存在對於注 射之RB蛋白質活性之影響的良好測試系统。在G1早期K截 短之RB蛋白質注射,併入BrdU之同步化CV-1细胞之百分比 ,至少低於以單獨RctG注射者之5倍(表3)。但是,同步 化之COS-7細胞完全未被抑制進化至S期。該结果顯示内 源之T-抗原之存在,或以T-抗原胜肽共注射可中和RB蛋白 質之抑制性活性。因此,熟於此藝者可利用該系统篩選 RB蛋白質片段,透過在RB蛋白質之存在下比較進入s期之 CV-1和COS-7细胞之百分比,鑑定均能封姐细胞循環進化 之片段。 前述结果提供功能性証明,顯示RB蛋白質能經由细胞循 環抑制進化。注射截短之p56rb蛋白質並不能抑制DHA合 成作用本身*因為經由蚜可林或羥棊脲所停滞之细胞不受 影響,因而是澍姐經由G1期之進化》該循環進化之抑制作 用是劑量-依賴的,並非因為對细胞之一般毒性而是特定 於RB蛋白質•因為抗體特定的和截短之RB蛋白質结合可減 弱其活性。循環之细胞對RB蛋白質之抑制作用非常敏感, 直至開姶DNA複製前約6-10小時;此後*外源添加截短之 RB蛋白質不再抑制進化至S期。假設在注射截短之RB蛋白 -92 - 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X297公釐) ---Γ-------)-裝------、訂---- (諳先閱讀背面之注意事項弄堪寫本頁) 1,Printed by H Consumer Cooperative, Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of Invention (sp Therefore, it can be used as a good test system for the effect of the presence of endogenous T-antigens on the activity of injected RB proteins. K truncated RB proteins in early G1百分比 The percentage of injected synchronized CV-1 cells incorporating BrdU * is at least 5 times lower than that of those injected with RG alone (Table 3). However, the synchronized COS-7 cells did not inhibit evolution to S phase at all. The results show endogenous T-antibodies and show a large amount of T-antibodies. Therefore, they can be used as a good test system for the effect of the presence of T-antigens on the RB protein activity injected. In the early G1 period, K is truncated. The percentage of synchronized CV-1 cells that were injected with RB protein and incorporated into BrdU was at least 5 times lower than those injected with RctG alone (Table 3). However, the synchronized COS-7 cells did not inhibit evolution to S phase at all The results show that the presence of endogenous T-antigen or co-injection with T-antigen peptides can neutralize the inhibitory activity of RB protein. Therefore, those skilled in this art can use this system to screen RB protein fragments and Comparative entry in the presence of RB protein The percentages of CV-1 and COS-7 cells in the period are identified as fragments that can cycle the evolution of the sister cell. The foregoing results provide functional proof that RB protein can inhibit evolution through cell cycle. Injection of truncated p56rb protein does not inhibit DHA synthesis itself * Because the cells that are stopped by aphids or hydroxyurea are not affected, it is the evolution of G1 through G1. The inhibitory effect of this cycle of evolution is dose-dependent, not because of the general effect on cells. Toxicity is specific to RB protein • Because antibody-specific and truncated RB protein binding can reduce its activity. Circulating cells are very sensitive to the inhibitory effect of RB protein, until about 6-10 hours before opening DNA replication; thereafter * Exogenous addition of truncated RB protein no longer inhibits evolution to S. It is assumed that injection of truncated RB protein -92-This paper size applies to China National Standard (CNS) A4 (210X297 mm) --- Γ- ------)-install ------, order ---- (谙 first read the precautions on the back to write this page) 1,

! I I J t. * I 661 1 T 4! I I J t. * I 661 1 T 4

五、發明説明(产) 質和在核内出現其活性形式之間存在很短的遲延期,可下 结論RB蛋白質是在G1期的一個關鍵點抑制進化至S期。 DNA合成作用前6-10小時時間窗可能類似於G1限制點後之 間期,該限制點是哺乳類细胞湄進入S期之不可逆點。 定義之時間窗未必精確的反應當1ΪΒ蛋白質在正常生理條 件下作用之時間點。自該類實驗無法明瞭注射之全長RB蛋 白質或截短之RB蛋白質箱時多久能以其活性構型和/或位 置出現。但是,RB蛋白質在细胞質注射後15分鐘内埋至细 胞核*在釋放和標記前持鑛Kaphidicolin培養注射Κ截 短之RB蛋白質之细胞並不會減少併入BrdU之细胞百分比。 該頬觀察顯示,注射後RB蛋白質轉變成功能所裔之時間很 短0 經濟部中央標準局員工消費合作社印製 由全長RB蛋白質之活性形式轉變成失活形式已假設是發 生在G1/SS界·因為蛋白質在該點進行密集的磷酸化作用 。但是*由於前述已定義出一個較早期間*似乎對於截短 之RB蛋白質之活性具翮鍵性。因此,RB可能涉及在G1/S過 渡前約6-10小時,细胞在該點所作的調節性決定。RB蛋白 質在體內和腊外均可在多重位置瞵酸化,但並不明瞭那— 磷酸化位置對RB之功能最重要。在G1期些微增加鱗酸化作 用可能和细胞轉化自RB-感應至不-感應狀態有闞°已在 G1期観察到重姐體,全長RB蛋白質之一些磷酸化作用,雖 然也可能是因為不完全同步化之细胞造成的。 RB之菝基-端56千道耳呑是足以抑制經由G1期之進化。 顯示重姐產生之全長蛋白質之羧基-端半部對於其细胞循 93 -本纸張尺度適用中國國家標準(CNS ) A4規格(2丨0X297公釐) 年5. Description of the invention There is a short delay between the quality of the product and its active form in the nucleus. It can be concluded that the RB protein inhibits evolution to the S phase at a key point in the G1 phase. The 6-10 hour time window before DNA synthesis may be similar to the period after the G1 limit point, which is the irreversible point at which mammalian cells enter the S phase. The defined time window does not necessarily accurately reflect the point in time when the 1ΪΒ protein acts under normal physiological conditions. From this type of experiment, it is not clear how long the injected full-length RB protein or truncated RB protein box can appear in its active configuration and / or location. However, RB protein was buried in the nucleus within 15 minutes after cytoplasm injection. * Kaphidicolin cultured K-truncated RB protein-injected cells prior to release and labeling did not reduce the percentage of cells incorporating BrdU. The observation shows that the time for RB protein to become functional is very short after injection. Because the protein is densely phosphorylated at this point. But * because an earlier period has been defined as described above * it seems to be bondable to the activity of the truncated RB protein. Therefore, RB may involve regulatory decisions made by the cell about 6-10 hours before the G1 / S transition. RB protein can be acidified at multiple positions in vivo and in vitro, but it is not clear that the position of phosphorylation is most important for the function of RB. A slight increase in scalylation during G1 may be related to the cell's transformation from RB-sensing to non-sensing. ° Some phosphorylation of full-length RB proteins has been observed in G1, although it may also be due to incompleteness. Caused by synchronized cells. The basal-terminal 56-kilophones of RB is sufficient to inhibit evolution through the G1 phase. Shows that the carboxyl-terminal half of the full-length protein produced by her sister is used for her cell cycle 93-This paper size applies the Chinese National Standard (CNS) A4 specification (2 丨 0X297 mm) years

A B7 五、發明説明(f/) 環之影響,事賁上是其功能部位。靥於該蛋白質之羧基-端半部之二個生化活性,DN A结合和蛋白質结合作用。根 據目前之發現,和DH A结合之RB序列專一性很低,雖然Μ 高G/C内含S Κ些微較高之親和力和DNA结合•但並不特 別偏好某一特殊序列◊另一方面,在RB和蛋白質之结合作 用上觀察到專一性。數個DNA轉化病毒之轉化蛋白質Κ及 细胞蛋白質之次體和重姐體製造之全長RB蛋白質之同一功 能部位结合,因此可彼此競相與RB蛋白質结合。該區域是 大多數天然存在失活之RB突變型位置所在。似乎RB蛋白質 封阻G1期之進化有賴於特定的蛋白質-蛋白質交互作用。 經濟部中央標準局負工消費合作社印製 —r--------ri—I (請先閱讀背面之注意事項耳填寫本頁) 訂 截短之RB蛋白質和衍生自SV 40 Τ-抗原,並可與截短之 RB蛋白質結合之胜肽混合*可避免其抑制性後果。截短之 RB蛋白質和含有單一胺基酸取代之胜肽K多過500至 1000倍克分子量共注射,亦可減弱*至某一程度*對細胞 循環進化之封阻作用。雖然胺基酸之取代降低其賭外對 RB蛋白質之親和力*該突變型T胜肽當K懸殊過霣之克分 子量存在時,仍可在體内和截短之RB蛋白質结合。相反的 ,注射完金無效之P53胜肽對於RB蛋白質之抑制性活性毫 無影響*因而加強在ΙΪΒ蛋白質和T-抗原胜肽之間所観察到 之交互反應之專一性。在G1早期以截短之RB蛋白質注射之 CV-1细胞在S期前停滯,而表現大量T-抗原之COS-7细胞 則未停滞。該類觀察一起顯示T-抗原结合作用對RB蛋白質 確實具有功能性之影轡。由於注射用截短之RB蛋白質是未 經磷酸化的,測試之結果和對细胞分化之抑制作用有胡之 張 紙 本 準 標 家 國 國 中 用 適 2I /1« 釐 公 97 2 46611 7 年月 η 修正 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(f>) KB蛋白質之活性形式是未經磷酸化之形式之假說—致。因 此* 一些DNA腫瘤病毒之轉化蛋白質,包括SV40 T-抗原 和腺病毒E1A ,透過结合和失活化低度瞵酸化重姐體製造 之全長RB蛋白筲可促進细胞之生長,至少一部分。细胞之 不滅和表現該類轉化蛋白質時所誘發之無法靜息和细胞循 環失去調節作用之表瑱型一致。 假設RB蛋白質之羧基-端半部是具生物活性的,問題則 是RB的胺基-端半部之功能為何》該區域內之序列可能是 適當之蛋白質璘酸化作用所需。在老鼠细胞中,類似於截 短之RB蛋白質之多胜肽未被過度磷酸化。而且,cdc2/ MPF激酶之數個一致位置出現在該區域内。和RB蛋白質之 胺基端半部可能含有調節性功能部位•可抑揚調節RB之功 能的說法一致。截短之Ο蛋白質對G1進化之封阻作用的解 除直至注射後3-4天始發生;該冗長停滞期間可能是因為 细胞無法K正常的方式調節RB蛋白質*或是因為所注射之 相當大量RB蛋白質。在本測試中*在瞵酸化位置上具突變 之各種RB蛋白質,比較其活性有助於解答該問題。若截短 之RB蛋白質结構上具活性•因突變而產生之多胜呔懕可抑 制细胞之分化並因而置细胞於劣努。該現象可解釋在RB之 胺基端半部缺乏天然存在之突變型。 在此所描述之结果顯示RB透過作用於G1期內之一個控制 點參與细胞循環之控制。該點明顯的早於當細胞進入S期 時所觀察到之重姐體產生之RB蛋白質過度磷酸化作用。因 此’可合理的提出一個合併測試结果和其它RB蛋白質之已 ___________- Q S -_ 本紙張尺度適用中國國家標準(CMS ) A4規格(210X297公釐) ll·---------}.裝—— <請先閲讀背面之注意事項—樣寫本頁) 訂 /m 466117 年月 : δ5·1ΐ·0 6 / /:f -yr- j A7 B7 五、發明説明(严;>) 經濟部中央標準局員工消费合作社印製 知特性Μ模型。由於RB已顯出與數個细胞之蛋白質相關, 並且RB之蛋白質结合之功能部位足以封阻细胞循環之進化 *细SSS白質之结合作用似乎非常有可锭對所観察到之 RB功能具關_性。該模型建議rb透遇在G1期之一特殊時間 束縛對DN A合成作用和/或循環進化緊要的细胞蛋白質, 參與细胞循環之調節作用。藉突變失活PH〇RB·在關鍵位 置進行磷酸化作用•或與轉化之蛋白質结合,促使其提供 繼續细胞循環所必需之功能。一旦细胞釋放該類蛋白質使 本身繼續细胞循環|全長RB蛋白質不能再有效抑制其功能 因此解除葑细胞循環進化之封阻作用。 RB之次核定位可能對於其以失活形式束縛其它蛋白質之 能力非常重要。RB蛋白質K失活之形式分離其它蛋白質。 RB蛋白質在感染時K细胞之複製蛋白質分離至泡疹病毒 DNA複製位置,其係细胞循環之正常調節作用被破壊之情 況。在(Π期,重姐體,全長RB之低度磷酸化形式與特殊之 核位置緊密结合。該純化蛋白質亦傾向於聚合化,可解釋 在高湄度時難於維持其溶解度,且對某類纖絲蛋白質中間 體具有限之同質性。該類観察建議重姐體全長蛋白質可能 提供某些核的结構成分,而蛋白質與該成之結合是抑制细 胞進化所必須的。推測高度磷酸化作用可自其次一核位置 釋放蛋白質使其得K提供一些其它功能,或重新恢復其在 後績细胞循環中束縛其它蛋白質之能力。該模型預測RB活 性之調節作用可透過特定其核位置和/或其所结合之细胞 蛋白質而達成。 本紙汝尺度適用中國國家標準(CNS } A4現格(210X297公釐) (請先聞讀背面之注意事項再填寫本頁) .——r . •裝_A B7 Fifth, the effect of the invention (f /) ring is the functional part. The two biochemical activities of the carboxy-terminal half of the protein, DNA binding and protein binding. According to the current findings, the specificity of the RB sequence that binds to DH A is very low. Although M high G / C contains a slightly higher affinity for SK and DNA binding, but does not particularly prefer a particular sequence. On the other hand, Specificity was observed in the combination of RB and protein. The transforming proteins K and cell proteins of several DNA-transformed viruses bind to the same functional site of the full-length RB protein produced by the older sister, so they can compete with each other for binding to the RB protein. This region is where most naturally occurring inactive RB mutants are located. It appears that blocking the evolution of G1 by RB proteins depends on specific protein-protein interactions. Printed by the Central Bureau of Standards, Ministry of Economic Affairs, Consumer Cooperatives—r -------- ri—I (please read the notes on the back first and fill out this page) Order truncated RB protein and derived from SV 40 Τ- Antigen and can be mixed with peptides that bind to truncated RB proteins * to avoid their inhibitory consequences. Co-injection of truncated RB protein and peptide containing K with a single amino acid substitution more than 500 to 1000 times the molecular weight can also weaken * to a certain degree * the blocking effect on cell cycle evolution. Although amino acid substitution reduces its affinity for RB protein * The mutant T-peptide can still bind to truncated RB protein in vivo when K disparity is exceeded. In contrast, the injection of P53 peptide, which was not effective after injection of gold, had no effect on the inhibitory activity of the RB protein *, thus enhancing the specificity of the interactions observed between the ΙβΒ protein and the T-antigen peptide. CV-1 cells injected with truncated RB protein early in G1 stagnated before the S phase, while COS-7 cells exhibiting a large number of T-antigens did not stagnate. These observations together show that T-antigen binding is indeed functional for RB proteins. Since the truncated RB protein for injection is not phosphorylated, the results of the test and the inhibitory effect on cell differentiation have been shown to be on paper. The standard standard is 2I / 1 «centimeter 97 2 46611 July 7 η Corrected the hypothesis that A7 B7 was printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of invention (f >) The active form of KB protein is an unphosphorylated form-due. Therefore * some of the DNA tumor virus transforming proteins, including SV40 T-antigen and adenovirus E1A, can promote cell growth, at least in part, by binding and deactivating low-level, full-length RB proteins produced by the older sister. The immortality of the cell is consistent with the phenotype of the inability to rest induced by the expression of such transformed proteins and the loss of regulation of cell cycle. Assuming that the carboxyl-terminal half of the RB protein is biologically active, the question is what is the function of the amine-terminal half of the RB. The sequence in this region may be required for proper protein acidification. In mouse cells, peptides similar to the truncated RB protein were not overphosphorylated. Moreover, several consistent positions of cdc2 / MPF kinase appear in this region. It is consistent with the statement that the amine-terminal half of the RB protein may contain regulatory functional sites. The unblocking effect of the truncated 0 protein on the evolution of G1 does not occur until 3-4 days after injection; this lengthy stagnation period may be due to the inability of cells to regulate RB protein in a normal manner * or because of the considerable amount of RB injected protein. In this test * various RB proteins with mutations in the phosphonium acid position, comparing their activities can help answer this question. If the truncated RB protein is structurally active • Multiple wins due to mutations can inhibit cell differentiation and thus place the cell at a disadvantage. This phenomenon may explain the lack of naturally occurring mutants in the amine terminal half of RB. The results described here show that RB participates in the control of the cell cycle by acting on a control point in the G1 phase. This point is significantly earlier than the hyperphosphorylation of RB protein produced by the heavy body when the cells enter the S phase. Therefore, it is reasonable to propose a combined test result and other RB proteins. ___________- QS -_ This paper size is applicable to the Chinese National Standard (CMS) A4 specification (210X297 mm) ll · --------- } .Installation-< Please read the precautions on the back-sample page) Order / m 466117 Month: δ5 · 1ΐ · 0 6 / /: f -yr- j A7 B7 V. Description of the invention (strict; >) The Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs printed a model with known characteristics. Since RB has been shown to be related to the protein of several cells, and the functional part of RB's protein binding is sufficient to block the evolution of cell cycle * The binding effect of fine SSS white matter seems to be very relevant to the function of RB observed _ Sex. This model suggests that rb encounters cell proteins that are important for DNA synthesis and / or cyclic evolution at a special time in the G1 phase, and participates in the regulation of cell cycle. Inactivation of PHORB by mutation • Phosphorylation at key locations • or binding to transformed proteins, prompting them to provide the functions necessary to continue cell circulation. Once the cell releases this type of protein, it will continue the cell cycle itself. The full-length RB protein can no longer effectively inhibit its function, thus removing the blocking effect of cell cycle evolution. The secondary nuclear localization of RB may be important for its ability to bind other proteins in inactive form. The RB protein K is inactivated to isolate other proteins. When RB protein is infected, the replication protein of K cells is isolated to the replication site of herpesvirus DNA, and its normal regulation of cell cycle is broken. In (II period), the low-phosphorylated form of full-length RB is tightly bound to the special nuclear position. The purified protein also tends to polymerize, which can explain the difficulty in maintaining its solubility at high maize degrees, and the Fibrillar protein intermediates have limited homogeneity. This type of observation suggests that the full-length protein of the heavy body may provide certain nuclear structural components, and the combination of the protein and the composition is necessary to inhibit cell evolution. It is speculated that high phosphorylation The protein can be released from a second nuclear position to provide some additional functions to K, or to restore its ability to bind other proteins in the posterior cell cycle. This model predicts that the regulatory effect of RB activity can be achieved by specifying its nuclear position and / or The binding of the cell protein is achieved. This paper is compliant with the Chinese national standard (CNS) A4 (210X297 mm) (please read the precautions on the back before filling out this page) .—— r. • 装 _

.1T , .:4 46611 7 經濟部中央標準局員X消費合作社印製 "H5. ii.'OF 午月£3 五、發明説^ 完全 視網膜 參與提 化直至 RB功能 中腫瘤 綜觀 進行磷 化,含 經截短 G1早期 S期。 注射至 Brd!J 之 之合成 循環進 修正 A7 B7 喪失RB基因和 胚细胞瘤腫瘤 供解釋該琨象 细胞收到繼續 可能因為容許 之生成作用。 前述* RB基因 酸化狀態之改 有T-抗體结合 者•注射至细 K任一種蛋白 共注射導引對 停滯在G1/S邊 併入並無影粱 。該结果提供 化Μ調節細胞 /或蛋白質功能之生 和其它績發性腫瘤。 之方法。RB可作用Μ 細胞循環之適當訊號 不規律细胞分化作用 物性後果是產生 细胞循環中RB之 停止經由G1之進 。因此•喪失 ,造成不同姐織 產物是一核 變。為測試 區域之纯化 胞再測定對 質注射同步 抗RB之抗體 界或G1结束 ,建議RB蛋 R Β可能透過 之分化作用 磷蛋白, 是杏RB調 RB蛋白質 於進入S 化细胞, 可拮抗該 前6-10小 白質並不 在G1之一 的直接証 和细胞 節细胞 *不論 期之影 可抑制 作用》 時之细 在S期 特定點 明》亦 循環同步 循瑁之進 是全長或 響。在 其進化至 RB蛋白質 胞對 破壊DNA 限制细胞 建立RB蛋 射 S 性 注至能 共化功 之進有 肽胞具 胜细質 原止白 抗防蛋 - JU, Β T i R 和不對 質並用 白內作 蛋胞合 RB细结 。之之 試原原 测抗抗 物 T T 生現化 的表強。 性至驗說 活射實假 之注該的 質或-響 白-期影 本紙張尺度適用中國國家標準(CNS > Α4規格(210Χ297公釐) {請先閲讀背面之注意事項务.填寫本頁).1T,.: 4 46611 7 Printed by X Consumer Cooperative, Member of the Central Standards Bureau of the Ministry of Economic Affairs " H5. Ii. 'OF Afternoon £ 3 V. Invention ^ Full retina participation in enhancement until phosphorylation of tumors in RB function. Contains truncated G1 early S phase. The synthesis injected into Brd! J was recirculated and modified A7 B7 lost the RB gene and blastoma tumors to explain the phenomenon that the cells continued to receive may be due to the permissive effect. The aforementioned changes in the acidification status of the RB gene. T-antibody binding. • Injection of any protein into fine K. Co-injection guide pair. Stagnation on the G1 / S side. Incorporation without shadow. This result provides that BM regulates the function of cells and / or proteins and other progressive tumors. Method. RB can act as an appropriate signal for M cell cycle. Irregular cell differentiation The physical consequence is that RB in the cell cycle stops passing through G1. Therefore, the loss of the product is a nuclear change. In order to test the purified cells in the test area and then test the anti-RB antibody boundary or G1 at the end of the injection, it is suggested that the RB protein R Β can penetrate through the phosphoprotein, which is the apricot RB modulates the RB protein into S cells, which can antagonize the first 6 -10 small white matter is not directly evidenced in one of G1 and ganglion cells * regardless of the period of the shadow can inhibit the effect of "the specific point in the S phase" is also cyclically synchronized and the progress is full-length or loud. After its evolution to the RB protein cell, it broke the DNA restriction cells and established the RB egg shooter. It was able to co-operate with the peptide cells. The peptide cell had a finer quality. Anti-egg-JU, Β T i R Inner whites make RB fine knots. The test of the original test resistance T T emerges the strength. The nature of the test is true or false. Note that the quality of the paper or the size of the white paper is applicable to the Chinese national standard (CNS > A4 specification (210 × 297 mm)) {Please read the precautions on the back first. Fill out this page )

6 6 4 經濟部中央標準局—工消費合作社印製 ,、發明説明(知)6 6 4 Printed by the Central Bureau of Standards of the Ministry of Economy—Industrial and Consumer Cooperatives, Invention Description (Knowledge)

A7 B7A7 B7

表3. SV40 T-抗原解除P56RB對01進化之封姐作周 — … _ ~ 细胞源 蛋白質β 注射细胞 之數目b BrdU染色 细胞之數目 進入S期之 經注射细胞》 S a 〇 s - 2 p56RS 247 10 4 P56RB+T P56RB+ 724 203 28 p53 727 7 1 CV-1 p56rb 459 46 10 Histone 471 259 55 R a G 332 176 53 COS-7 p56rb 257 224 87 組織脒 191 159 83 全部蛋 白質以約1 毫克/毫升濃度注射 ,除了 Saos-2细 胞中p56rb是以約.3-,5毫克/毫升注射 细胞源在自尼可唑處理釋放後6-8小時微注射。茲顯示 注射细胞(德州紅陽性)之總數。 .细胞在注射後和染色前K BrdU培養於生長培養基中。 -98 - :尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 请先閔讀背面之注意事^再4'寫本頁) ...·'裝------訂------)d.---1--^--..Table 3. SV40 T-antigen releases P56RB for the evolution of 01 for the sister-in-law —… ~ ~ cell-derived protein β the number of injected cells b BrdU-stained cells the number of injected cells entering the S phase ”S a 〇s-2 p56RS 247 10 4 P56RB + T P56RB + 724 203 28 p53 727 7 1 CV-1 p56rb 459 46 10 Histone 471 259 55 R a G 332 176 53 COS-7 p56rb 257 224 87 Tissue 脒 191 159 83 All proteins at about 1 mg / Injection at a concentration of milliliter, except that p56rb in Saos-2 cells was microinjected at approximately .3-, 5 mg / mL of injected cell source 6-8 hours after release from nicozole treatment. The total number of injected cells (Texas red positive) is shown. K BrdU cells were cultured in growth medium after injection and before staining. -98-: The dimensions are applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm). Please read the notes on the back ^ and then 4 'write this page) ... ·' installation ----- ----) d .--- 1-^-..

I A7 B7 4 8 6117 五、發明説明(fg ) 5.外源RB蛋白質抑制腫瘤生長 RB蛋白質之鈍化作用 p110rb使用 Nature (199 1 ) 350:160-162 所描逑方法之 修飾方法自大腸桿菌BL21(DE3>/pLyS/pETRBc鈍化。簡言 之| 120克潮濕细胞齋再懸浮於微液化處理機以13,000 Psi處理之溶胞煖衝液,(10毫莫耳湄度三羥甲基胺基甲 烷-Cl, 10¾甘油,1毫萁耳湄度EDTA,1毫莫耳濃度 DTT, 1毫莫耳濃度苄胖· 1微克/毫升白胜肽素,pH δ.5) *可溶部分加50¾硫酸铵。沉澱之蛋白質K1 0,000 X s離心回收並再溶化於溶胞壊衝液中•以離心澄清化並 對溶胞緩衝液透析。透析物加至瞵酸纖雄素P-11 . (Wa tun)管柱之10奄莫耳濃度三羥甲基胺基甲烷-C1, 經濟部中央標準局員工消費合作社印製 10¾甘油,1奄莫耳濃度EDTA,1毫莫耳湄度DTT ,pH 8.5中,並K0-0.7莫耳NaCl梯度清洗和離析。含有 p56RB*pllORB(由SDS-凝膠霉泳判定)之部分合併,蛋白 質K 70%硫酸銨沉溉。K離心回收沉激物並透析至20毫莫 耳濃度瞵酸納鹽* 0.2莫耳濃度HaCl, 10¾.甘油* 1毫莫 耳濃度£0丁点,?}{7.5中*再装至36?卜3(;1^1-200 (Pharmacia)分配管柱中。在該純化步琢中* t>56RB自 p110rb分雛。pll〇RB之合併部分再裝至DEAE管柱中( 肫以11131>)並以10毫莫耳湄度三羥甲基胺基甲烷-(:1,105(!甘 油,1毫莫耳濃度£0了為,卩}18.8清洗,以〇-〇_25莫耳濃度 NaCI梯度離析。用於該類研究之pllORm p56rb純度Μ考 馬斯藍染色之SDS-聚丙烯酵胺凝膠判定>95Χ。烴純化之 _-99-_ 本紙張尺度適用中國國家標準(CNTS ) Α4規格(210Χ 297公釐) 466117I A7 B7 4 8 6117 V. Description of the invention (fg) 5. Exogenous RB protein inhibits tumor growth. Passivation of RB protein. (DE3 > / pLyS / pETRBc passivation. In short | 120g of moist cell suspension was resuspended in a lysate warming solution treated at 13,000 Psi with a micro-liquefaction processor, (10 millimolar Metridotrimethylolamine- Cl, 10¾ glycerol, 1 millimolar EDTA, 1 millimolar concentration DTT, 1 millimolar concentration benzyl fat · 1 μg / ml leucopeptin, pH δ. 5) * 50¾ ammonium sulfate is added to the soluble portion The precipitated protein K1 10,000 X s was recovered by centrifugation and re-dissolved in the lysate solution. • The solution was clarified by centrifugation and the lysis buffer was dialyzed. The dialysate was added to the cellulose androgen acetate P-11. (Wa tun) tube. Column 10 奄 mole concentration of trimethylolaminomethane-C1, printed by 10¾ glycerol, 1 奄 mole concentration EDTA, 1 millimolar DTT, pH 8.5, and K0-0.7 Mol NaCl gradient washing and isolation. The part containing p56RB * pllORB (determined by SDS-gel mold swimming) was combined, and the protein K 70% ammonium sulfate precipitation. K centrifugal recovery of precipitates and dialysis to 20 millimoles concentration of sodium sulphate * 0.2 mole of HaCl, 10¾. Glycerol * 1 millimoles concentration £ 0 Ding,?} { Refill in 7.5 * into 36? 3 (; 1 ^ 1-200 (Pharmacia) distribution column. In this purification step * t > 56RB was split from p110rb. The combined portion of pllOB was reloaded into DEAE (Column 11131>) and 10 millimoles of trimethylolamine methane-(: 1,105 (! Glycerol, 1 millimoles concentration of £ 0), 卩} 18.8, washed with 0- 〇_25 Molar concentration NaCI gradient analysis. The pllORm p56rb purity M Coomassie blue stained SDS-polyacrylamide gel used for this type of research> 95 ×. Hydrocarbon purification _-99-_ Paper size Applicable to China National Standard (CNTS) Α4 specification (210 × 297 mm) 466117

A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(%) pllOR”Dp56Re分成整分並在-80t3儲存於20毫其耳濃度 隣酸納· 0.2莫耳溏度HaCl, 10¾甘油* pH 7.5中。 RB蛋白質之各部分MNC1-H596 NSCLC细胞•使用下述之 3H-胸腺核苷吸收法測試其生物活性。Pii〇RB之失活(對 照)部分使用上述程序製備,除了溶胞和管柱辑衝液不含 甘油。P110RB失活部分在體外低於50微克/毫升濃度下不 會造成之ΝΠ-Η596细胞之生長抑制作用。 125I-p110rb 和 125I-P56RB是使用氛胺-T方法(Nature (1962 194:495)製備自纯化之p110rbSp56rb蛋白質和 125 I (ICH Bi〇Bedica 1 , Irvine , CA)。 . 细胞源 用於本研究之细胞源是得自美國式培養收集所。细胞源 NC1-H596(肺腺癌),A5 49 (鱗狀细胞肺癌)* 5637(人賭膀 胱癌),ΝΠ-Η69 (小细胞肺癌)| MDA-MB468 (乳房癌)* Saos (贵肉瘤),FHs 738B1(正常人體膀胱)· MRC-9和 VI-38(正常人體肺)和CCD 976Sk(正常人髁包皮继維母細 胞)横過杜背克修飾易葛培養基:在37t:下*潮濕化空氣 /7S; C〇2培養器中,2毫莫耳漉度麩胺豳胺和10¾ (v/v) 胎牛血清(熱失活化)之F-12(v/v)。 细胞源表現型:於該研究中RBPC)S表示其中有野生-型 p110rb2表現细胞源。RBne*表示產生突變型,非功能性 RB之细胞源或其中RB蛋白質之表現Kot-RB MAb 3C3 (J.A7 B7 Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. 5. Description of invention (%) pllOR ”Dp56Re is divided into wholes and stored at -80t3 at a concentration of 20 mils of sodium acid. 0.2 Molar degree HaCl, 10¾ glycerol * pH 7.5. MNC1-H596 NSCLC cells, each part of the RB protein • The 3H-thymidine absorption method described below was used to test its biological activity. The inactivation (control) part of PiiOB was prepared using the above procedure, except for lysis and The column column flush solution does not contain glycerol. The inactivated part of P110RB does not cause the growth inhibition of ΝΠ-Η596 cells at a concentration of less than 50 μg / ml in vitro. 125I-p110rb and 125I-P56RB use the amine-T method ( Nature (1962 194: 495) was prepared from purified p110rbSp56rb protein and 125 I (ICH BioBedica 1, Irvine, CA). Cell Source The cell source used in this study was obtained from the American Culture Collection. Cell Source NC1 -H596 (lung adenocarcinoma), A5 49 (squamous cell lung cancer) * 5637 (human bet bladder cancer), ΝΠ-Η69 (small cell lung cancer) | MDA-MB468 (breast cancer) * Saos (precious sarcoma), FHs 738B1 (Normal human bladder) · MRC-9 and VI-38 (normal human (Lung) and CCD 976Sk (normal human foreskin fortinoblastic mother cells) across Duback-modified Yage medium: at 37t: under humidified air / 7S; in a C02 incubator, 2 millimoles F-12 (v / v) of glutamine and 10¾ (v / v) fetal bovine serum (heat deactivation). Cell-derived phenotype: RBPC in this study) S indicates wild-type p110rb2 expression Cell-derived. RBne * means the cell-derived source of mutant, non-functional RB or the expression of RB protein in it Kot-RB MAb 3C3 (J.

IfflBuno 丨.Meth. (1994) 1δ9··231-240)進 ίτ 之免疫染色或 西向塗抹無法測得之细胞源。 一 100 _ 本纸張尺ϊίίΓ用中國国家標华(CNS ) A4規格(2!0X 297公釐) L---------- t請先閱讀背面之注意事項系蛾^本育)IfflBuno 丨. Meth. (1994) 1δ9 ·· 231-240). Immunostaining or westward smearing of cell sources that cannot be measured.一 100 _ This paper ruler is used in Chinese National Standard (CNS) A4 size (2! 0X 297 mm) L ---------- tPlease read the notes on the back first. Moth )

•1T 4 6 61 1 經濟部中央標準局員工消費合作社印裳 85.IUS修正 年Ft α Α7 Β7 五、發明説明—--—— 體外生長抑制測試 pllORB-媒介之生長抑制作用之劑量-感應曲線,2x 104细胞種在96-槽培養盤中,靜置過夜使其附著並以在 RPMI-1640,10Χ胎牛血潦(熱失活化)中之0-25微克/毫升 fesiB釀夏辑培赛共茲輋缠抒__细應練3ίΐδ咿睦捶翁基每 C1之Η-胸腺核苷至各榷。收集细胞並依Proc. Hatl. A c a d . S c i . (J S A (19 8 δ) 8 3 : 4 7 4 9 - 4 7 5 3 和 A n a 1 · B i o c h e m . (1 97 1 ) 44 : 1 43-153)中所述測試3H-胸腺核脊之吸收。對 於P110RB-媒介之生長抑制作用之時間過程,2 X 104 HCl-H596(RBne*, KSCLC)细胞種在96槽之培養盤中,Μ RPMI 1 640, 1 0¾胎牛血清(熱失活化)中之50微克/毫升之 p110rb處理。在所示時間收集细胞並進行3H-胸腺核苷之 剷試。 P110RB之核定位作用 p110rb之時間-依賴核定位作用依下述測定:NC1-H596腫瘤细胞MlOe细胞/槽(各時間點三重槽)種在於 RTMI-1640 (103! FBS)之6-槽培養盤中,靜置過夜使其附 著。0.75wCi之12M-pllORB每8小時間隔加至培養基中 共72小時。培養基每24小時更換。0,8, 24, 48和72小時 ,细胞冷卻至4¾,以1毫升PBS連續冲洗3次除去殘餘 之1 2 s I - P 11 0 R B 。细胞K 0 5毫升0 . 2 5 S!之胰蛋白酶( Irvine Scientific)在正常食鹽水中培養5分鐘,接著添 加含有10¾胎牛血清(熱失活化)之RPMI-1640 。收集卸胞 -101 - 本紙張尺度適用中國國家標準(CMS ) Α4規格(2]〇Χ 297公釐) (請先聞讀背面之注意事項再填寫本頁) '裝.• 1T 4 6 61 1 Yin Sang 85, the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs, 85.IUS revised year Ft α Α7 Β7 V. Description of the invention ------- In vitro growth inhibition test pllORB-Dose-induction curve of growth inhibition of media 2x 104 cells were seeded in a 96-well culture plate, allowed to stand overnight and allowed to attach and cultured at 0-25 μg / ml fesiB in RPMI-1640, 10X fetal bovine blood maggot (heat deactivation). Sai Gongzi 輋 抒 __ Xi Ying Lian 3 ΐ ΐ 咿 咿 捶 捶 捶 每-thymidine per C1 to each question. Collect cells and follow Proc. Hatl. A cad. S ci. -153) to test the absorption of 3H-thymic nucleus spines. For the time course of P110RB-mediated growth inhibition, 2 X 104 HCl-H596 (RBne *, KSCLC) cells were seeded in 96-well culture plates, and RPMI 1 640, 1 0¾ fetal bovine serum (heat deactivation) 50 μg / ml of p110rb. Cells were collected at the indicated times and subjected to a 3H-thymidine spatula. The nuclear-localization effect of P110RB The time-dependent nuclear localization effect of p110rb was determined as follows: NC1-H596 tumor cells MlOe cells / slots (triple troughs at each time point) were seeded in a 6-slot culture dish of RTMI-1640 (103! FBS) , Let stand overnight to allow it to adhere. 0.75wCi of 12M-pllORB was added to the medium at 8-hour intervals for a total of 72 hours. The medium was changed every 24 hours. At 0, 8, 24, 48, and 72 hours, the cells were cooled to 4¾ and rinsed 3 times with 1 ml of PBS to remove the remaining 12 s I-P 11 0 R B. Trypsin (Irvine Scientific) of cells K 0 5 ml 0.2 5 S! Was cultured in normal saline for 5 minutes, and then RPMI-1640 containing 10 ¾ fetal bovine serum (heat deactivation) was added. Collecting detached cells -101-This paper size applies Chinese National Standard (CMS) Α4 specification (2) 〇 × 297 mm) (Please read the precautions on the back before filling this page) 'Pack.

、1T ,豫 Η, 466117 -ψ~~η Α7 Β7 五 發Μ説明充 請 先 閣 l· t- 事 項 再- 填 寫 本 頁 並在4lCM5 00 x g離心5分鐘粒化细胞。除去上清物* 细胞粒再懸浮於1毫升冰冷之低張嬅衝液(0.01莫耳漉度 三羥甲基胺基甲烷-HC1; 1毫莫耳湄度MsCU, pH 7.6 ) 中。在15毫升東£均質機(dounce)(yheaton)中播拌15下 K均質化细胞。均質物再在4t:下,M 500 X s離心5分 鐘*粒子(核部分)再懸浮於1毫升冰冷之低張緩衝液中。 含有膜和细胞質之上潦液在下;以10,400 X g再離心 45分鐘。餘去所產生之上清液细胞質部分,粒(膜部分) 再懸浮於1毫升冰冷之低張媛衝液。各部分之10分之1 (0.1毫升)進行液娌閃爍計算(Cytoscint液體)。 在HC1-H596核部分中125i-pllORB之免疫沉澱和鑑定 3 X 10e NC1-H596非-小细胞肺(HSCLC)细胞種在100 毫米组織培養皿(Costar)lO奄升RPMI-16 40培養基中 (10X胎牛血清(熱失活化)*靜置過夜使其附著。除去培養 基,各培養皿中添加10奄升含有1036胎牛血清(熱失活化 )和 0.8wCi 125I-p110rb(比活性 0.008wCi/微克)之新 鮮RPMI-1640 。在所示時間點* Μ 5毫升HBSS清洗细胞二 經濟部中央標準局貝工消費合作社印製 次,收集並依上述分級分雔细胞。在48小時收集细胞,在 24小時Κ含有(ΟΧ胎牛血清(熱失活化)和0.8/iCi 125Ι-pllORB 之新鲜 RPMI-1640 更換培養基。125I-p110rs Μ α -RB MAb 3C8 (揭示於 J, Immunol. Meth. (1 994) 1 69: 23卜240 )免疫沉澱,經免疫沉豭之複合物在8-16¾三羥 甲基胺基甲烷-甘胺酸SDS-聚丙烯醢胺凝膠上分级分離, 轉移至硝基缴維素上並以磷酸影象器型號SF(分子生物糸 -109 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0X297公釐) 4661 1 7 修正 年月曰卜 δ5. II. Oli -fit! A 7 B7 五、發明説明((0) 统)分析。其它之肺細胞源Μ相同之方法測試·除了在 24小時時除去培養基並更換以含有胎牛血清(熱失活 化)和 0.8iuCi 125I-p110rb 之新鲜 ΚΡΜΙ-1640 。核和细 胞質之部分之纯度以依_據&丨〇£;}^111. Biophys. Acta, (1971) 233:334-347 及 Biochen. J. (1982) 203 :245-251中所描述之方法測量各部分之NADH氧化酶和 5'核苷酸酶之酶活性測定。 依下逑進行pllOR”np56RB SHCI-H596 NSCLC细胞内核 定位之比較:5 X 10s NCI-H596细胞種在各榷有1毫升 RPMI-1640培養基(10¾胎牛血清(熱失活化)之6-槽姐雜培 養盤中(Costar)並靜置過夜使其附著。除去掊養基*在各 個槽内添加1毫升含有10¾胎牛血清(熱失活化)和230 pci 12BI-pllORB (比活性 9.23 pCi/微克)或 991 pCi 12eI-p56RB (比活性 39.6 pCi/ 微克)之新鮮 RPMI-1640 。在所示之時間點•來自3槽之细胞Ml毫升HBSS清洗2 次•收集•合併,並依上述離析核部分。在閃爍計數 器内定量核-特定放射性。 皮下腫瘤之腫瘤周圍處理 經濟部中央標準局員工消費合作社印製 三隻裸鼠一组(Ba lb/C NCR nu/nu 雌性,SiBonsen, Gilroy, Ca)各 M107 Ν(Π-Η596 (RBn··)或 107 A549 (RBPCJS)NSCLC细胞皮下接種。有腫瘤之老鼠隨楗分配至 不同籠子。當腫瘤尺寸約9平方奄米時,在腫瘤四周皮下 注射RB蛋白質。各腫瘤分成4份,每6小時輪流皮下注射 25微克RB蛋白質至各四分中共10天。各動物每天一共收受 -103 -_ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公嫠) 4 6 611 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(id ) 100微克RB蛋白質,在10天之檐送期間總共1毫克。每週 二次使用游標測徑器以二度空間測量腫瘤。 靜脈施用pllO 三十九(39)隻雌性Ba〗b/C裸M (S丨nonsen Labora-iUWfeS, 81ΠΡδ}腫豳细羑窜爾斑射靜1鋩騸臌细彘81天 再K測徑器測量外腫瘤尺寸。老鼠根據腫瘤尺寸隨楗化一 次一隻分至四姐,每姐含9-10隻老鼠。在三週期間,老鼠 每夭接受一劑(5劑/週)之活性Pll〇RB 50微克/劑;活性 P110RB 200微克/劑;或失活性p110rb 200微克/劑。 p110rb之生物活性是K在圖22所述之3H-胸腺核苷吸收測 試中抑制HC1-H596腥瘤细胞之能力而定。腫瘤尺寸(1, w, h)和體重由二位個別調査員每週測量二次並每天觀察 老鼠之病態徵象。假設球狀幾何之半徑和所測腫瘤長度的 一半相等,估計各動物之腫瘤容量。使用史特威(Abe us Software Berkeley, CA)所完成之曼-惠特尼U -試驗比 較各姐間平均腫瘤尺寸。 RB蛋白質對腫瘸细胞分化作用之影響 RB蛋白質選擇性抑制RBnee非-小细胞肺癌细胞源 NC1-H596生長之能力示於圖19A 。结果証明?110^是Μ劑 童依賴之方式抑制NC卜Η596细胞之生長。該研究中 pllORStIC50是約5微克/毫升〔約5 0微莫耳濃度]。有趣 的是,含有生長抑制作用所必須之” 口袋"區域的p110r6 C-端衍生物,p56RB (胺基酸 379-928) (Hoi , Cell -104 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210Χ_297公釐) (請先閲讀背面之注意事項*,,填寫本頁) 訂 I. 6117 半a g修正心1.〇移’補克 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明 (1993) 13:3384-3391; Genes and Develop. (1992) 6 :953-964),在Ν(Π-H596腫瘤细胞中僅微弱的抑 制生長(圖19Α)。更重要的是,再重要的是pii〇rb較镐向 於抑制RB"e* NSCLC细胞源NC1-H596,因為無論?110^或 p56rb均不會抑制rbp〇s HSCL{:细胞源A549之生長(圖 19A)。 p110rb媒介之NU-H596腫瘤细胞生長抑制作用之時間依 賴性亦予Μ調査。當腫瘤细胞以25微克/毫升P110RB處理 時,在24小時後觀察到3H-胸腺核苷吸收減少(画20B)和 48小時之最大生县抑制作用。該延遲可能是因為數種因素 之结合所造成的*包括内在化作用動力和细胞族群是-非 同步化之事實。 為了証明所観察之生長抑制作用可發生在各種腫瘤细胞 型式,4種腫瘤细胞源,1種ΙΪΒμ»腫瘤细胞源和 4種正常上皮细胞源以等量之?110^皮下處理(表4)。所 有測試之RBne腫瘤细胞源顯示在72小時處3Η-胸腺核苷 吸收明顯下降(60-80¾抑制DNA合成作用)。相反的*在 該條件下* RBPCS HSCLC细胞源A549,正常肺上皮细胞源 HRC-9和VI-38 ,正常膀胱上皮细胞源FHs 739B1 ,和包 皮潘維母细胞源CCD 976S1C未被抑制生長。該資料和關於 經由在正常细胞中大量表現RB基因對细胞生長之適度影饗 一致,锥然大量的p110rb表現可能是生長抑制性的。, 1T, Yu Η, 466117 -ψ ~~ η Α7 Β7 Five instructions, please fill in the l t t-item and then-fill out this page and centrifuge at 4lCM5 00 x g for 5 minutes to granulate cells. The supernatant was removed * and the cell pellet was resuspended in 1 ml of ice-cold hypotonic solution (0.01 moles of trimethylolaminomethane-HC1; 1 millimolar degree of MsCU, pH 7.6). K homogenized cells were sown for 15 times in a 15 ml dounce (yheaton). Centrifuge the homogenate at 4 t for 5 min * at 500 sec *. The particles (core) are resuspended in 1 ml of ice-cold hypotonic buffer. Contain the membrane and cytoplasm above the mash; below, centrifuge at 10,400 X g for 45 minutes. The remaining cytoplasmic fraction and granules (membrane fraction) of the supernatant were removed and resuspended in 1 ml of ice-cold low Zhangyuan solution. Liquid fraction scintillation calculation (Cytoscint liquid) was performed for 1/10 of each part (0.1 ml). Immunoprecipitation and identification of 125i-pllORB in the nuclear part of HC1-H596 3 X 10e NC1-H596 non-small cell lung (HSCLC) cells were seeded in 100 mm tissue culture dishes (Costar) 10% RPMI-16 40 medium (10X fetal calf serum (heat deactivation) * Allow to stand overnight to allow it to adhere. Remove the culture medium and add 10 liters of 1036 fetal calf serum (heat deactivation) and 0.8wCi 125I-p110rb (specific activity 0.008 wCi / μg) of fresh RPMI-1640. At the indicated time point * Μ 5 ml of HBSS-washed cells were printed by the Central Standards Bureau of the Ministry of Economic Affairs, Shellfish Consumer Cooperative, and collected and classified according to the above classification. Cells were collected within 48 hours Cells were replaced with fresh RPMI-1640 containing 0 × fetal bovine serum (heat deactivation) and 0.8 / iCi 125Ι-pllORB at 24 hours. 125I-p110rs Μ α-RB MAb 3C8 (Revealed in J, Immunol. Meth (1 994) 1 69: 23b 240) Immunoprecipitation, the complexes were subjected to fractionation on an 8-16¾trimethylolaminomethane-glycine SDS-polyacrylamide gel by immunoprecipitation, and transferred To nitropyroxin and phosphate imager model SF (Molecular Bio- 糸 -109 paper size) According to the Chinese National Standard (CNS) A4 specification (2 丨 0X297 mm) 4661 1 7 correction date δ5. II. Oli -fit! A 7 B7 5. Analysis of the invention ((0) system) analysis. Other lungs Cell source M is tested in the same way except that the culture medium is removed at 24 hours and replaced with fresh KPMI-1640 containing fetal bovine serum (heat deactivation) and 0.8iuCi 125I-p110rb. The purity of the nucleus and cytoplasm is determined by _Measure the NADH oxidase and NADH oxidase of each part according to the methods described in & 丨 £;} ^ 111. Biophys. Acta, (1971) 233: 334-347 and Biochen. J. (1982) 203: 245-251 5 'Nuclease enzyme activity measurement. The comparison of pllOR ”np56RB SHCI-H596 NSCLC cell core localization was performed as follows: 5 X 10s NCI-H596 cells were seeded in 1 ml RPMI-1640 medium (10 ¾ fetal calf Serum (heat deactivation) in a 6-slot hybrid culture plate (Costar) and let stand overnight. Remove the nutrient base * Add 1 ml of 10¾ fetal bovine serum (heat deactivation) to each tank And 230 pci 12BI-pllORB (specific activity 9.23 pCi / μg) or 991 pCi 12eI-p56RB (specific activity 39.6 pCi / micro ) Of fresh RPMI-1640. At the indicated time points • Ml ml of HBSS cells from 3 wells were washed twice • collected • pooled, and the nuclear fraction was isolated as described above. Nuclear-specific radioactivity is quantified in a scintillation counter. Treatment of subcutaneous tumors around the tumor The Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs printed a group of three nude mice (Ba lb / C NCR nu / nu female, SiBonsen, Gilroy, Ca) each M107 Ν (Π-Η596 (RBn ··· ) Or 107 A549 (RBPCJS) NSCLC cells are inoculated subcutaneously. Mice with tumors are allocated to different cages with the urn. When the tumor size is about 9 square meters, RB protein is injected subcutaneously around the tumor. Each tumor is divided into 4 portions every 6 hours. Alternately inject 25 micrograms of RB protein subcutaneously into each quarter for a total of 10 days. Each animal receives a total of -103 -_ This paper size applies to China National Standard (CNS) A4 (210X297 gong) 4 6 611 Employees of the Central Standards Bureau of the Ministry of Economic Affairs A7 B7 printed by the consumer cooperative V. Description of the invention (id) 100 micrograms of RB protein, a total of 1 milligram during the 10-day eaves. Use a vernier caliper twice a week to measure the tumor in two dimensions. Intravenous pllO 30 Nine (39) female Ba and b / C naked M (Sonnonsen Labora-iUWfeS, 81 Πδ) were swollen, stunned, and stunned for 1 day, and then measured by a K caliper for 81 days. Mice are randomized according to tumor size Each time it is divided into four sisters, each sister contains 9-10 mice. During the three-week period, the mice received one dose (5 doses / week) of active P110RB 50 micrograms per dose per dose; the active P110RB 200 micrograms per dose Or inactivated p110rb 200 micrograms / dose. The biological activity of p110rb is determined by the ability of K to inhibit HC1-H596 tumor cells in the 3H-thymidine absorption test described in Figure 22. Tumor size (1, w, h ) And body weight were measured twice a week by two individual investigators and observed the pathological signs of mice every day. Assuming that the radius of the spherical geometry is equal to half of the measured tumor length, the tumor volume of each animal was estimated. Using Abe (Abe us Software Berkeley, CA) completed the Mann-Whitney U-test to compare the average tumor size between sisters. The effect of RB protein on tumor cell differentiation The RB protein selectively inhibits RBnee non-small cell lung cancer cell source NC1- The ability of H596 to grow is shown in Figure 19A. The results demonstrate that 110 ^ is a M-dependent way to inhibit the growth of NC cells 596 cells. In this study, pllORStIC50 was about 5 μg / ml [about 50 μmole concentration]. Interesting Yes, it contains growth inhibitory P110r6 C-terminal derivative of the "pocket" region, p56RB (amino acid 379-928) (Hoi, Cell -104-This paper size applies to China National Standard (CNS) A4 specification (210 × 297 mm)) (Please Please read the notes on the back *, and fill in this page) Order I. 6117 Half ag correction heart 1.0. Move 'Punch A7 B7 Printed by the Staff Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of Invention (1993) 13: 3384 -3391; Genes and Develop. (1992) 6: 953-964), which only slightly inhibited growth in N (Π-H596 tumor cells) (Figure 19A). More importantly, what's more important is that pii〇rb is more resistant to picking RB " e * NSCLC cell source NC1-H596, because whatever? Neither 110 ^ nor p56rb inhibited the growth of rbpos HSCL {: cell-derived A549 (Figure 19A). The time dependence of p110rb-mediated NU-H596 tumor cell growth inhibition was also investigated by M. When tumor cells were treated with 25 μg / ml P110RB, a decrease in 3H-thymidine uptake was observed after 24 hours (drawing 20B) and a maximal inhibitory effect at 48 hours was observed. This delay may be due to a combination of several factors * including the internalization dynamics and the fact that the cell population is non-synchronized. In order to prove that the observed growth inhibitory effect can occur in various tumor cell types, 4 types of tumor cell sources, 1 type of ΙμΒμ »tumor cells and 4 types of normal epithelial cells in equal amounts? 110 ^ subcutaneous treatment (Table 4). All RBne tumor cell sources tested showed a significant decrease in 3Η-thymidine uptake at 72 hours (60-80¾ inhibition of DNA synthesis). In contrast * under these conditions * RBPCS HSCLC cell source A549, normal lung epithelial cell source HRC-9 and VI-38, normal bladder epithelial cell source FHs 739B1, and foreskin Panveum cell source CCD 976S1C did not inhibit growth. This data is consistent with the modest effect of RB gene expression on cell growth in large numbers in normal cells, and a surprisingly large number of p110rb manifestations may be growth-inhibitory.

請 先 聞 讀 背 it 之 注 意 事 項 再, 填J裝 I 訂 0_5_ 本紙張尺度適用中國國家標筚(CNS ) A4規格(210X297公釐) 4661 1 7 Β5.Π.〇δ 年月a A7 B7 五、發明説明 细胞源 细胞形式 RB狀態 相對生長速率 正常细胞源 FHs739Bl 膀胱上皮细胞 + 84 士 1 CCD976SK 包皮纖雄母细胞 + 89士 1.5 HRC-9 肺上皮细胞 + 86 士 3 VI-38 肺上皮细胞 + 76 士 3 腫瘤细胞源 A549 NSCLC + 99 士 1,5 H596 NSCLC 11 土 1.5 HC1-H69 SCLC - 30士 8 MDA-HB-468 乳房 腺癌 - 24土 4 5637 膀胱癌 - 37 土 1.5 表4 在72小時處pll〇RB對细胞源中3H-胸腺核苷併人之影響。 5 X 103细胞種在96槽培養盤之各槽中,靜置過夜使其附 著。添加p110rbM培養基中至終濃度為25微克/毫升。含 經濟部中央標準局員工消費合作社印製 有pi 10RB之培養基每12小時更換,共更換72小時◊收集细 胞,依前述測試3Η-胸腺核苷之吸收。所示细胞分裂速率 是12個個別數據點之平均,並Μ媛衝液對照之百分比士平 均之標準誤差。” + ” RB狀態表示野生-型之RB狀 態表示突變型RB或缺乏可測之Ο表現。 -1 0 fi - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 4661 17 修正^1…補4 A7 B7 五、發明説? P110RB之细胞吸收和核定位作用 經濟部中央標準局貝工消費合作社印製 p110rb是種核磷蛋白,而其和闞鍵轉錄元素如E2F之交 互作用,低估其在细胞循環中之調節性角色(參看TIBS (1992) 17:312-315 和 Science (1992) 25δ: 424-429 供研 究)。因此*若P110RB進入细胞並Κ其正常途徑影響其 生長,則必須定位於標的细胞之细胞核。據此•添加 12SI- ?110118至^1(:1-11596腫瘤细胞之培養物中。收集细胞 並根據本專利說明書所述分鈒分皤至膜•细胞質和核之富 集姐分。圖21A顯示之時間-依賴性内在化 作用成為各種次细胞部分。可酸-沉源之故射性的堆積在 核內最早發生*雖然可測得之量在處理後8-14小時之間出 現在膜的部分。時間過程(高峰出現在48小時處)和核定 位作用(在核内70X之内在化放射性)和較早描述於圄 21A之p110rb之時間-依顆性生長抑制作用一致。為了証 明完整的12βΙ -Ρΐ10κβώ現在處理细胞之核内*離析核的 部分。M ct -110RB抗體所製備之免疫沉澱物在SDS-聚丙烯 醯胺凝膠上分级分離並進行放射自顯術分析(圖21B)。一 個110 kD放射標記帶Μ時間依賴性之方式出現*顯示完整 之126I-p110rb出現在核内。在RBPQS肺腫瘤细胞源 MRC-9和A549中檢驗可酸沉溉之12*1 cpm之時間-依賴性 核堆積作用和可免疫沉澱之12eI-i>110RB,所得结果和 Η(Π-Η596類似(画21C)。结果顯示該類RBP°S细胞源對於 RB蛋白質之相對不敏感性並不是因為其無法內在化或定位 p11〇rb於核。RB"e«细胞源對於p56rb之微弱生長抑制反 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 466117Please read the precautions before reading it, and then fill in J and I. 0_5_ This paper size applies to China National Standard (CNS) A4 (210X297 mm) 4661 1 7 Β5.Π.〇δ month a A7 B7 5 Description of the invention: Cell-derived cell form RB status Relative growth rate Normal cell-derived FHs739Bl Bladder epithelial cells + 84 ± 1 CCD976SK foreskin fibroblasts + 89 ± 1.5 HRC-9 lung epithelial cells + 86 ± 3 VI-38 76 ± 3 tumor cell source A549 NSCLC + 99 ± 1, 5 H596 NSCLC 11 ± 1.5 HC1-H69 SCLC-30 ± 8 MDA-HB-468 Breast adenocarcinoma-24 ± 4 5637 Bladder cancer-37 ± 1.5 Table 4 in 72 The effect of pllOB on human 3H-thymidine in cells at hour. 5 X 103 cells were seeded in each well of a 96-well culture plate and allowed to stand overnight for attachment. Add p110rbM medium to a final concentration of 25 μg / ml. Including pi 10RB medium printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs is replaced every 12 hours for a total of 72 hours. Cells are collected and the 3Η-thymidine absorption is tested as described above. The cell division rates shown are the average of 12 individual data points and the standard deviation of the percentage ± mean of the M Yuan wash control. "+" RB status indicates wild-type RB status indicates mutant RB or lack of measurable performance. -1 0 fi-This paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) 4661 17 Amendment ^ 1 ... Supplement 4 A7 B7 V. Invention? Cell absorption and nuclear localization of P110RB Central Bureau of Standards, Ministry of Economic Affairs P110rb printed by Shelley Consumer Cooperative is a kind of nuclear phosphoprotein, and its interaction with the transcript elements of the bond such as E2F underestimates its regulatory role in the cell cycle (see TIBS (1992) 17: 312-315 and Science ( 1992) 25δ: 424-429 for research). Therefore * If P110RB enters the cell and its normal pathway affects its growth, it must be located in the nucleus of the target cell. Accordingly • Add 12SI-? 110118 to ^ 1 (: 1-11596 tumor cell culture. Collect the cells and tiller to the membrane according to this patent specification. • Enriched sister fraction of cytoplasm and nucleus. Figure The time-dependent internalization shown by 21A becomes various subcellular parts. The acidic-sinking source of radioactive accumulation occurs earliest in the nucleus * although the measurable amount appears between 8-14 hours after treatment. Part of the membrane. The time course (peak appears at 48 hours) and nuclear localization (internal radioactivity within 70X in the nucleus) are consistent with the time previously described for p110rb in plutonium 21A-growth-inhibitory effect by particle. To prove The complete 12βΙ-Ρΐ10κβώ is now processed in the nucleus of the cell * to isolate the nucleus. The immunoprecipitate prepared by Mc ct-110RB antibody was fractionated on an SDS-polyacrylamide gel and analyzed by autoradiography (Figure 21B) ). A 110 kD radiolabeled band appears in a time-dependent manner * shows that the complete 126I-p110rb appears in the nucleus. The acid-irrigable 12 * 1 cpm was tested in RBPQS lung tumor cell sources MRC-9 and A549. Time-dependent nuclear accumulation The results are similar to those of 12eI-i> 110RB which can be immunoprecipitated, and the results are similar to Π (Π-Η596 (drawing 21C). The results show that the relative insensitivity of this type of RBP ° S cell source to RB protein is not because it cannot be internalized or Locate p11〇rb in the nucleus. The RB " e «cell source's weak growth inhibition of p56rb is reversed. The paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) 466117

A7 B7 五、發明説明Ui) 懕可解釋為细胞内P561 21D)過少。 姐織内ppRB11<?之診斷 來自患者活體切片姐 或32P-磷酸標記並根據 沉澱。或者*提取自活 用K放射性或非放射性 向塗抹分析直接診斷。 作為判斷視網膜胚细胞 之其它疾病的診斷工具 肺癌之腫瘤抑制基因蛋 腫瘤抑制基因在突變 腫瘤生成作用。腫瘤抑 識•首先出現的是視網 膜胚细胞瘤中*視網膜 製本被遣傅,第二茵基 中失活性。RB基因之描 (pi 10Re)。Pi 10RB似乎 因子E2F ·结合而調節 ίΒ之量保存在標的细胞之核内(圖 性鑑定 織分離之腫瘤细胞Μ 355甲硫胺酸 上述程序Μ抗-ppRBUo Is(3免疫 體切片姐織之蛋白質溶胞產物可使 標記之抗-RB特定抗體探針化之西 免疫沉澱之蛋白質之存在或不存在 瘤或視網膜狂细胞瘤之基因所控制 〇 白質療法 失活化二痼正常對偁基因後達到其 制基因對於人類癌症之重要性的認 膜胚细胞瘤之研究。在遺傳性視網 胚细胞瘤(RB)基因的一個失活化複 因複製本在後代之生長和分化作用 述已顯示其編碼一個核磷蛋白 透過與數屆標的蛋白質*包括轉錄 细胞循環之進化。RB基因结構和表 - · 1 I II I - 1 I---. 1 I n (請先閣讀背面之注意事項再^;寫本頁)A7 B7 V. Description of the invention Ui) 懕 can be interpreted as too little P561 21D) in the cell. The diagnosis of ppRB11 <? was obtained from biopsies of patients or labeled with 32P-phosphate and precipitated. Or * extracted from active radioactive or non-radioactive direct diagnosis to smear analysis. As a diagnostic tool for judging other diseases of retinal germ cells. Tumor suppressor gene of lung cancer. Tumor suppressor gene plays a role in mutating tumors. Tumor Suppression • The first to appear is the retina in retinoid meningoblastoma. The retinal specimen is rejected and the second indactyl is inactive. Description of the RB gene (pi 10Re). Pi 10RB appears to be factor E2F binding and regulates the amount of ΙΒ stored in the nucleus of the target cell (graphical identification of isolated tumor cells M 355 methionine above procedures M anti-ppRBUo Is (3 immunostaining protein) The lysate can be controlled by the presence or absence of proteins labeled with the labeled anti-RB specific antibody Western immunoprecipitated protein or the absence of tumor or retinoblastoma gene control. Deactivation of white matter therapy. A study of the importance of its genes for human cancers in human germ cell tumors. The deactivation of a hereditary reticuloblastoma (RB) gene has been shown to have an effect on the growth and differentiation of progeny in the offspring. Encodes a nuclear phosphoprotein through several times the target protein * including the evolution of the transcriptional cell cycle. RB gene structure and table-· 1 I II I-1 I ---. 1 I n (Please read the precautions on the back first ^; Write this page)

*1T .•tl* 1T. • tl

I 經濟部中央標準局員工消費合作社印裝 乳因首為, ,基。型二 癌RB的黎第 線的重突。 列異雙因胞 前變是基细 -持據RB的 癌支証Μ標 肺。的至或 括疾義本型 包惡意製現 ,性床複表 關液臨性性 有血的能惡 疾和要功制 惡癌重之抑 類统具因將 人糸上基内 多殖成RB胞 許生生常細 和尿瘤正瘤 異泌腫入腫 雙-在納之 之癌現-點 現滕表先特 本纸張尺度通用中國國家標準(CNS ) A4规格(210X297公釐) 46611 7 經濟部中央標準局貝工消費合作社印製 S5.U.㈣ 修正.¾ A7 B7 五、發明説明((Ά) 最近p110rb表現之減少已顯示是指急性骨随性白血病和早 期勝胱癌病患,病症惡化之預警(在Annual Rev. Biochea· (1993) 62:623-651 之研究)。 以在P110RB之表現時發生RB基因之突變或變異為特徵之 睫螽揸定興療珐治麈磨癱癀士個糠番導瘗的研镯蘼掙悬前 蛋白質更換療法”*其中p11〇rb •或其功能性衍生物纳入 K喪失野生型腫瘤抑制基因蛋白質之表現為特徵之腫瘤细 胞内。其结果顯示在培餐物中外源添加之pll〇RBM進入细 胞,定位於核區並抑制腫瘤细胞之DN Α合成作用。再者, pH〇rb#經腸的施用在人體肺癌之臨床上有效之動物棋體 上可封姐腫瘤生長。PllORBt截短體,稱作p56rb在體內 橫髏中亦具有限之活性。該结果更進一步支持應用腥瘤抑 制基因蛋白質療法在K缺陷之RB表現為特徵之人類肺癌上 〇 p110rb體内抑制腫瘤之形成 上述所觀察之RB-媒介之體外生長抑制作用延伸至裸鼠 異種移植腫瘤棋體上。據此,在裸鼠建立皮下NC][-H59S腫 瘤,開始RB蛋白質療法並維持10天。皮下*腫瘤周圍施用 RB蛋白賣造成對腫瘤生長之明顯抑制作用(圃24A)。在 p110rb-處理之老鼠中腫瘤之尺寸在約8週時並未明顯 的增加*而在M p56RB或對照緩衝液處理之老鼠中,腥瘤 進展的較快》RB蛋白質處理之效應是長效的,因為在第 75-90天時,在pll〇RB-處理之老鼠中腫瘤璨増加之速率 -109 - 本紙張尺度適用中國國家標牟(CNS ) A4規格(210X297公釐) (請先聞讀背面之注意事項再魂寫本頁) 裝· h. 訂 線 466117 i5.il. 06 年月£) 修正 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(t ~------------- (約3平方毫米/天)較緩衝液處理之老鼠明顯較低(約 20平方奄米/天)。 在裸鼠體内建立A549 NSCLC腫瘤並用圖22A所描述之相 同處理方法。數據(圖22B)証明pll0R”Bp5 6Ra蛋白質療 法對於A549腫瘤g·.生長沒有作用,顯示只有RBne«腫描之 腫癯生長減少。 當定位時,皮下療法可用以証明RB蛋白質在體内減少肺 癌細胞源之腫瘤生成作用之能力,系统療法則是試驗 ρΠ0κβ可能之醫療價值較為嚴密之試驗。據此*使用靜脈 施察以输送多重劑量之活性或失活性之p110rb至有上述皮 下NC1-H596人類肺腫瘤之Balb/C裸鼠。數據(圖23)証明糸 铳输送之pU0rbK劑量依賴之方式有效封阻腫瘤之生長。 在第49天•以200微克/劑量之活性p110rb處理之老鼠之 平均腫瘤尺寸明顯小於K等劑量之失活性 p110rb(p<0.01)或較低劑量(50微克/劑量)之 pU0rb(p<0.05)處理之老鼠。所觀察最高之腫瘤生長速率 是在接受RB蛋白質失活性製備物(依在體外3H-胸腺核苷 併入測試中缺乏活性作為判斷)或鍰衝液對照處理之老鼠 。K活性p110rb處理之老鼠在研究中無中毒或病態之跡象 〇 過去之研究依據測量在軟瓊脂上之生畏和裸鼠髁內皮下 腫瘤之形成已証明重新纳入RB基因至RBne*背景中可逆轉 在許多细胞種類中腫瘤生成之表琨型。纳入功能性RB基因 至RBne腫瘤綑胞中,造成细胞内RB蛋白質之產生(參看 -110- 本紙张尺度適用中國囿家標隼(CMS > A4規格(210X297公釐) lr--------='}彳裝-- (請先閱讀背面之注意事項H寫本買) 訂 4 6 61 17I Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. Leiden line of a type II cancer RB. The presynaptic change of necrosis factor is basic- RB-based cancer support M standard lung. The orthodox disease type includes malicious control, sexual bed complexes, fluids, sexually-prone blood, can-eating diseases, and essential malignant cancers, which can cause severe cancer. The main causes are polymorphism of humans into RB. Cell Xu Shengsheng often thin and urinary tumors are heterogeneous edema and swelling into the tumor-cancer in the present-spot Teng table first special paper size common Chinese National Standard (CNS) A4 size (210X297 mm) 46611 7 Printed by the Central Standards Bureau of the Ministry of Economic Affairs, Shellfish Consumer Cooperative, S5.U.㈣ Amendment. ¾ A7 B7 V. Description of the invention ((Ά) The recent decrease in p110rb has been shown to refer to patients with acute bone-associated leukemia and early cystic carcinoma Early warning of disease deterioration (Researched in Annual Rev. Biochea · (1993) 62: 623-651). Eyelash fixation therapy enamel characterized by mutation or mutation of RB gene during the expression of P110RB The paralysis researcher's research on pre-suspension protein replacement therapy "* wherein p11〇rb • or its functional derivative is incorporated into tumor cells characterized by the loss of K-type wild-type tumor suppressor protein. It The results showed that exogenously added pllORBM entered the cells in the culture. It is located in the nuclear region and inhibits the DN Α synthesis of tumor cells. In addition, pH〇rb # can be used to intestine tumor growth on clinically effective animals in human lung cancer. PllORBt truncated body is called p56rb. It also has limited activity in vivo. This result further supports the application of tumour suppressor gene protein therapy in human lung cancer characterized by K-deficient RB. P110rb inhibits tumor formation in vivo. The in vitro growth inhibitory effect extends to nude mice xenograft tumor bodies. Based on this, subcutaneous NC] [-H59S tumors were established in nude mice, and RB protein therapy was started and maintained for 10 days. Subcutaneous * peripheral tumor administration of RB protein sold resulted in Significant inhibition of tumor growth (Pu 24A). In p110rb-treated mice, tumor size did not increase significantly at about 8 weeks *, but in mice treated with M p56RB or control buffer, the progression of the tumor was relatively Fast "The effect of RB protein treatment is long-lasting, because at day 75-90, the tumor rate in tumors in pll0RB-treated mice is increased by -109.-This paper applies Chinese national standards CNS) A4 specification (210X297 mm) (Please read the precautions on the back before writing this page) H. Thread 466117 i5.il. June 2006 £) Amend A7 B7 Staff Consumption of Central Bureau of Standards, Ministry of Economic Affairs Printed by the cooperative V. Description of the invention (t ~ ------------- (about 3 square millimeters / day) is significantly lower than that of buffer-treated mice (about 20 square millimeters / day). A549 NSCLC tumors were established in nude mice and treated in the same manner as described in Figure 22A. The data (Figure 22B) demonstrates that pll0R "Bp5 6Ra protein therapy has no effect on the growth of A549 tumors, showing that only RBne« swelling and swollen growth are reduced. When localized, subcutaneous therapy can be used to demonstrate that RB protein reduces lung cancer in vivo For the ability of cell-derived tumorigenesis, systemic therapy is a more rigorous test to test the possible medical value of ρΠ0κβ. Based on this * intravenous inspection is used to deliver multiple doses of active or inactive p110rb to humans with the above-mentioned subcutaneous NC1-H596 Balb / C nude mice with lung tumors. Data (Figure 23) demonstrate that pU0rbK transported by radon effectively blocked tumor growth in a dose-dependent manner. Day 49 • Mean tumors in mice treated with 200 μg / dose of active p110rb Dimensions significantly smaller than inactive p110rb (p < 0.01) or lower doses (50 micrograms / dose) of pU0rb (p < 0.05) treated mice at the same dose as K. The highest tumor growth rate observed was when receiving RB protein inactivation Preparations (determined by lack of activity in in vitro 3H-thymidine incorporation test) or sham control group-treated mice. K-active p110rb-treated mice No signs of poisoning or morbidity in the study. Previous studies based on measurements of soft agar and subendothelial tumor formation in nude mice have been shown to reincorporate the RB gene into the RBne * background to reverse tumorigenesis in many cell types The phenotype of RB. Including functional RB gene into RBne tumor bundle cells, resulting in the production of RB protein in cells (see -110- This paper size applies to the Chinese family standard (CMS > A4 size (210X297 mm) lr -------- = ') Outfit-(Please read the note on the back first to buy in H copy) Order 4 6 61 17

經濟部中央標準局員工消费合作社印製 五、發明説明q4)Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs.

Cancer Res. ( 1 992) 52 : 1968- 1 973)。若 p 11 0RB是納入腫 瘤细胞内,亦可觀察RB基因之更換所產生之生長抑制作用 «該應用顯示在G1早基从?110»^或956»*8微注射之同步 Saos2细胞停滯生長並被封阻而無法進入S期。由於微注 射非常費時且在糸统性疾病之治療上不實際,因而決定鏟 定是否细胞源可對外源添加之RB蛋白質反應。 最初為該研究選出二種NSCLC细胞。NC-H596依免疫塗 抹判斷無法表現可測得量之pll〇Re *而A549產生正常量之 p110rb(參看《I. Immunol. Heth. (1994) 169 :23 卜 240) 。在本專利說明書中所報告之數據明白的証明Ρ11〇κΒ對於 體外HC卜H549 NSCLC腫瘤细胞之有效的劑量-感應作用。 I?BPes a549 NSCLC癌细胞源未被p1〗0rb抑制,顯示 P110RB對於在RB表現上有缺陷之细胞的偏好作用。該结果 亦建議以Ntn-H596 NSCLC所觀察到之生長抑制作用並非因 為所申請之RB製備物的非特定有毒组分。Cancer Res. (1 992) 52: 1968-1 973). If p 11 0RB is included in tumor cells, the growth inhibitory effect of RB gene replacement can also be observed. «This application is shown in the G1 early base? 110 »^ or 956» * 8 microinjection synchronization Saos2 cells stopped growing and were blocked from entering S phase. Because microinjection is very time-consuming and impractical for the treatment of traditional diseases, it was decided to determine whether the cell source can respond to externally added RB proteins. Two NSCLC cells were originally selected for this study. NC-H596 cannot express a measurable amount of pllORe * based on immunosmearing and A549 produces a normal amount of p110rb (see I. Immunol. Heth. (1994) 169: 23 bu 240). The data reported in this patent specification clearly demonstrate the effective dose-sensing effect of P11OκB on HC and H549 NSCLC tumor cells in vitro. The source of I? BPes a549 NSCLC cancer cells was not inhibited by p1 orb, showing the preference effect of P110RB on cells with defective RB expression. This result also suggests that the growth inhibition effect observed with Ntn-H596 NSCLC is not due to the non-specific toxic component of the applied RB preparation.

PllORB抑制其它三種RBne*细胞源之生長。乳房癌细胞 源MDA-MB-463藏有一個部份RB基因之刪除序列和於其p53 基因上之定點突變(參看Mol. Cell Biol. ( 1 990) 9:1628-1634和Oncogene (1993) S : 279-28S)。使甩逆轉 錄酶載體納人RB基因之單-複製本至MDA-MB-468中,造成 裸鼠體内腫瘤生成之減少並減少在軟瓊脂土之生長能力, 但在培養物中之生長速率則未受影堪。在本專利說明書中 所示之實驗中,外源之pU〇rb抑制MDA-MB-468之生長。 MDA-MB-468體外生長抑制作用之程度可能和這類實驗所達 ________" 1 1 1 ~ 本紙張尺度通用中國國家標準(CNS ) A4規格(210X297公釐)PllORB inhibits the growth of three other RBne * cell sources. MDA-MB-463 derived from breast cancer cells contains a partial deletion of the RB gene and site-directed mutations in its p53 gene (see Mol. Cell Biol. (1 990) 9: 1628-1634 and Oncogene (1993) S : 279-28S). The single-copy copy of the human RB gene was incorporated into the reverse transcriptase vector into MDA-MB-468, resulting in a reduction of tumorigenesis in nude mice and a reduction of growth ability in soft agar soil, but a growth rate in culture Not affected. In the experiments shown in this patent specification, exogenous pUORb inhibited the growth of MDA-MB-468. The degree of MDA-MB-468's in vitro growth inhibition effect may be similar to that achieved by such experiments. ________ " 1 1 1 ~ This paper is in accordance with China National Standard (CNS) A4 (210X297 mm).

4 6 6117 經濟部中央標準局貝工消費合作社印製 S5.1L (16.修毛 A7 B7 五 '發明説明 到較高细胞内pllORSfi有顒。 當M SDS-聚乙烯醢胺凝膠電泳分析時,雖然5637和 MDA-MB-46S细胞源無法產生可測得之ϋΒ蛋白質,但SCLC细 胞源NCI Η-69產生RB之錯亂遷移品種(Proc. Hatl . Acad. Sci. USA (1990) 87:2775-2779)。在 NCI H-69上 棊因姐之定點突费造成raRHA前驅體之異常接合•使得 nRNA中表現序列21结構上融合至表現序列23,除去表現序 列22密磚序列的33個胺基酸。在該類细胞產生之RB蛋白質. K較PllORB少〜4 kD之表面分子量遷移*並且對E1A和 SV-40 T-抗原结合作用而言是缺陷的。重新纳入野生-型 ?110~至《(:1 H-69,所產生之狀況是功能性野生-型和非 -功能性突變型KB蛋白質並存。在NCI H-69中突變型RB之 出現,在本測試糸铳中似乎不干搜野生-型PllORB所造成 之生長抑制作用。 在該類實驗中RB媒介之生長抑制作用是特定於RBn·»细 胞源。ΡΠ0並不抑制正常膀胱,包皮堪雄母细胞,肺上皮 细胞源和RB NSCLC细胞源之生長。在正常培養狀況下*過 量表現pU0rb&不影響HIH 3T3纊雄母细胞之生長速率 (Exp. Cell Res. (1 9 9 3) 2 0 7 : 99 - 1 0 6 )。該數據與另一報 告正好相反,過量表現野生-型pnoRB等致正常细胞之生 長停滞(Oncogene (1993) 8:2659-2672)。在該研究中 * 肺上皮细胞源如WI-38之生長停滯是以質體過虽表現RB cDHA轉移感染再選擇安定之轉移感染物達成。無法看到 正常细胞源中之生長抑制作用可能是受限於本方法中所達 -112- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) - ]/ --------:.>裝-- (請先聞讀背面之注意事項#,恭寫本頁) I. >ar .诛 4 6 61174 6 6117 Printed S5.1L (16. Shaving A7 B7 5 'invention by Central Laboratories of the Central Bureau of Standards, Ministry of Economic Affairs, PillORSfi has been found to be higher in cells. When M SDS-polyvinylamine gel electrophoresis analysis Although 5637 and MDA-MB-46S cell sources cannot produce measurable ϋΒ protein, SCLC cell source NCI Η-69 produces a disordered migration species of RB (Proc. Hatl. Acad. Sci. USA (1990) 87: 2775 -2779). On the NCI H-69, the abnormal conjugation of the raRHA precursor was caused by the sister's site-specific burst fee. • The expression sequence 21 in the nRNA was structurally fused to the expression sequence 23, and 33 amines in the expression sequence 22 dense brick sequence were removed. RB protein produced in this type of cells. K has less surface molecular weight migration than PllORB by ~ 4 kD * and is defective for E1A and SV-40 T-antigen binding. Reintegrated into wild-type? 110 ~ To "(: 1 H-69, the resulting condition is the coexistence of functional wild-type and non-functional mutant KB proteins. The appearance of mutant RB in NCI H-69 does not appear to be in this test. Dry search of growth inhibition caused by wild-type PllORB. Growth of RB media in this type of experiment The inhibitory effect is specific to the RBn · »cell source. PΠ0 does not inhibit the growth of normal bladder, foreskin-like androgenic cells, lung epithelial cell source, and RB NSCLC cell source. Under normal culture conditions * excessive expression of pU0rb & does not affect HIH 3T3纩 The growth rate of male mother cells (Exp. Cell Res. (1 9 9 3) 2 0 7: 99-1 0 6). This data is contrary to another report, which overexpresses wild-type pnoRB, etc. Growth arrest (Oncogene (1993) 8: 2659-2672). In this study, growth arrest of lung epithelial cell sources such as WI-38 was achieved by plastids that showed RB cDHA metastasis infection and then selected stable metastatic infections. The inability to see the growth inhibitory effect in normal cell sources may be limited by the amount reached in this method -112- This paper size is applicable to China National Standard (CNS) A4 (210X297 mm)-] / ------ -:. > equipment-(please read the notes on the back #, write this page) I. > ar. 诛 4 6 6117

Α7 Β7 經濟部中央標準局員工消費合作社印製 五、發明説明(,〆) 到之细胞内piiorb之濃度。放射標記之pn〇RB的吸收顯示 僅小部份(添加之0.5-13; cpm)之l25I-pllORB被细胞吸收 0 在同步化细胞中微注射RB蛋白質之研究已顯示在蛋白質 注射之時間和所觀察到之生長抑制之時間之間的明顯延遲 (Cell (1991) 67:293-302)。P110RB-媒介之生長抑制作 用之時間過程(圖21B)亦反應該延遲。該類數據和圈21B 所見之12SI-p110rb之時間-依賴性核定作用一致。外源 添加之p110rb2核定位作用和為了具有生長抑制活性箱要 p110rb定位於核之報告一致(Mol . Cel I . Biol . ( 1 993) 13:4588-4599) ° RB蛋白質是细胞之增殖作用的一個重要之調節劑。本專 利說明書中所提出之研究,提供不需要基因修飾可在 RBne«腫頫中恢復正常之RB功能。其深具意義*因為RB功 能之喪失發生在非常多種之腫瘤類別中。體外各種 腫瘤细胞之生長抑制作甩証明外源RB蛋白質可功能性的取 代内源之野生-型RB。而正常细胞可吸收p110rb*其生長 不被抑制証明pU〇rb對於RBnee腫瘤细胞具選擇性抗-增 殖活性。由於體內減少之腫瘤生成是恢復腫瘤抑制功能較 敏感的指標*實驗包括裸鼠異種移植模型。最近觀察顯示 重新納入RB基因至帶有其它基因爱異之RB SCLC细胞中可 抑制其在裸鼠體内之腫瘤生成(Oncogene (1993) 8:2175-2181)。 ‘ 各種RBn*·腫瘤细胞體外之生長抑制作用証明外源〇蛋 _:----_ 1 1 3 - 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) /..裝-- (請先閲讀背面之注意事項再4·'寫本頁) 訂 第831 1 1748號專利申請案 4 6 β 1 1 7中文說明書修正頁(9〇年8月)^ - 五、發明説明()Α7 Β7 Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs 5. Description of the invention (, 〆) The concentration of piiorb in the cells. Absorption of radiolabeled pn〇RB shows that only a small portion (0.5-13 added; cpm) of 1.25I-pllORB is absorbed by cells. Studies of microinjection of RB protein in synchronized cells have shown that the time and duration of protein injection A significant delay between the times of growth inhibition observed (Cell (1991) 67: 293-302). The time course of P110RB-mediated growth inhibition (Figure 21B) also reflects this delay. This type of data is consistent with the time-dependent verification of 12SI-p110rb seen in circle 21B. The nuclear localization effect of exogenously added p110rb2 is consistent with the report that p110rb should be localized to the nucleus in order to have a growth-inhibitory active box (Mol. Cel I. Biol. (1 993) 13: 4588-4599) ° RB protein is a cell proliferative effect An important regulator. The research presented in this patent specification provides RB function that does not require genetic modification to return to normal in RBne «. It is significant * because the loss of RB function occurs in a wide variety of tumor types. The growth inhibition of various tumor cells in vitro proved that the exogenous RB protein can functionally replace the endogenous wild-type RB. And normal cells can absorb p110rb * and its growth is not inhibited, which proves that pU〇rb has selective anti-proliferative activity against RBnee tumor cells. Because reduced tumorigenesis in vivo is a more sensitive indicator of restoring tumor suppressive function * experiments include nude mice xenograft models. Recent observations have shown that reintroduction of the RB gene into RB SCLC cells with other gene love can inhibit tumorigenesis in nude mice (Oncogene (1993) 8: 2175-2181). '' Various RBn * · Tumor Cell Growth Inhibition Prove Exogenous 0 Egg_: ----_ 1 1 3-This paper size is applicable to Chinese National Standard (CNS) Α4 size (210X297 mm) /..Package- -(Please read the precautions on the back before you write this page) Order No. 831 1 1748 Patent Application 4 6 β 1 1 7 Chinese Manual Correction Page (August 1990) ^-Description of the invention ( )

白質可功 pllORB > 胞具選擇 復腫瘤抑 横型。 圖1是 藉兔疫沉 圃2是 基酸序列 圃3是 圖4是 物之侏留 圖5 A是 圖5B是 位作甩之 圃6A是 {請先聞讀背面之注意事項存填莴本萸) 能性取代内源野生-型RB。而正常细胞可吸收 其係生長不被抑制建議pllORB對於RBne*腫瘤细 性抗-增殖活性。由於腊內減少之腫瘤生成是恢 制功能較敏感的指標*各實驗包括裸鼠異種移植 層析譜,閜述在各種细胞源中Μ兔子抗-RB IsG 澱法鑑定RB蛋白質。 完全的RB cDNA核苷酸序列和RB蛋白質之推測胺 ‘。 層析譜*閫釋RB蛋白質之修飾。 層析譜*關釋在不同的脊椎動物品種中RB基因產 〇 層析譜*顯示RB蛋白質之定位作用。 層析譜*顯示在贵肉瘤细胞源U20S內RB蛋白質定 免疫螢光研究之结果。 單股DNA纖維素中RB基因瞵蛋白之管柱層析照片 圖6B是雙股DNA纖維素中RB基因磷蛋白之管柱層析照片 經濟部中央樣準扃員工消費合作社印製 0 圖7A是圖示,闌述TRPE-RB融合蛋白質之產生。 圖7B是重姐體TRP E-RB融合蛋白質之聚丙烯醯胺凝膠電 泳之照片。 圖8A是層析圖,顯示來自各種人體细胞源之RB蛋白質/ 抗ΙΪΒ蛋白質IsG之免疫沉澱物。 114 - 本紙張尺度適用中國國家標準(CNS > Α4规格(210X297公釐) 83111748號專利申謫案 中文說明書修 (90年8月 A7 B7 明(修正丨 ^補充1 圖8B是層析圃•顯示 RB蛋白質/抗-RB蛋白 圄9是層析圖•顯示 之作用。 圖10 A閭述加至10 Χ 白質和桿狀病毒表現之 圖10Β是自平行凝膠 的放射自顯術譜。 圖11是層析譜,顥示 (p110rb)與 SV40 Τ-抗 圓12是照片•閬述撖 化蛋白質之细胞核的移 圖13閜釋用作微注射 SDS-PAGE分析》 圖14至14F是顯微照 注射和免疫染色。 画15M画表闞釋經標 來自數個視網膜胚细胞瘤细胞之 質IgG之免疫沉澱。 生化分鈒分離作用以証明〇蛋白質 SDS-PAGE,考馬斯藍染色之融合蛋 P110RB之南西向DNA结合测試。 至用K產生圖10A之凝瞭之塗抹物 經稈狀病毒表現之RB蛋白質 原之複雜的形成作用。 注射至Soas-2妞胞之细胞質後經鈍 位作用。 之蛋白質製備物之濃度和純度之 片;閫釋烴標記之Saos-2细胞之微 記之细胞直至注射後4天之百分比 (請先閲讀背面之注$項再填寫本頁) 經濟部中央標隼局貝工消費合作社印製 圖16从圖表闞釋經檷記细胞之百分比和P56湄度之闍係 0 , 国17以圖表闡釋當?56^在5期注射對细胞之影響。 圖18 A至18CK圖表閭釋细胞循環對注射截短蛋白質之期 間之依賴。 -114i 本紙張尺度適用中國國家梂準(CNS ) A4规格(210X297公嫠) 經濟部中央標準局貝工消費合作社印製 第83111748號專利申謫案 4*6611*7中文說明書修正頁(9〇年8月)^ - B7 年月#亡 . .. —_ 圖19顯示pllORB抑制在Rb蛋白質表琨中是缺陷之小细胞 和非小细胞肺癌细胞源之生長。 圖20是RB-介質生長抑制作用之時間過程研究之结果。 圜21A顯示125I-pll〇aB對各次细胞部份之時間-依賴 性定位作用。 圖21B顯示在HC1-H596细胞核部份125I-p110rs之兔疫 沉澱和鑑定。 圖21C顯示i2SI-pll〇RB在肺癌细胞源细胞核部份之免 疫沉澱和鑑定。 圖21D顯示在Ν(Π-Η596 NSCLC细胞中經细胞核-定位之 la5I之定量。 圆22A顯示所示之NC1-H596 (RB"*«)腫瘤尺寸表示各賁 驗姐3種動物之平均值土 S.D.。 圖22B顯示所示之A549 (RB〜腫瘤尺寸表示各實驗姐 3種動物之平均值土 S.D.。 B 23顯示p110rb之靜脈注射對裸鼠内人體肺腫瘤细胞生 長之影響, 蹰24顯示pllORB可體外抑制非小细胞肺癌细胞之生長, 但對正常细胞源之增殖作用不具影響》 圖25顯示pi 10RB抑制在Rb蛋白質表現中是缺陷之小细胞 和非小油胞肺癌细胞源之生長。 圃26顯示pi 10RBq進入细胞並定位於细胞核。 圃27顯示完整之p110rb可在K 標記之Pii〇w處理 之H5 96腫瘤细胞之细胞核中測得。 -114b - 本紙張尺度適用中國國家標準(CNS > A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)White matter can work pllORB > Cells have a choice of complex tumor suppression horizontal. Figure 1 is a rabbit epidemic nursery 2 is a basic acid sequence nursery 3 is a figure 4 is a stubborn figure 5 A is a figure 5B is a dumping garden 6A Ii) Capable of replacing endogenous wild-type RB. While normal cells can absorb the growth of their lines and are not inhibited, it is suggested that pllORB has a fine anti-proliferative activity against RBne * tumors. As the reduced tumorigenesis in wax is a more sensitive indicator of recovery function * Each experiment includes a chromatogram of nude mice xenograft, which describes the identification of RB protein by M rabbit anti-RB IsG precipitation method in various cell sources. Complete RB cDNA nucleotide sequence and putative amine of RB protein. Chromatogram * Reveals modifications to RB protein. Chromatograms * show RB gene production in different vertebrate species. Chromatograms * show the localization of RB proteins. The chromatogram * shows the results of immunofluorescence studies of RB protein in U20S from noble sarcoma cells. Column chromatography photo of RB gene 瞵 protein in single strand DNA cellulose Figure 6B is a column chromatography picture of RB gene phosphoprotein in double strand DNA cellulose The figure shows the production of TRPE-RB fusion protein. Fig. 7B is a photograph of a polyacrylamide gel electrophoresis of the TRP E-RB fusion protein. FIG. 8A is a chromatogram showing immunoprecipitates of RB protein / anti-ILB protein IsG from various human cell sources. 114-This paper size applies the Chinese national standard (CNS > A4 size (210X297 mm) No. 83111748 patent application Chinese manual revision (A7 B7 in August 1990 (Amendment 丨 ^ Supplement 1 Figure 8B is a chromatography garden • The RB protein / anti-RB protein 圄 9 is a chromatogram and shows the effect. Figure 10 A shows the performance of white matter and baculovirus added to 10 × Figure 10B is the autoradiography spectrum from a parallel gel. Figure 11 is a chromatogram, p110rb and SV40 T-anticircle 12 are photographs. • Nucleus shift of the described protein is described. Figure 13 is used for microinjection. SDS-PAGE analysis. Figures 14 to 14F are micrographs. According to injection and immunostaining. Draw 15M to show the immunoprecipitation of IgG from several retinal blastoma cells. Biochemical separation is used to prove the protein SDS-PAGE, Coomassie blue-stained fusion egg. P110RB's south-westward DNA binding test. The complex formation of RB protein protease expressed by culm virus by the coagulated smear shown in Figure 10A with K. Injected into the cytoplasm of Soas-2 female cells and passed through the blunt position. The concentration and purity of the protein preparation Percentages of micro-reported cells labeled with released hydrocarbon-labeled Saos-2 cells up to 4 days after injection (please read the note on the back before filling this page) Figure 16 illustrates the percentage of meridian cells and P56 of the meridian system 0, and Figure 17 illustrates the effects of the 56? Injection on cells in phase 5. Figure 18 A to 18CK chart illustrates the cell cycle response to injection Dependence on truncation of protein. -114i This paper size is applicable to China National Standard (CNS) A4 (210X297 gong). Printed by the Central Bureau of Standards of the Ministry of Economic Affairs, No. 83111748, patent application case 4 * 6611 * 7 Chinese manual correction page (Aug. 90) ^-B7年月 # 死. .. —_ Figure 19 shows that pllORB inhibits the growth of small cell and non-small cell lung cancer cell sources that are defective in the Rb protein epithelium. Figure 20 is the result of the time course study of RB-medium growth inhibitory effect. 圜 21A shows the time-dependent localization effect of 125I-pll0aB on each cell part. Figure 21B shows the 125I- Precipitation and identification of rabbit epidemic of p110rs. Figure 21C shows Immunoprecipitation and identification of i2SI-pll0RB in the nucleus portion of lung cancer cells. Figure 21D shows the quantification of nuclear-localized la5I in N (Π-Η596 NSCLC cells. Circle 22A shows the NC1-H596 (RB " * «) Tumor size represents the mean ± SD of the three animals tested. Figure 22B shows the A549 (RB ~ tumor size represents the mean ± SD of 3 animals of each experimental sister. B 23 shows the effect of intravenous injection of p110rb on the growth of human lung tumor cells in nude mice, and 蹰 24 shows that pllORB can be used in vitro. Inhibits the growth of non-small cell lung cancer cells, but has no effect on the proliferation of normal cell sources "Figure 25 shows that pi 10RB inhibits the growth of small cells and non-small oil cell lung cancer cell sources that are deficient in the expression of Rb protein. Figure 26 shows pi 10RBq enters the cell and localizes to the nucleus. Plant 27 shows that intact p110rb can be measured in the nucleus of K-labeled Pii〇w-treated H5 96 tumor cells. -114b-This paper size applies Chinese national standards (CNS > A4 Specifications (210X297mm) (Please read the notes on the back before filling this page)

第83111748號專利申請案 文說明書修正頁(90年δ月)^ — 五、發明説!g () 念修正 _補充 Η 2δ顯示?110!^和?5611&對動物棋體内非-小细胞肺癌 之皮下治療具生物活性。 圖29顯示在適當模體中使用pil〇RB之肺癌非烴腸療法。 圖3 0顯示在大腸稈菌内產生之視網膜胚细胞瘤蛋白質之 胺基酸序列。 圖31圖示供pp110rb合成作用之桿吠病毒表現載體之構 築。 圖32A和32B是ppRB感染昆蟲细胞之西商塗抹物(蹰32A) 和鑑定细胞提取物之塗抹钧•該细胞提取物是來自感染後 72小時之感染细胞。 圖33是放射自顳譜,閏釋在昆蟲细胞內RB蛋白質之磷酸 化作用和去磷酸化分析之结果。 (請先閲讀背面之注$項再填寫本頁) 經濟部中央標準局員工消費合作社印製 -114c - 本紙張尺度適用中國囷家標準(CNS > Α4规格(210X297公釐)Revised page of Patent Application No. 83111748 (90 months in 1990) ^-Invention theory! g () Read correction _ supplement Η 2δ display? 110! ^ And? 5611 & is biologically active for subcutaneous treatment of non-small cell lung cancer in animals. Figure 29 shows non-hydrocarbon enteric therapy for lung cancer using piloRB in an appropriate phantom. Figure 30 shows the amino acid sequence of the retinoblastoma protein produced in E. coli. Figure 31 illustrates the construction of a baculovirus expression vector for pp110rb synthesis. Figures 32A and 32B show the smear of shangxi spores (蹰 32A) and identification of cell extracts from ppRB-infected insect cells. The cell extracts are from infected cells 72 hours after infection. Figure 33 is the result of phosphorylation and dephosphorylation analysis of RB protein released in insect cells radiated from temporal spectrum. (Please read the note on the back before filling in this page) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs -114c-This paper size is in accordance with Chinese standards (CNS > Α4 size (210X297 mm)

Claims (1)

苐83111748號專利申請案 4 6 6,本士g請專利範圍修正本(9〇年8月) A8 C8 D8 申請專利笼圍苐 83111748 patent application 4 6 6, the applicant asked the amendment of the patent scope (August 90) A8 C8 D8 patent application 經濟部中央標隼局具工消費合作社印製 著^制病態增殖细胞增殖作用之酱蔡姐合物,其中细 _ , ♦ 胞之病態¥殖作用是细胞内缺乏或具所裔量.以下之功能 性視網膜胚细胞瘸多胜肽或蛋白質之结果*該轚藥姐合 物包、括、育效量之p56rb。 2. 根據申請專利範圍第1項之發藥姐合物,其中缺乏或具 - · · . 所需量K下之功能性視網膜胚细胞換多胜肽或蛋白質是 病態突變之視網膜胚细胞瘤基因之结果》 3. 根據申請專利範圍第1項之路藥姐合物*其中病態增殖 细胞之抑制作用Μ無群落増生(apoptosis) *细胞死亡 *分化或良性表現型為特徵。 4. 根據申請專利範圍第1項之路藥姐合物,其中病態增殖 妞胞是視網膜细胞,前列腺细胞,结腸细胞,肺细胞, • ' 肉瘤细胞*白血病细胞*或淋E瘤细胞。 .5. 根據申請專利範圍第1項之翳藥姐合物,拜中病態增殖 妞胞是哺乳類细胞。1 ; ’ ,V * 6. 根據申請専利範圍第1項之醫禁姐合物,其中該细胞係 ,/ . · ' 於轉內或'賴外與P56RB接觸p / * ' ; ' '… 7. ,種用於治療患者賴內原發性(primary)或績發性· L . ΐ '· _ (secondary)之視網膜胚细胞瘤相關棒之癌症之路蔡组 合物I其包括:教患者施用‘效.!1之p5 6RB。 • \ _ . 8. 根據申請專利範圍第7項之轚藥姐合物 網膜.相關埋之癌症是視=網膜胚细胞瘤。. 9. 根據申請專利範圍第7項-之路藥组合物 .乳類動.物。 其中原發性視 其中患者是哺 10..根據申.請專利範圍第7項之S槩姐合物*其中該轚蔡组 本紙張尺度適用中國國家梂準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) _ j AS 4 6 6117 as D8 六、申請專利範圍 合物係對患者經由靜脈施藥,口服施藥,腫瘤內注射或 0 腌 内 膜 腹 (請先閣讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局負工消費合作社印裝 本紙張尺度逋用中國國家標準(CNS ) A4規格(2〖〇Χ2打公釐)The Central Bureau of Standards, Ministry of Economic Affairs, and the Industrial Cooperative Cooperative has printed ^ Jie Caijie compound, which produces the proliferation of diseased proliferating cells. Among them, the morbidity of the cells is the lack of cells or the amount of cells. The following Result of functional retinal germ cells with polypeptide or protein 2. The drug compound according to item 1 of the patent application scope, which lacks or has-· ·. Functional retinal germ cell replacement polypeptide or protein at the required amount of K is a pathologically mutated retinoblastoma gene Results "3. According to the first patent application scope of the road medicine sister compound * which inhibits the pathologically proliferating cells M no community proliferation (apoptosis) * cell death * differentiation or benign phenotype is characterized. 4. According to the first patent application scope of the road drug sister compound, the pathologically proliferating female cells are retinal cells, prostate cells, colon cells, lung cells, • 'sarcoma cells * leukemia cells * or lymphoma cells. .5. According to the peony compound of the first patent application scope, the morbidly proliferated female cells are mammalian cells. 1; ', V * 6. According to the medical contraindication compound in item 1 of the scope of the application, the cell line, /. ·' Is in contact with P56RB or 'external contact with p56RB p / *'; '' ... 7 . A kind of Lu Cai Cai composition I for treating patients with primary (primary) or epidemiological L. retinal germ cell tumor-related rods. It includes: teaching patients to administer 'Effect.! 1 of p5 6RB. • \ _. 8. According to the 7th patent application scope of the peony medicine omentum. The relevant buried cancer is visual = omental blastoma. 9. According to the scope of patent application No. 7-Road medicine composition. Dairy animals. Among them, the primary view is that the patient is lactating 10. According to the application, please apply for the S-sister compound in item 7 of the patent scope *, where the paper size of this paper is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) ) (Please read the precautions on the back before filling this page) _ j AS 4 6 6117 as D8 VI. Application for Patent Scope Compounds are administered to patients via intravenous administration, oral administration, intratumoral injection or 0 pickled endometrial abdomen (Please read the precautions on the back before filling out this page) Set the paper size of the printed papers of the Central Standards Bureau of the Ministry of Economic Affairs and the Consumer Cooperatives, using the Chinese National Standard (CNS) A4 specification (2 〖〇 × 2 dozen mm)
TW83111748A 1994-09-13 1994-12-15 Pharmaceutical compositions of the retinoblastoma susceptibility gene product TW466117B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/306,513 US5851991A (en) 1987-08-31 1994-09-13 Therapeutic use of the retinoblastoma susceptibility gene product

Publications (1)

Publication Number Publication Date
TW466117B true TW466117B (en) 2001-12-01

Family

ID=23185640

Family Applications (1)

Application Number Title Priority Date Filing Date
TW83111748A TW466117B (en) 1994-09-13 1994-12-15 Pharmaceutical compositions of the retinoblastoma susceptibility gene product

Country Status (1)

Country Link
TW (1) TW466117B (en)

Similar Documents

Publication Publication Date Title
TW379227B (en) Broad spectrum tumor suppressor genes, gene products and methods for tumor suppression gene therapy
US5891857A (en) Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
RU2222600C2 (en) Adenovirus-recombinant carrying adenoviral vector structure (variants), method for recovery function of protein p53 in tumor cell with deficiency of natural p53, method for producing adenovirus-recombinant
Urbanska et al. The CSC proteins FAP61 and FAP251 build the basal substructures of radial spoke 3 in cilia
JP2011244827A (en) CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS
JP2000507815A (en) CFTR gene regulator
ES2361044T3 (en) A DESIGNATED TUMOR SUPPRESSOR TS10Q23.3.
JP2002536995A (en) Genes associated with colon disease
JP2021508253A (en) Nucleotide sequence encoding CAR, ROBO1 CAR-NK cells expressing this CAR, preparation and use thereof
JP2002538789A (en) Novel human kallikrein-like gene
CA2044940A1 (en) Transdominant negative proto-oncogene
JP2003508011A (en) Compositions, kits and methods relating to a novel tumor suppressor gene that is the human FEZ1 gene
TW466117B (en) Pharmaceutical compositions of the retinoblastoma susceptibility gene product
JP4771576B2 (en) GASC1 gene
CA2251264A1 (en) Human hyaluronan receptor
US5851991A (en) Therapeutic use of the retinoblastoma susceptibility gene product
JPH09511236A (en) DNA encoding CAI resistance protein and use thereof
CN1157828A (en) Truncated form of inhibitory kappa B protein (IKB) recombinant production and uses thereof
WO1995007708A2 (en) Therapeutic use of the retinoblastoma susceptibility gene product
CZ178396A3 (en) Novel tumor-suppressor gene
JP2002513272A (en) BRCA1 compositions and methods for diagnosis and treatment of breast cancer
JP2001517954A (en) NOEY2 gene compositions and methods of use thereof
US20130122028A1 (en) Novel vaccine that targets tumor vessels as an efficient tool in tumor therapy
JP2000509255A (en) Gene family associated with sensory neuropathy
US20030166586A1 (en) C/EBP beta isoforms and methods of use in cell regulation and anti-tumorigenesis

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees